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List of Abbreviations
AIS:  androgen insensitivity syndrome
AMH:  anti-Müllerian hormone
CAIS:  complete androgen insensitivity syndrome
CAH:  congenital adrenal hyperplasia
DHT:  dihydrotestosterone
DSD:  disorders of sex development
GA:  gestational age
GD:  gonadal dysgenesis
LH:  luteneizing hormone
MIS:  Müllerian inhibiting substance
MRKH:  Mayer-Rokitansky-Küster- Hauser syndrome
PAIS:   partial androgen insensitivity syndrome
QOL:  quality of life
SPL:  stretched penile length
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17ß hydroxysteroid dehydrogenase deficiency (17ß HSD): 
genetic disorder of steroid formation, caused by a  deficiency of the testicular enzyme 17ß 
hydroxysteroid dehydrogenase that produces testosterone from androstenedione. Plasma 
testosterone and dihydrotestosterone (DHT) are decreased and androstenedione is increased. 
It is characterized in XY individuals by ambiguous or feminine-appearing external genitalia at 
birth, with masculinization at puberty. 
5α reductase deficiency (5α RD): 
genetic disorder of steroid formation, caused by a  deficiency of the testicular enzyme 
5α reductase that produces dihydrotestosterone (DHT) from testosterone. Plasma DHT is 
decreased, testosterone is increased. It is characterized in XY individuals by ambiguous or 
feminine-appearing external genitalia at birth, with masculinization at puberty.
Androgen insensitivity syndrome (AIS): 
X-linked genetic disorder that results in the inability of receptors to respond to androgens. 
The receptor deficiency can be partial (PAIS) or complete (CAIS). In  XY individuals with CAIS, 
the external genitalia appear feminine at birth and at the time of puberty, breasts develop in 
response to estrogen produced from androgen, catalysed by aromatase. However, female 
internal genitalia are absent and menstruation does not occur. XY individuals with PAIS can be 
born with ambiguous genitalia.
Cloaca: 
in mammalian embryology, the terminal end of the hindgut before division into rectum, bladder 
and genital primordial.
Cloacal exstrophy: 
a developmental anomaly in which two segments of the bladder (hemibladders) are separated 
List of  Definitions 
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by an area of intestine with a mucosal surface, which appears at birth as a large red tumor in 
the midline of the lower abdomen. It is more common in XY individuals, and they are typically 
born with a small or absent penis, which, like the bladder, can be bifid.
Congenital adrenal hyperplasia (CAH): 
family of inherited  (autosomal recessive) disorders caused by enzymatic defects in adrenal 
steroid biosynthesis. CAH  results in hypersecretion of adrenocorticotropic hormone as well 
as excessive androgen production. In girls, it causes masculinization of the external genitalia 
(enlarged clitoris, fusion of labia, urogenital sinus).
Disorder of Sex Development (DSD): 
a congenital condition in which development of chromosomal, gonadal or anatomical sex is 
atypical.
Epididymis: 
the elongated cordlike structure along the posterior border of the testis. It provides for storage, 
movement and maturation of the spermatozoa and is continuous with the ductus deferens.
Gender identity: 
the sense of oneself as male or female.
Gender role behavior (sex-typical behavior) : 
behaviors that are culturally associated with gender or that show sex differences.
Gender dysphoria: 
unhappiness with one’s biological sex or its usual gender role, with the desire for the body and 
role of the other sex.
Genotype: 
the entire genetic constitution of an individual.
Gonad: 
gamete-producing gland; an ovary, testis or ovotestis (combined ovary and testis).
Gonadal dysgenesis: 
incomplete or defective formation of the gonads, as a result of a disturbed process of migration 
of germ cells and/or their correct organization in the fetal gonadal ridge.
Gonadectomy: 
surgical removal of one or both gonads (castration).
Gynecomastia: 
excessive growth of the male mammary glands, in some cases including development to the 
stage at which milk is produced. Gynecomastia is usually associated with metabolic disturbances 
that lead to estrogen accumulation, testosterone deficiency and hyperprolactinemia. 
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Hermaphrodite: 
an individual with both ovarian and testicular tissue.
Hypervirilization: 
the presence of ambiguous or male external sexual characteristics in a 46, XX individual, 
exposed to androgens (endogenous, due to genetic defects in enzymes involved in adrenal 
steroid hormone production or of exogenous origin) during fetal life or thereafter. 
Hypogonadism: 
a condition resulting from abnormally decreased gonadal function, with retardation of growth, 
sexual development and secondary sex characteristics.
Hypospadias: 
anomaly characterized by a defect on the ventral surface of the penis so that the urethral 
meatus (urethral opening) is more proximal than normal; may be associated with chordee. 
Idiopathic hypogonadal hypogonadism:  
a disorder involving reduced testicular production of androgens and other hormones caused 
by low levels of pituitary hormones and consequently reduced stimulation of the testes.
Intersex: 
condition in which a person displays a mixture of both male and female physical forms of 
reproductive organs. Now called Disorder of Sex Development.
Libido: sexual desire, drive or interest.
Micropenis: 
abnormally small penis (stretched penile length ≤ 2.5 cm at birth or ≤ 7cm in Caucasian adults).
Müllerian ducts:
paired embryonic ducts adjoining the urogenital sinus that develop into the fallopian tubes and 
the uterus in the female and regress into a rudimentary structure in the male.
Perineal hypospadias: 
hypospadias with anomalous development of the genitalia in which the rudimentary penis may 
be engulfed by an overlying bifid scrotum.
Perineum: 
the pelvic floor and the associated structures occupying the pelvic outlet. Also the region 
between the thighs, bounded in the male by the scrotum and anus and in the female by the 
vulva and anus.
Phenotype: 
the entire physical, biochemical and physiological makeup of an individual as determined both 
genetically and environmentally, as opposed to genotype.
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Pseudohermaphroditism: 
condition in which the external genitalia are at odds with the karyotype, gonadal morphology 
and internal genitalia.
Rough-and-tumble play: 
a juvenile behavior characterized by overall body contact or playful aggression.
Scrotum: 
the pouch that contains the testes in males.
Sexual dimorphism : 
technically meaning ‘two forms’, mostly interchangeable with sex difference: any psychological 
or behavioral characteristic that differs on average for males and females of a given species.
Sexual orientation: 
erotic attraction to and interest in sexual partners of the same versus the other sex.
Tomboy: 
a girl who likes toys, clothes and activities associated with or usually preferred by boys and who 
likes to play with boys.
Transsexualism: 
the most severe manifestation of gender identity disorder in adults. It is characterized by a 
prolonged, persistent desire to relinquish one’s primary and secondary sex characteristics and 
acquire those of the other sex. It particularly describes those persons who go so far as to live as 
members of the other sex, and undergo hormonal treatment and surgical reassignment.
Undervirilization: 
the presence of an ambiguous or female phenotype in a 46, XY individual with bilateral (intra-
abdominal, inguinal or scrotal) well-differentiated testes, in whom testosterone production or 
action is inadequate.
Urethra: 
the membrane canal conveying urine from the bladder to the exterior of the body.
Urogenital sinus: 
anomaly in which the vagina and urethra open into a common channel, rather than separately. 
In a low confluence urogenital sinus anomaly, the common channel is short, the urethral 
opening is close to its normal location and the vagina is almost normal in length. In a high 
confluence urogenital sinus anomaly, the common channel is long, the urethral opening is 
internal and the vagina is quite short. This type is sometimes associated with an anus that is 
located too far forward.
Vanishing testes syndrome: 
a disorder in males characterized by the absence of the testes and gonadal tissue at birth. When 
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it is bilateral, the individual will not undergo puberty or adolescent masculinization without 
testosterone supplements. The testes are thought to have been present in the embryo, but 
to have ‘vanished’ before completion of male sexual differentiation, also called embryonic 
testicular regression syndrome.
Vas deferens: 
the excretory duct of the testis, which unites with the excretory duct of the seminal vesicle to 
form the ejaculatory duct.
Virilization: 
masculinization
Wolffian ducts: 
either of the pair of ducts that are present in the human embryo (alongside the pair of Müllerian 
ducts). They develop into the male internal reproductive tract if embryonic testes are present
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Sex is everywhere. Sex sells. Sex is a biological urge, a natural part of life, and the most fun you 
can have without laughing- though it’s even better when you do [1]. For as many times as sex is 
painted as a natural enjoyable activity, it’s also portrayed as problematic. For every stereotype 
of the undermotivated female, there is a supposedly sexually rampant male. For every prim 
and modest woman, there is someone whose sexuality is dark, threatening and dangerous. 
For every Eve, a Lilith [1]. Media coverage, as well as the commercial agenda of pharmaceutical 
companies only reinforce an oversimplification of human sexuality [2,3]. 
While sexual manuals like the Kama Sutra have existed for centuries, the systematic study of 
human sexuality really started in the late nineteenth century with Von Krafft-Ebings’ ‘Psycho-
pathia Sexualis’ and has only been a cohesive academic discipline since the mid-twentieth 
century [4]. Attitudes, tools of research and analysis have changed since. The focus on what is 
testable and verifiable has taken root in the study of sex and gender and there is less acceptance 
of personal opinion as the only source of evidence [1].
Although some are realizing the advantages of interdisciplinary study, with social science 
enriching the finds of quantitative methods and vice versa, the polarization of psychological 
research in sex differences and psychosexual development remains, however, enormous 
[5]. Researchers approach their work mainly from either a social (nurturist) perspective or 
hormonal/genetic perspective. Social factors do matter; parents, teachers and peers treat –
intended or not- boys and girls differently. Society in general expects and encourages different 
behaviors from men and women (gender stereotypes). However, social learning research is 
limited mainly to the study of gendered social behavior, but these may not be connected to 
sexual activities or to gender identity [6]. Within a naturalistic sex research framework, sex is 
a biological fact, with only two mutually exclusive and oppositional sexual categories: male 
and female. The development of different facets of sexuality is assumed to be congruent with 
either male or female sex chromosomes, hormonal profile, brain, physique and reproductive 
capacity [6]. Within this framework, research is focused upon the correlational relationships 
between physiological variables and observable behavior. For instance, experiments are set 
up to identify ‘masculine’ and ‘feminine’ preferences and behaviors in boys and girls and to 
measure sex differences [7]. Studies have concentrated on the role of prenatal androgens in 
gender differentiation, while others have examined the activation potential of sex hormones, 
in casu testosterone, on sexual functioning (such as desire or partner orientation). To this 
Foreplay
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date, it remains unequivocal as to how closely adult human sexuality relates to the hormonal 
environment during fetal life. In animal research, the explanatory and predictive power of 
naturist hypotheses is great (for instance in relation to courtship and mating behavior), but 
the extent to which animal data can be extrapolated to humans remains a moot point [6]. 
Cultural determinants and socialization processes are probably competing influences next to 
‘pure’ hormonal effects in human gendered development. Moreover and more importantly, 
the question remains how likely it is that the identification of hormones and culprit genes will 
remove blame from or accept people considered sexual anomalies in society.
Recent years have seen the surfacing of important clinical issues related to the proper guidance 
of children born with Disorders of Sex Development (DSD) in which atypical prenatal hormonal 
environments lead to atypical genitalia. Biological causes are crystal clear, but stigma remains 
[8]. Most psychological theories have failed to appreciate the force of the dominant culture and 
to question the (heterosexist) imperatives of sex. Our cultural ideology requires two oppositional 
sexual categories, their certification through acceptable frequency and duration of genital 
intercourse - consigning all other sexual activities to the secondary status of ‘foreplay’ - and 
the capacity for procreation [6]. In scrutinizing the sexuality of people with a non-normative 
physico-sexual development, we may have to pay more attention to the personal meanings 
of genital a-normality, the experience of living with genital ambiguity and how meanings and 
experiences are produced by dominant discourses of body and sex. We need to pay attention 
to the ways in which our own practice such as the treatment choices we offer, the language 
we use and our silence might lead to some of the negative effects we observe in patients with 
stigmatizing diagnoses [9-11]. 
By celebrating the complexity and power of human bodies and further unravelling entrenched 
gender stereotypes and myths, we should finally accept a greater truly natural variation and 
diversity of human sexuality [12,13]. We need to come out of our sexual closets and be able to 
talk about sex without shame and take pride in how we choose to enjoy our bodies and genitals 
[14]. Otherwise, the public discourse on sex, as well as the debate within the DSD community, 
will continue to focus on dysfunction and not sucsex.
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CHAPTER 1
Genital (a)typia
The profound significance to parents of the 
sex of their newborn is without doubt. Two of 
the questions most usually asked immediately 
after the birth are ‘Is it allright?’ and ‘Is it a girl 
or boy?” [11]. We assume that the answer to the 
latter will be easy. Penis and scrotum define 
a boy; clitoris and labia a girl [5]. However, 
parents and pediatricians sometimes find 
it difficult to answer this seemingly simple 
question. ‘Disorders of Sex Development’ 
(DSD) – formerly called ‘intersex disorders’ – 
refer to all congenital conditions in which there 
is a disagreement between a person’s  genetic 
(i.e. chromosomal)  sex and the appearance 
of external and internal reproductive struc-
tures [15]. This chapter addresses sex 
differentiation as it occurs in DSD, as well as 
etiologies, physiological presentations, clinical 
management, and psychological outcomes. 
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Sex is not a simple matter. In fact, sex may be defined biologically in many ways [16]. The 
complete process of sex determination and differentiation involves a series of sequential events 
and is considered to occur within four stages [17]. 
Genetic material including sex chromosomes is contributed from two parents. The female 
parent contributes the female sex chromosome, X, the male parent contributes either the 
female sex chromosome, X, or the male chromosome, Y, thus determining the genotypic sex 
of the fetus. The end result is an embryo who has a pair of sex chromosomes that are either 
XX (genetic female) or XY (genetic male). In a few instances, the chromosomal constitution, 
or karyotype, is more complex, such as in cases of mosaic individuals who carry a patchwork 
of cells with different chromosomal constitution, e.g. XX and XY or X and XY cells. In other 
situations, the karyotype appears to be normal, but the appearance of the individual is opposite 
the expectation. This disparity is caused by mutations in genes important for sex determination, 
thereby leading to XX males or XY females (see [16]).
A pair of primordial gonads, the genital ridges, appear in both genetic males and females during 
the fourth week of embryonic life. Two associated ducts develop, the Müllerian and Wolffian 
ducts, while presumptive external genitalia appear as folds of cloacal tissue [4,5]. The precursor 
organs for sexual development in the developing embryo are bipotential, meaning that they 
contain the intrinsic capability to evolve either along the male or female pathway [18]. The fate 
of these undifferentiated internal and external structures depends on the chromosomal sex of 
an embryo. The presence and expression of the testis-determining gene SRY, located on the 
distal part of the short arm of the Y chromosome (Yp) [19], determines the gonadal sex of an 
embryo by directing the development of the bipotential embryonic gonad into testes. Without 
the influence of the sex-determining gene, the development of the embryonic gonad will be 
driven along the female pathway [17] (Figure 1). 
Genes involved in the organogenesis of the gonads are important for the development of 
the gonads in both sexes. They include SF1 (Steroidogenic Factor 1) and WT1 (Wilms Tumor 
1) (for a full overview, see [16,20]). Both genes are transcription factors that, when mutated, 
are responsible for a severe defect of gonad formation.  Mutations in these genes are also 
associated with other malformations, such as adrenal defects for SF1, and kidney disorders for 
WT1 [16]. Other genes are responsible for promoting male development, such as SOX9 (SRY 
related HMG-box, gene 9). Finally, some genes seem to antagonize male development, such 
Several sexes?  
Sexual determination and differentiation
1.   Chromosomal sex
2.   Gonadal sex
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The gonadal sex of a fetus directs the diff erentiation of external genitalia and internal 
reproductive structures (i.e., phenotypic sex) [18]. Genes involved in sexual diff erentiation are 
those that encode enzymes for testosterone biosynthesis, the androgen receptor (AR), and 
anti-Müllerian Hormone (AMH, also known as Müllerian inhibitory substance) and its receptor.
as DAX 1 (DSS-AHC critical region on the X chromosome protein 1) and WNT 4 (wingless-type 
MMTV integration site family, member 4), Both genes are expressed preferentially in female 
gonads, but there is no evidence, besides their “anti-testis ”role, that they are actively involved 
in ovarian development [16].
Figure 1. Gonadal diﬀ erentiation. 
Before the fetus reaches the gestational age 
of 8 weeks, gonadal tissue has the potential 
to develop into either ovaries, or testes. The 
absence or presence of the SRY gene, usually 
located on the Y chromosome, determines 
whether this tissue will diff erentiate into 
ovaries (when SRY is absent) or testes (when 
SRY is present). If the SRY gene is missing 
or does not work. Then the baby will not 
grow healthy testes despite having a male 
genetic sex (XY). Conversely, if a baby who 
is genetically female (XX) possesses the SRY 
gene on any chromosome, then testes will 
develop instead of ovaries  (adapted from [21]).
1 SRY acts as a transcription factor, initiating the expression of a complex cascade of genes, controlling and fi ne-tuning testicular 
diff erentiation by activating and inhibiting mechanisms and gene-dosage eff ects [18,24]. Immediately after the expression of SRY, 
SOX9 is up-regulated in the male gonad, which is the main sex determining gene.
3.   Phenotypic sex: external and internal genitalia
SRY gene
YXXX
Figure 1
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Sertoli cells of the fetal testes synthesize AMH which induces Müllerian duct regression during 
the 9th to 12th week of gestation, only between this narrow time interval [22].  Meanwhile, 
testosterone secretion from Leydig cells of the fetal tetes induces Wolffian duct differentiation 
into vasa deferentia, epididymides and seminal vesicles [22,23]. The production of both 
testosterone and AMH is needed for a baby to develop male internal reproductive anatomy 
(Figure 2). In the absence of AMH, the Müllerian ducts are free to develop into the Fallopian 
tubes, cervix, uterus and upper portion of the vagina. In the absence of testosterone, the 
Wolffian ducts regress [22] (Figure 2).
2 The androgen receptor has a 10 fold greater affinity for DHT as compared to testosterone and its binding 
to DHT results in a more stable complex [22].
No testosterone
No AMH
A lot of 
testosterone
A lot of AMH
8 weeks
11 weeks
Birth
Testis
Müllerian 
ducts
Regression
Müllerian 
ducts
Seminal
vesicle
Epididymis
Penis
Müllerian 
ducts
Uterus
Cervix
Vagina
Fallopian 
tubes
Wolffian
ducts
Wolffian
ducts
Vas 
deferens
Prostate
Regression
Wolffian
ducts
Ovary
Fetal ovaries produce negligible amounts 
of testosterone and AMH, whereas testes 
produce significant amounts of both 
hormones. The presence or absence of these 
hormones influences the development of the 
internal sex ducts. Müllerian ducts are the 
forerunners of the uterus, cervix, fallopian 
tubes and upper portion of the vagina. They 
are found in both male and female fetuses but 
typically disappear in male fetuses when the 
testes produce AMH. Wolffian ducts are the 
forereunners of vasa deferentia, epididymides, 
prostate gland and seminal vesicles. They 
are likewise found in all fetuses but typically 
disappear in female fetuses because there are 
no testes to produce testosterone (adapted 
from [21]).
Figure 2. Development of internal reproductive structures. 
Figure 2
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Virilization of the external sexual anatomy is established by conversion of testosterone by 
the enzyme 5α reductase into dihydrotestosterone (DHT) . Binding of DHT to the androgen 
receptors of the identical urogenital sinus in males and females leads in males to growth of 
the genital tubercle, which develops as a penis; fusion of the urethral folds to form the corpus 
spongiosum and penile urethra, fusion of the labioscrotal swellings to form the scrotum and 
ventral epidermal covering of the penis and diff erentiation of the prostate and bulbourethral 
glands [5,24] (Figure 3). 
In the absence of androgens, the genital tubercle develops as a clitoris, the urethral folds form 
the labia minora and the labioscrotal swellings give rise to the labia majora. Proliferation of the 
vesicovaginal septum pushes the vagina posteriorly so that the urinary and vaginal opening 
become separated. Proper vagina formation additionally requires the contact and interaction 
of the urogenital sinus with the fused Müllerian structures [22]. 
The sensitivity of the urogenital sinus to DHT is limited to a critical time period between 8 and 
12 weeks GA, because of a downregulation of the androgen receptors in the urethral folds and 
labioscrotal swellings. Complete masculinization of the external genitals is accomplished at 14 
weeks of gestation, except for the genital tubercle; penile/clitoral growth continues after that 
period. Therefore, in females, exposure to androgens after 12 weeks GA can only result in clitoral 
hypertrophy and not fusion of labia minora and majora [22]. Since the genital tubercle consists 
of corpora cavernosa and glans tissue, the distinction between a penis and clitoris is primarily 
based on size and whether the urethral folds have fused to form the corpus spongiosum [22]. 
Around the seventh month of GA, the testes start to descend in the scrotum [25]. This process 
is considered to occur in two stages, comprising a transabdominal and transinguinal phase. 
The mechanisms controlling testicular descent are not fully understood. However, based on 
studies in mice and children with androgen insensitivity syndrome, it is currently believed that 
androgens are of importance in the transinguinal phase, whereas the transabdominal phase is 
relatively androgen independent and mainly controlled by the action of AMH and Insulin-like 
Factor 3 (INSL3), secreted by the Leydig cells [25,26].
Figure 3. Development of external genitals. 
At 8 weeks of gestational age, the external 
genitals are bipotential, and can go on to form 
female-typical or male-typical structures 
depending on hormone exposure. The 
absence of DHT results in female external 
genitalia: the genital tubercle stays small and 
forms a clitoris, the urethral groove develops 
into a urinary opening that is located on the 
perineum and the labioscrotal swellings form 
the labia (majora and minora). In the presence 
of DHT, male external genitalia develop: 
the genital tubercle grows into a penis, the 
urethral fold develops so that the urethral 
opening is at the tip of the penis and the 
labioscrotal swellings fuse to form a scrotum 
(adapted from [21]).
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The fi nal stage of sex diff erentiation occurs when hormones produced by the gonads further 
direct the development of the full complement of secondary sex characteristics at puberty. 
Such characteristics include breast growth and menarche in girls and increases in body hair 
and muscle mass as well as penile and testicular growth in boys. Sexual reproduction becomes 
possible at this stage [17]. 
In sum, the genetic sex (the presence or absence of the Y chromosome) determines the gonadal 
sex (the development of the bipotential gonad into a testis or an ovary) [18]. The production and 
4.   Secondary sexual diff erentiation
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“One is not born a woman, one becomes one,” said Simone de Beauvoir (1949) in The Second 
Sex [28]. From a biological standpoint, it seems that during all stages of fetal development, 
maleness is a permanent molecular fight [16]. The female phenotype is considered to be the 
“default” pathway in that the differentiation of female somatic sex structures is independent of 
gonadal hormones and can take place even in the absence of ovaries [22,23], making Eve, rather 
than Adam, the first or prototypical human being [5].  
During the past decade, a number of genes responsible for the making of a male have been 
characterized. When mutated, these genes are responsible for “demasculinization” of fetuses 
carrying a male, XY, chromosomal constitution, resulting in individuals born “intersex” or females. 
The discovery of these sex-determining genes is the direct result of the study of patients with 
ambiguous genitalia, also known as “intersex”4 or “Disorders of Sex Development” (DSD). 
The umbrella term  DSD was introduced in 2005 by the Lawson Wilkins Pediatric Endocrine 
Society (LWPES) and the European Society for Paediatric Endocrinology (ESPE)  for describing 
those congenital  disorders in which there is a mismatch between chromosomal, gonadal and 
anatomical sex [15].5 Revision of the nomenclature was necessitated, because terms such as 
"intersex" were controversial, perceived as potentially pejorative by patients, and confusing to 
practitioners and parents alike [15]. To some parents, "intersex" meant a third gender, something 
in between male and female, and was a label as off-putting and freakish as ‘hermaphrodite’. 
Moreover, a modern lexicon was needed to integrate progress in molecular, genetic and 
3 Genetics matter. The ability to distinguish the contributing role of genes versus gonads was markedly advanced by the development 
of the four core genotypes model of mice. These mice bear a Y chromosome from which the SRY gene has been deleted (denoted 
Y–) or carry SRY on an X chromosome or autosome, allowing the development of XX individuals with testes and XY individuals in 
which testes development has failed. Analysis of this model supports the view that sexual differentiation of reproductive endpoints 
is largely driven by the testicular hormone testosterone or estradiol synthesized in the developing nervous system from this 
testosterone. Conversely, many nonreproductive endpoints involve direct genetic contributions to variability between males and 
females [27].  
4 Richard Goldschmidt was the first to coin the term ‘intersex’, after he had produced a sexual continuum of gypsy moths which 
were typically sexually dimorphic. Extending his theory to vertebrates, he proposed an intersexuality grounded in both genetic 
difference (labeled zygotic intersexuality) and hormonal action (labeled hormonal intersexuality). Intersexuality in invertebrates was 
grounded in genetic differences present in the zygote, whereas intersexuality in vertebrates included sexual differentiation later in 
life mediated by hormones and controlled by hormone-producing tissues [29]. Clinicians thereafter adopted this term intersex and 
began extending it to humans, because of the association of hermaphroditism with mythical creatures and perhaps even monsters. 
When the Intersex Society of North America (ISNA) was founded in 1993, ‘Intersex’ took on a political valence by consciously 
reclaiming the term ‘hermaphrodite’ (cfr Hermaphrodites with attitude), in an effort to call attention to the pathological associations 
with the congenital conditions that fall under that rubric and to erase stigmatization [8,30,31]
1.2 Disorders of Sex Development
action of hormones by the functional gonads lead to a further differentiation in typical female 
or male anatomy [18]. At last, at puberty, the development of sex-specific secondary sexual 
characteristics confirms the established sex and reinforces the existing sexual dimorphism 
between individuals [22]. Errors occurring at any stage in this cascade may result in ambiguity 
of the external genitalia and/or incomplete or malformed internal reproductive structures [17]. 
From the sequence of these events, it becomes clear that the impact of sex chromosomes on 
differentiation is indirect. While genetic sex directs the development of the bipotential gonad, 
the male phenotype is strictly determined by gonadal hormones [17].3  
 Nomenclature and current classification 
of disorders of sex development (based on [15,35])
SEX CHROMOSOME DSD
45,X 
(Turner syndrome     
and variants)
Disorders of gonadal 
(testicular) development
1. complete /partial gonadal  
dysgenesis (e.g. SRY, SOX 9,  
SF1, WT1)
2. testis regression
3. ovotesticular DSD
Disorders in androgen 
synthesis or action:
1. androgen biosynthesis defect 
(e.g. 17ß HSD , 5α RD)
2. defect in androgen action  
(e.g. CAIS, PAIS)
3. LH receptor defects (e.g. leydig 
cell hypoplasia, aplasia); and
4. disorders of AMH and AMH 
receptor (persistent Müllerian 
duct syndrome)
Other: e.g.
1. Syndromic associations  
of male genital development  
(e.g. cloacal exstrophy)
2. Vanishing testes syndrome
3. Isolated hypospadias
4. Congenital hypogonadotropic 
hypogonadism
5. Cryptorchidism
Other: e.g.
1. Syndromic associations   
(e.g. cloacal exstrophy)
2. Mayer-Rokitansky-Küster 
-Hauser syndrome
3. Vaginal atresia
Androgen excess:
1. fetal (e.g. 21-hydroxylase 
deficiency, 11-hydroxylase 
deficiency)
2. fetoplacental (aromatase 
deficiency, oxidoreductase 
deficiency)
3. maternal (maternal virilizing 
tumors e.g.luteomas), 
androgenic drugs)
Disorders of gonadal 
(ovarian) development:
1. ovotesticular DSD
2. testicular DSD (e.g.   
SRY+, duplicate SOX9)
3. gonadal dysgenesis
46, XXY 
(Klinefelter syndrome  
and variants)
45,X/46, XY 
(mixed gonadal 
dysgenesis, 
ovotesticular DSD)
46, XX/46, XY 
(chimeric, 
ovotesticular DSD)
46, XY DSD 46, XX DSD
endocrine aspects of sex development. A descriptive terminology was agreed upon, reflecting 
genetic etiology when available, and accommodating the spectrum of phenotypical variation. 
The nomenclature and classification of DSD is shown in Table 1 (based on [15]). 
Abbreviations: Complete androgen insensitivity syndrome (CAIS), Partial androgen insensitivity 
syndrome (PAIS), 17ß hydroxysteroid dehydrogenase deficiency (17ß HSD), 5α reductase 
deficiency (5α RD), Luteneizing hormone (LH), Anti-Müllerian Hormone (AMH),  sex-determining 
region on Y (SRY), SRY-related HMG (High Mobility Group)- box, gene 9 (SOX9), Steroidogenic 
factor 1 (SF1), Wilms tumor 1 (WT1) 
TABLE 1
5 This nomenclature change has , however, not been universally embraced, because of the loaded word ‘disorder’, suggesting that 
atypicality is necessarily wrong and in need of repair. The term ‘divergence or difference of sex development’ has been proposed 
instead, underlying one of intersex activism’s central tenets: unusual sex anatomy does not inevitably require surgical or hormonal 
correction (for a discussion, see [30]).
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DSD is not rare. In its traditional definition (conditions where it is impossible to distinguish 
whether the individual is male or female), the incidence is estimated at 1 in 4,500 births [15]. If 
all minor variants of genital conformation are included in the definition of DSD, the incidence 
rises to close to 1%, due to the high frequency of hypospadias, an abnormal placement of 
the urethral opening (about 0.4%), and of cryptorchidism, undescended testes (around 1% at 
3 months of age)[16]. These numbers show that, although not discussed as openly as other 
medical conditions, DSD is present at a high frequency throughout the world. Ethnic groups 
with high rates of consanguinity hailing from Southern Europe, North Africa and Asia are affected 
even more often [32]. Genetic diagnosis represents often an early stage in clinical management, 
but the tremendous heterogeneity associated with DSD conditions results in slow progress in 
the field [16]. More than a dozen medical diagnoses are associated with the same appearance of 
genitalia that taken alone gives the observer little or no clue to the underlying physiopathology 
[16]. A specific molecular diagnosis is identified in only approximately 20% of persons with 
DSD, and remains especially problematic in 46,XY gonadal dysgenesis and undervirilization 
syndromes [33,34].
Current classification
As sexual differentiation in humans is essentially determined by the presence or absence of 
male sex hormones, disorders of sexual differentiation can roughly be divided into 46, XX 
DSD and 46, XY DSD. 46, XX individuals with a DSD condition have an excess of male sex 
hormones (overvirilization) and 46, XY individuals with a DSD have a deficiency or resistance to 
male sex hormones (undervirilization). These can further be subdivided into defects of gonadal 
determination or subsequent differentiation, biosynthetic defects of male sex hormone 
synthesis/metabolism and sex hormone receptor defects [23]. In addition to 46, XX DSD and 46, 
XY DSD, other types of DSD exist, with an  incomplete or defective formation of the gonads, due 
to structural or numerical sex chromosome anomalies. 
The presence of ambiguous or male external sexual characteristics in developing 46, XX 
embryos results from exposure to androgens from several sources, during fetal life. These 
include exogenous androgens either ingested (progesterone, testosterone) or produced by 
the mother (ovarian and adrenal tumours, maternal congenital adrenal hyperplasia, virilizing 
luteoma of pregnancy) which cross the placenta. Approximately half of the 46, XX individuals 
with a DSD are due to virilizing neonatal Congenital Adrenal Hyperplasia (CAH)[36]. CAH 
comprises a group of autosomal recessive disorders with defects in the synthesis of steroid 
hormones in the adrenal cortex (Figure 4). More than 90% of the cases are caused by mutations 
in the CYP21 (21-hydroxylase) gene [37]. The incidence is approximately 1:140000 births and 
carrier status is found in about 1:80 individuals [38,39]. The enzyme deficiency results in impaired 
synthesis of cortisol and aldosterone. Reduced cortisol synthesis interrupts feedback inhibition 
of adrenocorticotropic-hormone (ACTH) release from the pituitary, leading to continuous 
stimulation of the adrenals by ACTH and, consequently, adrenal hyperplasia [40] (Figure 5). 
1.2.1 46, XX DSD
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Figure 4. Genes associated with steroid biosynthesis in the adrenal cortex (adapted from [39]). 
The three major types of adrenal ste-
roid hormones, glucocorticoids, minera-
locorticoids, and adrenal androgens, are each 
produced through a separate biosynthetic 
pathway. All three pathways, however, 
share common precursor molecules. If an 
enzymatic block occurs in any of the three 
biosynthetic pathways, precursor molecules 
are shunted into the remaining functional 
pathway(s). Each step is catalyzed by a 
specific enzyme. Loss-of-function mutations 
in the gene CYP21A2 account for about 90% 
of all cases of CAH. Other, rarer forms of CAH 
are due to loss-of-function mutations in the 
genes CYP11B1, CYP17A1, HSD3B2, or StAR 
(steroidogenic acute regulatory protein or 
lipoid CAH) [37].
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Increased androgen synthesis, before the 12th week of GA6, leads to a variable degree of 
virilization of the urogenital sinus (labioscrotal fusion, development of a penile urethra and 
clitoral enlargement), but ovarian development and differentiation of the Müllerian ducts 
occur normally.  Prader developed a scoring system by which the degree of virilization can be 
quantified [41] (Figure 6). In severe cases the virilization can result in uncertain or wrong gender 
assignment at birth. 
6 After week 12, androgen exposure causes isolated clitoromegaly [22].
7 Deletions or mutations that completely abolish the enzyme activity are referred to as null mutations. Patients who are homozygous 
for null mutations have the salt-wasting form of CYP21 deficiency. The I172N mutation causes the simple virilizing form. The V281L 
and P453S mutations cause the milder non-classical form [43].
The hypothalamic-pituitary-adrenal axis 
is controlled by negative feedback. In the 
untreated patient with CAH, a block in corti-
sol biosynthesis leads to a build-up of 
cortisol precursors and lack of negative 
feedback. Corticotropin is oversecreted, and 
adrenal hyperplasia occurs. The combination 
of accumulated cortisol precursors and 
increased ACTH results in massive androgen 
production. In the treated patient with CAH, 
exogenous hydrocortisone replacement 
reduces androgen production and inter-
rupts the vicious circle of corticotropin 
hypersecretion. However, supraphysiologic 
doses of hydrocortisone are often necessary 
to adequately suppress androgen production 
(CRH = corticotropin- releasing hormone)
[40]. 
Figure 5. Hypothalamus-Pituitary-adrenal (HPA) axis.  
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There is a wide spectrum of severity of the disease with a good correlation between the 
CYP21 genotype (i.e. degree of enzyme deficiency) and clinical manifestations, with very 
few exceptions [42,43]7. Patients with the classical salt-wasting form of CAH typically develop 
electrolyte disturbances and adrenal crises at 2–3 weeks of age - characterized by life-
threatening hyponatremia, dehydration, and shock - and girls with this form develop severe 
prenatal virilization of the external genitalia. Boys with this condition are more vulnerable to 
neonatal adrenal crises than girls, because, unlike girls, they are not diagnosed at birth because 
of genital ambiguity [43], making neonatal screening of utmost importance [44]. In patients with 
the classical simple virilizing form, there is no or little risk of developing salt loss, and there are 
varying degrees of virilization of the genitalia in girls [43]. In the milder non-classical form , there 
is no virilization of external genitalia at birth and no risk of developing electrolyte disturbances. 
Untreated, these patients develop symptoms of androgen excess later in life, such as growth 
acceleration, pseudoprecocious puberty, or hirsutism. Some patients with non-classical 
21-hydroxylase deficiency are diagnosed as adults, when they seek help for infertility [45]. 
Grade 1 represents external genitalia of female 
appearance, with an enlarged clitoris. Grade 
2 represents a further enlargement of the 
clitoris, associated with a posterior fusion of 
the labioscrotal folds, but without a urogenital 
sinus. Grade 3 represents a significant 
increase in clitoral size, associated with almost 
complete fusion of the labioscrotal folds 
and the presence of a urogenital sinus with 
perineal opening. Grade 4 represents a clitoris 
with penile appearance, associated with 
complete fusion of the labioscrotal folds, and 
a urogenital sinus with perineal opening at the 
base or ventral opening of the clitoris. Grade 
5 represents a clitoris with the appearance 
of a well-developed penis, associated with 
complete fusion of the labioscrotal folds, and 
a urogenital sinus and opening in the body of 
the clitoris/phallus [41].
Figure 6. Prader’s classification of genital ambiguity at birth. 
No virilization Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Figure 6
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Unfortunately, there is a serious lack of data to provide adequate guidance as to the best timing 
and surgical approach. In recent years, ethicists and patient support groups have come forward 
to call a moratorium on any genital surgery in infancy, arguing that patients should be able to 
give informed consent before undergoing such procedures. However,  consequences of this 
policy to patients and families have not been properly addressed either. Because the nature and 
timing of these feminizing genital procedures remain extremely controversial topics, they will 
be explored in more depth and detail later.
Classical CAH is currently the only DSD amenable to prenatal diagnosis and intervention. 
Because of the autosomal recessive nature, it is possible to test the developing genetic off-
Patients with CAH require life-long medications, such as glucocorticoids with or without 
mineralocorticoids, and follow-up at specialist centers. Proper treatment prevents adrenal 
crisis and further virilization and enables normal growth and development [46]. However, 
certain features of this condition such as short final adult height, subfertility, adrenomedullary 
insufficiency, obesity, and insulin resistance cannot be completely overcome by glucocorticoid 
treatment [45]. Moreover, as CAH is in most cases characterized by an confluence of the vagina 
and the urethra, feminizing genitoplasty is often performed. The vaginal cavity can join the 
posterior wall of the urethra at any level between the bladder neck (high urogenital sinus) and 
the very distal urethra (low urogenital sinus) (Figure 7). Usually, the higher the sinus, the smaller 
the vaginal cavity [39]. In vaginoplasty, the vaginal cavity is opened to the perineum and the labia 
majora are reconstructed as separate structures [39]. In cases with severe clitoris hypertrophy, 
a nerve-sparing clitoral reduction (with preservation f the erogenous neurovascular bundle) 
usually is performed as well [47].
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For male sexual differentiation to proceed normally, the testes need to make sufficient amounts 
of the hormones AMH (to suppress female internal sex duct development) and testosterone (to 
For male sexual differentiation to proceed normally, the testes need to make sufficient amounts 
of the hormones AMH (to suppress female internal sex duct development) and testosterone (to 
promote male internal sex duct development). Testosterone must be converted into the potent 
hormone DHT, which masculinizes indifferent external genitalia into a fully formed penis and 
scrotum [21]. The External Masculinization Score (EMS) was developed to assess the degree of 
undervirilization in an individual with 46, XY DSD. The score is based on the presence or absence 
of a micropenis (stretched penile length < 2.5 cm at birth), and bifid scrotum, the location of the 
urethral meatus and the position of the testes (Table 2) [53].  The Internal Masculinization Score 
(IMS) provides useful information about the internal anatomy and can be used to complement 
1.2.2 46, XY DSD
spring of a known carrier or affected individual. In such cases, mothers may be prescribed 
the synthetic cortisol, dexamethasone, which prevents virilization of the external genitalia 
by influencing the negative feedback system and shutting down the excess production of 
adrenal androgens. It is as yet unclear whether or not treatment with dexamethasone prevents 
behavioral masculinization (e.g. preferences for boys’ toys, rough-and-active play) which is 
often seen in CAH girls [7,48]. It is also possible that synthetic steroid administration may have 
detrimental effects on developing brain structures such as the hypothalamus [17]. Further 
studies are needed to determine if this is a desirable intervention [49,50].
Defects in 46, XX sex differentiation not associated with androgen defects occasionally occur in 
association with malformations of the intestine and urinary tracts. These can involve persistence 
of a primitive cloaca and may be accompanied by renal failure. Unlike other forms of 46, XX 
virilization, the internal genital ducts are often affected. The most common form of 46,XX DSD 
without associated androgen effects is Mayer-Rokitansky-Küster-Hauser syndrome (MRKH). 
Women with MRKH have normal functioning ovaries but an absent or rudimentary uterus and a 
short vagina resulting from failed embryonic development of the Müllerian duct. MRKH may be 
isolated (type I) but it is more frequently associated with renal, vertebral, and, to a lesser extent, 
auditory and cardiac defects (MRKH type II or MURCS association) [51]. Surgical and non-
surgical enlargement procedures for the absent or short vagina exist, each with advantages 
and disadvantages [52]. The low incidence of side-effects, with the major psychological benefit 
of the woman being in control, would make non-surgical vaginal dilation therapy a logical first 
choice, with surgery reserved for those women unable to achieve adequate vaginal length via 
dilators. However, the few good long-term outcomes studies to date, claiming success rates in 
the range of 80%, do not always consider compliance or sexual function [47]. In general, vaginal 
dilation protocols (e.g. frequency of dilation, maintenance dilation), patient selection criteria 
and outcome parameters (e.g. what is success?) are lacking, adding to the controversy around 
this genital treatment (see infra for more details).
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EMS
Scrotal fusion
Micropenis
Urethral meatus
Normal
Glandular
Penile
Perineal
Right and left gonad 
(score for each)
Scrotal
Inguinal
Abdominal
Absent
IMS
Uterus 
Fallopian tube 
(right and left score each) 
Epididymis
(right and left score each) 
Vas deferens 
(right and left score each) 
3/0
0/3
3
2
1
0
1.5
1
0.5
0
0/3
0/2
2/0
2/0
TABLE 2
The External Masculinization Score (EMS) (total score 12) is based on external genital features 
and the IMS (total score 10) on internal sexual organs. In its present format, the EMS can only 
be zero if the testes are documented to be absent (instead of abdominal) in combination with 
a micropenis, perineal hypospadias and a bifid scrotum. Consequently, the minimum EMS on 
initial inspection cannot be <1 out of 12.
The masculinization score  based on points allocated to a variety 
of anatomical features (adapted from [53]). 
FEATURE FEATURESCORE FOR YES/NOOR CONDITION
SCORE FOR YES/NO
OR CONDITION
the information gained from the EMS. These scores cannot replace a detailed description of the 
clinical examination, but might provide an indication of which newborns warrant a thorough 
endocrine evaluation for male undermasculinization (EMS < 11) [53,54]. 
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Figure 8. Schematic representation of the pathogenetic mechanisms in undervirilization syndromes 
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In general, hormones can only exert their infl uences on specifi c tissues where functioning 
receptor cells are present. Errors in androgen biosynthesis or receptor availability lead to a 
disrupted sex diff erentiation (Figure 8, adapted from [24]).
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Errors in the action of certain transcriptor factors (such as SRY,DAX-1,SOX9), result in the absent 
or incomplete differentiation of the bipotential gonad into a testis, leading to a deficiency of 
Sertoli and Leydig cells. These cells are however necessary to produce AMH, testosterone, or 
DHT in sufficient amounts to support male sex differentiation. In some cases, the hormone 
deficiencies are incomplete and babies with 46, XY are born with: 1) testes (because of the 
presence of the SRY gene) 2) partial development of the internal female sex ducts (because 
the testes did not produce enough AMH to suppress the development of these structures)  3) 
partial development of the internal male sex ducts (because the testes did not produce enough 
testosterone to completely support the development of these structures) and 4) ambiguous 
external genitalia (because DHT was not produced in sufficient amounts to masculinize the 
external genitalia) [21]. 
46,XY gonadal dysgenesis is a DSD due to absent or incomplete testes differentiation, causing 
a (partial) lack of the Sertoli and Leydig cells. Affected individuals can respond to androgens, 
however, the abnormal testes are incapable of producing (sufficient amounts of) androgens. 
The phenotype and gonadal differentiation pattern of a patient with gonadal dysgenesis can 
be anywhere on the axis connecting the two opposite poles of normal male and female 
development8 [24].
Complete gonadal dysgenesis (Swyer syndrome) is characterized by streak gonads that did not 
fully differentiate on the pathway to becoming testes and as a consequence, do not produce 
testicular hormones. These babies will develop internal female ducts in the absence of AMH, 
no internal male sex ducts in the absence of testosterone and female external genitalia in the 
absence of DHT. Vaginal length is predicted to be in the normal ranges.  Pubic and axillary hair 
development at puberty is normal, but there is a lack of or poor breast development [55]. Streak 
gonads are removed due to high risk of malignancy, and hormone replacement therapy (with 
both estrogen and progestogen components) is initiated to stimulate uterine and breast growth 
and the onset of menstruation [55]. 
In partial gonadal dysgenesis, (Figure 9) (bilateral dysgenetic testes) and mixed gonadal 
dysgenesis (an abnormal testis on one side and a streak gonad on the other side) the 
incomplete formed testes do not produce enough AMH or testosterone to result in male-
typical reproductive structures. Some of the female internal reproductive structures are usually 
retained [56]. The karyotype is usually 46,XY or a varying degree of 45,X/46,XY mosaicism and 
genital appearance is usually ambiguous.
1.2.2.1 Problems with  testis differentiation: testicular dysgenesis
8 Diagnostic work-ups usually reveal a 46, XY karyotype, but the karyotype can contain structural or numerical anomalies of the sex 
chromosomes, e.g. mosaicism for a Y bearing cell line eventually only detectable in the gonad and not in peripheral blood [24].
In 46, XY undervirilization syndromes, affected individuals have well-differentiated bilateral 
(intra-abdominal, inguinal or scrotal) testes, but enzyme deficiencies have disrupted the 
androgen biosynthesis or action (Figure 8).
1.2.2.2 46,XY Undervirilization 
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In partial gonadal dysgenesis (top panel), the 
testes are incompletely formed and do not 
produce enough AMH or testosterone (T). 
This hormonal environment may result in a 
situation where both Wolffian and Müllerian 
internal structures remain partially developed 
and the external genitalia are ambiguous. 
Typical male differentiation is displayed in the 
bottom panel (adapted from [21]).
Figure 9. 46,XY DSD due to partial gonadal dysgenesis. 
Some enzyme deficiencies only affect the testosterone synthesis, such as 17ß hydroxysteroid 
dehydrogenase deficiency-3 (17ß-HSD-3) and 5α reductase deficiency-2 (5αRD-2). In 
17ß-HSD-3 the fault lies with impaired ability to convert androstenedione to testosterone. 
Patients with the disorder have testes and normally developed Wolffian ducts derivatives ; 
however, they show severe to complete undervirilization of the external genitalia, often with 
normal appearing clitoris and labia majora [22]. Individuals with 17ß-HSD-3 are primarily raised as 
A.  Disorders in androgen biosynthesis
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females and do not present with symptoms until the onset of puberty, at which time virilization 
occurs. Such characteristics include increased muscle mass and hair growth, lowering of the 
voice, and growth of the penis (though it is unlikely to reach normal male size) [17]. Deficiency 
of 5α reductase-2, which normally converts T into DHT,  results in a deficiency of DHT, and an 
undervirilization of the external genitalia [23]. The result is a newborn 46,XY male with functioning 
testes, normally formed male internal reproductive structures, a penis that resembles a clitoris, 
and a scrotum that resembles labia majora [17]. In cases where undervirilization is complete, the 
diagnosis may be missed and the child is  assigned to the female gender and unambiguously 
raised as a girl [57]. However, because secondary sexual development at puberty is dependent 
on testosterone, and DHT that has been converted by an 5α -reductase isoenzyme  (e.g. type 1, 
not expressed in fetal life), individuals with 5α -RD-2 will virilize in adolescence [58,59]. 
Some other biosynthetic defects can affect both glucocorticoids and androgens [23] (Figure 4). 
These include cholesterol side-chain cleavage deficiency, 17α hydroxylase/17, 20 lyase defi-
ciency and 3β- hydroxysteroid dehydrogenase deficiency-2 (3β HSD-2). These conditions are 
all autosomal recessive and very rare [60] (Figure 4).
In steroidogenic tissues, such as the adrenal cortex, testis, ovary and placenta, the initial and rate-
limiting step in the pathway leading from cholesterol to steroid hormones is the cleavage of the 
side chain of cholesterol to yield pregnenolone. This reaction, known as cholesterol side-chain 
cleavage, is catalysed by a specific cytochrome P450, and by the steroidogenic acute regulatory 
(StAR) protein. (Figure 4) [61]. Individuals with a cholesterol side-chain cleavage deficiency  are, 
in general, phenotypic females irrespective of gonadal sex or, sometimes, have slightly virilized 
external genitalia with or without cryptorchidism, underdeveloped internal male organs and 
an enlarged adrenal cortex, engorged with cholesterol and cholesterol esters [61]. Individuals 
with 17α hydroxylase deficiency,  and thus experiencing difficulties with  the conversion of 
pregnenolone into 17α-hydroxypregnenolone, have a phenotype similar to 46,XX or 46,XY 
complete gonadal dysgenesis, with the presence of systemic hypertension and absent or sparse 
pubic hair in post-pubertal patients. 46,XY Patients with isolated 17,20-lyase deficiency, whom 
cannot convert 17α-hydroxypregnenolone into dehydroepiandrosterone (DHEA),   present with 
ambiguous genitalia with micropenis, perineal hypospadias and cryptorchidism. Gynecomastia 
can occur at puberty [61]. 46,XY patients with 3β-hydroxysteroid dehydrogenase (3β-HSD) type 
II deficiency, who have trouble converting DHEA in androstenedione,  present with ambiguous 
external genitalia, characterized by micropenis, perineal hypospadias, bifid scrotum and a blind 
vaginal pouch that may or may not be associated with salt loss [61]. Individuals without salt 
wasting show clinical features in common with the deficiencies of 17β-HSD-3 and 5α-RD-2.
To respond to masculinizing hormones, functioning androgen receptors (AR) must be present. 
Although testicular hormones are adequately produced by the testes, absent or malfunctioning 
androgen receptors (complete or partial androgen insensitivity syndrome, respectively,) result 
in an unambiguous external female phenotype in the former and an ambiguous phenotype 
B.  Disorders in androgen action
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Defects in testosterone biosynthesis due to homozygous mutations in the gene for the LH 
receptor, resulting in Leydig cell hypoplasia or agenesis, have also been described [23]. In 46,XY 
DSD due to Leydig cell hypoplasia, there is a failure of intrauterine and pubertal virilization due 
to the scarcity of interstitial Leydig cells to secrete testosterone. Leydig cells are stimulated 
by both hormones, chorionic gonadotrophin (CG) and luteinizing hormone (LH), which act 
by binding and activating a common receptor (LHCGR) located in the cell membrane (Figure 
8) [61]. Investigation will show high LH levels associated with low testosterone levels that fail 
to rise with hCG stimulation. The typical phenotype due to the complete form of Leydig cell 
hypoplasia is female external genitalia, undescended testes slightly smaller than normal with 
relatively preserved seminiferous tubules and absence of mature Leydig cells, presence of 
epididymides and vasa deferentia and absence of uterus and fallopian tubes [61]. As in CAIS, 
some degree of vaginal shortening is expected as a result of the action of AMH; in contrast to 
CAIS, there should be normal pubic and axillary hair growth [55]. The phenotype in the partial 
form of Leydig cell hypoplasia is heterogenous [61]. Most patients have predominantly male 
external genitalia with micropenis and/or hypospadias, and  cryptorchidic or scrotal testes. 
During puberty, partial virilization occurs and testicular size is normal or only slightly reduced, 
while penile growth is significantly impaired [61].
C. Luteinizing Hormone receptor defects
in the latter (due to the partial ability to respond to DHT) (Figure 10). Wolffian duct structures 
are absent or hypoplastic (due to the inability to respond to testosterone) and Müllerian duct 
structures are also absent (due to the AMH action) [17] (Figure 8). Because the external genitalia 
are completely feminine in appearance, all newborns with complete androgen insensitivity 
syndrome (CAIS) are assigned the female gender and raised as girls. In addition, feminizing 
puberty partially progresses as testosterone is converted to estrogen by P450 aromatase 
action, thereby promoting spontaneous breast development, though axillary and pubic hair are 
sparse [24]. As such, the diagnosis of CAIS is usually not made until (late) adolescence when the 
individual fails to menstruate. Appearance of external genitalia in partial androgen insensitivity 
(PAIS) is highly variable, with the genital tubercle being intermediate between a clitoris and a 
penis and the labioscrotal folds often only partially fused with frequent perineal hypospadias. 
Individuals with PAIS experience breast development at puberty, often resulting in pronounced 
gynecomastia in boys, as well as minimal axillary and pubic hair growth.
Deficiencies in AMH production or a resistance to its action due to receptor mutations will result 
in an 46, XY individual with internal and external male genital duct structures with the retention 
of Müllerian duct structures (Persistent Müllerian duct syndrome), often in combination with 
cryptorchidism [62, 63].
D.  AMH receptor defects
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Figure 10. Sex diﬀ erentiation in partial and complete androgen insensitivity syndrome.
In PAIS (top panel) and CAIS (lower panel), 
testosterone is produced, but due to a muta-
tion in the androgen receptor gene, its eff ect is 
partially or completely blunted. Therefore, the 
external genitals appear ambiguous (in PAIS) 
or female (in CAIS), but no internal female 
structures remain because the action of AMH is 
unimpeded. The testes  are structurally normal 
during fetal development and at birth, but 
remain in the abdomen, or more frequently in 
the inguinal channel because androgens are 
needed to complete the second phase of the 
testicular descent [21]. 
GENITALIA
MASCULINIZE
PARTIALLY
AHM
AHM
T, but its eff ect 
is partially 
blocked
T, but its eff ect 
is completely 
blocked
Female sex ducts 
do not develop
Female sex ducts 
do not develop
Limited male sex 
ducts develop
DHT has no 
eff ect on external 
genitalia
Male sex ducts 
develop partially
DHT but its eff ect 
is partially blocked
GENITALIA
REMAIN 
FEMALE
Figure 10
46, XY Testes develop
43
The new DSD classifi cation also includes disorders of undermasculinization not further 
specifi ed. At least part of them are due to environmental factors (endocrine disruptors10), 
aff ecting androgen production or causing an excess in estrogen production in boys, and their 
incidence in many Western countries is rising (for an overview see [24,64-66])11. In hypospadias, 
the urethral opening is positioned on the ventral surface of the penis or on the scrotum or even 
on the perineum, resulting from an incomplete fusion of the urethral folds [24]. Hypospadias is 
a common congenital penile defect with an average of 1 in 250–350 male births [67].
In the condition of micropenis, the stretched penile length is at or below 2.5 SD of the 
population mean, adjusted for age [68]. In a newborn, stretched penile length is ≤2.5 cm 
[69]. The penis has fully diff erentiated from the bipotential genital structures but is very small, 
possibly caused by undervirilization during the second stage of androgen release in gestation. 
Syndromes often associated with micropenis include hypogonadotrophic hypogonadism and 
vanished testes syndrome. An example of the former is Kallmann's syndrome,  characterized by 
secondary hypogonadism –inadequate gonadotropin-releasing hormone due to hypothalamic 
or pituitary dysfunction (and thus absent spontaneous puberty) with testicular failure, and a 
defective sense of smell [70]). In the latter, there is a bilateral absence of testes in a genotypically 
and phenotypically normal male. Absence of müllerian-derived tissue implies that functional 
testicular tissue was present in the fetus, but disappeared after 14 weeks of gestation [71]. 
Individuals with micropenis have been assigned as male and female, largely depending on 
circumstantial factors (i.e., policy of medical staff , parental wishes, cultural prescriptions).
Severe genital structural abnormalities can also occur despite normal male prenatal sex 
chromosome activity, testicular development, and androgen activity [72]. Cloacal, bladder or 
classic exstrophy – in which the lower abdominal organs such as bladder and intestines are 
exposed instead of sealed in the abdominal wall - are characterized by severe inadequacy or 
absence of genitalia [73]. Before 1959, survival was apparently nil; with vast improvements in 
neonatal medical and surgical care in the last 30 years approximately 90% or more babies who 
are born with these defects survive into adulthood [73]. Clinical success demands addressing 
the inadequate or absent penis in males.12 
10 An endocrine disrupter (ED) is any exogenous substance that causes adverse health effects in an intact organism or its progeny, 
secondary to changes in endocrine function. Such substances can act through many mechanisms, which may be dose-dependent, 
such as agonist or antagonistic action at the receptor and post-receptor level, and interference with synthesis, transport and 
metabolism. EDs may simultaneously affect more than one hormonal system [64].
11 In 2001, Skakkebæk et al. put forth the hypothesis that some male reproductive disorders were interlinked and originated from a 
disturbed testicular development in utero. This hypothesis was called the testicular dysgenesis syndrome (TDS). The TDS hypothesis 
was based on clinical, epidemiological and basic scientific evidence for a fetal origin of testis cancer, the well-established link 
between genital malformations in newborn boys and adult reproductive disorders, and on observations from experimental animal 
studies and wildlife. Together, this existing evidence suggested that the prenatal period may be the most vulnerable phase in which 
impairment of testis differentiation may result in permanent adverse effects. Such impairment of testis development could be 
caused by genetic disorders or polymorphisms, environmental exposure, lifestyle, intrauterine growth disorders or all these factors 
in combination [65, 66].
12  Cloacal exstrophy is rare; it occurs in approximately 1 in 400,000 live births with about a 2:1 male:female ratio.  Because the penis 
is seriously inadequate or absent, clinical recommendations for the past 25 years have included sex assignment of biological males 
at birth to females socially, legally, and surgically through neonatal bilateral gonadectomies and surgical feminizing genitoplasty [73].
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In addition to 46, XX DSD and 46, XY DSD other types of DSD include sex chromosomal DSD 
and ovotesticular DSD. Sex chromosomal DSD refers to conditions with an atypical number of 
sex chromosomes. Complex karyotypes exist in which different cells from the same individual 
have different karyotypes (mosaicism), for instance 45X/46,XY (indicating that some cell lines 
are 45,X and others are 46,XY). This situation may result in gonadal differentiation defects, such 
as the formation of a streak gonad or testicular dysgenesis, or the gonad may remain largely 
in an undifferentiated stage. Individuals with either of these karyotypes may have ambiguous 
genitalia and thus such a mosaic karyotype  may be a cause of DSD [74]. 
Other examples of sex chromosomal DSD are Klinefelter (47, XXY) and Turner (45,X0). Klinefelter 
patients (incidence 1 :1000) have an extra X chromosome (47,XXY; [75]) and present as tall 
males with small, dysgenetic testes, and often exhibit a delayed puberty. Their testes become 
increasingly fibrous over time and do not contain sperm [16]. Turner patients typically lack one X 
chromosome (1:2500 live female births [76]), and they appear as females with short stature and 
have a delayed puberty, lack of menses, and a variety of congenital malformations including 
heart and kidney defects. The ovaries are underdeveloped and composed essentially of fibrous 
tissue with a very premature loss of oocytes, which results in infertility and low levels of 
estrogens already during childhood or in early adult life. Genital ambiguity is not an associated 
feature in both Klinefelter and Turner syndrome [16,77].  
Ovotesticular DSD is defined by the presence of both ovarian and testicular tissue in the 
gonads. The karyotype can be 46,XX, 46, XY or some other sex chromosomal constitution. 
Development of the internal and external genital structures is highly variable from one person 
to another [16,55]. In 46, XX testicular DSD,  genotypically female individuals develop as males, 
i.e. the gonads develop varying degrees of testicular tissue and may produce testosterone, 
leading to virilization of external genitalia. The occurring testis development  is likely due to a 
translocation of SRY to the X chromosome or one of the autosomes [67]. In a minority of cases 
(10%), no such SRY translocation can be detected (SRY- XX testicular DSD). A limited number 
of gene mutations and copy number variations have been associated with this phenomenon 
(e.g. SOX9 duplication, R-spondin 1 (RSPO1) mutations)(for an overview see [67]).  Possibly, XX 
ovotesticular and XX testicular DSD represent different variants of a common mechanism, in 
which the testis differentiation pathway is activated independent of SRY (for a discussion, see 
[67]).
1.2.3 Other types of DSD 
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Genital atypia has its written origin in the ancient Greek myth of Hermaphroditus, whose male 
body was merged by the gods with the female body of the nymph Salmacis. Although this 
figure found no counterpart in the human world, the idea of one body exhibiting two sexes, 
able to couple with either sex, raised over the past centuries curiosity and host of anxieties, 
because of its implications for the binary model of sex as unequivocally male or female [29, 
30].  Dreger [78,79] and Foucault [80] have focused on the late 19th and early 20th centuries – a 
time when the social order was threatened by war and by women’s demands for the vote and 
a greater role in public life – as the beginning of the modern preoccupation with demarcating 
two sexes; biologically, socially and psychologically [10].13, 14 
The concept of gender becomes complicated when the commonplace distinction between 
one’s anatomy and one’s identity is made, in that sex is considered by many to be anatomical 
(i.e. genitals, gonads, chromosomes) and gender is considered a social category (i.e. the 
subsequently developing sense and presentation of self as a sexed individual).  We tend to infer a 
child’s gender from its genital sex at birth, and subsequently interpret its behaviors as ‘feminine’ 
or ‘masculine’ [84]. As children age, the reverse process occurs. Because we are unfamiliar 
with a child’s genital apparatus, we infer a child’s sex from its behavior. In a culture that is 
heteronormative, there is the presumption that boys and girls will grow up to desire each other. 
Judith Butler calls this set of linear and causal assumptions of sexual identity development the 
heterosexual matrix [85,86] (Figure 11).
1.3 
Quest for a ‘true’ and ‘best sex’: 
Management of genital ambiguity 
and gender assignment
13 Identification of the ‘true sex’ became over the centuries 
important, as  many civil and religious codes regarding marriage 
and property ownership differed significantly for males and 
females [80, 81] 
14 Kessler and McKenna summarize them as follows [83]:
1. There are only two genders 
2. Gender is invariant
3. Genitals are the essential sign of gender 
4. Any exceptions to the two genders are not to be taken 
seriously
5. There are no transfers from one gender to another except 
ceremonial ones 
6. Everyone must be classified as a member of one gender 
or the other 
7. The female/male dichotomy is a natural one 
8. Membership in one gender or the other is natural
Western culture beliefs are based on the 
assumption that anatomical sex causes gender 
development which, in turn, causes sexual 
desire. In this sense, one is assumed to be 
‘anatomically’ hard wired to develop a gender 
identity (i.e. the sense of self as being male or 
female) and gender role behavior (i.e. behavior 
that is culturally associated with gender) that 
correlate with one’s birth genitalia. In addition, 
the model assumes heterosexuality, that one 
will be naturally attracted to individuals whose 
genitals are different from their own and that 
penile-vaginal intercourse functions as the 
exclusive heterosexual act [84].
Figure 11.  Butler’s Heterosexual Matrix [85,86].
By the middle of the twentieth century, the birth of a baby with ambiguous genitals had come to 
be labelled a medical and social emergency, and anguished parents and physicians considered 
it essential to assign the infant definitely as male or female and to minimize any discordance 
between somatic traits and gender assignment [29]. Interventions enabled the individual to 
fit into the binary model of sex and avoid possible social stigmatization and alienation [84]. 
The central issue became then how to best intervene. Urologists were inclined to resolve 
contradictions of sex through corrective surgery. Endocrinologists, by contrast, tried to apply 
theories of hormone secretions to treat intersexuality with the administration of hormones [29]. 
There was also vigorous debate over the extent to which the biological/anatomical sex could be 
overruled by socialization processes and the extent to which the psyche should be considered 
in treatment decisions15. People were often unaware of their chromosomal and hormonal 
(gonadal) status and ethical questions regarding a gonadal definition of ‘true’ sex multiplied. 
Until then, whether an individual had ovaries or testes, determined if he was ‘really’ male or 
female16. However, does the presence of testes make one a real man? The quest for ‘best’ sex 
became based on an assessment of one’s likely gender identity [87], or sense of self as being 
male or female. Psychological testing became part of sex determination, based on the premise 
that an optimal personality integration can be guaranteed when there is congruity between 
external genitalia, the sex of rearing and the patient’s psychological sense of wellbeing as male 
or female [88]. 
15 One of the crucial topics within this literature remains the unresolved debate on nature versus nurture and the question of 
whether and how early children learn gender roles versus the influence of genes and hormones on the development of behavior, 
gender identity, and sexual orientation.
16 In 1876, the German pathologist Theodore Klebs was the first to suggest a taxonomy based on the analysis of gonadal tissue and 
on whether an individual had ovaries or testes. He distinguished between pseudo-and true hermaphroditism. True hermaphrodites 
had both ovarian and testicular tissue in the same body. This simultaneous overlap of gonadal tissues may be represented in one 
gonad (e.g. one gonad with both testicular and ovarian parts) or may be presented separately in each gonad (e.g. one gonad is 
a testicle, the other is an ovary). True hermaphrodites more commonly have a 46, XX karyotype than 46, XY but may have either 
karyotype, and their external genitalia are typically ambiguous. In Klebs’ system, pseudohermaphrodites have  either ovarian or 
testicular tissue; these individuals were ‘really’ female or male, as indicated by their gonads, but their mixed external anatomy 
(genitals) obscured their sex [29, 83].
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Since the 1950’s, clinicians have used a treatment protocol developed by John Money and 
his followers from the Johns Hopkins Medical School, based on his work on gender identity 
and role . These were, according to Money, not something individuals were born with, but 
something built up cumulatively over time. He suggested a small window of gender flexibility and 
opportunity (until eighteen months of age) before which gender should be assigned; otherwise 
children might risk ‘psychological disturbance’ [29]. Thorough clinical workups were important 
to identify the etiology, so that clinicians could determine a sex and select the optimal gender 
for the individuals and surgeons could modify the infant’s body  through surgical and hormonal 
treatment to conform to the assigned sex. This had to ensure that the child avoided physical 
developments incongruous with the assigned gender and was important with respect to future 
(hetero)sexual function (Table 3) [88, 89]. Money’s research demonstrated that although it was 
critical to asses fully all the markers of biological sex –chromosomes, gonads, genitals and 
hormonal functioning- none of these sufficed alone or together to predict or explain gender. 
His theory of gender development, which suggested that sex of rearing was critically important 
for gender acquisition, filled this gap. He introduced psychological principles and advocated 
psychological support into the medical treatment of DSD and provided a link between the fields 
of psychology, endocrinology and surgery in gender assignment and treatment [29]. 
For roughly four decades, Money’s recommended treatment was widely adopted and 
unchallenged, in part because it provided practitioners with a detailed guide for carrying out 
the treatment, one backed by empirical evidence, and because it was an innovative and more 
nuanced model of gender development [29].
17 A thorough history on the development of Money’s model can be read in [29], but a short description is given here. Money was 
critical of the treatment practices of the 1950’s, which were too based on the microscopic study of gonadal tissue. By reviewing the 
literature on so-called hermaphroditism for his dissertation, he found that neither anatomy alone, nor genetics or hormones could 
indicate the status of psychosexual differentiation and identity (Hermaphroditism: An inquiry into the nature of a Human Paradox, 
John Money, 1952). He did a comparative analysis of 248 published and unpublished case histories (from 1895 to 1951) and patient 
files, as well as an in-depth assessment of 10 living individuals classed a hermaphrodites.  His first set of questions concerned the 
origin and determinants of one’s ‘libidinal inclination, sexual outlook and sexual behavior’. The second concerned the origins of the 
‘psychosexual role’ (the social manifestation of sex differences or gender roles). On the first question, Money found that sex drive 
(or libido) was hormone  dependent, whereas sexual orientation was not, bearing a strong relationship to ‘teaching and the lessons 
of experience’ (Money, 1952). His second finding was that so-called hermaphrodites generally fared well psychologically, with low 
incidences of mental illnesses. He argued that this finding suggested that the field of psychoanalysis had placed undue emphasis 
on psychosexual etiologies for mental disorders. Moreover, most hermaphrodites grew up to accept their sex of rearing, despite 
physiological contradictions.  In general, those facing the greatest contradictions among their physical characteristics, psychosexual 
orientation and sex of rearing fared the worst.  His emergent 1955-theory stated that the sex of rearing was a primary determinant 
of an individual’s gender role and sexual orientation. To mitigate the possibility of severe contradictions between somatic sex traits 
and the sex of rearing, hormonal and surgical interventions had to be employed.
1.3.1 Optimal gender policy
TABLE 3 Parameters of the Optimal Gender Policy of Psychosocial 
and Medical Management. Based on [88, 89].
1.  Reproductive potential (if attainable at all)
2.  Good sexual function
3.  Minimal medical procedures
4.  An overall gender-appropriate appearance
5.  A stable gender identity
6.  Psychosocial well-being
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Although research on brain differentiation has not been used specifically in any classificatory 
or treatment schema for DSD [90], this research has also been at the center of debates 
about gender-identity formation. Structural sex differences – from the macroscopic to the 
ultramicroscopic level– have  been observed in the adult brain, together with a large number of 
functional sex differences in a variety of brain regions, such as the sexually dimorphic nucleus 
of the preoptic area, the hypothalamic ventromedial nucleus, and the corpus callosum (for an 
overview, see [5,91]). Structural differences in the brain resulting from the interaction of genes, 
sex hormones, and developing brain cells are thought to be the basis of sex differences in 
e.g. gender identity, gender role behavior and sexual orientation [91]18. When Money published 
his gender socialization hypothesis in 1955, androgens were understood as the hormones 
responsible not only for masculinizing genitalia and for the pubertal development of secondary 
sex characteristics [92,93], but also for brain sexual differentiation and hence observed behavioral 
differences between male and female animals [94] 19. This paradigm, often referred to as 
organization-activation theory, suggested that androgens directly (or via the local conversion 
into estradiol) organized the brain in early development and pubertal androgens would further 
activate the already organized brain, resulting in the expression of masculine behaviors. In the 
absence of exposure to androgens, the brain and resulting behavior would be feminine (Figure 
12) [27, 95]. On the basis of subsequent work, Milton Diamond proposed that male or female 
human embryos begin with a predisposition for psychosexual development as either male or 
female; however, as development proceeds, the predisposition is limited by biological and 
cultural factors.  He advanced this view in opposition to Money, which he characterized as 
arguing that humans were ‘psychosexual neutral’ at birth. Diamond saw gender as determined 
primarily by biology; the environment could only modify effects of an ‘inherent and previously 
organized soma’ [96] (p.160) on which it was superimposed [29].
Money however also built further on previous biological and hormonal work. In the 1960’s, 
Money and Ehrhardt reported masculinized gender role behavior  (understood as a preference 
for boys toys and an active rough-and-tumble play style) in girls with congenital adrenal 
hyperplasia, subsequent to prenatal androgen exposure [97]. They concluded that the 
organization theory applied to humans only to some extent, since gender identity in these 
individuals was female, despite more masculine gender role behavior. In their 1972 book, Man 
and Woman, Boy and Girl, they further suggested that prenatal hormones proved important in 
18 For instance, women have an increased risk of suffering from depression and most anxiety disorders.Morphometric studies 
have shown sexual dimorphism in several brain structures, such as the cingulate and ventrolateral prefrontal cortices (larger in 
women) and the medial temporal structures, including the amygdala (larger in men), to be implicated in emotional processing. 
Immunocytochemical studies of vasopressinergic neurons and corticotropin-releasing hormone (CRH)  neurons in the human 
paraventricular nucleus have shown a larger amount of neurons in men compared to women. These physiological differences in the 
male and female brain,hypothesized to be programmed by sex steroids early in development,  might have  important implications 
for vulnerability in disorders associated with stress or mood [91].
19 The two critical periods in human development when testosterone levels are known to be higher in boys than in girls are 
midpregnancy and the first three months after birth . These fetal and neonatal peaks of testosterone, together with functional 
changes in steroid receptors, are thought to program to a major degree the development of structures and circuits in a boy’s brain 
for the rest of his life. As sexual differentiation of the genitals takes places much earlier in development (i.e. in the first 2 months 
of pregnancy) than sexual differentiation of the brain (the second half of pregnancy), these two processes may be influenced 
independently.This means that in the event of ambiguous genitals at birth, the degree of masculinization of the genitals may not 
always reflect the degree of masculinization of the brain [91]. 
1.3.2 Organization-activation theory
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gender development, but they were not determinative. In that same book, Money also provided 
the fi rst application of his theory to an individual without a DSD condition: a young boy, one of 
two identical twin boys, whose penis was accidentally destroyed during circumcision (‘ablatio 
penis’) and for whom he recommended a female reassignment [98-100]. The child’s upbringing 
as a girl, transitioning to live as a male in his teens and enduring psychiatric distress was highly 
publicized, both in the popular media [101,102] and in psychiatric and pediatric medical journals, 
in particular by Diamond [103,104]. This case, known as the John/Joan case in the medical 
literature  (and later identifi ed as David Reimer) reanimated the long-standing nature versus 
nurture disputes regarding gender-identity formation and psychosexual development [29]. Most 
of the popular debate over the David Reimer case – also refl ected in  Colapinto’s book title ‘As 
nature made him’ [102]-  focused on the idea of a true, underlying sex, determined primarily by 
chromosomes and hormones that connected in a direct and predictable way with gender, and 
on the notion that DSD management protocols have been wrong because they were not based 
on the idea that biology determines gender [29]20.
20 This case had failed, but it doesn’t invalidate Money’s other empirical research in DSD cases, nor does it follow that this case 
provides unequivocal support for Diamond’s theory. As Karkazis [29] points out, most researchers still use a causal model of gender 
identity development that relies on a nature-nurture binarism. If nurture is demonstrated to be incorrect, it is assumed that nature 
must be the cause. This conclusion reaffirms the opposition between nature and nurture, more than it affirms or refutes claims 
about how gender identity develops.
In this iconic model, based on the 
organizational/activational hypothesis, chro-
mosomal sex determines gonadal sex, which 
determines brain sex. Feminization of the brain 
is the default process that occurs in the absence 
of high levels of gonadal steroids during a 
perinatal sensitive period. Masculinization 
and defeminization are separate hormonally 
driven processes that organize the neural 
substrate to promote male-typical behaviors 
while suppressing female-typical behaviors. 
The organized neural substrate is activated 
by adult gonadal steroids and required for 
sex-typical behaviors to be expressed [27].
Figure 12. Twentieth-century linear view of sexual diﬀ erentiation.
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In a twenty-fi rst-century view of sexual 
diff erentiation of the brain, the importance of 
genetics and environment are incorporated 
along with the eff ects of hormones to 
provide a more nuanced portrayal of the 
types of variables that cause sex diff erences. 
Hormones, sex chromosome genes and sex-
specifi c environments or infl uences have 
independent parallel diff erentiating eff ects 
that can interact with each other, often 
synergistically, resulting in a continuum of 
sex diff erences in the brain. However, there 
are also compensatory sex-specifi c variables 
that act to reduce sex diff erences rather than 
induce them. The result is that some aspects 
of male and female brain, behavior and 
physiology are unique, whereas others are 
highly similar. Two important aspects are not 
illustrated here: 1) sex diff erences are pervasive 
throughout the brain and not restricted to 
reproductively relevant neural circuits, and 2) 
variability in the degree to which brain regions 
are masculinized or feminized in one individual 
results in a continuum of relative maleness 
or femaleness and thereby greatly increases 
the variance between individuals of the same 
sex in a population [5,27]. If gender identity 
is indeed the product of complex genetic, 
hormonal and environmental factors, it is 
plausible that sexual identity is not an all-or-
nothing phenomenon, but rather represents 
a continuum  from feeling male to feeling 
female, which would depend on the degree 
of genetic infl uences, prenatal concentrations 
of hormones and the environment in which 
the individual is raised [74].  
Figure 13. Redefi ning sexual diﬀ erentiation.
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21 Reiners’ work on cloacal, bladder or classic exstrophy was frequently cited in debates of gender assignment, although clinicians 
are adamant that these children do not have intersex conditions. Like Diamond, Reiner had also argued for a strong inborn bias for 
gender identity, depending on androgen exposure [29]. Although only half of the 46, XY individuals in his sample identified as male, 
he felt it would be a matter of time before the rest switched to live as men. 
22 The uncertainty of how to deal with certain diagnoses was for instance reflected in the title of Mouriquand’s article (2004): How 
to make the least bad choice in children with ambiguous genitalia. 
The resurgence of an interest in the role of pre-and postnatal hormones in sexual differentiation 
has forced the rethinking of the traditional model of gender assignment [5]. Curiously, the 
debate emanated from the sensationalistic case histories involving a gender change in 
individuals without DSD conditions (such as the John/Joan case) and evidence about gender-
identity change in 46,XY individuals with cloacal exstrophy and severe phallic inadequacy, 
who were treated according to the treatment protocol for DSD [73,105,106]21. Money’s model 
was challenged by researchers, such as Diamond and Reiner, targeting his belief that gender 
identity and sexual behavior at birth are not fixed but can be influenced by rearing. Their 
search for definitive biological markers of sex was based on the notion that prenatal androgen 
levels contribute to a masculine sexual differentiation of the brain and to subsequent gender 
difference. The extent to which androgens only masculinize gender role behavior or also 
masculinize gender identity remains a point of discussion. Researchers have to rely mainly 
on proxy measurements of the degree of prenatal androgen exposure, as it is difficult to 
reliably and accurately assess an infant’s degree of androgens prior to birth. One proximate 
determinant is for instance the degree of genital virilization, which is thought to correspond 
to brain virilization. Whereas the relationship between the degree of genital masculinization 
and masculine play behavior is moderate [107,108], others found no relationship with gender 
identity [109,110]. Conceptual problems however arise by completely downplaying the role of 
socialization and relying exclusively on the explanatory power of biology – in casu androgen 
exposure- in the development of gender behavior and identity. The  assumption of a neural 
and biological dimorphic body established early and being quite similar over time, across and 
within subjects is too simple, since recent research has shown brain plasticity and an ability of 
the nervous system to adapt to changing circumstances, as well as genes affecting behavior. 
Genes, or hormones do not act independently of their context to produce certain characteristics 
[15,17,22,89, 111-113] (Figure 13). Moreover, with a focus on biology, much less attention is paid to 
the world in which the child is born in, how parents react, the effects of possible peer rejection, 
education, race, class or culture. In sum, most studies do not model the interactive nature 
of biological and social effects, but underline too often the biological and social as distinct 
[29]. Though excellent progress has been made in understanding biological and environmental 
factors that contribute to healthy psychosexual development, it is still the case that variability 
in behavioral outcomes makes it difficult to be certain of optimal sex assignment (Table 4). The 
question seems then how to make the least bad choice [22]. Cautious and careful case-by-
case management by multidisciplinary teams, balancing out all advantages and disadvantages 
and with parents fully involved in management decisions, is always indicated [17]. Gender 
assignment  remains one of the most contentious areas in the field of DSD . 
1.4 Current issues
        
TABLE 4 Gender assignment in 46, XX and 46,XY Disorders of Sex Development.
Abbreviations: CAH= Congenital Adrenal Hyperplasia, CAIS= Complete Androgen Insensitivity 
Syndrome, PAIS= Partial Androgen Insensitivity Syndrome, 5α RD-2= 5α reductase deficiency-2, 
17β HSD-3= 17β hydroxysteroid dehydrogenase deficiency-3, GD= Gonadal dysgenesis, Y=Yes, 
N= No, F= Female, M= Male a One case report has been described of gender change to male 
b No actual gender change but only gender dysphoria, c although satisfied with their gender 
identity, most had questioned their gender of rearing at some point.
Syndrome 
(karyotype)
Prenatal T 
exposure
Gender 
Identity
Gender 
dysphoria 
and change
Assigned 
Gender
Gender role 
behavior
References
CAH (46,XX)
CAIS (46,XY)
PAIS (46,XY)
5α RD-2 
(46,XY)
17β HSD-3 
(46,XY)
Complete GD 
(46,XY) 
Partial GD 
(mostly 46,XY)
Micropenis 
(46,XY)
Y
N
Y
Y
N
N
Y
Y
Mostly F
F
Mostly F
Both
Mostly F
Female
Both
Both
[7, 48, 
114-119]
[113, 120-
123]
[113, 120, 
124, 125]
[126]
[126]
[17, 127]
[56, 128]
[120, 129]
F
F
As reared
M
M
F
As reared
As reared
Masculine
Feminine
Masculine
Masculine
Masculine
Feminine
Masculine
As reared
5% F → M
0%a
9.1%
5% F → M
4% M → F
56–63% F → M
39–64% F → M
0%
0%b M → F
0%b M → F
0%c F → M
The other particularly controversial field is genital treatment and its timing.  
In October 2005, fifty international experts in such fields as pediatric endocrinology, pediatric 
urology, genetics and gender identity development were gathered in Chicago to revise the 
treatment guidelines for infants born with DSD. The meeting would not have happened without 
DSD activists' growing chorus of demands for changes in medical treatment practices. Beginning 
in the early 1990’s, criticism on the traditional treatment paradigm- with its focus on rapid gender 
assignment,  genital surgery and secrecy about the diagnosis- came from a number of adults 
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who had been treated as children and felt that they had suffered extraordinary and irrevocable 
harm. They pointed to the lack of complete and honest disclosure to parents about the child’s 
anatomy and condition and to the child about its treatment history, to the rush to normalize 
atypical genitals by performing surgery and to the desire to erase gender atypicality and 
differences in the name of care [29]. By the year 2000, the topic had received extensive coverage 
in documentaries, newspapers, magazines, on television and even in novels (e.g. Eugenides’ novel 
‘Middlesex’), with the field being in a deep crisis.Providing recognition and advising caution, the 
new guidelines stated that DSD conditions are not shameful and suggest that psychological 
care should be integral to medical treatment. Although these new guidelines encompass 
positive developments and incorporate important changes, they have been criticized as well 
for sustaining the assumption that physicians should intervene in controlling the ‘sex of the 
body’ [29]. While descriptions of the various genital treatment procedures, their  advantages 
and disadvantages, risks and benefits along with the outcome literature are addressed in detail 
in subsequent chapters,  we provide the reader with a short overview. The purpose of this 
overview is to engender in medical clinicians less familiar with genital reconstructive surgery 
or treatment a better understanding of the nuances of reconstructive procedures and how the 
various procedures may relate to the underlying anatomy of each DSD patient. In addition, we 
hope to fuel a discussion of the need for future development and research in the field. 
The areas of genital treatment currently under review within this doctoral thesis are:
1.5 
Understanding and weighing 
genital treatment options
   
Surgery for 
ambiguous 
genitalia
Treatment for 
the absent or 
short vagina
Masculinizing 
genital 
surgery
1.   Genital surgery for ambiguous genitalia
Since John’s Money’s work, it has become routine to recommend feminizing genital surgery to 
all infants with ambiguous genitalia raised female - with congenital adrenal hyperplasia (CAH) 
being the most common cause of genital ambiguity. Surgical treatment of girls with CAH usually 
involves 1) clitoroplasty to reduce the clitoral size and improve the cosmetic appearance of the 
genitals, and 2) vaginoplasty, with the goal of exteriorizing the vagina and creating 2 separate 
openings for the urethra and vagina, and to achieve an unobstructed, sex-typical manner for 
urination and to allow for vaginal-penile intercourse [175].
Clitoral and vaginal surgery
Cosmetic surgery on the prominent clitoris has gone from simple amputation of the clitoris 
to techniques for recession (i.e. burying the clitoral shaft under the pubic bone without 
removing any erectile tissue) and nerve-sparing reduction (i.e. preserving the glans clitoris and 
neurovascular bundle running along the dorsal aspect of the clitoral shaft while removing most of 
the erectile tissue), with a focus presently on not only producing a normal cosmetic appearance 
but also at preserving (erotic) sensation and vascularity of the glans [134] and incorporating the 
preserved parts of the enlarged clitoris under a reconstructed clitoral hood [135]. There is much 
debate but little data on all aspects of clitoral surgery including the appropriate size and site for 
incisions on skin and crura, whether or not to anchor the clitoris to the bony pelvis, how much 
corporal tissue to remove as well as the requirement for reduction of the glans clitoris and what 
techniques best achieve this [175]. Most descriptions of clitoral reduction techniques usually 
report small series of patients with limited follow-up; there are no comparative studies of the 
short or long-term advantages of specific techniques [175].
State -of -the -art techniques for vaginoplasty, in which the vaginal cavity is opened to the 
pelvic floor allowing passage for menstruation, and later sexual activity, also have changed 
drastically over the years [132]. Flap vaginoplasty and vaginal pull-through techniques separating 
the urethra and vaginal components, have been replaced by total and partial urogenital sinus 
mobilization [136]. The former involves a 360° mobilization of the entire urogenital sinus, which 
is then brought to the perineum [137,138]. In the latter, dissection is avoided superior to the 
urethra under the pubic bone, a nerve-rich zone that contains the sphincteric musculature 
necessary for urinary continence [138].
In rare cases, the residual vaginal cavity is too small to be connected to the pelvic floor and a 
vaginal substitution appears necessary to bridge the gap [39]. A vaginoplasty with a skin graft 
substitution is particularly prone to contracture, making postoperative dilation necessary 
at least until a regular sexual relationship is established [47]. Many pediatric urologists 
and surgeons prefer therefore bowel vaginoplasty, as it is believed to obviate the need for 
postoperative dilation. However, this is a major surgical procedure that carries significant long-
term complications, including mucous production, vaginal stenosis, vaginal prolapse, diversion 
colitis, bowel obstruction and rarely carcinoma [47]. Urinary incontinence and the need for re-
operation for tampon use or intercourse remain postoperative concerns whatever technique 
is used [139].
Timing of surgery
Issues around timing of repairs are truly unsettled, although they have been conducted for 
decades [47,132,133]. The surgical challenge may be approached either separately (i.e., a 2-stage 
procedure, where the clitoroplasty is performed in infancy followed by vaginoplasty delayed 
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until near puberty) or as a 1-stage procedure (in which the clitoroplasty and vaginoplasty are 
performed in one setting in early childhood or infancy) (for an overview, see [39,132]). 
Recent clinical practice guidelines published by the Endocrine Society suggest that: 
1. for severely virilized (Prader stage ≥ 3) females, clitoral reconstruction be performed in 
infancy by an experienced surgeon [137,138]
2. for less severly virilized females (Prader stage < 3), clitoroplasty may be performed 
in adolescence, if necessary. Although a clitoris looks large on a small baby, the 
appearance relative to the rest of the genitals will change as the child grows older. 
Mild to moderate clitoral hypertrophy may also regress with medical therapy for CAH 
[142].
As a general rule, the more virilized the patient, the higher the vagina inserts in the common 
channel (urogenital sinus), which is technically more demanding for repair.
1. In patients with a low vaginal confluence, complete repair including vaginoplasty, 
perineal reconstruction, and clitoroplasty (if necessary) is recommended to be done 
simultaneously at an early age [138]. 
2. For individuals with a higher vaginal confluence, the timing is less certain, but most 
agree on deferring it to adolescence [137,140,141], with the excepting in some severe 
CAH cases, in which early surgery is necessary to avoid urinary tract infections. Thus, 
even in cases where the urogenital sinus is long and vaginal entry high, vaginal surgery 
may be delayed until adolescence as, in most cases, menstruation can occur through 
the common urogenital sinus [175].
Advocates of surgery in infancy, maintain that the procedures are easier to perform and the 
results better in the young child [175]. In infants with severe virilization where clitoroplasty is being 
considered, the redundant clitoral skin can also be used as part of the vaginal reconstruction 
and gives the surgeon much more flexibility. In the neonatal period, the recent exposure to 
placental estrogens leads to more elastic vaginal tissue, facilitating vaginal reconstruction 
[138]. Other presumed values in seeking early surgery are reducing parental anxiety and easing 
acceptance of the child’s congenital anomaly, avoiding stigmatization of a girl with masculinized 
genitals [144], and avoiding the psychological trauma of genital surgery during adolescence 
[138]. Some surveys completed by adult patients with CAH suggest that most women favor 
surgery before adolescence [182,183]. In addition, its has been shown that mothers of children 
for whom genitoplasty was delayed beyond 12 months experienced greater parenting stress 
than those whose children had surgery within the first year of life [188].
Those favoring later reconstructive surgery note that the decision more appropriately rests 
with the patient rather than the family and that the surgical options for genital reconstruction 
will be preserved in the event that the initial sex assignment was incorrect and a sex change 
desired, or the patient does not desire genitoplasty [47,175]. It has also been suggested that a 
vagina is not necessary for a young girl prior to menarche or sexual intercourse [47]. Moreover, 
the implied surgical advantage of delayed reconstruction is that the risk of vaginal stenosis and 
the need for subsequent dilation is diminished, as well as the risk of repeat operations because 
of a narrow introitus and/or for more extensive reconstruction because of vaginal strictures or 
vaginal insufficiency [142,143]. 
Psychosexual function after clitoral and/or vaginal surgery
To date (and despite clinical practice guidelines), there have been no studies comparing early 
and delayed feminizing genitoplasty with regard to psychological and sexual outcomes [139] 
and the time span needed to conduct such studies, poses a methodological challenge [175]. 
Some studies suggest poor cosmetic and functional results of genitoplasty done in infancy 
[139,142,147,148,115,179] with a high re-intervention vaginoplasty rate in adulthood for stenosis 
[143,184]. Sexual QoL seems particularly impaired with regard to intercourse frequency, 
avoidance of sex, penetration difficulties and problems with orgasm [115,179], which the women 
with CAH attributed to their genital surgery. However, it is important to acknowledge that 
worse psychosexual function compared to controls might not be entirely related to surgical 
interventions since the null genotype alone (homozygous 21-hydroxylase mutation) has been 
associated with poorer long-term psychosexual outcomes regardless of having had surgery 
performed or not [189]. Furthermore, there is no information in regard to psychosocial and 
sexual outcomes of patients adequately supported and prepared for romantic and sexual 
relationships , e.g. with comprehensive sex education [174]. There are many confounds in the 
available reports on surgical interventions and psychosexual function , and it remains unclear 
why sexual lives of women with CAH differ compared to control groups in terms of timing of 
psychosexual milestones (delayed), sexual experiences (less), sexual activity and imagery (less), 
sexual motivation (less), partnership and marriage (less), and sexual self-image (less favorable)
[190-192]. For instance, repeated genital exams and medical photography, treatment by 
clinicians experienced as disrespectful, or an atypical genital appearance might be particularly 
anxiety provoking for some adolescents, and uncertainty about masculinity/femininity, sexual 
adequacy, or sexual orientation and fear of rejection may lead to postponing initiating intimate 
relationships [193]. It is equally important to acknowledge that there are publications indicating 
that adult patients with CAH who had surgery early in life score similarly to those with other 
surgical and nonsurgical chronic medical conditions in quality of life, and physical and mental 
health tests [180,181].
Prospective long-term studies evaluating the results of modern feminizing genitoplasty 
techniques, including the nerve-sparing techniques, are needed as current evidence is based 
on outdated operations that are no longer used. Many authors, together with patient support 
groups, ethicists and DSD activists [8,31] have recommended a moratorium on genital surgery 
until better empirical evidence of risks and benefits are available [47,142, 145, 146] (Table 5). For 
women considering clitoral reduction surgery for dissatisfaction with cosmetic appearance, 
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sexual dysfunction or socially distressing erections, the surgical risk of damage to clitoral 
sensation and future orgasmic capacity is currently estimated at 25% [147,148]. All families 
should be counseled regarding the controversies and treatment options, including the watchful 
waiting approach.
 
TABLE 5
Risks and benefits of (early) feminizing surgery 
for ambiguous genitalia (adapted from [55]).
  
Benefits Risks
Prevention of psychological 
distress from ambiguous 
genital appearance
Gender development in accordance 
with assigned sex of rearing
Creation of psychological distress from undergoing 
childhood hospitalization, surgery and genital 
examination; possible lack of control over or consent 
for surgical interventions
Gender development not in accordance 
with sex of rearing and irreversible surgery 
has been performed
Good cosmetic outcomes
‘Normal’ female appearance
Stability in psychosexual development
Relief of parental anxiety
Poor cosmetic outcomes, surgical complications 
(including urethra-vaginal fistulae and vaginal stenosis) 
Few reports in the literature regarding overall female 
genital appearance, or the dimensions or positioning 
of the vagina, clitoris, labia and urethra 
Instability in psychosexual development 
Damage to sexual function
Damage to parent-child relationship
Vaginal introitus for adult 
penetrative sexual intercourse
Vaginal passage for menstrual flow
Stenotic or fibrosed introitus causing dyspareunia
Obstruction to menstrual flow from 
postsurgical scarring and fibrosis
Controversies regarding types of genital treatment and their timing remain also unresolved in 
conditions involving vaginal hypoplasia, commonly diagnosed late, such as Mayer-Rokitansky-
Küster-Hauser syndrome (MRKH) or Complete Androgen Insensitivity Syndrome (CAIS), in 
which older girls/women need to decide whether they will opt for vaginal surgery or dilation to 
create a vagina and when it is optimal to proceed based on psychological readiness. 
Surgical vaginoplasty is historically the cornerstone of treatment for vaginal hypoplasia and 
has been performed as early as the first half of the nineteenth century. Different techniques, 
including split-thickness skin grafts (e.g., McIndoe procedure [149], local flaps [150], bowel and 
peritoneal vaginoplasty (e.g., Davydov procedure [151]), or the use of a traction and pressure 
device (e.g., Vecchietti procedure [152]) have been proposed, each addressing difficulties 
encountered with previous methods, and yielding new barriers to overcome [52]. Non-surgical 
vaginal creation with the use of graduated vaginal dilators involving intermittent pressure on 
the vaginal introitus has first been proposed by Frank in 1938, but has not gained popularity for 
a long time. However, in view of the high complication rate associated with surgical vaginal 
creation [153], along with a societal trend towards preference of more conservative as well as 
cost-effective solutions for different medical problems, the non-surgical treatment option for 
MRKH is since 2002 recommended by the American College of Obstetricians and Gynecologists 
(ACOG) as first line therapy [154]. Meanwhile, advocacy groups of patients with DSD increasingly 
emphasized their right for self-determination and opposed to genital surgery. The idea of self-
dilation as a first choice for women with CAIS and a short vagina was adopted by DSD experts, 
as well as the ACOG, in 2006 [185].
It seems that about an 80% success rate can be expected from any of the techniques, and using 
a more selective approach to surgery, it is estimated that only around 15% of patients who use 
the non-surgical approach will need to proceed to a surgical one [187]. Reasons for failure, 
however, need further clarification (e.g. age of the patient, sturdy or flat perineum). Moreover, 
it is not known if failed vaginal dilation therapy jeopardizes further surgical success outcomes, 
especially because in a number of these procedures ongoing vaginal dilation is required. 
In addition, if surgery is needed, there is a lack of evidence to inform physicians regarding 
the optimum surgical technique to use. Most series in the literature are by a proponent of a 
certain technique, reviewing the outcome of their series of cases, and concentrating mainly 
on immediate postoperative outcome. Long-term outcomes remain unknown. In addition, 
some follow-up on genital procedures is limited to assessments of patency or penetration 
without considering the quality of the sexual experiences. Papers refer to the vagina being 
‘satisfactory’, without saying to whom it was satisfactory or by what means satisfaction was 
measured. These issues of practitioner-driven selection of intervention method versus patient-
driven selection, and quality of sexual experience is highly relevant to the outcomes. In general, 
concise long-term comparison of treatment-specific and condition-specific outcomes (e.g. 
MRKH vs CAIS) and protocols for vaginal dilation, as well as recommendations ensuring 
therapeutic compliance remain largely unexplored, contributing to the controversies around 
the topic. In addition, the effect of adjunctive therapies used with surgery or vaginal dilation, 
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2.   Treatment for the absent or short vagina
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such as professional psychological or peer support, on psychosexual outcomes needs to be 
evaluated. Finally, as with all rare conditions sample sizes tend to be small, making statistical 
analysis difficult and subject to erroneous interpretations, a bundling of findings is necessary to 
draw reasonable conclusions and to enable an evidence-based ground for individual decision-
making in women seeking care for vaginal hypoplasia. 
The sex of rearing approach by Money and coworkers was also clearly influenced by Freudian 
psychoanalytic ideas. Like Freud, Money assumed that the presence or absence of the penis 
was of prime importance in psychosexual differentiation. Gender must be fixed before entry 
into the Freudian phallic stage, because children are then supposed to be very preoccupied with 
their genitalia and would notice penis presence or absence [6]. However, unlike Freud, who did 
not specify the size of the phallus as the main determinant of masculine development, Money 
thought it best to avoid problems of having a small penis in adulthood by assigning children 
with concurrent or anticipated small penis to the female gender [155]. Feminizing surgery was 
also considered more feasible compared to masculinizing surgery, i.e. it was easier to create a 
penetrative conduit than a penetrating organ. 
The recent concern that has been raised regarding in utero brain masculinization and its 
effects on gender identity development, has resulted in more male sex assignments during 
the last decades, particularly in patients with less severe undervirilization [15,125,156]. Also, 
significant changes have been made in surgical techniques for masculinizing genitoplasty. 
The aims of male genitoplasty are in general (1) straightening of the penis so that full painless 
erection enabling satisfactory penetration can be achieved (with or without prosthesis); (2) 
hypospadias repair and urethroplasty enabling functional micturition (including urination from 
the standing position); (3) reconstruction of the tissues forming the ventral surface of the glans 
(glanuloplasty, repair of division of the corpus spongiosum and skin); and (4) reconstruction 
of the scrotum and orchiopexy [157]. These procedures (and mainly hypospadias repair) are 
frequently completed during the first year of life, because of presumed lower complication 
rates and better wound healing (for an overview, see [175]). However, despite significant 
advances in male genitoplasty procedures, there remain several questions to be answered. Will 
the reconstructed genitalia function normally and will they be well-adjusted when the patients 
grow up? What information can we provide about the functional and psychological outcomes 
in adulthood? The complications of these reconstructive techniques can take decades before 
becoming evident. Rapid pubertal growth can alter the final functional and cosmetic aspects 
of the corrected genitalia (e.g. the neourethra might fail to grow adequately during puberty 
causing new curvature) [169]. Moreover, psychosexual development is only completed after 
puberty, so the psychological and sexual function of patients who have undergone genital 
reconstruction can only be evaluated after puberty [169]. 
3.    Masculinizing genital surgery
There is in general a paucity of data on the long-term effects of different male genital 
reconstruction techniques during childhood due to a lack of validated measurement tools 
and validated questionnaires, and high loss of patients during follow-up [169]. In addition, the 
varying standards of treatment (e.g. improved nursing practice adapted to children’s needs) 
make direct comparisons of results difficult. Also, it is a challenge to perform high-quality 
research that is powerful enough to generate broad conclusions; a recent systematic review 
of the literature on hypospadias treatment from the last 20 years concluded that the current 
management of severe hypospadias is based on weak evidence, and even the definition of 
severe hypospadias is not the same between centers [194]. According to the available data, it 
seems that patients who have undergone masculinizing genital surgery (mainly hypospadias 
repair) are less satisfied with their urinary function in comparison with controls, and usually 
experience spraying, post-void dribbling and urinary stream deviation, symptoms that are more 
prominent in patients with a history of severe and proximal hypospadias [169]. A higher rate of 
avoiding sexual relationships is noted, as well as a higher prevalence of dissatisfaction about 
sexual function and a negative genital appraisal, in adulthood (for an overview, see [169, 195]). 
From the few studies specifically including male patients with a DSD diagnosis and hypospadias 
repair in childhood, the most frequent complaint is short penile length in comparison with the 
norm [124,170,177,178]. Virilization during puberty may be sufficient in some cases with DSD, 
however, severe micropenis and/or penile insufficiency often persist into adulthood, despite 
hormonal treatment, and may constitute a psychological burden for these patients. Are penis 
size and masculinity on the one hand, and masculinity and sexual wellbeing on the other hand 
really conflated?[6] Further controlled studies with direct interviews are needed to evaluate the 
functional and cosmetic outcomes after masculinizing surgery. The cosmetic aspect of the 
operation should not be underestimated, since over 70% of adults followed after hypospadias 
repair reported that appearance was as important as having a functionally appropriate phallus 
[176].In addition, one may argue that patients with a DSD diagnosis have differential outcomes 
from genital surgery than their counterparts without a specific diagnosis and that long-term 
effects might differ in DSD conditions with different molecular backgrounds. In reality, and 
especially in cases with 46,XY gonadal dysgenesis and severe undervirilization, a specific 
molecular diagnosis is identified in only approximately 20% of cases [33,34]. Therefore, strict 
clinical inclusion criteria , with accurate descriptions of the specific genital situation (e.g. degree 
of hyspospadias), are necessary to integrate these patients in clinical outcome studies [166]. 
One of the pitfalls of studies in men with DSD is that there is a great range of severity in genital 
anomalies which has confounded previous reports. Also, the effects of hormonal treatment on 
adult penile length in DSD patients should be further investigated [170]. Is postpubertal penile 
inadequacy predictable before or during puberty? Again, the importance of considering each 
DSD distinct from the others might prove critical for insights that go unnoticed otherwise.
Lastly, phalloplasty is a relatively novel technique that is traditionally applied in female to male 
transsexuals with reassuring outcome results [171,172]. It might offer perspectives for DSD 
patients with a male gender identity, and a small penis. However, evidence-based data on the 
application and outcome of this technique on the long-term are lacking and highly needed, 
despite satisfactory psychological and cosmetic results in younger patients with congenital 
or secondary penile insufficiency [173]. Optimal protocols for phalloplasty and follow-up 
are actually non-existent and need to be established, with specific emphasis on the specific 
indications for this type of surgery (e.g. what are objective criteria to define postpubertal penile 
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inadequacy), optimal timing (for preparation of surgery, for performing surgery), possible 
complications on the short-and long-term and the need for re-intervention.
The heated debate between DSD activists, scholars and clinicians centers on the appropriate 
response to physical sexual variation [158]. Primary points of discussion between these 
groups are whether or not most genital interventions in DSD are necessary for physiological 
or psychological health, or whether these procedures are primarily cosmetic or potentially 
physiologically and mentally harmful and alienating [84]. Crucial to the debate on the role of 
genital treatment, are however data on the long-term effects. Although the goal of genital 
treatment is an improvement of psychosexual and social outcomes, there is little long-term 
follow-up of these children into adult life to confirm that an improvement in these outcomes 
is actually achieved. Moreover, studies on DSD patients have been hampered by a widespread 
policy of non-disclosure, leaving patients unaware of their diagnosis, unable to access medical 
or peer support and unavailable for recruitment into outcome studies [130]. In addition, genital 
surgery has become so universal that it is difficult to recruit those patients who have not had 
surgery and their opinions remain mainly absent [131]. Beyond selection/recruitment bias and 
small sample sizes, outcome studies and evidence-based treatment of patients with DSD are 
also hampered by a missing independence of care provider and researcher, possibly leading 
to social desirability, and a lack of control groups and standardized instruments, reducing 
comparability between studies which employ different methodologies [120,166]. Lastly, there 
are also confounds inherent in the critiques of surgical intervention specific to the field of DSD, 
i.e., the rapid development/improvement of surgical techniques and the unfortunate delay 
between the intervention and assessment of outcome/functionality. Surgical techniques have 
largely changed by the time we see outcome data. In essence, as a field we are presented with 
potential moratoria based on practices that no longer exist. We risk throwing the baby out with 
the bathwater [165].
The described problems show that the rareness of disorders of sex development, the 
heterogeneity of the clinical symptoms and variation in both surgical and medical treatments 
over time, requires more national and international cooperation on the long-term to increase 
sample sizes and to get high-quality outcome data [166]. The Belgian and Dutch-wide outcome 
studies, with the establishment of DSD patient registries, were designed to overcome at least 
some of the described problems, and to further drive multidisciplinary research and clinical 
quality improvement by fostering rapid translation and integration of standardized diagnostic 
and treatment protocols into ongoing clinical care of patients.
1.5.1
1.5.2
Why further study genital treatment practices in DSD? 
Further contributions of this thesis 
Before further discussing the concrete aims that we pursue and outline of this dissertation, 
a few words of caution are in order, which are already briefly touched upon. Psychosexual 
function and wellbeing may be affected by many variables, including physical and hormonal 
factors and body-image perception, genital interventions, emotional health, relationship 
quality, the environment, and cultural beliefs. Evaluating sexuality is a complex task in the 
‘normal’ population but can be expected to be even more difficult in patients with a DSD. Not all 
individuals feel able to discuss sexual matters with their doctors [10,11] (or with researchers), so 
an absence of complaints (in medical records) may not mean that sexual experience is positive. 
Also, it remains difficult to separate psychosexual issues directly related to genital treatment 
from the underlying difficulties associated with other aspects of a DSD condition. Although 
individuals with DSD and their families face some of the same challenges as other chronic 
medical conditions (such as the intrusion of medical authority into their lives [6]), they differ in 
certain condition factors, such as the social stigma attached to having a DSD condition, and/
or clinical management practices and attendant experiences, including medical photography 
and frequent genital examinations [6]. It can be questioned that too much emphasis is given 
to genitals and genital ‘abnormality’ in the context of DSD. Surgeons and clinicans have been 
criticized for labeling DSD and genital ambiguity as an emergency situation . Rather, it should be 
considered a social problem as genital ambiguity mainly installs social disruption and discomfort 
[84]. However, the ever popular reference to the “medical emergency” continually fails, in the 
extant literature, to acknowledge that genital ambiguity at birth invariably signals hormonal 
dysfunction which must be investigated immediately to avoid potentially life-threatening 
complications associated with some of the disorders, such as salt-wasting congenital adrenal 
hyperplasia. This is the crux of the emergency [165]. On the other hand, the attention given to 
genitals and treatment in DSD, may become a hook on which to hang all anxieties, including 
those which are probably most excruciating: the need to come to terms with the potential 
“loss” of a healthy (perfect) child [165]. A diagnosis of DSD in a child or adolescent is increasingly 
being understood as a traumatic event for parents, who report levels of posttraumatic stress 
symptoms, that are comparable to those reported by parents of children diagnosed with other 
disorders such as cancer [167]. Parent distress can be amplified by shock that DSD was even a 
possibility and never previously having heard of it; confusion and misconceptions about the 
origins of DSD; and the belief that maintaining secrecy about the condition is required to ensure 
their child's healthy psychosexual development [168]. In sum, with the presence of (any) birth 
defect or chronic disorder, the risk of a disturbed psycho-emotional and social development is 
increased, as parental anxiety, invasion of personal privacy, pain or physical discomfort, frequent 
visits to hospitals, early or late physical development (e.g. lack of pubic hair, primary amenorrhea) 
may all lead to feelings of being ‘different’ from one’s peers [6]. Any differences in social and 
sexual dimensions (including the formation of close relationships and sexual function) found 
for these children (and adults) with DSD, would need to be explained within a biopsychosocial 
framework that could take account of the transactions with the social systems of hospital, 
school or work, family and friends, the type of condition and bodily presentation and/or 
pathology (e.g., hormonal deficiencies) and treatment demands (e.g., life-long medication and 
its side effects, the need for gonadectomy) [6]. Ultimately, a linear model in which psychosexual 
outcomes are hypothesized to be directly determined by biological (i.e. hormonal, genetic) 
factors and/or medical/surgical interventions proves to be an oversimplification that leaves 
substantial variability in endpoints unaccounted for, and (more) consideration should be given 
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to mediating and moderating social contextual factors and their potential import for clinical 
management [174].
Previous extensive social scientific work on DSD, with its focus on gaining a deeper and broader
understanding of people’s experiences, has made notable contributions, by including different 
actors i.e. clinicians [29,82,159], adults with DSD [29,84] and parents [29,160] and by using different 
methodologies i.e. interviews [29,82,84,160] and textual analysis [161-163]. There remains, 
however, a call for research using more ‘objective’ criteria to evaluate treatment outcomes 
(e.g. objective genital sensation measurements or validated standardized questionnaires). It is 
important to be very cautious about ‘objectivity’, given the implicit assumptions that may inform 
some of the ‘objective’ criteria for treatment success (e.g. ‘normal’ pudendal nerve latencies 
after clitoral surgery indicating ‘normal’ sensation, whereas sexual function is impaired) [10,164]. 
The routine inclusion of patients’ accounts of outcomes remains essential. Therefore, we used 
a mixed-methods approach, combining the questionnaire approach designed for statistical 
analysis and allowing methodological comparability with other studies and control groups, with 
personalized qualitative interviews. Semi-structured interview formats were chosen to balance 
a structure imposed by the researchers with the need to allow participants to speak about 
what was relevant to them. By giving a voice to affected persons and combining this with 
more ‘objective, quantitative’ analyses, our hope is to provide a more balanced viewpoint in 
conceptualizing some of issues related to past, present and future genital treatment practices 
for patients with a DSD. 
The empirical part of this dissertation consists of three chapters (Chapter 2, 4, 5) that map 
psychosexual experiences after different genital treatment practices in patients with DSD and 
one chapter (Chapter 3) that maps self-perceived genital anatomy and sensitivity in women 
without DSD and genital treatment. Each empirical chapter consists of empirical studies that 
may be read as stand-alone research articles. The order of the empirical chapters takes the 
reader along a series of steps that largely mirror the thought processes of the multidisciplinary 
DSD teams of Ghent University Hospital, Belgium and Erasmus Medical Centre Rotterdam, 
the Netherlands. Both teams have for many years investigated the clinical, psychological and 
molecular genetic pathophysiology of genital development in a multidisciplinary approach and 
started their official structural collaboration in January 2007. This collaboration continues to 
offer an excellent platform for patient discussions and scientific research on a wider scale, 
also in the context of European research initiatives (EURO DSD), with the aim of ameliorating 
diagnosis, follow-up and treatment of DSD patients. 
Chapter 2 reflects work conducted as part of a large scale Dutch multi-center clinical 
evaluation study on quality of life, sexuality, gender identity, treatment satisfaction, coping, 
psychosocial adjustment and problems associated with diagnoses and therapies in individuals 
with DSD (Study centers: Erasmus Medical Centre Rotterdam, VU Medical Centre Amsterdam, 
1.5.3 Thesis outline
UMC St Radboud Nijmegen, UMC Utrecht and UMC Groningen; coordinators Dr. Arianne 
Dessens and Dr. Sten Drop). Although there are several other criteria to evaluate treatment (e.g. 
health related quality of life, mental health), obviously, psychosexual aspects remain important 
outcome parameters in the context of DSD to improve clinical care. Therefore, my co-authors 
and I explore first cosmetic and functional outcomes and treatment satisfaction in three 
different etiological groups as medical and surgical care varies for these groups, i.e., women 
with congenital adrenal hyperplasia who had surgery for ambiguous genitalia (vaginoplasty 
and/or clitoroplasty) , women with vaginal hypoplasia, who had either vaginoplasty or vaginal 
dilation therapy to enlarge the vagina, and men with DSD who had hypospadias repair in 
childhood. The main goal of this work is to generate hypotheses for evidence based guidelines 
which should be tested in further studies, as until now, the scientific knowledge is not sufficient 
to generate a-priori hypotheses. This chapter constitutes a first attempt at showing variation 
regarding the relevance of cosmetic versus functional outcomes for psychosexual wellbeing in 
women and men with DSD. Moreover, the results suggest that patient reports may be valid for 
an objective assessment of cosmetic outcomes, and that invasive genital examinations may not 
be necessary for studies of outcomes. 
The work presented in Chapter 3 is conducted at Ghent University Hospital, Belgium as part 
of a different collaborative project (with Dr. Hoebeke and Mr Bronselaer), further assessing the 
genital rating concordance between clinicians and women without DSD and a history of genital 
treatment. In this chapter, the importance of self-perceived genital anatomy and sensitivity 
for female sexuality and wellbeing is further elucidated, by means of a large-scale validation 
study establishing norms for techniques of genital self-assessment. The data collected should 
provide a much needed comparison standard for assessments in the case of atypical genitalia. 
Chapter 4 and 5, of which the studies are conducted at Ghent University Hospital, Belgium 
(coordinators: Dr. Martine Cools, Dr. Piet Hoebeke), further elaborate on typical treatment 
sequences and decisions for special genital and psychological interventions. Chapter 4 first 
dissects the extant literature reporting outcomes for varied methods of vaginal creation 
methods for women with vaginal hypoplasia. The treatment algorithm developed within the 
context of the analysis possibly allows for better controlled, prospective and comparative 
studies, and may lead to vast improvements in patient experiences and outcomes. Further 
interviews with these women, in the context of a long-term prospective intervention study 
after vaginal dilation therapy, are highly informative as they suggest that psychological support 
services in their current form should be re-evaluated. In Chapter 5, my co-authors and I 
investigate the importance of penile size and satisfaction with genital appearance for sexual 
quality of life in male DSD patients with a micropenis. Male genitoplasty in its current form, 
with or without hormonal treatment to increase penile length, seems not able to replicate 
the complexity of penile anatomy and function and conducting phalloplasty procedures might 
improve physical and sexual outcomes. The subsequent report characterizes sexual quality of 
life outcomes with state-of-the-art phalloplasty procedures in a very specific cohort of male 
DSD patients ,which may lead to increased numbers of surgeries and more complete transition 
for those who wish to do so. This chapter however again highlights that - although the move to 
integrate behavioral and psychological health in clinical teams specializing in sex development 
is significant - it remains an empirical question whether the psychologist’s role in this setting 
64
65
delivers substantive therapeutic contributions, beyond managing support and information flow.
Finally, we summarize and discuss the empirical findings in a concluding Chapter 6, in which 
we also propose a broader perspective and future directions for research on psychosexual and 
social wellbeing in DSD patients.
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CHAPTER 2
Functional and 
cosmetic outcomes 
in (wo)men with DSD
A compilation of three retrospective studies
Based on:
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Introduction. Women with the classical form of congenital adrenal hyperplasia (CAH) are 
born with different degrees of virilization of the external genitalia. Feminizing surgery is often 
performed in childhood to change the appearance of the genitalia and to enable penile–vaginal 
intercourse later in life. There are suggestions that this affects sexual functioning. 
Aims. The aim is to study the anatomical, surgical, cosmetic, and psychosexual outcomes in 
women with CAH.
Methods. Forty women with CAH, aged over 15 years, from two referral centers for management 
of Disorders of Sex Development in the Netherlands were included. Physical and functional 
status were assessed by a gynecological interview and examination. Sexual functioning was 
assessed with the Female Sexual Function Index and Female Sexual Distress Scale—Revised 
scales and compared with a reference group.
Mean Outcome Measures. Surgery performed, anatomy, cosmetic score, sexual function and 
distress.
Results. Thirty-six of the 40 women had undergone feminizing surgery; 25 women (69%) 
underwent more than one operation. Resurgery was performed in seven of the 13 (54%) women 
who had had a single-stage procedure. Anatomical assessment showed reasonable outcomes. 
Multiple linear regression showed that only level of confluence had a significant effect on 
cosmetic outcome, the impact depending on the number of surgeries performed. Cosmetic 
evaluations did not differ between the women and the gynecologists. Only 20 women had 
experience of intercourse. Eight women reported dyspareunia; seven women reported urinary 
incontinence. The women’s perceived sexual functioning was less satisfactory than in the 
reference group, and they reported more sexual distress.
Conclusion. The level of confluence was the major determinant for cosmetic outcome; the 
impact depended on the number of surgeries performed. Fifty-four percent of the women 
required resurgery after a single-stage procedure in childhood. Anatomical assessment showed 
reasonable outcomes. The women evaluated their sexual functioning and functional outcome 
less favorable than the reference group, and they experienced less often sexual intercourse.
Introduction
2.1 
Severity of Virilization Is Associated with 
Cosmetic Appearance and Sexual Function 
in Women with Congenital Adrenal Hyperplasia: 
A Cross-Sectional Study
Congenital  adrenal  hyperplasia  (CAH)  is 
a group of autosomal recessive disorders 
resulting from the deficiency of one of the 
five enzymes required for the synthesis of 
cortisol in the adrenal cortex. About 90–95% 
of individuals with CAH have a mutation in the 
CYP21A2 gene, encoding the 21-hydroxylase 
enzyme [1]. There are two types of CAH: the 
ABSTRACT
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classical and a nonclassical form or late onset 
CAH. Genital ambiguity at birth is present 
only in the classical form, which can be 
subdivided in simple virilizing CAH (SV-CAH) 
when only a defect in cortisol biosynthesis 
is present and salt wasting CAH (SW-CAH) 
when the patient also shows a concurrent 
defect in aldosterone biosynthesis. Patients 
with the nonclassical form and untreated or 
insufficiently treated patients with the classical 
form have manifestations of androgen excess 
such as hirsutism, menstrual dysfunction, and 
acne [2].The excessive amount of androgens 
circulating in the fetus probably also affects 
brain development in a masculine direction, 
leading to virilization of personality and 
cognitive, psychosocial, and psychosexual 
functioning [3,4]. Female patients with 
moderate or severe genital virilization may 
undergo feminizing surgery, e.g., clitoroplasty, 
vaginoplasty, and labioplasty, with the aim to 
create female appearing external genitalia 
and to enable sexual intercourse. Genital 
surgery is controversial as loss of sensitivity 
resulting in diminished sexual functioning has 
been reported [5–12]. Unfortunately, available 
data are conflicting because of confounding 
factors. Patient satisfaction with surgery is 
likely to be affected by many factors, such 
as the policy of nondisclosure and secrecy 
around the diagnosis, repeated genital 
examinations or being exhibited as a curiosity 
for medical photography, or inadequate 
professional support. These may all lead to a 
poor body image, a lack of self-confidence 
and general (sexual) unhappiness [29]. Further 
controlled studies with direct interviews 
are needed to evaluate the functional and 
cosmetic outcomes after feminizing surgery.
Aims
The aim is to study the long-term anatomical, 
surgical, cosmetic, and psychosexual out-
comes of a large cohort of women with CAH.
Methods
Study Design
Cross-sectional study.
Patients
Eighty-nine patients with CAH (>15 years of 
age) were invited to participate in the study 
between 2007 and 2009. Participating centers 
were Erasmus MC Rotterdam (N = 53) and 
Radboud University Nijmegen MC, Nijmegen 
(N = 36), The Netherlands. The study was 
approved by the Medical Ethics Committees 
of both centers. Participants signed a written 
consent. Participants were free to refuse 
parts of the gynecological examination or the 
psychological assessment.
Procedure
The study consisted of two parts. Data on 
genital virilization at birth and genital surgery 
were collected retrospectively from medical 
files. Patients were invited to take part in a 
follow-up study consisting of a standardized 
gynecological examination, psychosocial 
assessment on sexual functioning, and an 
interview.
Outcome Measures
Surgery and Level of Confluence
A description of the urogenital sinus (UGS) 
was available in the medical records [13]. 
Therefore, the degree of virilization was 
classified by the level of confluence of the 
vagina into the UGS at birth. Three levels were 
distinguished: low, i.e., the junction of the 
vagina and urethra is near the perineum (N 
= 14); high, i.e., the junction is near the neck 
of the bladder (N = 8); and no confluence, 
i.e., clitoral hypertrophy only (N = 5). From 
13 patients, we had no data on level of 
virilization.
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Gynecological Examination
The standardized gynecological examination 
consisted of visual inspection (size of 
clitoris, labia majora, and labia minora; 
pigmentation; and meatus urethrae externus, 
hair growth, labial scarring, and perineal 
length), speculum examination (assessment 
of vagina, internal hair growth, granulation 
tissue, epithelial atrophy, and presence of a 
cervix), and pelvic examination (accessibility 
of the vagina by number of fingers, vaginal 
length, and width [measured by Hegar], 
strictures, pelvic floor tone, and vaginal 
discharge). The three gynecologists who 
performed the gynecological examination 
had not been involved previously in the care 
of these patients.
The gynecologist and the patient herself 
independently rated the general appearance 
and the appearance of different parts of the 
vulva (i.e., clitoris, labia majora, and minora) 
on a 1–10 scale (1 = extremely poor, 10 = 
excellent, <6 was considered insufficient). 
The cosmetic outcome score per patient was 
calculated as the mean of the gynecologists' 
or patient's scores for the different parts of 
the genitalia.
Psychosexual Assessment
Psychosexual functioning was assessed by the 
Dutch versions of the Female Sexual Function 
Index (FSFI) [14,15] and the Female Sexual Dis-
tress Scale—Revised (FSDS-R) [15,16]. The 
FSFI assesses sexual functioning by six key 
dimensions of female sexual function in the 
preceding 4 weeks: desire, subjective arousal, 
lubrication, orgasm, global emotional/
relational satisfaction, and pain. The FSDS-R 
assesses perceived stress with respect to 
sexuality. The combined results of the FSFI 
and FSDS-R suggest the diagnosis of one or 
more sexual dysfunction(s) according to the 
Diagnostic and Statistical Manual of Mental 
Disorders (version four, text revision) (DSM-
IV-TR) [17]. An FSFI score <26.55 combined 
with a FSDS-R score >11 implies the existence 
of at least one sexual dysfunction according 
to the DSM-IV-TR [17]. As questions in the 
FSFI and FSDS-R relate mainly to the 4-week 
period before completing the surveys, and 
some items can only be filled out when 
having a partner (i.e., satisfaction domain 
of the FSFI), or when having intercourse 
(i.e., pain domain of the FSFI), a “valid” total 
FSFI score could only be calculated for a 
minority of the women. Therefore, we did 
not interpret zero responses (“no sexual 
activity in last 4 weeks”) as extreme degrees 
of dysfunction but excluded these women 
from further analyses [18,19]. Patients’ 
psychosexual scores were compared with 
data of a Dutch reference group of 108 
healthy women with a mean age of 27.1 years 
(standard deviation 9.4) [15]. These authors 
had made up a reference group of women 
who were all engaged in heterosexual 
partner relationships and had reported they 
had no sexual dysfunctions. By making use of 
these inclusion criteria, the reference group 
is probably not representative for the Dutch 
female population. Analysis showed that the 
reference group is similar to our study group 
with respect to age (P = 0.43) and educational 
level (P = 0.67). On the FSFI and FSDS-R, the 
reference group did not report problems in 
psychosexual functioning. The psychologi-
cal interview inquired about the ages sexual 
developmental milestones had been passed, 
such as age at first engagement in a romantic 
relationship, including kissing and touching 
the partner without sexual intercourse, 
and age at sexarche (i.e., first peno-vaginal 
intercourse).
Statistical Analysis
Univariate and backward stepwise linear 
regression analyses were used to identify 
factors associated with cosmetic outcome. 
Intercorrelated variables were evaluated for 
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the presence of confounding and/or effect 
modification in stratified analyses. Effect 
modification was twice identified: between 
“level of confluence,” and “number of 
surgeries,” and between “level of confluence,” 
and “age at first surgery.” We looked for a 
significant contribution of the interaction 
effects to the predictive ability of the model 
by adding the interaction effects to the main 
effects (backward stepwise linear regression 
analysis).
Comparisons between groups were assessed 
with descriptive statistics: the chi-square 
test for nominal/ordinal variables, Student’s 
t-test for normally distributed continuous 
variables, and the Wilcoxon signed-rank test 
for paired variables with skewed distributions. 
Comparisons of continuous variables with 
skewed distributions were evaluated with the 
Mann–Whitney U-test (two groups) or the 
Kruskal–Wallis test (three or more groups).
A P value <0.05 (two sided) was considered a 
significant difference. As patients were free to 
refuse parts of the gynecological examination 
and the psychological assessment, number 
of participants may vary across analyses.
Results
Patient Group
Forty of the 89 invited women participated
(response rate: 45%). The remaining 49 
women either declined participation (45%), 
or could not be reached personally (i.e., by 
phone, e-mail, or post mail). Characteristics 
from the nonresponders and participants are 
depicted in Table 1. By inspection, it seems 
that the groups did not significantly differ in 
the medical variables. 
Of the 40 participants, 38 fulfilled the criteria 
of 21 hydroxylase deficiency (32 had SW-CAH 
and six had SV-CAH) and two had 11 beta-
hydroxlyase deficiency. The median age at 
participation was 29 years (range 15–46).
Most patients with SV-CAH, and those with 
SW-CAH, had been diagnosed within the first 
year of life; only three SW-CAH and two SV-
CAH patients were diagnosed after the age of 
1 (mean age 3.3 and 4.0, respectively). Those 
with late onset CAH (N = 2) were diagnosed 
at a mean age of 12 years and were included 
because they attended the clinic with virilized 
genitalia; they both had clitoral hypertrophy. 
Main features of the 40 women are presented 
in Table 2. Height was below -2 standard 
deviation score (SDS) in 12 of the women, 
calculated on Dutch reference data for age 21 
years [20]. Family history was positive for CAH 
in 13 patients, and parental consanguinity 
was present in three patients, all of whom 
had SW-CAH.
Surgical Procedures
Thirty-six of the 40 patients had undergone 
feminizing surgery of the external genitalia. 
Figure 1 gives an overview of the surgical 
procedures performed.
In 13 of those 36 patients, surgery consisted 
of a single-stage clitoroplasty and vagino-
Age and medical characteristics 
of nonresponders and participants.TABLE 1
Characteristics Participant    Nonresponders P values
We did not find statistical differences between the two groups.
*Student’s t-test - †Chi-square test - ‡Mann–Whitney U-test
SW = salt wasting; SV = simple virilizing; LO = late onset; LOC = 
level of confluence
Mean age (range) 
Type
SW 
SV
LO
LOC
High
Low
No 
Unknown
Mean number of
surgeries (range)
29 ( 15-46)
32
6
2
8
14
5
13
1.8 (0-4)
30 (18-54)
37
9
3
10
15
12
12
1.5 (0-5)
0,75*
0.88†
0.51†
0.15‡
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TABLE 2
plasty. The median age at surgery was 3 
years (range 0–17 years). Seven patients 
(7/13, 54%) needed resurgery later in life. In 
20 patients (median age 2 years, range 0–19), 
first surgery comprised only clitoroplasty. 
Additional vaginoplasty was performed in 
16 patients (16/20, 80%) at the median age 
of 13 (range 4–22 years). Several patients 
(see Figure 1) had more than one additional 
surgical procedure.
In three patients (median age 11, range 
2–16 years), first surgery comprised only 
vaginoplasty.
One of these women requested additional 
clitoroplasty at the age of 17 even though 
clitoromegaly was only mild.
A redo-operation was performed in 25 of the 
36 patients (69%). Eleven of these patients 
had their first surgery before the age of 13 
months, and 14 patients had their first surgery 
between 13 months of age and 6 years.
In almost all cases (N = 32), clitoroplasty 
comprised reduction of the clitoris with 
All visited the endocrinologist on a regular basis. Only one had hirsutism (patient number 30, Ferriman Gallway Score for hirsutism was 25). 
In general, the women were small, with 12 women below -2 SDS in height. SW = salt wasting; SV = simple virilizing; LO = late onset; Hc = 
hydrocortisone; Dexa = dexamethasone; Fc = fludrocortisone; SDS = standard deviation score; BMI = body mass index; CAH = congenital 
adrenal hyperplasia
Main features of the participants.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
36
37
28
37
32
23
29
22
38
36
18
21
28
22
19
24
30
40
40
26
23
19
34
44
24
16
19
38
46
22
46
44
35
18
19
46
25
32
45
20
23.4
28.3
23.9
24.8
36.3
25.7
26.3
27.8
32
23.3
25.4
27
22.6
24.6
29.1
25.3
28.2
29.3
35.5
21.8
19.6
26.1
22.6
29.7
22.8
26.7
20
22.6
37.3
26
23.6
28.8
19.7
-1.64
-1.02
-0.86
-0.40
-0.71
2.07
-1.33
-2.72
-2.10
-1.17
-3.03
-1.64
1.61
0.06
-0.40
-1.02
-1.17
-1.33
-2.88
-0.94
-2.10
-3.34
-2.72
-1.17
-0.86
-2.72
-2.41
-0.17
-3.88
-1.95
-1.10
-2.10
-4.34
No
No
Yes
Yes
No
Yes
Yes
No
Yes
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
No
No
No
No
No
Yes
Yes
No
No
No
Yes
Yes
No
Yes
Yes
No
Yes
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
No
No
No
No
No
Yes
Yes
No
SW Fc 62.5-62.5 ug Fc 62.5-62.5 ug
SV Dexa 0.25 mg 
LO Hc 10-5-5 mg 
SW Hc 10-0-25 mg Fc 62.5 ug
SW Hc 10-0-5 mg Fc 62.5-94 ug
SW Hc 15-0-20 mg Fc 125-125 ug
SW Hc 7.5-5-2.5 mg Fc 62.5-62.5 ug
SW Hc 10-10 mg Fc 62.5-62.5 ug
SW Dexa 0.125-0.125 mg Fc 125-125 ug
SW Dexa 0.25-0.25 mg Fc 62.5 ug
SW Dexa 0.25-0.25 mg Fc 62.5 ug
SW Hc 15-10 mg Fc 30-30 ug
SW Hc 5-5-15 mg Fc 25-25 ug
SW Hc 10-10 mg Fc 50-50 ug
LO Hc 10-10 mg 
SW Hc 10-5-10 mg Fc 62.5-62.5 ug
SW Hc 15-5-5 mg Fc 62.5-62.5 ug
SW Dexa 0.50 mg Fc 62.5 ug
SW Hc 10-10 mg Fc 125 ug
SW Hc 10-15 mg Fc 62.5-62.5 ug
SW Dexa 0.25-0.25 mg Fc 45-45 ug
SW Dexa 5 mg Fc 62.5 ug
SV Hc 20-0-10 mg
SV Dexa 0.5 mg 
SW Dexa 0.5-0.5 mg Fc 100-100 ug
SW Hc 8-4-8 mg Fc 62.5-62.5 ug
SV Hc 10-10 mg 
SW Hc 10-10 mg Fc 100 ug
SW Hc 5-5-5 mg Fc 62.5 ug
SW Hc 20 mg, Dexa 1.5 mg Fc 100-50 ug
SW Hc 25 mg Fc 62.5 ug
SW Hc 15-15 mg Fc 62.5-62.5 ug
SW Hc 7.5-5-12.5mg Fc 125-125 ug
SV Hc 12 mg, dexa 0.2 mg
SV Hc 10-10-10 mg
SW Hc 25 mg Fc 62.5-62.5 ug
SW Hc 15-10 mg,Dexa 0.10 mg Fc 40 ug
SW Hc 10-10 mg Fc 62.5-62.5 ug
SW Hc 15-15 mg Fc 75-75 ug
SW Hc 6-3-3 mg Fc 62.5-62.5 ug
Age (years) BMI Height (SDS) Partner CAH type
THERAPY
Glucocorticoids Mineralcorticoids
Menarche
(years)
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preservation of the neurovascular bundle and 
glans. Two patients had a clitorectomy: for 
one patient, that was the standard procedure 
at that time (42 years ago), the other patient 
underwent clitorectomy because of persisting 
painful erections. The total number of 
surgical procedures in the patients assigned 
to the high confluence group (N = 8) was 
significantly higher than that in the patients 
assigned to the low confluence group (N = 
14) or that in patients with no confluence (N = 
5) (P = 0.004). As expected, the total number 
of clitoral or vaginal surgeries was higher in 
the SW group than the SV group but, given 
the small sample size, the difference did not 
reach statistical significance (P = 0.381 and P 
= 0.092, respectively).
Gynecological Examination
The results of the anatomical assessment 
during gynecological examination are 
presented in Table 3. Assessment data 
were available for 17 (Hegar examination) 
and 29 (speculum examination) women. 
Characteristics between patients who refused 
gynecological examination compared with 
who did not were not different for CAH type 
(i.e., SW or SV), or number of surgeries (1.8 
[1–4] vs. 1.8 [0–4]), but the groups did differ 
in age of attendance. The patients who 
participated were significantly older with a 
mean age of 32.6 years (18–46) compared 
with a mean age of 23.1 years (16–34) for 
those who did not participate (P = 0.03).
The clitoris was scored absent in two cases 
(due to clitorectomy), small in five patients, 
normal in 15 patients, and enlarged in six 
patients. Visible labial scarring was present 
in 15 patients; only in one woman the scars 
were very pronounced. One patient had a 
vagina shorter than 6 cm after a pull-through 
procedure. In four patients, digital exami-
nation was possible with one finger only; 
they were virgins, i.e., had never had sexual 
intercourse. The Hegar width of the vagina 
was in the normal range in almost all patients; 
in only one woman it was smaller than 20 
mm. Thirteen women refused speculum 
examination. Speculum examination was 
physically impossible in five patients. One 
Figure 1 Numbers of clitoroplasties and vaginoplasties performed in the total patient group (N = 40). 
(A) Number of clitoroplasties performed. (B) Number of vaginoplasties performed and total number of 
vaginoplasties with breakdown by severity of virilization.
Number of clitoroplasties performed Number of vaginoplasties performed
0
5
0 1 2 3 4 0 1 2 3 4
10
15
20
25
30
0
2
4
6
8
10
12
14
16
18
0
5
0 1 2 3 4 0 1 2 3 4
10
15
20
25
30
0
2
4
6
8
10
12
14
16
18
Total
High Confluence
Low Confluence
No Confluence
Confluence 
Unknown
A B
(Figure 1)
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patient was diagnosed with vaginism, 
whereas another had recently undergone 
a vaginoplasty. Only two patients showed 
abnormalities (increased vaginal secretions 
and atrophy, respectively). Seven patients 
had vaginal strictures. Although variations in 
genital appearance were established during 
gynecological examination, appearance was 
in the normal range in the majority of women. 
Again, differences between the SW-CAH 
and SV-CAH groups did not reach statistical 
significance because of small sample size 
(see Table 3).
Cosmetic Ratings
Cosmetic results of surgical and medical 
treatment was evaluated in 28 patients. Both 
the patient and the gynecologist who did the 
examination of the patient scored cosmetic 
outcome for various parts of the external 
genitalia on a 10-point scale. The median 
total score of all parts was 7 for patients and 7 
for gynecologists, which reflects overall sat-
isfaction with cosmetic outcome (P = 0.467 
for comparison of patients and gynecologists 
[N = 27 Wilcoxon signed-rank test]). Twenty-
five percent (7/28) of the patients vs. 21% 
(6/28) of the gynecologists scored the 
cosmetic outcome as insufficient (i.e., a 
mean score <6).
Age at first surgery and level of confluence 
were significantly associated with the mean 
cosmetic outcome score (univariate analysis, 
P = 0.021 and P < 0.01, respectively [N = 27, 
Kruskal–Wallis test and one-way analysis of 
variance]). Stratified analyses revealed that 
number of operations and age at first surgery 
were effect modifiers of the association 
between level of confluence and cosmetic 
outcome.
Multiple regression analysis (Table 4) showed 
that after adjustment for the effect modifiers, 
only level of confluence had a significant 
effect on cosmetic outcome. The adjusted 
impact of the level of confluence on 
cosmetic outcome is 1.055 - 0.987 x number 
of surgeries. The adjusted R2 of this model 
was 0.335.
Functional Assessment
Assessment of sexual function consisted 
of an interview with a gynecologist—as 
part of the gynecological checkup—and an 
interview and questionnaire assessment with 
a psychologist. The questionnaire results are 
shown in Table 5.
The gynecological interview was completed 
by 32 women. Twenty of the 32 (62.5%) 
women had experienced vaginal penetration 
(median 28.5 years, 19–46 years), and 12 
(37.5%) women had not (median 33.5 years, 
16–46 years). Two of the latter considered their 
vagina too narrow; two were embarrassed 
by the look of their body; two considered 
themselves too young (ages 16 and 19); three 
had sexual experiences in female homosexual 
relationships only, whereas three patients did 
not give a reason. 
Eighty-three percent of women reported they 
were able to achieve orgasm. Eight women 
reported dyspareunia (8/33, 24%), all of 
whom had experienced vaginal penetration. 
“I don 't want to think about 
it [genitals]. I don't have a clue 
how it should look like normally, 
but I don't even look at it. 
If the doctor thinks it's ok, 
it is allright. “
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Neither width nor length of the vagina 
correlated with dyspareunia (median Hegar 
width: 25.5 with dyspareunia   vs. 26.0 without 
dyspareunia, P = 0.86;  median length 10.0 cm 
vs.  10.0 cm, P = 0.152). Physical examination 
revealed vaginal strictures in two of the eight 
women who reported dyspareunia. Whereas 
five other patients with vaginal strictures did 
not report dyspareunia, two of them were 
virgins. Seven out of 33 women reported 
urinary incontinence (three stress incon-
tinence, three urge incontinence, and one 
both). None of them had sought medical 
attention for the incontinence. They lost 
small amounts of urine and sometimes used 
panty liners for this. Two women reported 
incontinence that started after genital 
surgery.
All but three women filled in the FSFI 
questionnaire, and all but five women filled 
in the FSDS-R questionnaire. However, many 
questions remained unanswered. Twenty-
five percent of the women (10/37) did not 
have sex regularly. 
Sexually experienced women with CAH had 
passed sexual milestones later than the Dutch 
reference sample (romantic engagement 17.7 
years vs. 15.6 years, P = 0.04; sexarche 18.9 
years vs. 18.3 years, P = 0.36). At the time 
of follow-up, half of the participant group 
(22/40) reported to be in a stable relationship.
“ Will it work? Does it 
look pretty? Will he notice? 
Because of your insecurity, 
you just end up postponing 
your sexuality.
Anatomical assessment.TABLE 3
Outcome
*Overall P value between SW and SV (chi-square test or # Fisher’s 
exact test) †Includes patients with CYP11B1 deficiency, ‡Short = 
0–6 cm, normal > 6 cm, §Physically impossible for the following 
reasons: virgin, recent operation, vaginism. Abnormal: too much 
fluor, atrophy, ¶2–3 cm = minimal, 1–2 cm = moderate SW = salt 
wasting; SV = simple virilizing
Clitoris     0.918
Absent  2 0  2
Small  4  1  5
Normal  12  3  15
Large  5 1  6
Labia majora     #0.126
Normal  13  5  18
Abnormal  11  0  11
Scrotal effect  9   9
Labia minora     0.393
Normal  9  3  12
Abnormal  14  2  16
Absent  5   5
Small  5   5
Labial scarring     0.502
Absent  10  3  15
Present  13  2  15
Satisfactory  6  0  6
Neutral  6  2  8
Not satisfactory 1  0  1 
Vagina Length ‡    0.531
Short  1 0  1
Normal  15  6  21
Digital 
Examination     0.191
1 finger  4  0  4
2 fingers  13  6  19
Introitus (Hegar)     0.588
<15 mm  0  0  0
15–20 mm  1  0  1
20–25 mm  3  0  3
25–30 mm  6  1  7
>30 mm  4  2  6
Speculum examination§    0.714
Physically impossible  4  1  5
Normal  15  5  20
Abnormal  2  0  2
Stricture¶
Minimal  2  2  4  0.147
Moderate  3  0  3
Meatus urethrae externus    0.694
Normal  6  2  8
Superficial  3  1  4
Deep  14  2  16
SW
(N = 32)
SV
(N = 8)†
Total
(N = 40)
P
value*
“I just can't have 
easy sexual intercourse 
with all guys.
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A total FSFI score can be calculated for 
women who had sexual intercourse in the last 
4 weeks; in our patient group, only 11 women 
had been sexually active during this period. 
The mean score of 29 (range 19.9–33.7) on 
the total FSFI did not differ significantly from 
the score of the Dutch reference group of 
108 non-affected women with a partner. 
All but one had had feminizing surgery and 
had no confluence or low confluence of the 
vagina into the UGS at birth. However, when 
considering the separate FSFI domains, 
women with CAH had significantly lower 
functioning on the subscales of desire, 
arousal, lubrication but also pain compared 
with the reference group. No differences 
were found for satisfaction, or orgasm. On 
the FSDS-R, women with CAH indicated
to experience more sexual distress in 
comparison with the reference group (Table 
5). Twenty-nine percent (10/35) had a 
score above the clinical cutoff of 11. When 
combining the (valid) FSFI and FSDS-R data, 
only one woman suffered from a sexual 
dysfunction, as defined in DSM-IV-TR. 
Kruskal–Wallis tests showed no significant 
differences between women with a high 
or low confluence level, or no confluence, 
possibly because of the small sample sizes. 
In addition, no significant difference existed 
in perception of sexual function between 
SW and SV women as tested with Mann– 
Whitney U-tests.
Discussion
We report on genital anatomy and ratings of 
cosmetic and functional outcome in women 
with CAH with and without feminizing 
surgery. We integrated gynecological and 
psychosexual outcomes with the aim to gain 
new insights in the long-term outcome of 
genital surgery in these women. 
Level of virilization, assessed as level of conflu-
ence, proved to be the most important factor 
in cosmetic outcome; cosmetic appearance 
was judged as less favorable in case of a 
high vaginal confluence. In addition, patients 
with a high vaginal confluence underwent 
significantly more surgical procedures than 
the remainder of the women. Our regression 
model clearly showed that the adjusted 
impact of level of confluence on cosmetic
outcome is modified by the number of sur-
gical procedures. As shown in Table 4, the 
impact of the level of confluence on cosmetic 
Multiple regression model for cosmetic 
appearance with mean gynecological 
score as dependent variable.
Mean scores (SD) on the different do-
mains of the FSFI (range 0–6), total 
FSFI (range 0–36), FSDS-R (range 
0–52) comparing CAH women and 
a non-affected reference group [18] 
(independent samples t-tests).
TABLE 4
TABLE 5
Multiple regression model for cosmetic appearance
Adjusted R2: 0.335
Only level of vaginal confluence had a significant effect on mean 
gynecological score. The adjusted impact of level of confluence 
depends on the number of surgical procedures performed.
**P < 0.01; *P < 0.05
SD = standard deviation; FSFI = Female Sexual Function Index; 
FSDSR = Female Sexual Distress Scale—Revised; CAH = congenital 
adrenal hyperplasia
Constant  4,631  1.278  0.002
Level of confluence  1.055  0.489  0.045
Number of surgeries  0.181  0.305  0.560
Age at first surgery  0.078  0.056  0.180
Level of confluence x -0.987  0.539  0.084
number of surgeries 
Desire  4.0 (0.8) N = 108  3.5 (1.2) N = 37  0.017*
Arousal  5.3 (0.8) N = 108  4.4 (1.6) N = 31  0.004**
Lubrication  5.7 (1.0) N = 108  5.0 (1.1) N = 26  0.004**
Orgasm  5.1 (1.1) N = 108  4.6 (1.6) N = 26  0.131
Satisfaction  5.4 (0.8) N = 108  5.2 (1.0) N = 22  0.442
Pain  5.7 (0.8) N = 108  4.5 (1.7) N = 13  0.025*
Total FSFI  31.2 (3.9) N = 108  29.0 (4.2) N = 11  0.107
Total FSDS  5.1 (6.4) N = 108  8.8 (8.8) N = 35  0.02*
B
Control
Standard
error
CAH
P
value
P value
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outcome is larger or smaller, depending on 
the number of surgeries performed. More 
than half of the patients who had single-
stage surgery initially underwent additional 
procedures. Our results are in line with 
Nordenström et al. [21], who reported that 
surgery is more extensive in severely virilised 
patients, whereas other groups have reported 
either disappointing, or reasonably good 
outcomes after resurgery in puberty [6,15,16]. 
A practical advice is that parents should be 
informed on the fair chance of reoperation in 
adolescence.
In this study, patients and gynecologists both 
rated genital appearance as sufficient. In 
contrast, Wisniewski et al. [10] and Nordenström 
et al. [21] reported that patients were more 
negative than doctors. This might be due to a 
different composition of the group, or different 
approaches toward surgery. Female genital 
self-image, assessed using a four-point scale 
(FGSIS), was shown to be related to sexual 
function [22]. Although further research is 
needed, especially in patients born with genital 
anomalies like CAH, this scale might be useful 
in a clinical setting to create talking points that 
enhance patient–doctor communication and 
to better understand requests for additional 
surgery [22,23].
Our findings probably underestimate the 
delay in experience of romantic and sexual 
encounters because there was a considerable 
number of virgins and a considerable number 
of non-responders.
Comparisons using the FSFI scores were 
limited to women who were sexually active in 
the last 4 weeks, having a partner, and having 
penile–vaginal intercourse as described by 
Brotto [18] Only one (1/11) of the women 
suffered from sexual dysfunction according 
to DSM-IV-TR criteria [17]. We suspect that the 
real number is considerably higher. Women 
with CAH achieved sexual milestones later 
than Dutch reference women, and a substan-
tial part never had been engaged in a sexual 
relationship. Women with CAH experienced 
a significantly less satisfactory sexual 
functioning (desire, arousal, lubrication, and 
pain) and experienced more sexual distress 
compared with a Dutch reference group 
of healthy females. These data are in line 
with findings from Wisniewski et al. [10] and 
Gastaud et al. [7] In our study, 24% of the 
CAH women reported dyspareunia (deep and 
superficial). In a large Dutch study, 5.4% of 
2,024 healthy females reported dyspareunia, 
whereas 29.6% sometimes experienced pain 
during intercourse [24]. In females who have 
undergone vaginal surgery, dyspareunia 
might be related to vaginal stenosis [25], but in 
our study, only two of the eight patients who 
reported dyspareunia had vaginal strictures. 
Eighty-three percent reported they were 
able to achieve orgasm, although with more 
difficulty compared with healthy reference 
women. 
Other authors [6,21] have reported that the 
“ I wasn' t well prepared for 
surgery and they showed 
me afterwards how it looked 
like. I don' t have to explain 
how shocking that was for 
a 12 year old. “
“ Why can' t I get 
a proper orgasm 
just like any other woman? 
This is an injustice “
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clitoral sensitivity was affected in nearly all the 
women who had had surgery. These findings 
indicate that clitoral surgery may affect 
genital sensitivity. However, additional factors 
are likely to play a role as well, for example, 
degree of virilization and psychological 
factors. They are likely to be interrelated and 
little is known about their effects on outcome. 
For example, women with CAH reported high 
satisfaction levels. One possible explanation, 
suggested by Minto et al., is that living with 
CAH has contributed to low expectations 
of sexual functioning, that is, the women 
might have felt that sexual difficulties were 
to be expected and that they should not be 
dissatisfied [26]. Additionally, the paternalistic 
attitude of physicians and past practice 
of secrecy relating to Disorders of Sex 
Development (DSD), especially experienced 
by the older women in this study, might have 
resulted in inadequate information and lack 
of opportunity for discussion. Alternatively, 
infrequent sexual contact, associated with 
sexual dissatisfaction, might indicate a 
withdrawal from sexual intercourse and 
a relief from facing problems of sexual 
difficulties [27].
This study has drawbacks that need to be 
addressed. First, the study has a cross-
sectional design, and part of the data have 
been retrieved retrospectively from medical 
files. Therefore, the study was limited by 
information available in these files. Second, 
55% of the CAH women who had been 
under medical treatment in childhood, ado-
lescence, and adulthood in our hospitals did 
not participate in the follow-up study. Most 
refused to participate, and in some cases, 
we were unable to contact them. We did not 
find significant differences, demographical 
and medical, in characteristics between 
responders and non-responders. However, 
we cannot exclude the possibility that the 
non-responders may have worse functioning 
than the participants. Women may not want 
to participate because participation meant 
a confrontation with a painful and distres-
sing aspect of their condition, i.e., sexual 
functioning. Women who participated in the 
gynecological examination were significantly 
older compared with those who did not. We 
cannot explain this difference, but assume 
that women, as they become older, for 
medical purposes have undergone several 
gynecological examinations before and 
got familiar with this type of examination. 
Familiarity probably makes them feel more 
comfortable to participate in a gyneco-
logical examination with a research goal. 
Third, to measure sexual functioning, we 
selected the FSFI and FSDS-R. These scales 
are considered as first choice screening tools 
because they have excellent psychometric 
qualities, are easy to administer, and are 
available in many languages [15,19]. Their 
utility has been demonstrated in diverse 
conditions, for example, after vaginoplasty 
in females with Mayer– Rokitansky–Küster–
Hauser Syndrome [28]. However, the FSFI will 
artificially inflate scores toward the sexual 
dysfunction pole in females who are not 
sexually active or who did not experience 
vaginal penetration in the 4 weeks prior to the 
test [18]. The results in our study revealed that 
only 55% of the women had a partner. The 
Dutch reference group only included women 
who had a sexual partner. In order to improve 
applicability of the scales in patient groups, 
“ They took almost my whole 
clitoris away. This should 
have happened differently,  
I wanted to have more 
information. I did want
to keep it. “
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the scales need adaptation. Additional data in 
different patient and reference populations 
including females suffering from different 
types of somatic, emotional, and sexual 
problems should be collected.
Clinical Implications
We showed that cosmetic appearance and 
functional outcomes are associated with 
the degree of virilization at birth and that the 
impact of level of confluence on cosmetic 
outcome depends on the number of surgical 
procedures performed. These data might 
be used in the discussion whether or not 
to treat pregnant women at risk of carrying 
a child with CAH with dexamethasone. 
Incidence of reported dyspareunia is high in 
women with and without vaginal strictures, 
stenosis, or other visible anomalies. Parents 
and patients need to be informed extensively 
about the multiple aspects that contribute 
to outcome after feminizing surgery. They 
need to be informed that there will be a fair 
chance that reoperations will be necessary in 
adolescence. Despite their sexual problems, 
only a few women reported sexual problems 
to a gynecologist or psychologist, or had 
sought help from a sexologist. We would like 
to make a plea for assessing sexual well-being 
at follow-up visits and to discuss sexuality 
and work toward acceptance of the genital 
anatomy that may always remain different 
from the perceived norm. Ultimately, referral 
to a sexologist may be needed.
Conclusions
The level of confluence appeared to be the 
major determinant for cosmetic outcome, 
and the impact depends on the number of 
surgical procedures performed. The outcome 
of corrective genital surgery is positive 
with respect to genital appearance but less 
favorable with respect to sexual functioning. 
Vaginoplasties carried out to improve 
sexual function should only be performed 
after consulting a multidisciplinary DSD 
team and after ample vaginal examination 
and counseling. We would advocate that 
surgeons inform and discuss these aspects 
with parents and patients so they can make a 
balanced decision.
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Introduction. In patients with disorders of sex development requiring creation of a neovagina, 
a number of techniques are available, including surgical vaginoplasty and self-dilation therapy. 
Vaginal dilation therapy has been recommended as a first-line treatment because of its less 
invasive character and high success rate. However, no data exist on long-term psychosexual 
functioning after vaginal dilation as compared with that after vaginal surgery.
Aims. The aim of this study is to compare the psychosexual and anatomical outcome of women 
with congenital vaginal hypoplasia followed in the same clinical setting after vaginoplasty with 
that after vaginal dilation. 
Methods. The sexual quality of life of 35 women at least 2 years after vaginoplasty (N = 15), 
vaginal dilation therapy (N = 8), or coital dilation/no treatment (N = 12) was investigated and 
compared with the Dutch test validation population (as control).
Mean Outcome Measures. Psychosexual functioning was assessed with the Female Sexual 
Function Index, the Female Sexual Distress Scale-Revised, and a semi-structured interview. A 
gynecological examination was performed to determine the anatomical outcome after both 
vaginal treatment regimens.
Results. After either treatment, 26% of these women had a shortened vaginal length of less than 
6.6 cm, i.e., more than two standard deviations below the published mean value (9.6 ±1.5 cm). 
Irrespective of the treatment, 47% of the patients had (a) sexual dysfunction(s) and experienced 
sexual distress. However, after vaginoplasty, patients reported significantly more problems with 
lubrication (P = 0.025) than after self-dilation therapy.
Conclusion. Both psychological and physical factors are predisposing for sexual difficulties. To 
optimize psychosexual comfort, the clinical management of women with vaginal hypoplasia 
needs to be multidisciplinary and individually tailored. With high success rates reported, vaginal 
dilation should remain the cornerstone of treatment.
Key Words. Vaginal Hypoplasia; Vaginal Agenesis; Disorders of Sex Development; Vaginoplasty; 
Vaginal Dilation; Psychosexual Functioning; Neovagina
Introduction
2.2 
Long-Term Psychosexual and 
Anatomical Outcome after Vaginal 
Dilation or Vaginoplasty: 
A Comparative Study 
Vaginal  hypoplasia  or  vaginal  aplasia  is 
an uncommon congenital anomaly with an 
estimated incidence of 1:5000 to 1:10000 
live female births; it involves the complete 
or partial absence of  the  vagina,  uterus, 
or  both  [1,2].  Implicated etiologies  are 
Mayer–Rokitansky–Küster–Hauser (MRKH) 
syndrome, Complete Androgen Insensitivity 
ABSTRACT
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Syndrome (CAIS), and certain other disorders 
of  sex  development  (DSD)  [3].  Although 
healthcare providers agree on the importance 
of the construction of a good functional 
vaginal substitute that is durable, requires a 
minimum of post-operative maintenance 
manipulation, and provides long-term sexual 
satisfaction, there is substantial disagreement 
as to which technique best accomplishes 
these goals [4,5].
Specific surgical vaginoplasty procedures, 
including split-thickness skin grafts (e.g., 
McIndoe procedure [6]), local flaps [7], bowel 
and peritoneal vaginoplasty (e.g., Davydov 
procedure [8]), or the use of a traction and 
pressure device (e.g., Vecchietti procedure 
[9]) can be complex, and the timing of surgery 
remains controversial. Complications, such 
as scarring, vaginal stenosis, vaginal prolapse, 
dry vagina, or excessive vaginal discharge 
have been described [10]. Therefore, the 
American College of Obstetricians and 
Gynecologists recommends a nonsurgical 
treatment option as first-line therapy—with 
the use of graduated vaginal dilators involving 
intermittent pressure on the vaginal introitus 
(Frank or Ingram method [11,12])—due to the 
absence of surgical risk and preservation 
of vaginal tissue [13]. However, while both 
approaches yield high anatomical success 
rates [14,15]—defined as an adequate vaginal 
depth between 5 and 10 cm [2,16]—functional 
results remain unclear. Functional outcomes 
refer to sexual functioning, but studies are 
difficult to compare due to the heterogeneity 
of reports. Some state these outcomes as 
satisfactory, adequate, or unsatisfactory [17], 
whereas others make use of standardized 
sexual function tools [15,16,18–20] and a more 
detailed assessment of psychosexual well-
being [21], including the effects of this lifelong 
condition on fertility and bodily integrity 
[22,23].
Aims
While most studies evaluate a specific 
treatment (either surgical or nonsurgical) 
to create a neovagina, the primary aim of 
this retrospective study is to compare in 
a standardized manner the psychosexual 
functioning—and the relationship with psy-
chological adjustment—of these women seen 
in the same clinical setting after vaginoplasty 
with that after vaginal dilation. This approach 
may lead to evidence-based practice 
guidelines and further clinical implications 
for the management of women with vaginal 
hypoplasia or vaginal aplasia to optimize their 
psychosexual and psychosocial comfort.
Methods
Participants and Procedure
The study was conducted as a long-term 
follow-up audit of DSD patients referred 
for management of vaginal agenesis to the 
University Hospital Ghent, Belgium; Erasmus 
Medical Center Rotterdam, the Netherlands; 
or Radboud University Nijmegen Medical 
Center, the Netherlands. Randomization 
to the two vaginal substitution treatments 
was not conducted when these patients 
initially received care, because operative 
vaginoplasty was in these institutions the 
standard procedure in the past. Exclusion 
criteria were: age <18 years and >60 years, 
recent diagnosis (<6 months), gonadal dys-
genesis (because of the heterogeneous 
clinical picture), and intellectual disability. 
After exclusion, 57 eligible participants were 
contacted in Rotterdam and Nijmegen, 
24 participants in Ghent, inviting them to 
attend a clinic visit with a gynecologist and 
psychologist, who were not previously 
involved in the care of these women.
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Eligible
N = 81
Figure 1 Study design.
Twenty-four patients in Rotterdam and 
Nijmegen (42%) and 11 patients in Ghent 
participated (46%) between February 2007 
and January 2010. A flowchart of the study 
design can be found in Figure 1. All patients 
gave written informed consent, and the study 
was approved by the Medical Ethics Com-
mittee of the different institutions. Each 
research participant was asked to complete 
standardized questionnaires assessing 
psychosexual functioning and was invited for 
a gynecological check-up.
Assessment 
of Psychosexual Functioning
A sexual dysfunction, according to the 
Diagnostic and Statistical Manual of Mental 
Disorders (Fourth edition, text revision) (DSM-
IV-TR), is diagnosed by increased sexual 
distress and decreased sexual function. 
Sexual distress was assessed by the Female 
Sexual Distress Scale-Revised (FSDS-R) [24], 
validated for the Dutch-speaking population 
[25]. Sexual function was assessed by 
the Female Sexual Function Index (FSFI) 
questionnaire [26] (Dutch translation with 
excellent psychometric properties) [25]. 
This short 19-item questionnaire assesses 
adult female sexual quality of life in the 
4-week period before completing the survey 
[27,28], and its score is unbiased regarding 
age, education, and economic status. The 
items are assigned to six separate domains 
of female sexual function: desire, arousal, 
orgasm, sexual pain, vaginal lubrication, and 
global sexual and relationship satisfaction. 
All items in the FSFI have a five-point basic 
response scale (1–5) denoting variations in 
frequency, intensity or degree of satisfaction. 
In addition, some items carry a zero-
category coding for “no sexual activity” or 
“did not attempt intercourse” in the last 
4-week period. Instead of interpreting zero 
answers as extreme degrees of dysfunction 
[29], women were also asked how they were 
sexually functioning on the six domains 
beyond the 4-week period (adjusted FSFI). 
In case women had not had a sexual partner, 
the domain score for satisfaction was solely 
based on item 16. However, the original FSFI 
scores were used when comparing women 
with vaginal agenesis to the test validation 
population and clinical cutoff scores [30]. 
Additionally, a semi-structured interview 
delivered in-depth information about 
psychosexual and psychosocial adjustment.
Gynecological Evaluation
The gynecological evaluation consisted 
of a (i) medical–somatic anamnesis and 
Participation
N = 35
Vaginoplasty
N = 15
Coitus
N = 9
No coitus
N = 3
Vaginal dilation
(Frank) 
N = 8
Vaginal substitution treatment
N = 23
Retrospective follow-up Prospective follow-up
No treatment
N= 12
Figure 1
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TABLE 1
(ii) a gynecological exam including visual 
inspection (clitoral size, labia majora, labia 
minora, pigmentation, meatus urethrae 
externus, hair growth, labial scarring, and 
perineum length), speculum examination 
(assess-ment vagina, internal hair growth, 
granulated tissue, atrophy, and cervix), and 
pelvic examination (accessibility by number 
of fingers, vaginal length and width [Hegar], 
strictures, pelvic floor tone, and vaginal 
discharge). Vaginal length, defined as the 
distance from the posterior fourchette 
to the most proximal part of the blind-
ending vagina, was compared with normal 
reference values previously established [29]. 
Both patients and gynecologists scored the 
cosmetic appearance of the external geni-
talia (vagina, clitoris labia majora, and labia 
minora) on a rating scale (going from 1 = 
extremely poor to 10 = excellent). In addition, 
an adapted version of the body image scale 
[31] was used to assess patient satisfaction 
with the external genitalia and total body 
image (based on 31 sex-specific and nonsex-
specific body characteristics) (scale 1 = very 
satisfied to 5 = very dissatisfied). Medical 
notes were reviewed to confirm the diagnosis 
and treatment procedures.
Statistical Analysis
Differences between proportions were tested 
by chi-square tests or Fisher exact tests, as 
appropriate. The Mann–Whitney U-test 
was used to compare sexual functioning in 
women after vaginoplasty with that after 
vaginal dilation. Student’s t-tests were used to 
compare women with vaginal agenesis with 
the test validation population (as control). 
Spearman correlations were used to assess 
associations; the Wilcoxon signed-rank test 
for intergroup comparisons. P < 0.05 was 
considered statistically significant. Two-tailed 
statistical tests were chosen to reduce the 
risk of type I errors. Sensitivity and specificity 
were further analyzed through the receiver 
operating characteristic (ROC) curve. Analysis 
was carried out by the sta-tistical software 
package SPSS 19.0 (SPSS Inc., Chicago, IL, 
USA), and the authors received help from a 
statistical expert.
Results
The median age of the 35 participants was 
26 years (18–48 years); 21 participants 
(60%) were in a stable relationship. The 
various treatment regimens are summarized 
in Table 1. Operative vaginoplasty was, in 
our institutions, the standard procedure in 
the past. The choice of surgical procedure 
relied greatly on the surgeon’s preference 
and experience. In the last decade, clinical 
practice has changed, and women are 
offered a choice between dilation therapy 
and surgery, with a suggestion to start 
with dilation first. Six out of 15 (40%) of 
the vaginoplasty patients had tried dilation 
therapy before having surgery but failed to 
reach sufficient vaginal length. Fourteen out of 
15 women who had undergone vaginoplasty 
followed a postoperative dilation program 
(mean 3.7 months, range 1–12 months) to 
Treatment details and diagnoses.
DIAGNOSIS
*Nineteen women had a diagnosis of Complete Androgen 
Insensitivity Syndrome (CAIS). Other diagnoses comprised 17β3 
hydroxysteroid dehydrogenase deficiency in four, Leydig cell 
hypoplasia in three, and 5α reductase deficiency and 17,20 lyase 
deficiency each in one woman. †In one woman the Vechietti failed 
and she then had an intestinal vaginoplasty. MRKH = Mayer–
Rokitansky–Küster–Hauser
None  No coitus  3  0  3
 Coitus  9  0  9
Dilators  Frank method  8  0  8
Surgery  Intestinal†  2  0  2
 Skin grafts  4  7  11
 Vecchietti  2  0  2
Total   28  7  35
Disorder of 
androgen action 
or synthesis*
TotalMRKH
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maintain their vaginal patency. Psychosexual 
counseling has only become a vast part of 
any of the treatment regimens in the last 
decade. Mean duration of follow-up for the 
23 medically treated patients was 6 years 
(0.5–23 years). Twelve patients received no 
treatment, because health providers and/or 
more likely patients themselves judged this 
was not necessary (yet). Nine of them were 
sexually active at the time of examination. 
It is likely that these women increased 
their vaginal length by regular coitus alone. 
Because this can be seen as a natural dilation 
method and because of the small numbers, 
these women were considered as part of 
the dilation group in the next analyses. The 
other three women who had no treatment 
were the youngest (M = 18.7 years, standard 
deviation [SD] = 0.6) and did not yet engage 
in coitus. Because this group is too limited, 
they were not considered as a separate group 
but were only included in analyses when the 
total group of women with vaginal agenesis 
was considered, irrespective of treatment.
The individual diagnoses of the participants 
are summarized in Table 1. Except for 
MRKH, all diagnoses were confirmed by 
gene mutation analyses. All 28 women with 
a disorder of androgen action or synthesis 
received bilateral gonadectomy. Twenty out 
of 28 women were on regular hormone 
replacement therapy (HRT), one woman 
refused this, and seven women were not 
compliant with this treatment.
Anatomical Outcome
Only 27 out of 35 women participated in 
the gynecological check-up (Table 2). Four 
out of eight women did not participate 
because they lacked the time to do so. Four 
other women refused because of repeated 
and shameful examination of the genitalia, 
including medical photography, experienced 
in the past. Only two women with MRKH 
participated.
Vaginal Length
Overall mean (±SD) vaginal length was 8.5 cm 
(±2.5), which was significantly shorter than 
TABLE 2
Data shown as mean (standard deviation), the standardization data for vaginal length were based on [32].
Variables: follow-up since last treatment, complications at follow-up, cosmetic appearance of the genitals according to the patient and 
gynecologist (scale 1–10),patient satisfaction with genital and total body image (scale 1–5) Used abbreviations: St data = standardization data; 
vag = vaginal; yrs = years; NA = not appropriate
Anatomical outcome grouped according to type of intervention for the vagina.
N  3  9  8  15  50
Median age (yrs)  19 (18–19)  28 (20–48)  24 (18–36)  29 (20–42)
Follow-up (yrs)  NA  NA  5 (0.5–17)  6 (2–23)
Vag length (cm)  7.3 (3.7) (N = 3)  8.9 (2.6) (N = 9)  7.3 (1.3) (N = 6)  9.1 (2.7) (N = 9)  9.6 (N = 50)
Complications  None  None  None  Moderate strictures 
    (1–2 cm): N = 2; internal 
    hair growth and vaginal 
    prolapse: N = 1
Cosmesis
    Patient  7.0 (0.9)  7.3 (1.2)  7.7 (1.0)  7.0 (2.1)
    Gynecologist  8.5 (1.3)  8.1 (0.5)  8.4 (1.1)  6.9 (1.7)
Satisfaction
    Genitals  3.3 (0.3)  2.7 (0.7)  2.5 (0.4)  2.8 (0.7)
    Body  2.7 (0.1)  2.3 (0.5)  2.4 (0.3)  2.5 (0.6)
None—no 
coitus
None—dilation
by coitus
Dilators Surgery St data
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the published mean value (9.6 ±1.5 cm) (P = 
0.027). The mean vaginal length of women 
(9.1 ±2.7 cm) who had surgery did not differ 
from the reference value and was on average 
greater than in women who had no treatment 
(8.5 ±2.8 cm) or followed a medical vaginal 
dilation program (7.3 ±1.3 cm), although no 
significant differences were found (Table 2). 
Coital dilation led to a mean vaginal length of 
8.9 cm (±2.6), compared with 7.3 cm (±1.3) 
when dilators were used (not significant 
[ns], P = 0.21). Seven out of 27 (26%) of the 
women had a shortened vaginal length of 
less than 6.6 cm, i.e., more than two standard 
deviations below the mean, irrespective 
of treatment [32] (22% after vaginoplasty, 
20% after vaginal dilation). Two out of the 
three women, who had no treatment, had 
a short vagina. Women with a short vaginal 
length, in both treatment groups alike, had 
a higher incidence of sexual dysfunction 
compared with those with a normal vaginal 
length (75% vs. 14%, respectively); however, 
because of the small numbers, this did not 
reach statistical significance (P = 0.088). No 
significant association was found between 
vaginal length and having had intercourse 
in the last 4 weeks (8.2 cm vs. 8.7 cm, P = 
0.723). Significant correlations were found 
between vaginal length and arousal (R = 
0.471, P = 0.015) and between vaginal length 
and orgasm (R = 0.409, P = 0.047). Because 
the vaginal length of only two women with 
MRKH could be measured (M = 8 cm), 
no meaningful comparison with the 25 
women with a disorder in androgen action 
or synthesis could be made (M = 8.5 cm). 
Specific data for the 19 women with CAIS 
are provided in Table 4. Overall mean (range) 
vaginal length was 7.8 cm (4.5–12 cm), which 
was significantly shorter than the published 
mean value (9.6 ±1.5 cm) (P = 0.004). Five out 
of 17 had a shortened vaginal length of less 
than 6.6 cm, irrespective of treatment. The 
four women, who underwent surgery, had 
on average a larger vaginal length (8.8 ±2.9 
cm) than the 12 women who dilated coitally 
(8.1 ±2.2 cm) or with dilators (7.3 ±1.4 cm), 
although not significant.
Complications at Follow-Up
At gynecological examination, three out of 
nine women (30%) in the vaginoplasty group 
displayed complications. No resurgery was 
required at the time of follow-up. However, 
six out of 15 women had had multiple 
operations in the past because of vaginal 
insufficiency or complications (strictures, 
excessive mucus production). Median time 
between the first and second surgery was 1.5 
years (2 months–10 years). No meaningful 
comparison of the complication rate after 
different types of surgery could be made 
because of the small numbers.
Cosmetic Outcome, Genital, 
and Body Image Satisfaction  
The patient and gynecologist scored different 
parts of the external genitalia (vagina, clitoris, 
labia majora, and labia minora) on a 10-point 
scale (Table 2). Gynecologists, in contrast 
with patients themselves, scored the genital 
appearance of women who had surgery 
significantly lower than women who dilated 
(regular coitus and Frank dilation combined) 
(M = 6.86 vs. 8.2, P = 0.01).
Participants were also asked to rate 
satisfaction with their genital and total body 
image on a 1–5 scale, with higher scores 
indicating more dissatisfaction. Women who 
had surgery reported more dissatisfaction 
with their genital and total body image than 
women who dilated (regular coitus and Frank 
dilation combined) (M = 2.78 vs. 2.6, P = 
0.642 for genitals; M = 2.47 vs. 2.31, P = 0.650 
for total body), but no statistical difference 
was reached. A positive association was 
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FSFI total  31.2 (3.9)  21.3 (9.6)† N = 17  6.2 (NA) N = 1  21.9 (9.5)† N = 8  22.7 (9.3)† N = 8  19.2 (4.9) N = 2  23.8 (10.5) N = 6
Adjusted total FSFI   24.2 (5.0) N = 22  24.8 (NA) N = 1  23.9 (5.7) N = 11  24.6 (4.8) N = 10 27.6 (4.8) N = 5 21.6 (2.5) N = 5
Desire  4.0 (0.8)  3.5 (1.0)† N = 35 3.4 (0.4) N = 3  3.8 (1.2)† N = 15  3.3 (0.9)† N = 17 2.8 (0.8)‡ N = 8  3.8 (0.6) N = 9
Adjusted desire   3.6 (1.0) N = 32 3.6 (0.0) N = 2  3.9 (1.2) N = 14  3.3 (0.9) N = 16  3.8 (0.6) N = 8  2.8 (0.8) N = 8
Arousal  5.3 (0.8)  3.4 (1.8)† N = 34  3.0 (2.8) N = 3  3.9 (1.9)† N = 14  4.3 (1.5)† N = 17  4.3 (1.0) N = 8  4.3 (2.0) N = 9
Adjusted arousal   4.5 (1.1) N = 31  4.5 (1.3) N = 2  4.3 (1.3) N = 13  4.6 (1.0) N = 16  4.8 (1.2) N = 8  4.3 (1.1) N = 8
Lubrication  5.7 (1.0)  3.7 (2.0)† N = 33  2.2 (2.8) N = 3  3.0 (2.2)† N = 14  4.5 (1.6)† N = 17  4.7 (1.4) N = 8  4.3 (1.8) N = 9
Adjusted lubrication   4.2 (1.6) N = 31  3.3 (3.0) N = 2  3.5 (1.8) N = 13  4.8 (1.1)§ N = 16  4.8 (0.9) N = 8  4.8 (1.3) N = 8
Orgasm  5.1 (1.1)  3.9 (1.8)† N = 32  2.8 (4.0) N = 2  3.6 (1.7)† N = 14  4.3 (1.7)† N = 16  4.3 (1.6) N = 8  4.3 (2.0) N = 8
Adjusted orgasm   4.4 (1.3) N = 29  5.6 (NA) N = 1  4.0 (1.3) N = 13  4.6 (1.4) N = 15  4.9 (1.0) N = 7  4.3 (1.6) N = 8
Satisfaction  5.4 (0.8)  4.5 (1.5)† N = 23  3.2 (NA) N = 1  4.6 (1.4)† N = 10  4.5 (1.7)† N = 12  4.4 (1.8) N = 4  4.5 (1.7) N = 8
Adjusted satisfaction   4.5 (1.1) N = 32  3.6 (1.7) N = 2  4.5 (1.2) N = 14  4.6 (1.0) N = 16  4.9 (1.0) N = 8  4.4 (1.0) N = 8
Pain  5.7 (0.8)  2.9 (2.6)† N = 27  0.0 (0.0) N = 3  3.3 (2.7)† N = 3  3.2 (2.4)† N = 11  2.1 (2.5) N = 5  4.2 (2.2) N = 6
Adjusted pain   3.6 (2.4) N = 24  0.0 (0.0) N = 2  4.1 (2.2) N = 12  3.7 (2.3) N = 10  5.0 (0.7) N = 5  2.4 (2.5) N = 5
FSDS-R distress  5.1 (6.4)  12.2 (10.3)† N = 33  7.7 (1.2) N = 3  13.9 (12.1)† N = 14  11.5 (9.5)† N = 16  9.4 (8.4) N = 7  13.1 (10.5) N = 9
found between genital and total body image 
satisfaction (Rs = 0.409, P = 0.015).
Psychosexual Outcome
Five women out of 35 (14%) had not been 
sexually active within 4 weeks before 
completing the surveys; two of them had 
undergone vaginal surgery and three did 
not have treatment. Sexual activity could 
include caressing, foreplay, masturbation, 
and/or vaginal intercourse. A further 13 
women (37%) specifically had no penile-
vaginal intercourse (four women did not 
have treatment, four women had undergone 
vaginal surgery, and five women had used 
dilators). Reasons for having no intercourse 
were varied: two women reported this was 
physically impossible, three women were 
still virgin, and one woman was involved in 
a homosexual relationship; in seven women, 
no specific reasons were given.
No difference in prevalence of sexual 
difficulties was found between women 
who also participated in the gynecological 
examination and those who only filled out 
psychological questionnaires (P = 0.596, ns).
FSFI
As a group, and irrespective of treatment, 
participants fall below the cutoff score of 
26.55 on the total FSFI score when compared 
with the Dutch test validation population, 
which implies they are significantly at risk 
for sexual difficulties [25] (Table 3). Sixty-five 
percent (11/17) of the participants had a total 
FSFI score below the cutoff score. Lower 
“There was no sex at all, 
not even masturbation after 
the operation. Everything 
related to your vagina was 
dirty, no fun.“
TABLE 3
Data shown as mean (standard deviation, adjusted scores go beyond a 4-week period), *Standardization data for FSFI and FSDS-R were used 
from [23] †Different from the standardization data, P < 0.01, ‡Different from the dilators group, P < 0.05, §Different from the surgery group, P 
< 0.05
Psychosexual outcome grouped according to type of intervention for the vagina.
St data*
(N = 108)
Total patient data
(N = 35)
No coitus 
(N = 3)
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scores were evident in all of the subscales 
equally: desire, arousal, lubrication, orgasm, 
satisfaction, and pain. On the basis of a 
clinical cutoff score of 26.55 or less, we 
determined that 100% of cases in the study 
sample (N = 6/6) were correctly classified 
as not sexually dysfunctional and 72.7% (N 
= 8/11) were correctly classified as sexually 
dysfunctional. The area under the ROC 
curve—as a combined measure of sensitivity 
and specificity— was 0.864, 95% confidence 
interval [0.686, 1]; which indicated the 
ability of the FSFI instrument to correctly 
demonstrate the presence or absence 
of sexual problems in this study sample. 
Women who had undergone treatment 
(surgery or vaginal dilators) did not have 
better FSFI indicators of sexual function than 
those who were untreated (regular coitus). 
When the adjusted FSFI was used, signifi-
cantly more problems with lubrication were 
reported after vaginoplasty than after vaginal 
dilation/coitus (P = 0.025) (Table 3, right 
panel). Within the vaginal dilation group, 
no significant differences were observed 
between the women who followed the 
Frank dilation program and women who 
had regular coitus, except for desire (Table 
3). Women who had a lower FSFI score were 
significantly more dissatisfied with their 
genital appearance (R = -0.553, P = 0.021).
No differences were found between MRKH 
patients and patients with a disorder of 
androgen action or synthesis on both the 
original FSFI and adjusted FSFI. Within 
the CAIS group, all but two women were 
sexually active. A further five women did 
not have sexual intercourse. In five out of 
nine women in whom the total FSFI score 
could be calculated, a score below the 
clinical cutoff of 26.55 was found, indicating 
that they are at risk for developing a sexual 
dysfunction (Table 4).
FSDS-R
Both treatment groups had a mean score 
above the cutoff value of 11 on the FSDS-R 
Used abbreviations: FSFI = Female Sexual Function Index (six domains of the FSFI, range 0–6), total FSFI (combined scores of the six domains, 
2–36); FSDS-R = Female Sexual Distress Scale-Revised (0–52); NA = not appropriate; St data = Standardization data
FSFI total  31.2 (3.9)  21.3 (9.6)† N = 17  6.2 (NA) N = 1  21.9 (9.5)† N = 8  22.7 (9.3)† N = 8  19.2 (4.9) N = 2  23.8 (10.5) N = 6
Adjusted total FSFI   24.2 (5.0) N = 22  24.8 (NA) N = 1  23.9 (5.7) N = 11  24.6 (4.8) N = 10 27.6 (4.8) N = 5 21.6 (2.5) N = 5
Desire  4.0 (0.8)  3.5 (1.0)† N = 35 3.4 (0.4) N = 3  3.8 (1.2)† N = 15  3.3 (0.9)† N = 17 2.8 (0.8)‡ N = 8  3.8 (0.6) N = 9
Adjusted desire   3.6 (1.0) N = 32 3.6 (0.0) N = 2  3.9 (1.2) N = 14  3.3 (0.9) N = 16  3.8 (0.6) N = 8  2.8 (0.8) N = 8
Arousal  5.3 (0.8)  3.4 (1.8)† N = 34  3.0 (2.8) N = 3  3.9 (1.9)† N = 14  4.3 (1.5)† N = 17  4.3 (1.0) N = 8  4.3 (2.0) N = 9
Adjusted arousal   4.5 (1.1) N = 31  4.5 (1.3) N = 2  4.3 (1.3) N = 13  4.6 (1.0) N = 16  4.8 (1.2) N = 8  4.3 (1.1) N = 8
Lubrication  5.7 (1.0)  3.7 (2.0)† N = 33  2.2 (2.8) N = 3  3.0 (2.2)† N = 14  4.5 (1.6)† N = 17  4.7 (1.4) N = 8  4.3 (1.8) N = 9
Adjusted lubrication   4.2 (1.6) N = 31  3.3 (3.0) N = 2  3.5 (1.8) N = 13  4.8 (1.1)§ N = 16  4.8 (0.9) N = 8  4.8 (1.3) N = 8
Orgasm  5.1 (1.1)  3.9 (1.8)† N = 32  2.8 (4.0) N = 2  3.6 (1.7)† N = 14  4.3 (1.7)† N = 16  4.3 (1.6) N = 8  4.3 (2.0) N = 8
Adjusted orgasm   4.4 (1.3) N = 29  5.6 (NA) N = 1  4.0 (1.3) N = 13  4.6 (1.4) N = 15  4.9 (1.0) N = 7  4.3 (1.6) N = 8
Satisfaction  5.4 (0.8)  4.5 (1.5)† N = 23  3.2 (NA) N = 1  4.6 (1.4)† N = 10  4.5 (1.7)† N = 12  4.4 (1.8) N = 4  4.5 (1.7) N = 8
Adjusted satisfaction   4.5 (1.1) N = 32  3.6 (1.7) N = 2  4.5 (1.2) N = 14  4.6 (1.0) N = 16  4.9 (1.0) N = 8  4.4 (1.0) N = 8
Pain  5.7 (0.8)  2.9 (2.6)† N = 27  0.0 (0.0) N = 3  3.3 (2.7)† N = 3  3.2 (2.4)† N = 11  2.1 (2.5) N = 5  4.2 (2.2) N = 6
Adjusted pain   3.6 (2.4) N = 24  0.0 (0.0) N = 2  4.1 (2.2) N = 12  3.7 (2.3) N = 10  5.0 (0.7) N = 5  2.4 (2.5) N = 5
FSDS-R distress  5.1 (6.4)  12.2 (10.3)† N = 33  7.7 (1.2) N = 3  13.9 (12.1)† N = 14  11.5 (9.5)† N = 16  9.4 (8.4) N = 7  13.1 (10.5) N = 9
Surgery 
(N = 15)
Dilation 
(N = 17)
Dilation by coitus
(N = 9)
Dilators
(N = 8)
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and experienced significantly more sexual 
distress than the control group (Table 3). No 
significant difference was found between
the vaginoplasty and dilation group (57% vs. 
50%, P = 0.667). Within the CAIS group, 10/18 
women had a score above 11 on the FSDS-R, 
which indicates that they experience sexual 
distress (Table 4). 
A significant but not clinically relevant 
association was found between sexual distress 
and satisfaction with genital appearance (R 
= 0.389, P = 0.025) but not with total body 
image satisfaction (R = 0.165, P = 0.360).
Combined Score
A score below 26.55 on the FSFI together 
with a score above 11 on the FSDS-R implies 
a sexual dysfunction according to the DSM-
IV-TR [30]. In general, 47% of the women 
(8/17 of whom the total original FSFI and 
FSDS-R score could be determined) had a 
sexual dysfunction vs. 6.5% of the Dutch test 
validation population (P < 0.001). There was 
no statistically significant difference between 
the different treatment groups (43% [3/7] 
after vaginoplasty, 50% [4/8] after vaginal 
dilation/ coitus, P = 0.595).
Psychosexual Counseling
Forty-two percent (13/31) of the women with 
vaginal hypoplasia received psychosexual 
counseling before or during either treatment. 
Only half of the women who attended 
counseling (7/13) thought this was useful. 
Some were already psychologically well 
adjusted and needed little in the way of 
counseling. Others had specific issues 
that they felt needed to be explored more 
such as feelings about infertility and other 
diagnosis related obstacles. Interestingly, 
83% of the women within the dilation group 
were satisfied with the usefulness of the 
psychological care they received, com-
pared with only 20% of the women within the 
vaginoplasty group (P = 0.048).
The influence of specific patient char-
acteristics on the obtained results was further 
explored. Women involved in a current 
relationship experienced less dyspareunia 
than women who had no partner (4.0 vs. 
1.5, P = 0.014). Women above the median 
age of 26 years had more problems with 
lubrication (2.8 vs. 4.4, P = 0.027). No 
associations were found between HRT use 
“My vagina 
is definitely not 
my best friend “
“How can she know. . . 
it 's impossible that she 
understands what I am 
going through. “
Functional and anatomical outcome 
within the CAIS and MRKH group.TABLE 4
CAIS MRKH
Data shown as mean (standard deviation) Used abbreviations: 
Female Sexual Function Index (six domains of the FSFI, range 0–6) 
and total FSFI (combined scores of the six domain, 2–36); FSDS-R 
= Female Sexual Distress Scale-Revised (0–52)
Desire  3.3 (0.9) (N = 19)  3.9 (0.8) (N = 7)
Arousal  3.7 (1.8) (N = 19)  4.5 (1.2) (N = 6)
Lubrication  3.7 (2.1) (N = 19)  3.1 (2.1) (N = 7)
Orgasm  3.8 (1.9) (N = 17)  3.6 (1.4) (N = 7)
Satisfaction  4.1 (1.8) (N = 11)  4.8 (1.3) (N = 6)
Pain  2.3 (2.5) (N = 15)  4.9 (1.6) (N = 7)
Total FSFI  20.7 (10.6) (N = 9)  25.0 (8.3) (N = 5)
FSDS-R  12.8 (9.6) (N = 18)  11.7 (11.9) (N = 6)
Vaginal length  7.8 (2.2) (N = 17)  8.0 (2.8) (N = 2)
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and sexual counseling on the one hand, and 
the prevalence of sexual problems on the 
other hand.
Discussion
Our study findings show that vaginal 
hypoplasia or vaginal aplasia, despite 
treatment, is associated with compromised 
sexual wellness (difficult lubrication and 
dyspareunia), as was found in previous 
studies [14,15,18,33–36]. Eighty-six percent 
of our sample was sexually active, but only 
49% had vaginal intercourse. Although a 
problematic sexual functioning was reported 
in both treatment groups, women who 
had undergone vaginal surgery had more 
complications at follow-up and experienced 
on average more sexual problems, specifically 
with respect to self-reported lubrication. 
This difference was not influenced by the 
underlying diagnosis, nor by compliance 
with estrogen therapy. Age was however 
positively correlated with lubrication 
problems, and women who had had vaginal 
surgery were older than the Frank dilation 
group (presumably reflecting a change in 
clinical practice). 
Other suggested interfering factors are 
the type of vaginoplasty procedure and 
the lack of cervical mucus [27]. Lubrication 
during intercourse is thought to be the 
result of several processes including 
transudation of plasma through the vaginal 
epithelium, secretions from the uterus, and 
the vestibular and Bartholin’s glands [1]. 
Although the vaginal lining may be normal 
in the neovagina created by dilators and 
the Vecchietti and Davydov techniques—in 
contrast to other surgical procedures—it is 
not known whether the blood supply of the 
neovagina and its capacity to produce the 
transudate is adequate. The lack of vestibular 
and Bartholin’s glands, which are a source 
of lubricating secretions during arousal, may 
also be relevant. Whether or not these glands 
are present in women with vaginal hypoplasia 
should be the topic of future studies [1].
Vaginal dilation has been put forward as a 
first-choice treatment, because it is a patient-
driven technique that is easy to perform, cost-
effective, safe, and can be highly successful 
[2,5,13,37]. Sixty-seven percent of the Frank 
dilation patients in this study acquired a 
normal-sized vagina within 3–12 months. 
It also obviates the need for postsurgery 
dilation therapy, which was required in 93% of 
women who underwent surgery. Moreover, 
six out of 15 women (40%) in the vagino-
plasty group needed resurgery, showing that 
these procedures carry significant long-term 
complications, including increased mucus 
production, vaginal prolapse, and strictures. 
The women who had had vaginal surgery 
acknowledged that it was not the “quick 
fix” (and also less emotionally involved) 
“I have sort of a vagina 
now, but it is not a real 
vagina. Every time when we 
have sex I think 'this is 
all so artifical '.“
“I really thought that this 
operation would solve all my 
problems. But that was only the 
beginning. . . my psychological 
status only got worse.  
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procedure that it initially appeared to be. 
However, success of dilation therapy as a 
first-line treatment depends on a large time 
investment and motivation of the patient. 
Forty percent of the vaginoplasty patients 
had tried dilation therapy first but without 
success. The reported problems can be 
summarized as persistent discomfort and 
pain or lack of privacy; the regimen was 
regarded as shameful and “distasteful” [38], 
or reinforced a feeling of being different. 
The profound emotional impact of this 
diagnosis inevitably evokes feelings of 
depression, anger, and loss of self-esteem. 
A poor organization of the therapy with little 
psychological input at that time may also 
reflect the lack of enthusiasm for the dilation 
technique; moreover, most of these patients 
were young (range 14–17 years). Roberts et 
al. [39] found that patients younger than 18 
years at the start of dilation treatment had 
a statistically significant dilation failure rate. 
Our study confirms previous reports that 
the compliance and patient satisfaction are 
generally low in vaginal dilation programs 
[40]. Every unsuccessful attempt will decrease 
the motivation of the young patient and lead 
to emotional instability, which highlights that 
adequate sexual and psychological support is 
an integral part of the management [10].
The description of long-term outcome 
taking into account different pathogenesis 
of vaginal hypoplasia is difficult because 
of several DSD enclosed. However, we 
provided specific data for 19 women with 
CAIS, allowing to further examine the effects 
of androgen deficiency on sexual function. 
Androgens are thought to influence sexual 
function in females by their affects on sexual 
motivation and desire [40]. When compared 
with the MRKH and the Dutch control group, 
desire and arousal scores in the CAIS group 
were lower, but 79% and 84% of the CAIS 
sample yielded scores within normal limits 
for desire and arousal, respectively. Vaginal 
hypoplasia and various psychological factors 
undoubtedly also impact sexual functioning 
in women with CAIS [40].
We recognize several weaknesses of this 
study. First, there was a potential selection 
bias, because participants in this study were 
recruited exclusively from a clinical sample. 
Further studies should also recruit from 
other samples such as peer-support groups. 
Additionally, data on nonresponders should 
be gathered. Fewer than half of the eligible 
women approached actually participated in 
the study, indicating that physical aspects 
of female sexuality are still a very sensitive 
subject. Second, due to the rarity of the 
condition, the actual number of patients did 
not lend itself to robust regression analyses. 
Because the sample of patients who followed 
a vaginal dilation program was rather small 
to draw definite conclusions, we included 
patients who created a sufficient vagina by 
coitus alone in this group. Although coitus 
can be considered as a form of dilation (with 
the penis as only dilator size) this might have 
influenced the results. Meanwhile, it has been 
demonstrated that the dimensions of the 
neovaginal increase at coitus is comparable 
in magnitude with the normal vagina. In 
young women with an understanding and 
“There was a time when for 
me the purpose of sex was just 
to keep the vagina open, to 
keep it dilated. That feels very 
double. It 's like a pornstar 
saying 'Sex is my job, but 
I don't enjoy it '. “
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cooperative sexual partner, the possibility 
of coital dilation should be taken into 
consideration as one of the available 
therapeutic procedures. Additionally, those 
women who had undergone treatments for 
vaginal hypoplasia had similar sexual function 
scores to women who had not undergone 
any treatment. It is likely that those offered 
treatment for vaginal hypoplasia were a 
group with more severe vaginal hypoplasia, 
so no definite conclusions can be made on 
the impact of vaginal hypoplasia treatment 
on the incidence of sexual difficulty. These 
results do suggest, however, that any 
treatment for vaginal hypoplasia may be 
of limited usefulness without concomitant 
psychological expertise to address other 
aspects of self-perception. 
Third, because randomization to the two 
treatments was not conducted, we mea-
sured several important confounders, such 
as age, HRT, genital appearance, satisfaction 
with total body image, and psychosexual 
counseling, which could influence sexual 
functioning. However, the long-term 
assessment of vaginal reconstruction 
methods remains difficult, and complications 
may be troublesome many years after the 
primary procedure. Patient satisfaction will 
be influenced as well by the procedure as 
the clinical (e.g., hormonal treatments) and 
psychosocial implications (e.g., infertility) 
of the underlying condition. Lastly, this was 
a retrospective study with a cross-sectional 
design, which does not permit interpretation 
of causal relationships. No information was 
available on vaginal length or psychosexual 
functioning and expectations of the 
participants before treatment. Prospective, 
longitudinal studies with a focus on 
diagnosis-related success rates (e.g., CAIS 
cases with distal third vaginal remnant vs. 
cases with vaginal aplasia or MRKH) should 
be undertaken. Comparison with normative 
data from other gynecological conditions 
may also be worthwhile.
Conclusion
The findings in this study have implications 
for clinical management as they suggest 
that long-term psychosexual outcome after 
vaginal dilation is at least equivalent to that 
of vaginoplasty. It appears reasonable to 
consider self-dilation as the first therapeutic 
procedure. However, if it wants to reach a high 
success rate, gradual self-dilation has to be 
supported by an expert multidisciplinary team 
that integrates endocrinology, gynecology, 
sexology, and clinical psychology expertise. 
Failed dilation therapy for neovaginal 
creation does not preclude subsequent 
surgical reconstruction. Equal priority should 
be given to quality of life outcomes, including 
psychosexual treatments, as is currently 
given to the traditional clinical concerns such 
as anatomical outcome [40]. Psychological 
counseling as both a primary and adjuvant 
treatment has a clear role in discussing any 
aspects of this lifelong condition. Further 
studies must clarify the multiple obstacles for 
women in different age groups and life stages 
“Women have scars from 
giving birth. In contrast, I have 
scars because I cannot. Every time 
you see yourself naked in the 
mirror, you notice that scar, 
reminding you of the operation and 
your syndrome. Every day again, 
despite the fact you are used to it. “
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and emphasize objective outcomes in a pro-
spective way using validated questionnaires 
for patients and partners, in addition to 
clinical examinations and patient interviews.
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Introduction. Indications that the prenatal action of testosterone in the brain is an important 
determinant of gender development and improved reconstructive techniques have caused 
a shift in male gender assignments in patients with 46,XY disorders of sex development. We 
report long-term outcome data on psychosexual development and sexual function of these 
individuals in a cross-sectional study. 
Materials and Methods. Physical status of 14 men with a mean age of 25 years with disorders 
of sex development was assessed by a structured interview and physical examination. 
Psychosexual outcome was evaluated by questionnaires and compared to a control group of 
46 healthy, age matched men.
Results. A total of 13 men underwent 1 to 6 (mean 2) genital surgeries. Mean age at first surgery 
was 2.7 years. Mean penile length was 6.6 cm. All men reported erections and were able to 
experience orgasms. Ejaculatory dysfunction was reported by 7 men. Mean penile length was 
7.9 cm in patients who were able to achieve penetrative intercourse and 4.9 cm in those who 
were not. Meatus was glanular in 5 patients, coronal in 7 and at the distal shaft in 1. Compared 
to controls, men with disorders of sex development were less satisfied with the appearance of 
the penis and scrotum but not with the total body image. These patients reported decreased 
sexual desire and activities.
Conclusion. Outcome in this group of men with disorders of sex development was poor 
regarding penile length, ejaculation, satisfaction with external genitalia and frequency of sexual 
activity. Other aspects, such as overall body image and psychosexual functioning, showed no 
difference from controls.
Key Words. body image; disorders of sex development; follow-up studies; sex reassignment 
surgery; urologic surgical procedures, male
2.3 
Long-Term Outcomes in Males 
with Disorders of Sex Development 
Introduction 
Disorders of sex development (DSD) are 
defined as congenital conditions involving 
atypical development of chromosomal, 
gonadal or anatomical sex [1]. The underlying 
chromosomal constitution of infants 
with markedly ambiguous genitalia may 
be 46,XY, 46,XX or a mosaic pattern. Of 
patients with DSD of sex development and 
46,XY hypovirilization syndromes a specific 
diagnosis can be made in only 20% [2]. 
Improved reconstructive techniques and 
observations of gender dysphoria and a wish 
for a gender role change in patients with 
46,XY hypovirilization raised as girls resulted 
ABSTRACT
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in more male sex assignments in the last 
decades, particularly in patients with less 
severe hypovirilization [1,3-7]. The aim of 
masculinizing surgery in patients with DSD 
is to improve cosmesis and function of the 
external genitalia, to enable sexual intercourse 
and to avoid stigmatization. Therefore, it is 
important to assess the functional and sexual 
outcomes of these patients. There have 
been a limited number of outcomes studies 
in males with DSD, including those with an 
undefined 46,XY condition [5,8-12]. However, 
studies with combined data on urological 
and in-depth psychological examination 
in relation to surgical history are scarce. 
We investigated the long-term physical, 
functional and psychosexual outcomes in 
males with DSD in a cross-sectional study.
Methods
A total of 37 males with DSD older than 14 years 
identified at 2 university hospitals between 
2007 and 2009, were invited to participate. 
Of these individuals, 14 (37%) participated, 
including 9 from Erasmus MC Rotterdam and 
5 from Radboud University Nijmegen Medical 
Center. Inclusion was based on diagnosis of 
DSD and phenotype (i.e. proximal hypospadias 
and unilateral/bilateral cryptorchidism). The 
study was approved by the medical ethics 
committees of both centers. All participants 
were informed about the study and signed a 
written consent form. Participant responses to 
the Male Sexual Health Questionnaire (MSHQ) 
were compared with those of a control group 
of 46 male students with a median age of 21.5 
years (range 18 to 36) who volunteered to 
participate in the study.
Data on genital appearance at birth and gen-
ital surgeries were retrospectively collected 
from the medical files. Subsequently, par-
ticipants underwent a urological exa-
mination, hormonal analysis and psy-
chological assessment between 2007 and 
2009. LH, FSH and serum testosterone levels 
were determined as described previously [13].
Surgeries were divided in hypospadias repair 
and additional procedures. Patients were 
grouped based on diagnosis. Cases without 
a molecular diagnosis were classified as 
undefined 46,XY DSD.
Standardized urological examination 
consisted of visual inspection (general 
impression, testes, localization and shape of 
meatus, penile curvature, distortion, peno-
scrotal transposition) and measurements 
(testis volume, penile circumference, 
stretched penile length, self-measured degree 
of curvature). The examiners had not been 
involved in the medical care of these patients.
Psychosexual functioning and satisfaction with 
genital image were assessed by questionnaires 
and a semistructured interview administered 
by psychologists not involved in the care 
of the patients. The MSHQ is a validated, 
self-administered instrument for assessing 
problems in the primary domains of erection, 
ejaculation and sexual satisfaction in men [14]. 
Aspects of sexual functioning and problems, 
as well as satisfaction with (surgical) treatment 
and impact of treatment on psychosexual 
functioning were addressed in the interview. 
Satisfaction with body appearance and 
appearance of the external genitalia was 
assessed using a 5-point Likert scale [15]. 
Comparisons between groups were done 
using the chi-square test for categorical 
variables and Student t-test for continuous 
variables. MSHQ scores were compared 
using a Mann-Whitney U test (not normally 
distributed). A p value of less than 0.05 was 
considered significant.
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Results
Participants
Of the 37 men invited to participate, 14 
agreed (response rate 37%). Mean age was 
25 years (range 14 to 32). There were no 
significant differences between participants 
and nonresponders regarding age (p= 0.81), 
diagnosis (p= 0.5) or number of hypospadias 
repairs (p= 0.97).
Characteristics of the participants are 
presented in the Appendix. One patient with 
45,X/46,XY DSD who presented with bilateral 
cryptorchidism without hypospadias at age 
8 months was excluded from the functional 
and psychosexual analyses. The others had 
been diagnosed at birth with hypospadias and 
cryptorchidism. Family history was positive in 
3 patients and consanguinity in 2. Based on 
Dutch reference data for age 21 years, height 
was below -2 SD in 5 men and borderline 
( 1.98 SD) in 1 man [16].
Of the 6 men with undefined 46,XY DSD, 
1 had a positive family history of proximal 
hypospadias. This patient was diagnosed with 
morbid obesity (body mass index 44 kg/m2), 
hypergonadotropic hypogonadism and small 
testes. Semen analysis revealed azoosper-
mia. Medical history consisted of unilateral 
testicular torsion, utricular cyst and epidid-
ymitis. Hormonal analysis, including human 
chorionic gonadotropin, adrenocorticotropic 
hormone and gonadotropin-releasing 
hormone tests, was normal. Genetic analysis 
of the androgen receptor was negative.
One man with undefined 46,XY DSD 
was suspected of having a 5α-reductase 
deficiency. Sequencing of the SRD5A2 gene 
did not demonstrate any abnormalities, but 
enzyme function was impaired in fibroblasts 
in vitro. In the remaining 4 patients with 
undefined 46,XY DSD, testosterone synthesis 
disorders were excluded, and sequencing of 
the androgen receptor gene did not show 
any abnormalities.
Surgeries and Urological Examinations
A total of 13 men underwent hypospadias 
correction involving a mean of 2 surgeries 
(range 1 to 6). Mean age at first surgery was 
2.7 years (range 3 months to 6 years). The 
undefined 46,XY DSD group differed from 
the other diagnostic groups with respect to a 
larger variation in age at first surgery. No other 
differences between groups were found. The 
groups were too small to assign statistical 
significance. One man with undefined 46,XY 
DSD had undergone 6 surgical procedures for 
hypospadias repair. One patient in the mixed 
gonadal dysgenesis (GD) group did not have 
hypospadias. Repeat surgery was needed 
in another patient with mixed GD at age 17. 
The other surgeries consisted of hypospadias 
repair in 2 planned sessions.
Additional procedures are listed in Table 
1. Both patients with partial androgen 
insensitivity syndrome (PAIS) had undergone 
gynecomastia correction, of whom 1 needed 
correction of recurrence after 1.5 years. 
Gonadectomy was performed in 4 patients. In 
the ovotesticular DSD group, all patients had 
a histologically confirmed ovotestis. One of 
these patients had undergone gonadectomy 
on the right and orchiopexy on the left side 
plus biopsy. In 2 patients a streak gonad 
was found, both of whom had a mosaic 
chromosomal constitution. Histological 
review of the gonadal tissue did not reveal signs 
of malignancy. The results of the urological 
examination are listed in the supplementary 
table. Mean penile length was 6.6 cm (range 4.2 
to 10.5), which was below -2.5 SD. Four men 
had a curvature of more than 10 to 60 degrees 
during erection. The meatus was glanular in 5 
patients, coronal in 7 and on the distal shaft in 1.
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Functional Assessment
All men reported erections and were able to 
experience an orgasm. Abnormal ejaculation 
was present in 7 men, of whom 3 were 
on androgen replacement. Two patients 
experienced dry ejaculations most of the 
time and 1 had dry ejaculations half of the 
time. Two men complained about the small 
amount of ejaculate (a couple of droplets), 
and 2 experienced weak ejaculation. The 
8 men who reported achieving penetrative 
intercourse had a mean penile length of 7.9 
cm, which was significantly greater than in 
the 4 not achieving penetrative intercourse 
(4.9 cm, p= 0.028).
Serum LH, FSH and testosterone measure-
ments demonstrated hypergonadotropic 
hypogonadism in the 3 patients with mixed 
GD (LH 18.7, 22.3 and 27.3 IU/L, FSH 46.6, 
66.0 and 54.4 IU/L and testosterone 7.0, 4.2 
and 2.7 nmol/L, respectively). All of these 
patients were on testosterone replacement 
therapy (Sustanon® 250 or testosterone 
undecanoate) after gonadectomy and 
thus had signs of under treatment. The 
remaining patient (with ovotesticular DSD) 
who was on testosterone replacement after 
gonadectomy, had slightly increased FSH 
values (11.1 IU/L) but normal LH (1.15 IU/L) and 
testos-terone values (19.5 nmol/L). The two 
patients with PAIS had high levels of LH (19.8 
and 12.4 IU/L) and testosterone (63.7 and 28.7 
nmol/L). The 6 men with undefined DSD had 
normal male values (2 patients) or increased 
FSH values and normal LH and testosterone 
levels (4). There was no relationship between 
libido and testosterone values (p= 0.892).
Men with sufficient urine volume (greater 
than 100 cc) during flow measurement (8 
patients) showed a mean maximum flow 
rate of 20.6 ml per second. One patient had 
a plateau curve and the others had a normal 
curve.
Men with DSD were significantly less satisfied 
with the appearance (p< 0.001), color (p< 
0.001), thickness (p= 0.03) and size (flaccid 
p< 0.001 and erect p< 0.001) of the penis, 
as well as the scrotum (p< 0.001) and size 
of the testes (p< 0.001) compared to the 
control group. Participants were dissatisfied 
regarding penile size (small), scrotum (asym-
TABLE 1
Used abbreviations: PAIS= Partial Androgen Insensitivity Syndrome;  Mixed GD= Mixed Gonadal Dysgenesis; DSD= Disorders of Sex 
Development: Pts= Patients; yrs= years
Surgical procedures.
Mean yrs age at first 
hypospadias repair (range)  3.3 (1.5–5.0)  3 (2.5–3.5)  3.2 (2.0–5.0)  2.3 (0.3–6)  2.7 (0.3–6.0)
Mean No. hypospadias 
repairs (range)  1 (1–1)  1.3 (0–2)  2 (1–3)  2.5 (1–6)  1.9 (0–6)
No. additional procedures:
      Inguinal herniorrhaphy  2  1  2  2  7
      Orchiopexy  2  1  2  2  7
      Penoscrotal transpositioning  2  0  0  0  2
      Gynecomastia correction  3  0  0  0  3
      Gonadectomy  0  2  2  0  4
      Fistula repair  1 0  0  2  3
      Utriculus excision  0  0  1  1  2
Totals  10  4  7  7  28
PAIS Mixed GD
Ovotesticular 
DSD
Undefined 46,XY 
DSD All Pts
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metry) and testes (too small). Satisfaction with 
the amount or appearance of pubic hair did 
not differ between participants and controls. 
There was also no difference in satisfaction 
with secondary sex characteristics (voice, 
body hair, facial hair, breasts, hips and Adam’s 
apple, p= 0.489) and nonsexual characteristic 
body parts (p= 0.267) or total body image 
between participants and controls (p= 
0.098). Six of the 10 men who answered 
the question, perceived that their sexual 
development was negatively influenced by 
their genital appearance. Only 3 men felt they 
were sexually hampered, especially regarding 
penile size.
Psychological Assessment
Detailed psychosexual functioning was 
assessed in 11 participants. One adolescent 
(14 years) had no sexual experience, and 
1 man (19 years) refused to complete the 
MSHQ. Mean age at first coitus was 18 years 
(range 15 to 23).
Frequency of sexual activity differed 
significantly between patients and controls. 
Of the controls 76% had been involved in 
sexual activities more than 6 times in the 
month preceding the study, compared to 18% 
of the patients (p< 0.001,  Table 2). One man 
(18 years) never had sex due to the absence 
of sexual desire and arousal, difficulties with 
erection and orgasm, and lack of a partner. 
Another man tried to avoid sex as much as 
possible but gave no further explanation. 
These statements suggest that both men 
might be asexual. Others reported difficulties 
with erection and orgasm (1 patient), low 
arousal (1 patient) and having no partner (1 
patient). The distress related to the frequency 
of sexual activity did not differ significantly 
between patients and controls. The same 
held true for the proportion of men involved 
in a steady relationship and satisfaction 
with sexual relationship. Ten out of 11 men 
had a heterosexual orientation and 1 had a 
homosexual orientation. No subject reported 
gender dysphoria. Men with DSD reported on
average more difficulties than men without 
DSD, although the difference did not reach 
significance, except regarding frequency 
of desire to have sex and problems with 
firmness of the erection ( Table 2).
Discussion
This study evaluates the long-term outcome 
in males with DSD. We found that mean 
penile length of postpubertal patients 
with DSD was below -2 SD and that penile 
Male Sexual Health 
Questionnaire results.TABLE 2
Controls Pts with DSD p-value
*p<  0.05 (2-tailed Mann-Whitney U test). † Based on 5 items 
(overall sexual relationship, quality of sex life, frequency of sexual 
activity with partner, communication about sex with partner and 
affection during sex).
Sexual frequency/mo:
 No. 0 (%)  0 (0)  3 (27)
 No. 1–6 (%)  11 (24)  6 (55)
 No. > 6-almost daily (%)  35 (76)  2 (18)
 Mean ±F SD frequency  4.0 ± 1.0  2.6 ± 1.4  0.002*
 Mean ± SD distress  1.6 ± 0.9  1.8 ± 1.3  0.900
Partner:
 No. with partner (%)  21 (46)  5 (45)  0.805
 Mean ± SD satisfaction†  4.4 ± 1.0  4.4 ± 0.8  0.610
Mean ± SD desire:
 Frequency  3.9 ± 0.6  3.3 ± 0.9  0.016*
 Level  3.8 ± 0.7  3.4 ± 0.9  0.121
 Distress  2.0 ± 0.8  1.9 ± 1.0  0.534
Mean ± SD erection:
 Frequency  4.7 ± 0.6  4.2 ± 1.2  0.155
 Frequency of 
 maintaining erection  4.6 ± 0.6  4.2 ± 1.3 0.465
 Firmness of erection  4.7 ± 0.6  3.8 ± 1.2  0.006*
 Distress  1.4 ± 1.1  1.3 ± 0.6  0.988
Mean ± SD ejaculation:
 Frequency  4.8 ± 0.5  3.7 ± 1.8 0.052
 Frequency dry orgasm  1.2 ± 0.6  1.5 ± 1.2  0.342
 Frequency 
 delayed ejaculation  1.5 ± 0.7  1.2 ± 0.9  0.222
 Force  4.7 ± 0.6  3.8 ± 2.1  0.395
 Vol  4.8 ± 0.5  4.2 ± 2.2  0.583
 Pain  1.2 ± 0.5  1.4 ± 1.6  0.394
 Distress  1.2 ± 0.6  1.3 ± 0.6  0.786
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length is correlated to the ability to achieve 
penetrative intercourse. Moreover, abnor-
mal ejaculations are common. The incidence 
of male gender assignment is increasing due 
to the awareness of prenatal testosterone 
effect on gender development, improved 
surgical techniques and change in attitudes 
toward tolerance of genital anomalies 
[1,5,6,12]. Generally, males with DSD need 
extensive genital surgery. The severity of 
hypospadias is correlated with adult penile 
length [17]. In our study, all but 1 patient had 
a history of hypospadias repair. The patient 
without hypospadias repair presented with 
an undescended testis and slight scrotal 
asymmetry, which triggered chromosomal 
analysis that revealed 45,X/46,XY mosaic 
DSD.
Mean penile length was below -2.5 SD. Mean 
adult penile length is 13.3 cm (SD 1.6) [18].
Reilly and Woodhouse reported the absence 
of a relationship between sexual functioning 
and penile length and the ability of men with 
a microphallus to achieve satisfactory sexual 
intercourse [19]. In our study the men who 
were able to achieve penetrative intercourse 
had a significantly greater mean penile length 
than those who were unable to do so. Phallo-
plasty might be an option for men who fail 
to achieve penetrative intercourse and are 
dissatisfied with this. However, there is little 
experience with the procedure, and long-
term results are lacking [20].
Men with DSD were less satisfied than 
controls with penile appearance, color, size 
and girth. This finding is in line with other 
studies demonstrating that small penile 
size is a major cause of dissatisfaction [9,21]. 
Sircili et al found that penile length is not 
significantly related to satisfaction with 
surgical results [11]. Patients in our study 
were significantly more dissatisfied with their 
genital image compared to controls, and 
those with a shorter penile length were the 
most dissatisfied. Interestingly, satisfaction 
with secondary sex characteristics and more 
neutral body parts did not differ significantly. 
This finding suggests that genital image and 
acceptance need special attention during 
psychosexual counseling of boys with DSD.
Our study confirms that males with DSD in 
general experience erections and orgasms. 
However, half of our study population 
reported abnormal ejaculation, as described 
previously [22,23]. Schönbucher et al re-
ported an increased incidence of sexual 
dysfunction and an overall low sexual quality 
of life in males with 46,XY DSD [24]. In our 
study, equivalent numbers of men with 
DSD and controls were involved in a steady 
relationship, and satisfaction with the partner 
and the sexual relationship did not differ be-
tween these groups. Men with DSD tended 
to be less sexually active and reported more 
erectile problems. However, no significant 
differences were found in terms of distress or 
dissatisfaction. The frequency of desire was 
significantly decreased in men with DSD, but 
not the intensity. Finally, sexual orientation 
was heterosexual in all but 1 patient, which is 
in line with previous studies [9,24].
Our study has some limitations that need to 
be addressed. First, the study had a cross-
sectional design, and some of the data 
were retrospectively retrieved from medical 
files. In addition, 61% of the men with DSD 
declined participation for unknown reasons. 
Therefore, our data might not be represen-
tative of the total group. Furthermore, sexual 
functioning was measured with the MSHQ, 
which inquires about sexual problems in 
the prior 4 weeks only and was designed to 
assess sexual problems in males. Regrettably, 
there are no validated questionnaires 
focusing on sexual impairment due to DSD. 
Lastly, the power of statistical analyses was 
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limited due to the small sample size and, 
therefore, associations might not have 
reached significant differences.
In conclusion, the outcome in this group of 
men with DSD was poor regarding penile 
length, ejaculation, satisfaction with external 
genitalia and frequency of sexual activity. 
Other aspects such as overall body image 
and psychosexual functioning showed no 
difference from controls.
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14  46 XY  Undefined 46 XY DSD  no  Negative
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116 SUPPLEMENTARY TABLE Physical examination results.
1 - 1.55 23 feminine inguinal 10/15 -
2   0.05 23 absent scrotal 15/20 6
3 -3.39 27 male scrotal 8/20 -
4 -3.67 20 feminine scrotal 0/8 8.5
5 -1.98 27 male scrotal prostheses 10 -
6 -2.97 25 male absent  0/<1 -
7 -2.12 18 male scrotal prostheses 10 9.2
8     -  - feminine scrotal 12/8 -
9 -2.40 20 male scrotal 10/0 -
10 -0.28 44 male scrotal 8 9
11 -0.99 28 male scrotal 10 8
12 -1.20 27 male high scrotal 8/25 9.5
13   0.01 24 male scrotal 10 12.5
14   0.15 21 feminine scrotal 30/35 10
Hair growth
Height
(SDS) BMI
position testis Volume testis (ml)
left/right
circumference
penis (cm)
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4.2 non non coronary irregular no
5 non non coronary irregular no
5.4 45° ventral non coronary irregular yes
7 30° lateral 30° left coronary irregular no
10.5 non non top glans vertical slit-shaped no
7 non non distal shaft vertical slit-shaped no
9.7 10°dorsal non top glans vertical slit-shaped no
- - - - - -
8 10° ventral non low glandular irregular no
5 non 10° left midglandular irregular yes
6 non non midglandular vertical slit-shaped no
5 20°dorsal non coronary horizontal no
6 60° ventral non low glandular irregular no
7.5 non 40° right top glans vertical slit-shaped no
Streched penile 
length (cm)
Curvature
penis
Distortion
penis
Penoscrotal
transpositionMeatus Shape meatus
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CHAPTER 3
Self-perceived genital 
anatomy and sensitivity 
in women without DSD 
and genital surgery
I was worried about vaginas. I was worried about what 
we think about vaginas, and even more worried that we 
don't think about them…There's so much darkness and 
secrecy surrounding them—like the Bermuda Triangle. 
Nobody ever reports back from there.
Eve Ensler – The Vagina Monologues
Based on:
Bronselaer, G*, Callens, N*, De Sutter, P., De Cuypere, G., T’Sjoen, G., Cools, M., Hoebeke, 
P. Self-Assessment of Genital Anatomy and Sexual Function in women (SAGAS-F): Validation 
within a Belgian, Dutch-Speaking Population, J Sex Med, 2013, in press.
*joint first authorship
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Introduction. Data on self-perceived genital anatomy and sensitivity should be part of the 
long-term follow-up of genitoplasty procedures. However, no normative data, based on a large 
sample, exist to date.
Aims. Validation of the Self-Assessment of Genital Anatomy and Sexual Function, Female 
version (SAGAS-F) questionnaire within a Belgian, Dutch-speaking female population.
Methods. Seven hundred forty-nine women with no history of genital surgery (aged 18–69 
years, median 25 years) completed an Internet-based survey of whom 21 women underwent 
a gynecological examination as to correlate self-reported genital sensitivity assessed in an 
experimental setting.
Mean Outcome Measures. The SAGAS-F enables women to rate the sexual pleasure, discomfort, 
intensity of orgasm, and effort required for achieving orgasm in specified areas around the 
clitoris and within the vagina, as well as genital appearance. The latter was similarly evaluated 
by an experienced gynecologist, and women were asked to functionally rate the anatomical 
areas pointed out with a vaginal swab.
Results. Sexual pleasure and orgasm were strongest, and effort to attain orgasm and discomfort 
was lowest when stimulating the clitoris and sides of the clitoris (P<.05). Vaginal sensitivity 
increased with increasing vaginal depth, but overall orgasmic sensitivity was lower as compared 
with the clitoris. Functional scores on the SAGAS-F and during gynecological examination 
corresponded highly on most anatomical areas (P<.05). Gynecologist’s ratings corresponded 
highly with the women’s ratings for vaginal size (90%) but not for clitoral size (48%).
Conclusion. Replication of the original pilot study results support the validity of the questionnaire. 
The SAGAS-F discriminates reasonably well between various genital areas in terms of erotic 
sensitivity. The clitoris itself appeared to be the most sensitive, consistent with maximum nerve 
density in this area. Surgery to the clitoris could disrupt neurological pathways and compromise 
erotic sensation and pleasure. 
3.1 
Self-Assessment of Genital Anatomy 
and Sexual Function within a Belgian, 
Dutch-Speaking Female Population:
A Validation Study
ABSTRACT
Key Words. Self-Assessment; Genital Anatomy; Genital Sensitivity; Sexual Function
Introduction
There is a consensus between multidisciplinary
teams treating disorders of sex development 
(DSD) that surgical genitoplasty procedures in 
females should be minimized and performed 
if possible according to the patients’ needs 
and with the patients’ consent, mainly in 
puberty and adulthood. Additionally, previous 
studies have shown that up to 80% required 
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further procedures to permit sexual function 
[1,2]. The long-term outcome of (childhood) 
genital surgery on sexual function in 
adulthood has been recently investigated 
extensively, with both positive and negative 
psychosocial and psychosexual outcomes 
[3–11]. However, only few reports considered 
systematic assessment of genital sensitivity 
and sexual function, whereas the latter, 
and particularly the experience of orgasm, 
appears to be closely related to sensitivity 
[12–14]. Genital surgery risks disruption of 
nerves and blood vessels, which may impair 
sensation to the genital area and aff ect future 
capacity for sexual pleasure [15,16]. On the 
other hand, it was argued that subjects may 
have normal objective-evoked responses 
or thermal/vibratory genital sensation in 
a laboratory setting, yet have little or no 
perceived sensation to sexual stimulation or 
capacity for orgasm in a real-life situation 
[17]. Moreover, although the provider (sur-
geon) may be pleased with the clinical 
outcome (such as cosmesis, structural and 
anatomical integrity, or coital capacity of 
the vagina), equal priority should be given 
to erotic sensitivity and orgasmic capacity, 
as judged by the patient. Discrepancies 
between physiological and subjective erotic 
responses are well documented in women 
[18]. Therefore, assessment of self-reported 
genital sensation and comparison between 
patients with and without a history of genital 
surgery is highly needed, but no normative 
data, based on a large sample, exist to date.
Aims
Tools are needed to systematically assess the
eff ects of surgical genital modifi cation on 
sexual sensitivity and orgasmic capacity, 
as reported by the patient, and to assess 
sensitivity of the human genitalia for relevant 
sexual stimulation in contrast to vibratory and 
hot/cold sensory input. The Self-Assessment 
of Genital Anatomy and Sexual Function, 
Female version (SAGAS-F) was originally 
designed to obtain a woman’s perception of 
what her genitals look like and to map her 
experience of cutaneous sensitivity, sexual 
pleasure, discomfort/pain, and orgasm 
across specifi c areas of her genital region 
[19]. The primary objective of the present 
study is to validate this questionnaire in a 
sample of Belgian, Dutch-speaking women 
and specifi cally to investigate whether a 
large population of women without genital 
surgeries can discriminate between various 
genital areas in terms of erotic function.
Methods
Participants and Procedure
Respondents were recruited by means of 
leafl ets that were randomly distributed 
at railway stations in Flanders to ensure 
participation of native Dutch speakers 
between January 2010 and May 2012. The 
leafl et explained that Ghent University was 
conducting a study on women’s sexuality 
and provided a URL for more information 
about the study. Each woman was invited 
to fi ll out an Internet-based questionnaire 
and was instructed in a cover sheet that by 
completing the questionnaire, she gave 
informed consent. Participants’ privacy and 
confi dentiality were protected by the use of 
a secured, anonymous database. We ensured 
that each response represented a unique 
individual participant.
To be included in this study, the women 
needed to be older than 18 years of age and 
sexually active in the last year. Quality control 
was assured by repetitive questions.Women 
with gross inconsistencies on these check 
questions were excluded from analysis. For 
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the gynecological examination, women were 
recruited through the same information 
leafl et between December 2012 and April 
2013 but were also asked to leave contact 
information. Two weeks after fi lling out the 
questionnaires, these women were invited 
to the University Hospital Ghent for the 
gynecological examination. Ethics approval 
was granted by the joint university and 
hospital ethics committee (EC2009/629).
Measures
Biographic Questionnaire
Relevant medical and demographic data 
were obtained. Additionally, the gender of 
their sexual partner(s) was assessed in a 
closed format (“my sexual partner[s] is [are] 
male, female, or both male and female”).
Assessment of Genital Anatomy 
and Sensitivity
The original version of the SAGAS-F [12] was
translated into Dutch by two independent 
persons. Consensus between the translators 
was sought in case of inconsistency. The fi nal 
version was back translated by a native Eng-
lish speaker and did not lead to substantial 
loss of information. In the original SAGAS-F, 
the participants are asked to select one of 
several options of appearance, size and 
position of clitoris, vagina, and labia minora 
and majora. In addition, they rated on fi ve-
point Likert scales the sexual pleasure, 
discomfort/ pain, orgasmic intensity, and 
eff ort for achieving orgasm for several 
graphically and verbally demarcated areas at 
and around the external genitalia, vagina, and 
anus (e.g., “sexual touch/stimulation of the 
area above the clitoris [area A] by a partner 
or yourself has produced sexual pleasure”: 1, 
none; 2, mild; 3, moderate; 4, strong; 5, very 
strong) (Figure 1).
Gynecological Examination
Women were placed in the lithotomy 
position. An experienced female gyne-
Figure 1
Figure 1. External genital areas (A–H) and vaginal areas (I–K)
Above clitoris (A) On clitoris (B) Sides of clitoris (C) Below clitoris (D) Labia majora (E) Labia minora (F)
Around vaginal
opening (G)
Around anus (H) Vaginal 
introitus (I)
Mid vagina (J) Deep vagina (K)
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cologist (P.D.S.) rated one of the same 
options of genital appearance and size as 
the women had rated before in the SAGAS-F 
questionnaire. A moistened cotton swab was 
used to designate the different anatomical 
areas for which women rated on five-point 
Likert scales the sexual pleasure, discomfort/
pain, orgasmic intensity, and effort for 
achieving orgasm when imagined being 
stimulated by themselves or a partner. The 
time lapse between filling in the SAGAS-F and 
gynecological examination was 2 weeks.
Statistics
As Kolmogorov–Smirnov tests and normal 
probability plots indicated that the data 
approximated a normal distribution, 
anatomical locations were compared for 
ratings of sexual pleasure, discomfort/pain, 
orgasmic intensity, and effort for achieving 
orgasm using a repeated measures ANOVA. 
These were followed by all possible pairwise 
group comparisons by paired t-tests 
using Bonferroni corrections for multiple 
comparisons. Nonparametric Wilcoxon 
paired t-tests were used to compare the 
functional ratings on the SAGAS-F and the 
gynecological exam. Multiple regression 
analysis was used to identify factors associated 
with the genital sensitivity outcomes. We 
looked for a significant contribution of the 
interaction effects on the predictive ability of 
the model by adding the interaction effects 
to the main effects. Differences between 
proportions were tested by chi-squared tests 
or Fisher exact tests, as appropriate. P < .05 
was considered statistically significant. Two-
tailed statistical tests were chosen to reduce 
the risk of type I errors. Analysis was carried 
out by the statistical software package spss 
20.0 (SPSS Inc., Chicago, IL, USA), and the 
authors received help from a statistical expert.
Results
Over a 10-month period, 728 women 
completed all applicable items. The median 
time needed to fill in the SAGAS-F was 18 
minutes (range 5–652 minutes).Women 
were offered the possibility to fill in the 
questionnaire in different sessions. The 
participants consisted of women without a 
history of genital surgery and with a variable 
educational background. All women were 
sexually active (clitoral and/or vaginal sexual 
stimulation by self or a partner in the last 12 
months). Detailed demographic data are 
provided in Table 1. As expected, there was
a significant association between age and 
parity status, with 71% of the women above 
the median age of 25 years having children, 
compared with 1.3% of the women below 
the median age of 25 years (χ2 (1, 728) = 
Demographics.TABLE 1
Median age (years)  25 (18–69)  22 (20–55)
Partner (% yes)  54.8  67
Education (%)
 No education or
 primary school level  0.7  0.0
 Lower secondary  3.2  0.0
 Higher secondary school  32.8  42.9
 Higher education 
 short type  19.2  4.8
 Higher education
 long type—university 44.1  52.4
Has a child (% yes)  35.2  14.3
 Median number 
 of children  2 (1–7)  2 (1–2)
Racial background (%)
 Caucasian  98.8  95.2
 African  0.3  4.8
 Asian  0.1  0.0
 Arabic  0.1  0.0
 Other (not specified)  0.7  0.0
Gender of 
actual sex partner(s) (%)
 Male  84.2  71.4
 Female  2.3  9.5
 Both  0.7  0.0
 Neither  12.8  19.1
Total group
(n = 728)
Gynecological
exam (n = 21)
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390.47, P < .001). Women who took part in 
the gynecological examination had a median 
age of 22 years (20–55 years) and were a 
representative sample of the total group of 
participants in terms of the other demographic 
details (Table 1).
Genital Anatomy
Women’s Responses
Women were asked to select the response 
option that best described their genital 
anatomy (for more details, see [19]). Table 2 
gives an overview of the perceived size ratings 
of the clitoris, labia (majora and minora), and 
vagina. For clitoral size, the majority chose 
moderate sized and raised (45.2%), and small 
and raised (43.4%). Regarding labial size, 68% 
of the sample chose average sized. For vaginal 
opening size options, up to 90% indicated that 
their vagina was adequate and deep enough 
for penetration. Significantly more women 
above the median of 25 years reported their 
vaginas to be very large as compared with 
women below the median age (χ2 (2, 728) = 
26.44, 11 vs. 2%, P < .001), as well as women 
who gave birth compared with nulliparous 
women (χ2 (2, 728) = 49.98, 14% vs. 2%, P < .001).
TABLE 2 Genital size ratings of the clitoris, vagina, and labia.
Small disk with brighter color than   Small dimple  0.4
the surrounding skin, not raised 4.3 
Small and raised  43.4  Not large enough to even insert small 
  dilator or finger or small tampon 0.5
Moderate sized and raised  45.2  Just large enough to insert finger or small 
  object but not large enough to insert average- 4.5
  sized penis, regular tampon, or speculum 
 
Large and slightly long  4  Adequate for sexual penetration  88.2
Large and raised  1.8  Very large  6.3
Larger and longer than average  0.7
Large and very long  0.7
Not able to locate them  1.1  Not able to locate them 0.001 Do not know if it is deep enough for  5.9 
Small  12.5 Small  4.5 intercourse with an average penis  
Average sized  59.1 Average sized  76.6 Not deep enough for intercourse 1.8 
Large 23.9 Large  17 Deep enough for intercourse  92.3  
Very large  3.4  Very large  1.6
Clitoris
Labia minora Labia majora Vaginal depth
( % )
( % ) ( % ) ( % )
( % )Vaginal size
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Gynecologist’s Responses
The response options chosen by the 
gynecologist corresponded highly with 
those of the women for vaginal size and 
vaginal depth (>90%) but much less for labia 
minora and majora and clitoral size (Table 
3). However, no systematic pattern was 
observed in terms of divergent answers (i.e., 
the gynecologist did not systematically rate 
the clitoris larger or smaller compared with 
the women and vice versa).
Genital Sensitivity
Overall Genital Sensitivity
For the sample as a whole, overall 
discrimination between the 11 genital regions 
(external and vaginal areas) was highly 
significant (P<.001) for ratings of sexual 
pleasure, discomfort/pain, orgasm intensity, 
and effort to achieve orgasm. Ranked by 
degree of “sexual pleasure,” the area on the 
clitoris was highest followed by the other 
regions as outlined in Table 4, but not all 
Bonferroni corrected pair differences were 
significant. In the vaginal area, the deep 
vagina was highest followed by midvagina 
and vaginal introitus. The rank order was 
similar for “orgasm intensity” (Table 4), both 
for the external and vaginal area, and for 
“orgasm effort” for the external area but 
not the vaginal area. There were also fewer 
significant pair differences. The likelihood of
reaching an orgasm was highest when 
stimulating the clitoral area (Figure 2). Ninety-
four percent of the women reported orgasm 
with clitoral stimulation (area B), followed by 
75% when stimulating the sides of clitoris, and 
64% below the clitoris. The region above the 
clitoris was reported to be orgasm sensitive 
in only 41% of the women. Sixty-one percent 
indicated that the area around the vaginal 
opening was orgasm sensitive. Stimulation 
of the labial area was reported to be orgasm 
sensitive in 41% of the women for the labia 
minora and in 27% for the labia majora. Only 
18% of the women reported their anal area to 
be sensitive for achieving orgasm. For vaginal 
sensitivity, the likelihood of orgasm estimate 
increased with increasing vaginal depth: 49% 
for the vaginal introitus area, 61% for the 
midvagina, 70% for the deep vagina (Figure 
3). “Discomfort/pain” was rated highest in the 
TABLE 3 Ratings of genital anatomy by gynecologist and women (n = 21).
Clitoral size  Average  Average  4  48
 Small  Small  6
 Average  Small  6
 Small  Average  5
Vaginal size  Adequate for sexual penetration  Adequate for sexual penetration  18  90
 Very large  Very large  1
 Adequate for sexual penetration  Very large  2
Vaginal depth  Deep enough for intercourse  Deep enough for intercourse  20  95
 Don’t know  Deep enough for intercourse  1
Labia minora size  Average  Average  7  57
 Small  Small  1
 Large  Large  4
 Average  Large  1
 Large  Average  3
 Small  Average  1
 Average  Small  4
Labia majora size*  Average  Average  11  55
 Large  Average  2
 Average  Large  3
 Average  Small 4
Women Gynecologist Match (%)N
*Based on n = 20; information from one woman is missing.
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external area around the anus, followed by 
clitoris, below clitoris, and around the vaginal 
opening. In the vaginal area, discomfort was 
rated highest in the deep vagina, followed by 
midvagina, and vaginal introitus (Table 4).
Clitoral and Vaginal Sensitivity
Ratings of “sexual pleasure” and “discomfort” 
were significantly higher for clitoral stimu-
lation by partner than by self (P<.001). Ratings 
for “orgasm intensity” were significantly high-
er, and ratings for “orgasm effort” significantly 
lower for clitoral stimulation by self than 
by partner (P<.001) (Table 5).Women who 
perceived their clitoris to be small experienced 
significantly less sexual pleasure and less 
orgasm intensity when clitorally stimulated by 
a partner and self as compared with women 
who perceived their clitoris to be of average 
size (for sexual pleasure: t (625) = −2.47, P =.014 
[partner] and t (583) = −2.01, P=.044 [self]; 
for orgasm intensity: t (627) = −2.91, P=.004 
[partner] and t (583) = −2.01, P=.045 [self]). 
Alternatively, women who perceived their 
clitoris to be large experienced significantly 
more sexual pleasure, t (59) = −2.34, P = 
.023) and more orgasm intensity when self-
stimulated as compared with women with a 
perceived small clitoris, t (340) = −2.81, P = 
.045 (Table 5). For vaginal sensitivity, scores for 
sexual pleasure, discomfort, orgasm intensity, 
and effort increased with increasing vaginal 
depth. There was a significant effect for 
perceived size of the vagina, with women
with a large perceived vaginal size reporting 
more effort to achieve orgasm in the vaginal 
introitus area but less in the mid and deep 
vagina compared with women who perceived 
their vaginal size to be average or small (Table 
5, ES r = 0.3 for introitus and 0.2 for mid and 
deep vagina). More discomfort was reported
in the mid and deep vagina by women with a 
perceived smaller vaginal size (ES r = 0.1 and 
0.2, respectively). ANOVA analyses with 
*Significant Bonferroni corrected pair comparisons (P<.05), †1 = 
none, 5 = intense; ‡1 = very strong, 5 = very little, SD = standard 
deviation
The scoring, listed in sequence 
from highest to lowest rating, of 
the various domains by genital area.
TABLE 4
Sexual pleasure† 
 External
 B Clitoris  4.1 (0.9)  A, C, D, E, F, G, H, I, J, K
 C Sides of clitoris  3.4 (1.0)  A, B, D, E, F, H, I, K
 G Around vaginal opening  3.4 (1.0) A, B, D, E, F, H, I, K
 D Below clitoris  3.0 (1.1)  A, B, C, E, F, G, H, J, K
 F Labia minora  2.7 (1.0)  A, B, C, D, E, G, H, I, J, K
 A Above clitoris  2.6 (1.1)  B, C, D, E, F, G, H, I, J, K
 E Labia majora  2.4 (1.0)  A, B, C, D, F, G, H, I, J, K
 H Around Anus  2.0 (1.2)  A, B, C, D, E, F, G,I, J, K
 Vaginal
 K Deep vagina  3.6 (1.1)  A, B, C, D, E, F, G, H, I, J
 J Mid vagina  3.4 (1.0)  A, B, D, E, F, H, I, K
 I Vaginal introitus  2.9 (1.0)  A, B, C, E, F, G, H, J, K
Orgasm intensity† 
 External
 B Clitoris  3.8 (1.1)  A, C, D, E, F, G, H, I, J, K
 C Sides of clitoris  2.8 (1.3)  A, B, D, E, F, G, H, I, J
 G Around vaginal opening  2.4 (1.3)  A, B, C, E, F, H, I, K
 D Below clitoris  2.4 (1.3)  A, B, C, E, F, H, I, K
 A Above clitoris 1.8 (1.1)  B, C, D, E, G, H, J, K
 F Labia minora  1.8 (1.1)  B, C, D, E, G, H, I, J, K
 E Labia majora  1.5 (0.9)  A, B, C, D, F, G, I, J, K
 H Around anus  1.4 (0.9)  A, B, C, D, F, G, I, J, K
 Vaginal
 K Deep vagina  2.8 (1.4)  A, B, D, E, F, G, H, I, J
 J Mid vagina  2.4 (1.3)  A, B, C, E, F, H, I, K
 I Vaginal introitus  2.0 (1.1)  B, C, D, E, F, G, H, J, K
Orgasm effort‡ 
 External
 B Clitoris  3.0 (0.8) n = 682  E, F, H, A, I
 C Sides of clitoris  2.8 (0.9) n = 544  E, F, H, A
 D Below clitoris  2.7 (0.9) n = 463
 A Above clitoris  2.6 (0.9) n = 295  B, C
 G Around vaginal opening  2.6 (1.0) n = 446  E, F, H
 H Around anus  2.6 (1.0) n = 134  G, B, C, K
 E Labia majora  2.5 (0.9) n = 194  G, B, C, K
 F Labia minora  2.5 (0.9) n = 297  G, B, C, K
 Vaginal
 I Vaginal introitus  3.3 (0.8) n = 359  J, K, B
 K Deep vagina  2.8 (1.0) n = 512  I, E, F, H
 J Mid vagina  2.7 (0.9) n = 447  I
Discomfort/pain† 
 External
 H Around anus  1.6 (1.0)  A, C, D, E, F, G I, J, K
 B Clitoris  1.5 (0.8)  A, C, D, E, F, G, I, J
 D Below clitoris  1.3 (0.7)  A, B, C, E, F, H,
 G Around vaginal opening  1.3 (0.7)  A, B, C, E, F, H, I,
 E Labia majora  1.2 (0.5)  B, D, F, G, H, I, J, K
 A Above clitoris 1.1 (0.4)  B, D, F, G, H, I, J, K
 F Labia minoora  1.1 (0.4)  A, B, D, E, G, H, J, K
 C Sides of clitoris  1.1 (0.4)  B, D, G, H, J, K
 Vaginal
 K Deep vagina  1.4 (0.7)  A, C, E, F, H, I, J
 J Mid vagina  1.3 (0.7)  A, B, C, E, F, H, I, K
 I Vaginal introitus  1.2 (0.5)  A, B, E, G, H, J, K
Mean (SD)Domain and area Areas significantly
different*
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Bonferroni corrections were not significant 
for orgasm intensity and sexual pleasure in the 
vaginal areas.
Genital Sensitivity During
Gynecological Examination
The results of the gynecological examination 
are summarized in Table 6. The functional 
ratings on the original SAGAS-F corresponded 
well with the functional ratings during 
the gynecological examination for most 
anatomical areas, showing again the highest 
sexual pleasure and orgasm intensity in the 
clitoral region and around the vaginal opening, 
as well as in the deep vaginal area. However, 
orgasm intensity of the clitoris (area B) was 
rated significantly lower on the gynecological 
exam compared with the SAGAS-F rating (Z = 
−2.06, P = .04). Additionally, sexual pleasure 
in the region above clitoris (area A) was rated 
significantly higher (Z = −2.18, P = .029) and 
orgasm effort lower (Z = −2.12, P=.034) during 
gynecological examination as compared 
with the rating on the questionnaire (Table 6).
Influence of Participant Characteristics
Multiple regression analyses corrected for 
age and parity status showed significant 
effects of both characteristics as well as 
a significant interaction effect on genital 
sensitivity outcomes, although effective 
sizes were small (Table 7). With increasing 
age, less discomfort in the clitoral area and 
around the vaginal opening was reported, as 
well as more orgasm intensity in the labial 
and vaginal introitus areas. The effects of age 
were different in the groups of women with 
and without children (i.e., with increasing 
age, women without children experienced 
more sexual pleasure and orgasm intensity 
in the clitoral area and less effort to achieve 
orgasm in the labia minora area than women 
with children).
Discussion
Data collected on the SAGAS-F, in a sample of 
749 Dutch-speaking Belgian women, proved 
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to be valid and reliable, adding to information 
about the utility of the scale as the results 
of the original pilot study by Schober and 
colleagues are replicated [19].
Genital Anatomy
Around 90% of women indicated their vaginal 
size and depth to be adequate for vaginal 
intercourse, and gynecologist’s ratings 
matched those of the women in majority of 
cases (>90%). As in the original pilot study, 
only 43% of the women indicated a clitoral 
size that typically would be regarded as 
normal (“small and raised clitoris”), whereas 
a similar proportion selected the descriptor 
“moderate sized and raised” and a picture 
showing a clitoris that experts reported to 
be relatively large or larger than normal. 
This suggests that women may accept a 
larger clitoral size than commonly believed, 
which could imply a diminishing need for 
clitoral reduction for esthetic reasons in the 
normal female population (i.e., without an 
underlying DSD condition) [19]. Perception 
of clitoral size seemed to infl uence the 
functional ratings (i.e., smaller perceived size 
was associated with less orgasm intensity 
and larger perceived size with higher orgasm 
intensity). In contrast with our fi ndings, 
limited data suggest that clitoral size is not 
necessarily a criterion of responsiveness or 
related to sexual function [20,21]. Quantitative 
measurements should be undertaken to 
further elucidate the relationship. Clitoral 
length variability is three-fold greater than that 
of vaginal length and compared with its male 
homologue, penile length, at least as variable,
which may be explained by the wider variation 
in exposure to prenatal androgens in women 
[22,23]. Although reports are available about 
the gross anatomy and diversity of the female 
genitalia (e.g., [24]), the further study of clitoral 
(and vaginal) neuroanatomy [22,25,26], as well 
as aff erent pathways and sensory cortex 
projections, as it relates to sexual function, 
is crucial for our understanding of female 
sexuality and may aid the strategic design of 
female reconstructive surgery [27].
Genital Sensitivity
Scores indicated that orgasm intensity and 
sensitivity were perceived largest in the area 
of the clitoris (i.e., clitoral glans) and sides 
of the clitoris, as was only partly predicted 
[19,28,29], and that the area above the clitoris 
(i.e., vestibule of the vulva) did not seem to 
be perceived as the most sexually sensitive 
area. However, during the gynecological 
examination, women did indicate this last 
area to be highly sensitive, which might 
suggest that this specifi c genital area is 
somewhat undervalued in Flemish women’s 
self-reported perception of genital sensitivity. 
Underlying this skin zone is the root of the 
clitoris and the location of the confl uence 
of clitoral erectile bodies, which is supposed 
Figure 3
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to be highly responsive to sexual stimulation 
[30,31]. Fetal clitoral studies have shown the
greatest nerve density superior to and fanning 
out above the clitoris [29] Consequently, as 
the clitoral area has the highest nerve density, 
it may not only be highly sensitive in terms 
of sexual pleasure but may also elucidate 
more pain/discomfort when stimulated 
(extensively), in accordance with underlying 
brain circuits that generate both pleasure and
pain [32]. Moreover, Masters and Johnson 
observed that in the preorgastic arousal 
phase, the visible part of the clitoris retreats 
under the clitoral hood as to protect the 
clitoral glans from direct contact. Thus, in 
manipulating the clitoris, only a small margin 
between stimulation and irritation seems 
to exist [33]. For vaginal sensitivity, scores 
for sexual pleasure, discomfort, orgasm 
intensity, and effort increased with increasing 
vaginal depth. Deep vaginal sensation scored 
the highest for erotic impact. Decreased 
orgasmic sensitivity was reported at the 
vaginal introitus site [19]. This is surprising, 
as the pleasurable area called the “G-spot” 
is supposed to be situated in the superficial 
vagina (i.e., the anterior vaginal wall) [34]. 
Objective measures (pathologic specimens, 
various imaging modalities, and biochemical 
markers) have not always provided consistent 
evidence for the existence of an anatomical 
site that could be related to this famed spot, 
but reliable reports exist [35]. Although the 
participants in the current study did not 
seem to report a unique “entity” within the 
anterior distal wall whose direct stimulation 
TABLE 5
†1 = none, 5 = intense; ‡1 = very strong, 5 = very little  § In 87.7% (593/676) orgasm was reached when stimulated by the partner; in 92.5% 
(583/630) orgasm was reached when self-stimulated. a Significant differences between the pairs (partner vs. self), P<.05. b Significant differences 
between perceived large and small size (P<.01) and average and small size (P<.01). c Significant differences between perceived large and small 
vaginal size, P<.01
Clitoral sensitivity when stimulated by a partner or self in the last 12 months    
and according to perceived size (upper panel) and vaginal sensitivity  
according to perceived size (lower panel).
 4.1 (0.8)  4.0 (0.8)a  1.4 (0.7) 1.1 (0.3)a    3.5 (1.2)  3.7 (1.1)a  2.8 (0.8)  3.2 (0.9)a
 n = 676  n = 630  n = 676  n = 630  n = 676  n = 630  n = 593  n = 583
Clitoral sensitivity according to size
    Small  4.0 (0.8)  3.9 (0.8)a  1.5 (0.8)  1.1 (0.3)a  3.4 (1.3)  3.6 (1.2)a  2.7 (0.8)  3.3 (0.9)a
 n = 319  n = 297  n = 319  n = 297 n = 319  n = 297  n = 273  n = 266
    Average  4.2 (0.8)  4.0 (0.8)a  1.3 (0.7)  1.1 (0.4)a  3.7 (1.2)  3.8 (1.0)  2.8 (0.7)  3.2 (0.9)a
 n = 310  n = 288  n = 310  n = 288  n = 310  n = 288  n = 277  n = 274
    Large  4.0 (0.8)  4.2 (0.8)  1.4 (0.5)  1.1 (0.3)a  3.5 (1.3)  4.1 (0.9)  2.8 (0.8)  3.3 (0.8)a
 n = 47  n = 45  n = 47  n = 45  n = 47  n = 45  n = 43  n = 43
    Small  2.7 (0.9)  3.1 (1.2)  3.2 (1.4)  1.3 (0.7)  1.6 (1.1)  1.9 (1.1)  1.9 (1.0)  2.3 (1.3)  2.7 (1.4)  3.2 (0.9)  2.7 (0.7)  2.6 (0.9)
 n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 22  n = 23 n = 27
    Average  2.9 (1.0)  3.5 (1.0)  3.6 (1.1) 1.2 (0.5)  1.3 (0.7)  1.3 (0.7)  1.9 (1.1)  2.4 (1.3)  2.8 (1.4)  3.4 (0.8)  2.7 (0.9)  2.7 (1.0)
 n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 309  n = 393  n = 449
    Large  3.0 (1.0) 3.2 (1.2)  3.8 (1.2)  1.2 (0.5)  1.1 (0.4)  1.3 (0.8)  2.3 (1.3)  2.6 (1.3)  3.2 (1.4)  2.8 (0.8)  3.1 (0.9)  3.2 (1.1)
 n = 46  n = 46  n = 46  n = 46  n = 46  n = 46  n =6  n= 46  n = 46  n = 28  n = 31  n = 36
Vaginal sensitivity according to size
Mean (SD)
Partner PartnerSelf Self
Sexual pleasure†
Sexual pleasure†
Discomfort/pain†
Discomfort/pain†
Area IArea I Area JbArea J Area KbArea K
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leads to vaginal orgasm, the question of 
whether enough investigative modalities 
have been implemented in the search of the 
G-spot is certainly raised. Also, the role of 
the area surrounding the urethral opening 
(periurethral glans)—which has been shown 
to move towards the vagina during coitus—
remains unclear in terms of vaginal orgasmic 
sensitivity [25]. On the other hand, studies 
on innervation and nerve distribution of the 
upper vagina, including apex and cervix, 
remain scarce [36]. Sensations evoked by 
deep vaginal (penetrative) stimulation are 
probably pressure related (e.g., stretch) rather 
than tactile [19]. However, other factors that 
have been, at least in part, related to deep 
vagino (cervical) responsiveness and orgasm 
intensity are greater thickness and/or length 
of the urethrovaginal space [37] or better 
pelvic region muscle function [38] (as been 
described by Costa et al. [39]), which might 
differ in our validation sample. The individual 
variability in terms of orgasm sensitivity for 
each location was considerable, indicating 
that there are many sites of sexual sensation
which differ in the kinds of orgasm they 
produce [40]. However, more women 
considered stimulation of the clitoral 
region—or in combination with stimulation 
of the vaginal region—necessary for reaching 
orgasm. Less women were exclusively 
vaginally oriented, and no women reached 
orgasm without stimulating the clitoris and/
or vagina. Scores for orgasmic sensitivity 
and intensity of the vagina at any depth were 
also less than scores for clitoral surfaces, 
which seems to be in line with studies where 
women rated surface orgasms (i.e., orgasms 
described as having originated on the surface 
of the genitalia) as more relaxing as well as
more intense and localized compared with 
deep orgasms (i.e., orgasms described as 
having originated deep inside the body) [41]. 
Currently, the most common view is that 
all women’s orgasms during intercourse 
are triggered by direct or indirect clitoral 
stimulation [33,42] (e.g., penile traction on 
the woman’s labia minora pulling them 
across the clitoral glans) [33]. Because studies 
on human female cadavers reported an 
anatomic relationship between the urethra, 
distal vagina, and the surrounding erectile 
clitoral tissue, some authors suggested to 
use the term “clitoral complex,” which is the 
location of female sexual activity, analogous 
to the penis in men [14]. Such an inclusive 
anatomical concept would also provide an 
answer to the somewhat artificial discussions 
on the precise trigger/ location of the 
orgasmic focus, that is clitoral vs. vaginal. 
However, our results do not fully support this 
d Significant differences between perceived large and average size, P 
<.05 SD = standard deviation
 4.1 (0.8)  4.0 (0.8)a  1.4 (0.7) 1.1 (0.3)a    3.5 (1.2)  3.7 (1.1)a  2.8 (0.8)  3.2 (0.9)a
 n = 676  n = 630  n = 676  n = 630  n = 676  n = 630  n = 593  n = 583
Clitoral sensitivity according to size
    Small  4.0 (0.8)  3.9 (0.8)a  1.5 (0.8)  1.1 (0.3)a  3.4 (1.3)  3.6 (1.2)a  2.7 (0.8)  3.3 (0.9)a
 n = 319  n = 297  n = 319  n = 297 n = 319  n = 297  n = 273  n = 266
    Average  4.2 (0.8)  4.0 (0.8)a  1.3 (0.7)  1.1 (0.4)a  3.7 (1.2)  3.8 (1.0)  2.8 (0.7)  3.2 (0.9)a
 n = 310  n = 288  n = 310  n = 288  n = 310  n = 288  n = 277  n = 274
    Large  4.0 (0.8)  4.2 (0.8)  1.4 (0.5)  1.1 (0.3)a  3.5 (1.3)  4.1 (0.9)  2.8 (0.8)  3.3 (0.8)a
 n = 47  n = 45  n = 47  n = 45  n = 47  n = 45  n = 43  n = 43
    Small  2.7 (0.9)  3.1 (1.2)  3.2 (1.4)  1.3 (0.7)  1.6 (1.1)  1.9 (1.1)  1.9 (1.0)  2.3 (1.3)  2.7 (1.4)  3.2 (0.9)  2.7 (0.7)  2.6 (0.9)
 n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 41  n = 22  n = 23 n = 27
    Average  2.9 (1.0)  3.5 (1.0)  3.6 (1.1) 1.2 (0.5)  1.3 (0.7)  1.3 (0.7)  1.9 (1.1)  2.4 (1.3)  2.8 (1.4)  3.4 (0.8)  2.7 (0.9)  2.7 (1.0)
 n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 641  n = 309  n = 393  n = 449
    Large  3.0 (1.0) 3.2 (1.2)  3.8 (1.2)  1.2 (0.5)  1.1 (0.4)  1.3 (0.8)  2.3 (1.3)  2.6 (1.3)  3.2 (1.4)  2.8 (0.8)  3.1 (0.9)  3.2 (1.1)
 n = 46  n = 46  n = 46  n = 46  n = 46  n = 46  n =6  n= 46  n = 46  n = 28  n = 31  n = 36
Partner PartnerSelf Self
Orgasm intensity†
Orgasm intensity†
Orgasm effort‡ if orgasm 
was reached§
Orgasm effort‡ if orgasm 
was reached§
Area I Area IcArea J Area JdArea K Area Kd
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notion as women made a clear distinction 
between vaginal and clitoral regions in terms 
of the value of erotic sensation, which is also 
in line with the separable and distinct sensory 
cortical regions activated by vaginal and 
cervical vs. clitoral stimulation [43]. Ironically, 
Freud’s distinction between vaginally and 
clitorally triggered orgasms may actually 
reflect a natural typology of women’s 
orgasm induction but not—as he argued—
the psychological maturity of women [44]. 
Although the specific mechanical and 
anatomical interplay are by no doubt of 
relevance in the further investigation of 
female orgasm (e.g., see [23,31]), this is beyond 
the scope of this study.
Limitations of the Study
We assessed the impact of certain 
demographic variables on the self-perceived 
genital sensitivity outcomes, such as 
age and parity status. However, genital 
sensation probably varies with phases of the 
menstrual cycle, differs between pre and 
postmenopausal women, and is influenced 
by estrogen replacement therapy. A first 
major shortcoming of the present study is 
that menopausal status was not assessed 
thoroughly, limiting the validity of the 
findings. In previous studies, hypoestrogenic 
postmenopausal women were noted to 
have reduced vulvar and clitoral sensitivity 
to vibration, pressure, and light touch [30–
32]. In our study, women above 50 years 
of age (presumably postmenopausal [45]) 
experienced significantly less sexual pleasure
in the area of the clitoris and deep vagina 
(P<.05). A second limitation of the present 
study is that the cross-sectional design 
prohibits inferences about causality. Thirdly, 
participants were limited to provide responses 
to predetermined categories selected by the 
researcher. Therefore, we might have missed 
a broad range of information relating to 
women’s own perception of sexual sensitivity
and anatomy. Open questions should 
be available, as well as the response “no 
experience in this genital area.” For instance, 
the anus as a sexual organ needs to be 
further investigated. Next, because of the 
multifactorial nature of the human sexual 
TABLE 6
Comparisons of genital sensitivity ratings on SAGAS-F 
and during gynecological examination (n = 21).
A Above clitoris  2.7 (1.0)  3.1 (0.9)*  1.0 (0.0)  1.0 (0.0)  2.0 (1.4)  2.1 (1.4)  2.4 (0.9)  3.2 (1.0)*
B Clitoris 4.0 (0.8)  3.8 (1.0)  1.2 (0.4)  1.4 (0.6)  3.7 (1.2)  2.8 (1.6)*  3.1 (0.9)  3.1 (1.0)
C Sides of clitoris  3.2 (1.1)  2.7 (1.1) 1.0 (0.0)  1.0 (0.0)  2.5 (1.4)  2.0 (1.3)  2.8 (0.8)  2.7 (1.1)
D Below clitoris  3.0 (1.0)  2.2 (1.3)  1.2 (0.6)  1.7 (0.9)*  2.2 (1.3)  1.6 (1.2)  2.6 (0.8)  2.8 (1.3)
E Labia majora  2.1 (0.9)  2.0 (0.9)  1.1 (0.4)  1.1 (0.4)  1.3 (0.8)  1.4 (0.9)  2.3 (1.5)  2.5 (1.0)§
F Labia minora  3.0 (1.0)  2.9 (1.2)  1.1 (0.5)  1.0 (0.0)  1.8 (1.2)  2.0 (1.4)  2.3 (1.0)  3.0 (0.8)
G Around vaginal opening  3.2 (0.8)  3.4 (1.0)  1.5 (0.8)  1.1 (0.4)  2.0 (1.1)  2.5 (1.5)  2.5 (0.8)  2.6 (1.0)
H Around anus  2.1 (1.0)  2.1 (0.8)  1.4 (0.6)  1.1 (0.7)  1.2 (0.7)  1.2 (0.5)  4.0 (0.0)  1.7 (0.6)§
I Vaginal introitus  2.8 (0.9)  2.9 (1.0)  1.0 (0.0)  1.2 (0.5)  1.8 (1.2)  2.1 (1.3)  3.0 (0.9)  2.6 (0.9)
J Mid vagina  3.4 (0.8)  2.4 (1.0)*  1.4 (0.9)  1.1 (0.4)  2.0 (1.2)  1.8 (1.0)  2.4 (1.1)  2.3 (1.0)
K Deep vagina  3.4 (1.2)  3.0 (1.0)  1.3 (0.6)  1.3 (0.9)  2.5 (1.4)  2.2 (1.4)  2.6 (1.0)  2.3 (1.3)
Mean (SD)
SAGAS-F PartnerGynecological
exam
Self
Sexual pleasure† Discomfort/pain†
*Significant differences between the pairs (SAGAS-F questionnaire vs. gynecological exam), P<.05, Wilcoxon paired t-tests, †1 = none, 5 = 
intense; ‡1 = very strong, 5 = very little, §Not enough valid cases to perform paired t-tests SAGAS-F = Self-Assessment of Genital Anatomy and 
Sexual Function, Female version
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response, the type of sexual stimulation that
triggers orgasm is very individualized for each
respondent. In hopes of advancing under-
standing of female sexual experience and the 
evolutionary basis of female orgasm, further 
investigation of different types of orgasm is 
needed as women report their orgasms to 
differ not only in intensity but also in location, 
phenomenology, and emotional components 
[42,46]. In general, other emotional, 
physiologic events, psy-chological, cultural, 
religious, medical (e.g., antidepressants), and 
social factors modulating female sexuality 
should be considered when assessing self-
reported genital anatomy and sensation 
[15]. For instance, increased access to 
pornography and the rising popularity 
of female genital cosmetic surgery may 
enhance feelings of distress about genital 
appearance [24]. Despite extreme variability 
of the female genitalia on an individual level, 
further objective investigative measures of 
genital anatomy (e.g.,clitoral size, distance 
between the clitoral glans and shaft relative 
to the vaginal opening, G-spot existence) 
demand further consideration. Only recently 
the clitoris has been found a much more 
complex and larger—largely internal or 
hidden— organ than commonly assumed 
[26], acknowledging that the visible external 
tip of the clitoris is not the only site of female 
TABLE 7
Multiple regression analyses corrected for age, parity, 
and the interaction between both variables.
A Above clitoris  2.7 (1.0)  3.1 (0.9)*  1.0 (0.0)  1.0 (0.0)  2.0 (1.4)  2.1 (1.4)  2.4 (0.9)  3.2 (1.0)*
B Clitoris 4.0 (0.8)  3.8 (1.0)  1.2 (0.4)  1.4 (0.6)  3.7 (1.2)  2.8 (1.6)*  3.1 (0.9)  3.1 (1.0)
C Sides of clitoris  3.2 (1.1)  2.7 (1.1) 1.0 (0.0)  1.0 (0.0)  2.5 (1.4)  2.0 (1.3)  2.8 (0.8)  2.7 (1.1)
D Below clitoris  3.0 (1.0)  2.2 (1.3)  1.2 (0.6)  1.7 (0.9)*  2.2 (1.3)  1.6 (1.2)  2.6 (0.8)  2.8 (1.3)
E Labia majora  2.1 (0.9)  2.0 (0.9)  1.1 (0.4)  1.1 (0.4)  1.3 (0.8)  1.4 (0.9)  2.3 (1.5)  2.5 (1.0)§
F Labia minora  3.0 (1.0)  2.9 (1.2)  1.1 (0.5)  1.0 (0.0)  1.8 (1.2)  2.0 (1.4)  2.3 (1.0)  3.0 (0.8)
G Around vaginal opening  3.2 (0.8)  3.4 (1.0)  1.5 (0.8)  1.1 (0.4)  2.0 (1.1)  2.5 (1.5)  2.5 (0.8)  2.6 (1.0)
H Around anus  2.1 (1.0)  2.1 (0.8)  1.4 (0.6)  1.1 (0.7)  1.2 (0.7)  1.2 (0.5)  4.0 (0.0)  1.7 (0.6)§
I Vaginal introitus  2.8 (0.9)  2.9 (1.0)  1.0 (0.0)  1.2 (0.5)  1.8 (1.2)  2.1 (1.3)  3.0 (0.9)  2.6 (0.9)
J Mid vagina  3.4 (0.8)  2.4 (1.0)*  1.4 (0.9)  1.1 (0.4)  2.0 (1.2)  1.8 (1.0)  2.4 (1.1)  2.3 (1.0)
K Deep vagina  3.4 (1.2)  3.0 (1.0)  1.3 (0.6)  1.3 (0.9)  2.5 (1.4)  2.2 (1.4)  2.6 (1.0)  2.3 (1.3)
Age  Discomfort  Clitoris  −0.11  [−0.01; −0.002], P < .01
  Vaginal opening  −0.12  [−0.011; −0.002], P < .01
  Orgasm intensity  Labia majora  0.17  [0.004; 0.009], P < .01
  Labia minora  0.15  [0.003; 0.009], P < .01
  Vaginal introitus  0.02  [0.002; 0.03], P < .05
Parity  Orgasm intensity  Clitoris  −0.40  [−0.68, −0.11], P < .01
 Orgasm effort  Vaginal introitus  0.35  [0.027; 0.67], P < .01
 Sexual pleasure  Labia minora  −0.32  [−0.584; −0.063], P < .05
  Around anus  −0.37  [−0.67; −0.062], P < .01
Age x parity  Sexual pleasure  Clitoris  0.02  [0.001; 0.031], P < .05
  Around anus  0.02  [0.003; 0.043], P < .05
 Orgasm intensity  Clitoris  0.03  [0.1; 0.05], P < .01
 Orgasm effort  Sides of clitoris  0.03  [0.007; 0.044], P < .01 
  Labia minora  0.03  [0.006; 0.059], P < .05
Variable Area CI, Pβ
Partner PartnerSelf Self
Orgasm intensity† Orgasm effort
‡ if orgasm 
was reached§
Only significant results are reported, constant included in equation, standardized slope beta. Confidence interval (CI): 95% CI
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sexual sensitivity and underlining that the 
clitoris cannot be conflated with the clitoral 
glans. Further quantitative genital sensation 
measures during sexual stimulation may be 
of added value, although assessment of any 
sensory pathway is complex, and sensation 
is a subjective personal experience [23]. 
Lastly, the sample consisted primarily of 
heterosexual, Caucasian women between 
18 and 28 years, with a high educational 
background. Generalization of findings to 
other segments of the female population 
or women of other cultures is accordingly 
compromised.
Conclusion
This current report replicates and extends 
earlier findings by showing that women 
indicate their clitoral region to be most 
important for sexual sensation when assessed 
with the SAGAS-F self-report measure as well 
as a gynecological examination. Therefore, 
some important implications for several 
populations exist. Great importance has been 
placed on achieving a normal appearance via
surgical means for children born with 
conditions that affect genital development 
(disorders of sex development). Genital 
surgery risks disruption of nerves and blood 
vessels, which may impair sensation to 
the genital area and affect future capacity 
for sexual pleasure. Surgery, including 
female genital cosmetic surgery in the 
general female population, should only be 
undertaken with a clear understanding of 
the variation in normal appearance and in 
cases which differ markedly from normal. 
Data on genital sensation should form part 
of the long-term follow-up of genitoplasty 
procedures. The SAGAS-F could be used for 
this purpose, as it is an easily administered, 
reliable self-reporting tool. Routine genital 
sensitivity assessment is also likely to facilitate 
psychosexual counseling.
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CHAPTER 4
Towards a new 
treatment strategy in 
women with DSD 
and vaginal agenesis  
Man’s mind, once stretched 
by a new idea, never returns 
to its original dimensions. 
Oliver Wendell Holmes
Based on:
Callens, N.,  De Cuypere, G., De Sutter, P.,  Monstrey, S., Weyers. S., Hoebeke, P. and Cools, M. Under 
construction: Vaginal creation methods for vaginal hypoplasia, 2013, submitted.
Callens, N., Weyers, S., Stockman, S., Van Hoorde, B., Monstrey, S., Van Hoecke, E., De Cuypere, 
G., Hoebeke, P. and Cools, M. Vaginal dilation treatment in women with vaginal hypoplasia: A 
prospective long term intervention study, 2013, submitted.
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In women with vaginal hypoplasia, such as in 46, XX Mayer-Rokitansky- Küster-Hauser 
syndrome (MRKH) and in 46, XY Complete Androgen Insensitivity Syndrome (CAIS), surgical 
vaginoplasty and non-surgical self-dilation treatments are available to lengthen the vagina 
and facilitate sexual intercourse, but the best treatment remains controversial. Vaginal dilation 
has been recommended as a first-line treatment, because of its less invasive character and 
high success rate. However, it may have a negative emotional impact on the women and the 
exploration of factors associated with compliance and long-term outcome is incomplete. As 
with surgical techniques, it is unclear whether maintenance dilation therapy in case of sexual 
inactivity is crucial to ensure functional success, and whether psychological counseling needs 
to be embedded in treatment to maximize efficacy. Moreover, diagnosis related success 
rates (i.e. MRKH vs. CAIS) have not been the focus of papers on vaginal agenesis. In general, 
the medical literature lacks comparative outcome studies, meaning that the current choice 
of reconstruction method relies greatly on the practioner’s preference and experience, and 
prospective, longitudinal studies are scarce. We present the available literature on the various 
approaches to vaginal reconstruction, focusing on the history of the specified technique, 
inherent advantages and disadvantages, complications and long-term durability in terms 
of sexual function. We reviewed known relevant factors which may impact on final clinical 
decision making, as to inform individual management of vaginal hypoplasia. Finally, we present 
a treatment algorithm for women with vaginal hypoplasia distilled from the available literature 
and propose a set of clinical care recommendations.
4.1 
Under construction: 
Vaginal creation methods 
for vaginal hypoplasia
ABSTRACT
Key Words. vaginal hypoplasia, vaginal reconstruction, vaginal dilation, vaginoplasty, sexual 
function, Mayer-Rokitansky-Küster- Hauser syndrome, Complete Androgen Insensitivity 
Syndrome, long term outcome, Disorders of Sex Development
Introduction
It is apparent that the clinical management 
of congenital disorders of sex development 
(DSD) - in which anatomical, gonadal 
or chromosomal sex is atypical - has 
been in a state of great flux, debate and 
controversy the last decade [1,2]. Advances 
in medical knowledge and understanding 
of psychosexual development, as well 
as an increased emphasis on the rights 
and autonomy of the individual, have all 
contributed to discussion about the role 
and efficacy of medical intervention [3-7]. 
Clinical practices developed to promote 
psychosexual wellbeing remain the subject of 
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critical review [8]. Patients with DSD requiring 
vaginal reconstruction, because of vaginal 
hypoplasia or aplasia, typically present with 
primary amenorrhea in adolescence with an 
otherwise normal growth and development 
[9]. The most commonly involved condition 
is Müllerian agenesis or Mayer-Rokitansky-
Küster-Hauser syndrome (MRKH), occurring 
1 in 4000 to 5000 females [9,10]. Women 
with MRKH have a XX karyotype and 
normal functioning ovaries, but an absent 
or rudimentary uterus and a short vagina 
resulting from failed embryonic development 
of the Müllerian duct [9]. The syndrome (i.e. 
vaginal hypoplasia) may be isolated (type 
I) but it is more frequently associated with 
renal, vertebral, and, to a lesser extent, 
auditory and cardiac defects (MRKH type II 
or MURCS association) [11]. In familial cases, 
the syndrome appears to be transmitted as 
an autosomal dominant trait with incomplete 
penetrance and variable expressivity, which 
suggests the involvement of either mutations 
in a major developmental gene or a limited 
chromosomal imbalance. However, the 
etiology of MRKH still remains unclear [12]. 
The differential diagnosis of MRKH mainly 
includes 46,XY DSD, specifically androgen 
insensitivity syndrome. In the latter, the lack 
of a functional androgen receptor results 
in phenotypically normal female external 
genitalia [13]. These women have testes, absent 
Müllerian structures and a blind short vaginal 
pouch due to the action of antimüllerian 
hormone [14,15]. Estimated incidences vary 
according to the population studied, ranging 
from 1 in 41 000 to 120 000 [13,16]. In addition, 
vaginal hypoplasia can be associated with 
disorders of testosterone biosynthesis or 
other rare complex conditions affecting 
the urinary and gastrointestinal tracts, such 
as cloacal and anorectal anomalies [17]. 
In pubertal females, differential diagnosis 
can be made assessing serum testosterone 
levels and karyotype analysis. Conventional 
transabdominal, translabial, or transrectal 
ultrasonography; three-dimensional ultra-
sonography and magnetic resonance 
imaging can be used to evaluate the absence 
of the uterus and vagina and can in individual 
cases be helpful in definitively characterizing 
anatomy [18]. Besides correct diagnosis of 
the underlying condition and evaluation 
for associated congenital anomalies, an 
important step in the effective medical 
management is psychosocial counseling 
before any treatment or intervention [18]. 
These women may experience variable levels 
of distress, connected to the perception 
of having a compromised womanhood 
and characterized by the fear of being 
devalued by others [19,20]. Sensitive pacing 
of information is recommended in order to 
allow young women and their family to make 
informed decisions about different treatment 
modes and a realistic adaptation to living with 
this condition [18].
Plethora of Vaginal 
Reconstruction Methods 
Sexually experienced patients may present 
with natural dilation of the vaginal dimple and 
occasionally require no additional treatment. 
Enlargement procedures for vaginal 
hypoplasia in non-sexually experienced 
women include surgical vaginoplasty and 
non-surgical dilation therapy [21]. Table 1 
and 2, and Figure 1 provide an overview of 
the variety of techniques and their main 
advantages and disadvantages (Based on 
[17,21-26]).
Vaginoplasty techniques
Dupuytren, in 1817 and later, Amussat, in 1835 
[27], are frequently mentioned as being the 
first proponents of surgical correction, which 
involved creating a perineal pouch between 
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bladder and rectum with strong digital 
pressure and then packing the cavity with 
linen [28]. Wharton (1938) and Counsellor 
(1948) subsequently refined this technique by 
using a mold covered with a rubber sheath 
to hold the perineal pouch open, which 
allowed spontaneous epithelization to take 
place [29,30]. It became quickly clear that the 
mold had to be used for several hours every 
day to reduce vaginal strictures due to scar 
formation. Permanent dilation to prevent 
stenosis of the neovagina (3- 6 months or 
longer) was further insisted upon by McIndoe 
& Banister [31]. They popularized a technique, 
first pioneered by Abbe (1889), in which 
split-thickness skin grafts, taken from the 
anterior surface of the thigh or buttock were 
inserted over the mold, after dissection of a 
space between rectum and bladder [32,33]. 
There were problems with fistula formation 
secondary to the use of the mold and the 
need for lubrication as the skin graft tended 
to be rather dry [34]. Numerous modifications 
of the mold material (soft, semi-rigid or rigid) 
or shape, and improvements in postoperative 
care have been suggested to reduce the 
incidence of complications [35-37]. However, 
marked scarring at the donor site and vaginal 
stenosis or contracture, particularly at its 
distal end, remains a problem. 
 
The problem of contraction of the vagina 
postoperatively was thought to be avoided 
with skin flap vaginoplasty and the use of 
TABLE 1 Vaginal reconstruction methods.
1. Simple pressure [85]
2. Pressure from a bicycle stool [93]
3. Regular coitus [83]
1. Surgical creation of a neovaginal space between bladder and rectum
 1.1 Simple reconstruction with insertion of form, without grafting [29,30] 
 1.2 Simple reconstruction with insertion of inlay graft over form 
    
 a) Split-thickness skin graft [31,32] 
     b) Full-thickness skin graft & Flap vaginoplasty
     Simple labia minora and thigh flaps [40] 
     Tubed pedicle flap from thigh [38]
     Pedicled bladder flap [59]
     Gracilis myocutaneous flaps [45] and transpelvic rectus abdominis myocutaneous flaps [46]:
     Perineal artery axial flap of Hagerty [303]
     Pudendal thigh flap vaginoplasty (Singapore flap) [47,304] 
     Free flap graft from scapula [48]
     Vulvoperineal fasciocutaneous flap (the Malaga flap) [50]
  c) Allogenic tissue: Amnion [53], epidermal sheets [305]
  d) Peritoneum [60,61]
  e) Artificial grafts: Interceed adhesion barriers [160], silicone membrane with incorporation   
     of recombinant fibroblast growth factor [56] 
 f) Tissue expanders [306]
 g) Autologous in vitro cultured vaginal tissue [58], autologous buccal mucosa [307] 
2. Bowel vaginoplasty  
 1.1 Ileum [67], sigmoid colon [308], or cecum and ascending colon [69] 
 1.2 Rectum [68]
 1.3 Free jejunal autograft  [70] 
3. Vulvavaginoplasty [51] 
4. Surgical traction 
       4.1 Vecchietti procedure [75]
       4.2 Balloon vaginoplasty [78,79] 
Non-surgical
Surgical
144
TABLE 2 Advantages and disadvantages of different vaginal reconstruction methods.
1. Dilation method (Frank/ Ingram) - Non-invasive  
 - No hospitalization
 - Psychological advantage of the subject      
    being in control
 - Preserves vaginal tissue
 - Cost-effective, inexpensive
 - Minimal morbidity and complications 
 - After failed treatment, the option still       
   exists to proceed to surgical       
   neovaginal creation 
2. Vecchietti procedure - Preserves vaginal tissue
 - Laparoscopic approach    
    minimally invasive
 - No excessive mucus    
    production or vaginal stenosis
3. Intestinal vaginoplasty - Lubricated segment with   
    (sigmoid colon, ileum, jejenum)    reliable blood supply 
 - Grows with the patient    
    (advantageous for younger children)
 - No scarring 
 - No dilation needed (?)
 - Low rate of stricture
 - Can be performed with previous   
    extensive surgery 
5. McIndoe procedure  - Vaginal approach avoids laparotomy
    (split-thickness skin grafts)  - No bowel anastomosis
 - High rate of graft take 
 - Low rate of prolapse
6.  Full thickness skin grafts - Good pelvic support following      
    exenteration
 - Can be done at time of exenteration
 - Good blood supply, low infection rate
 - Flap incision incorporated into   
    laparotomy site
 - Pedicled tissue form better than   
    free-tissue, because no dilation required 
 - No skin graft with pudendal thigh flaps
7. Williams Vulvavaginoplasty - Simple surgery
   (flaps from labia majora) - Non-invasive
Myocutaneous /  
fasciocutaneous flaps
Pudendal thigh flap
Labia minora flaps
Malaga flap
Singapore flap
Scapula flap
4. Davydov procedure (peritoneum) - Suitable for women who had   
    previous pelvic surgery
 - Lack of granulation tissue
 - No scar formation
- Motivated and mature patients required  
  (low compliance)
- Time-consuming (?)
- Discomfort and constant reminder of difference 
- Awkward sitting on Ingram stool
- Manual fatigue, boring, and unability to create      
   enough perineal pressure (Frank)
- Limited success in younger patients (<18yrs) (?)
- Long-term dilation needed (?)
- Poor results with skin dimple (?)
- Increased risk of vaginal prolapse (?) 
- Pain and need for strong analgesia   
   during daily tightening
- Postoperative self-dilation required
- Significant potential complications because of  
   the limited retrovesicorectal space into which the    
   traction threads need to be placed 
- Pliable tissue required (not recommended in the      
   presence of scars from previous reconstructive     
   surgeries) 
- Increased risk of vaginal prolapse (?)
- Requires laparotomy and bowel anastomosis
- Prolapse 3 to 8%
- Excessive discharge
- Complication rate between 16-26%    
   (postoperative ileus, bowel obstruction, diversion,  
   ulcerative colitis, adenocarcinoma)
- Postoperative dilation needed
- High rate of graft contracture   
   and neovaginal stenosis
- Disfiguring scar at the donor site
- Potential of graft infection
- Lack of lubrication
- Risk for squamous cell carcinoma
- Complication rate up to 14%
- High rate of prolapse and flap loss (gracilis)
- Skin appendages
- Deficient lubrication
- Disfiguring scar at the donor site
- Wound site infection
- Hair regrowth in the neovagina
- Hair bearing skin
- Sexual contact is difficult due to angle of   
   the external vagina
- Insufficient vaginal depth, no feeling of penetration
- Wound opening, haematoma, trauma infection
- Decreased lubrication
- Potential for bladder and rectum injury
- Potential infections and prolapse
- Postoperative dilation needed
Technique Advantages Disadvantages
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Figure 1
Figure 1. Diff erent vaginal reconstruction techniques. A) Vecchietti technique: pressure is 
applied on the vaginal dimple by an acrylic olive connected by threads that pass through 
the potential neovaginal space, are guided preperitoneally along the abdominal wall and exit 
via the anterior abdominal wall where they are connected to a traction device. The threads 
are tightened daily [28]. B) Williams’ procedure: the labia majora are used to line an external 
pouch formed by a U-shaped perineal incision [34] C)  Bowel vaginoplasty: a short segment of 
bowel (ileum or sigmoid colon) is isolated. The mesentary of the bowel segment is  extensively 
dissected upwards in order to connect this neovagina with minimal tension [34]. D) McIndoe 
procedure: split-thickness skin grafts are obtained from the thighs or buttocks and adapted 
around a mold to line the dissected space between rectum and bladder [28,99] E) Davydov 
procedure: A transverse incision is made below the urethra;  peritoneum is dissected off  the 
rectum, bladder and side wall of the pelvis using fi ngers, and developing a space; the canal 
is tightly packed and an incision is made in the peritoneum over the pack; stay sutures in the 
peritoneum are used to pull a tube of peritoneum towards the perineum; the edges of the 
peritoneal tube are sutured to the skin of the introitus and the abdominal end of the tube is 
closed [62,63]. F) Vaginal dilation techniques: Frank vaginal dilators of diff erent sizes increasing 
in length and width, and the Ingram stool method whereby patients are instructed to sit on 
bicycle seat-shaped stool for short periods with a vaginal dilator held in position in or at the 
vaginal opening to stretch the vaginal tissue [257].
A
B
C E
F
D
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full-thickness skin grafts from labia minora 
or thighs, first described by Graves in 1921, 
with disappointing results [34,38-40]. The 
technique was modified by Bhonsale and 
Sheares who lined the posterior wall of the 
rectovesical cavity with a single skin flap 
dissected from the vaginal dimple, retaining 
its attachment at the perineum [41]. Fortunoff 
utilized a U-shaped skin flap [42]. Other skin 
flaps used included rotated buttock flaps 
[43], and myocutaneous flaps, involving the 
gracilis muscle, a vulvobulbocavernosus 
myocutaneous graft [44] and rectus abdo-
minis muscle, which also have been used 
with success in vaginal deficiencies following 
neoplasms or trauma’s [45,46]. Pudendal thigh 
flaps [47], free flap graft from the scapula 
[48,49], and vulvoperineal fasciocutaneous 
flaps [50] have been used as well. Williams 
preferred vulvavaginoplasty, where an 
external pouch is created by suturing the 
labia majora to form a short vertical ‘vagina’ 
[51]. Most of these techniques can suffer from 
visible scars and keloid formation, and lack of 
vaginal lubrication and hair regrowth in the 
neovagina, which can become stenosed [52]. 
In addition, a risk of squamous cell carcinoma 
has been reported [6].
In an attempt to overcome some of the 
disadvantages of the skin graft techniques, 
a variety of other tissues have been used 
to line new vaginas. In 1934, Brindeau 
described a novel approach using chemically 
processed and sterilized freeze-dried human 
amniotic membranes that are considered 
immunologically inert and thus have low risk 
of graft rejection [53]. It has the advantage 
that no graft site is required, thereby leaving 
no external scars for the patient to have to 
tolerate. However, it is important that the use 
of this material is properly governed and that 
donors are suitably screened for transmittable 
diseases [54]. Various other authors have 
reported on the use of artificial or biological 
materials including buccal mucosa [55], 
artificial dermis (atelocollagen sponge) and 
with use of basic fibroblast growth factor 
to accelerate epithelization [56], oxidized 
cellulose [57], and autologous in vitro-
cultured vaginal tissue [58]. Pedunculated 
bladder wall flap [59] and peritoneum 
from the Douglas pouch (i.e. Davydov 
procedure) have been used in a combined 
abdominoperineal approach [60,61]. Davydov 
developed a three-stage operation involving 
dissection of the rectovesical space with 
abdominal mobilization of the peritoneum, 
attachment of the peritoneum to the created 
introitus, and finally closure of the neovaginal 
vault with purse-string suture [60,62,63]. 
The claimed advantages of this technique 
by the authors are the lack of granulation 
and scar formation. The procedure was 
modified to a laparoscopic approach, 
having the advantages of less bleeding, and 
postoperative pain in addition to shorter 
hospital stay, faster recovery, and better 
cosmetic outcome [64]. These merits are 
specifically important in adolescent patients 
in whom cosmesis may be very important 
and a faster recovery would allow for earlier 
return to school [65].
The use of bowel segments, reported 
as early as 1892 by Sneguireff [66], has 
gained enormous popularity for vaginal 
reconstruction in DSD and is also widely 
used following pelvic exenteration for cancer 
[28]. Because of the high morbidity and 
mortality rates when ileum segments were 
first used by Baldwin in 1904, the technique 
was largely abandoned until 1961, when the 
use of a sigmoid loop was described [67,68] 
and later the use of cecum and jejenum 
[69,70]. A laparoscopic approach is carried 
out since 1996 [71], but the procedure is still 
most frequently done through a laparotomy. 
Overall, the main advantages of this 
operation are said to be the lack of shrinkage 
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– with no long-term vaginal dilation needed 
- and the natural lubrication provided by the 
mucous production which obviates the need 
for artificial lubricants and decreases the 
risk of dyspareunia [72]. Greatest concerns 
surrounding this operation are bleeding 
or copious and smelly vaginal discharge, 
which also may mask adenocarcinoma [6,73]. 
Diversion colitis may also occur, possibly due 
to a lack of short-chain fatty acids normally 
present in colonic contents and required for 
mucosal integrity, but is less of a problem 
with ileum than with colon segments [28]. 
Finally, other surgical techniques are based 
on passive traction rather than dilation. In 
1965, Vecchietti proposed a device permitting 
an upwards traction on the retrohymenal 
fovea by an acrylic olive and the creation of a 
neovaginal space in 1 week, without the use 
of extraneous tissue [74,75]. The laparoscopic 
adaptation proposed in 1992 offers enhanced 
speed and ease [76]. The complication rate 
including bladder and rectal wall injury is 
reported to be low [77]. However, a more 
common drawback for this procedure is the 
pain resulting from the sustained traction 
which necessitates a hospital stay throughout 
the whole traction process [21]. Balloon 
vaginoplasty is based on the same principle, 
however, traction and dilation of the vaginal 
dimple is exerted by a Foley catheter with an 
inflated balloon [78,79]. Authors claim that 
the main advantage of this technique is the 
neovaginal width, which can be manipulated 
according to balloon distension. 
Vaginal dilation techniques
Because there is pliable perineal skin between 
the urethra and anus in women with vaginal 
hypoplasia, coitus has been shown to lead to 
an increase in vaginal depth and width [80-83]. 
In young women with an understanding and 
cooperative partner, excellent results can be 
obtained with little intervention from medical 
professionals [84]. When women do not have 
a partner or vaginal depth does not increase 
by coital dilation, supportive treatment with 
dilators has been proposed.
 
Frank described in 1938 the use of Pyrex 
tubes of gradually increasing sizes (0.8 cm, 
1.5 cm and 2.0 cm in diameter) to force the 
mucous membrane inward into the introital 
region [85,86]. Interestingly, for almost 40 
years this technique was only infrequently 
used, although his series and the majority of 
case reports suggested that this approach 
was one of promise [87-92]. In 1981, Ingram 
modified the technique based on presumed 
inconveniences of Frank’s method, such 
as sheer fatigue of the hands and fingers, 
the need to squat, and the inability to 
perform other productive activities during 
the procedure. He inserted dilators into the 
saddle of a bicycle stool and had the patients 
sit astride this to gently create perineal 
pressure [93]. The seat was later modified by 
Lee [86] and Lankford [94].
To dilate or not to dilate? 
Non-surgical vaginal dilation has been 
put forward by the American College of 
Obstetricians and Gynecologists (ACOG) in 
2002 as a first choice treatment, because it 
is a patient-driven technique that is easy to 
perform, cost-effective and safe [18,23,95]. 
Meanwhile, the concept of surgery for DSD 
conditions became increasingly controversial 
and led to a call in some quarters for a 
moratorium on genital surgery as long 
as long-term data are unavailable [6,96]. 
Successful neovaginal creation by dilation 
obviates the need for major surgery in 
most patients, while those not achieving 
adequate vaginal length with dilation can 
still undergo vaginoplasty as a second-line 
intervention. It is expected that only 85% 
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of women will achieve a functional vagina 
without a surgical approach [97]. Reasons for 
failure, however, need further clarification. 
Moreover, it is not known if failed vaginal 
dilation therapy jeopardizes further surgical 
success outcomes, especially because in a 
number of these procedures ongoing vaginal 
dilation is required. In addition, if surgery 
is needed, there is a lack of evidence to 
inform physicians regarding the optimum 
surgical technique to use. Also, the extent 
to which psychological interventions are 
needed to maximize treatment success 
needs to be further elucidated. In view of 
this ongoing debate and in order to provide 
a comprehensive, nonbiased reference 
tool, the available literature on the various 
approaches to vaginal reconstruction is 
reviewed below. The anatomical outcomes, 
referring to vaginal capacity, and functional 
outcomes, referring to sexual activity levels 
and successful coital or non-coital sexual 
TABLE 3 Summary of surgical studies.
100 % MRKH
Vagina of normal length 
and caliber, mean 
vaginal length of 12 cm 
[179]  
or between 7.5-9.5 cm 
[178]
98.5%MRKH
1.5% MRKH or AIS
≥ 6cm: 82% 
[114,181,183,187,184,190]
≥8cm : 100% 
[60,180,182,185,189]
Complete epithelization of 
the neovagina: 100% [118]
No shrinkage: 100% [188] 
(100%)  
Not further specified: 97.5% 
[62,64]
85% MRKH
8.3% AIS
6.7% other    
(e.g. CAH, mixed GD)
Note: Excluding [103,112]* 
Adequate or good anatomical 
result with no contracture or 
shrinkage: 94%
(103,107,112,115,191,193-95, 198, 
201,203,206,207,210,216,226,227] 
Cosmetically pleasing: 96%  
[208,221]
>7cm: 100% [209] 
>10cm: 100% [224]
>12 cm 100% [114,196,199, 
215,225,231]
> 15cm: 100% [164,220,228]
Note: NR in [192,204,205,211-
214,218,219,222,223,229,230]
98% MRKH
2% CAIS
≥6cm, except  
≥ 10cm in [239]
817
99%
912
95%
393
92%
286
97%
Traction 
vaginoplasty: 
Vecchietti 
or balloon traction 
[74,77-79,105, 
113,118,
232-243]  
Intestinal vaginoplasty:
Sigmoid colon, 
cecum or ileum 
[103,107,112,114,115,
164,191-226],  
jejenum 
[227,228], 
rectosigmoid 
[229-231]
Peritoneal vaginoplasty: 
laparatomically 
[60,62,180-182] 
or laparoscopically 
[64,114,118,183-190]
Vulvavaginoplasty:
[99,103,108,176-179]
Diagnosis
Definition
N  patients
Anatomical 
success
149
activities of the current techniques reported 
hitherto are discussed.
Outcome studies under scrutiny
For the purpose of this review, a total of 189 
studies were analyzed. Single case reports 
and manuscripts solely on patients born 
with ambiguous genitalia and associated 
vaginal hypoplasia (e.g. congenital adrenal 
hyperplasia) were excluded. When different 
vaginal reconstruction regimens were sepa-
rately discussed, the results were separately 
handled [74,98-118]. For analysis purposes, 
the surgical options were divided into seven 
major types: 1) Vaginoplasty without grafting 
(i.e. Wharton procedure) [29,98,103,112,119-
125] 2) McIndoe procedures [33,36,99-
104,108,109,112,115-117,120,126-153] and modi-
fied procedures (amnion, [54,116,117,154-159], 
absorbable adhesion barrier [57,160-162], 
88% MRKH  
1.5% AIS
8% vaginal agenesis with 
functioning uterus
2.5% other (chromosomal 
anomalies, male 
pseudohermaphrotism)1
No contractures: 91% 
[29,119,124],
Max 25% contracture   of 
vaginal space’: 50%  [103]
‘Normal’ vaginal depth’ (≥ 
7cm) [98,121-123,125]: 96%
‘Good/adequate’: 71.5% 
[112,120].
92% MRKH 
4.3% AIS 
2.1% male or female 
pseudohermaphroditism1 
0.7% vaginal atresia with 
functional uterus 
0.9% uterovaginal atresia
Note: Excluding 
[103,112,120,129,131,136,143]*
≥ 7cm: 89% 
[33,36,104,116,126,133,141]
≥8cm : 92%  [109,143,153]
≥ 10cm: 83%  [131,132,145,147]
Max 25% contracture: 82% 
[101,112,115,120,129,144]
‘Normal’ vagina: 33% -100%    
[99,128] 
‘Good’ or ‘adequate’result: 
89% [103,108,136,140,142,148]
Successful take of the graft: 
96% [134,149,152,309]
96% MRKH
2.6% AIS
1.4% cervicovaginal agenesis
Normal epithelization   
of the vagina and
≥7cm for amnion  
procedures: 97%
≥6cm for interceed 
procedures: 94%
≥8cm for buccal mucosa 
procedures: 100%
83% MRKH
8% vaginal agenesis   
and small uterus
4.5% trauma    
(e.g. oncological resection)
1% AIS
3.5% intersex   
(mixed GD or CAH)
≥ 7cm: 100% 
[41,168,169,171,175]
sufficiently spacious : 70-95% 
[167,170] 
fine cosmetic result  with 
natural angle: 100% 
[50,166,173]
no scar and polypoid 
formation or contracture 
[165,172,174]: 63-92%
171
91%
154
96%
1720
83%
209
93%
Skin flap 
vaginoplasty: 
[41,50,165-175,173]
Modified McIndoe:
Amnion 
[54,116,117,154-159],
Interceed oxidized cellulose 
[57,160-162], 
Buccal mucosa 
[55,163,164]
McIndoe procedure:
[33,36,99-104,108,
109, 112,115-117,120,
126-153]
Vaginoplasty 
without grafts: 
[29,98,103,112,119-125]
*Excluding some studies with mixed treatment regimens,  because the specific diagnosis was not known according to the specific  treatment 
regimen, although the majority had MRKH. 1 Not further specified. Abbreviations: MRKH= Mayer-Rokitansky-Küster Hauser syndrome;  (C)AIS= 
(Complete) Androgen Insensitivity Syndrome; GD= Gonadal Dysgenesis: CAH= Congenital Adrenal Hyperplasia
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Stitching and  
wound opening: 3%
Protruding hairs: 1%
Note: No complications 
were reported in studies 
in which women had  
previous failed dilation 
therapy
Vault granulations   
at the neovagina: 9%
Strictures, stenosis   
or contracture: 5%
Rectal, urethral or  
bladder injuries: 4%
Persistent discharge: 2%
Rectovaginal or  
vesicovaginal fistulae: 1%
Note: In those studies in 
which previous surgery 
had failed, complications 
of  stenosis, discharge 
and fistulae were higher 
(respectively 9% vs 1%, 3%  
vs < 1% and 4% vs < 1%)
Dilation under  
anesthesia for not  
complying with  
dilators   
[62,184]
Introital stenosis: 9%
Vaginal prolapse: 3.3%
Vaginal discharge: 2.6%
Bowel obstruction: 1.4% 
Note: Mortality due to bowel 
obstruction or heart failure 
occurred in n=5, in two older 
studies (115,192).  Intestinal 
obstruction only occurred in 
women who had had previous 
surgery. In studies in which 
women had previous surgery, 
higher stenosis and discharge 
complications (9% and 3%) 
were reported, compared 
to studies without previous 
surgery (4% and 1%). Prolapse 
complications were the same 
(3%)
[115,200-202,207,213,214,  
218,225,230,231]
Dilation under  
anesthesia   
[107,206,22] 
Bladder trauma 
(perforation or  
hematoma): 1.8%
Urinary tract infections  
or cystitis: <1%) 
Vaginal vault  
bleeding: < 1%
Note: Bladder perforation 
was more common in 
studies in which  women 
had previous failed 
surgery (9% vs 1.6%), but 
not other complications
[113,238,243]
Dilation under  
anesthesia   
[113]
7,7%
0,4%
96%
Traction 
vaginoplasty
Intestinal 
vaginoplasty
Peritoneal 
vaginoplasty
Vulvavaginoplasty
Proportion 
of patients 
with compli-
cations and 
main compli-
cations 
Proportion 
of patients 
with repeat 
vagino- 
plasty
Sexual  
activity
24,6% 14,2% 6%
3% 1,5% 0%
70% 88% 93%
0,4% 1,2%
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Vaginal contractures: 7%
Vaginal strictures: 4%
Rectovaginal or 
vesicovaginal fistulae: 3%
Note: complications  were 
only reported in studies in 
which a previous procedure 
(vaginoplasty or dilation) 
had failed, after both  
short-term (< 6m) and  
long-term follow-up
[29,112,120,122] 
Note: the majority (77%) 
already had previous  
surgery
Vaginal, urinary tract   
and graft infections : 7%
Strictures and contractures :5%
Fistulae : 3%
Hemorraghe and vaginal  
vault bleeding: 1%
Total or partial graft loss < 1%
Expulsion of the vaginal  
stent< 1%
Rectal perforation < 1% 
Note: Studies in which women 
had failed surgery reported 
an equal amount of strictures 
(5.4%) and fistula (2-3%), 
but more urinary tract and 
vaginal infections (11% vs 3.6%) 
compared to studies in which  
women  did not have surgery 
before. 
In  studies with failed vaginal 
dilation before surgery, 3% 
of strictures were reported, 
and urinary tract infections 
and fistulae were present in 
respectively 2% and 3.5%.
[100,104,108,112,115,  
116,120,128,129,131,135,  
137,140,145]
Note: >75%    
sexually active in all  
studies, except in   
[104,127-129,135,153,309]
Strictures: 4.5%
Urinary tract infections: 4.5%
Only in  amnion group:
Rectal injury: 2%
Labial inflammation: 3%  
Only in buccal mucosa group:
Vaginal bleeding: 9.5%
Note: Urinary tract infections 
were higher in studies with 
previous treatment  
(after failed surgery 12.5%, 
after dilation 8% vs  3% after 
no previous treatment), 
but no differences were 
found regarding strictures 
(respectively 6.3% and 5.4%,  
vs 6.6%)
[159]
Amnion: 78%, 
Interceed:97%
Buccal mucosa: 62%
Vaginal narrowing  
and scar formation: 6.4%
Hair growth: 6%
(Partial) necrosis   
of the graft: 3.5%
Fistulae: 2%
Note: No difference in 
complications rates was 
observed between the 
different skin flap techniques 
(labia minora flaps, gracilis 
musculocutaneous flaps, 
fasciocutaneous flaps, 
pudendal thigh flaps, and 
full-thickness skin grafts)
Fistulae were only  
reported in studies with 
previous failed surgery, 
complications of necrosis  
and vaginal narrowing were 
also higher (respectively   
9% vs 1.6% and 4.5% vs 2.4%). 
[165]
Note: with wide range: 0% 
-33% in [50,171,174]  
to  > 30% [41,168,169,172,173]
22,4%
1%
82%
16,4%
0,6%
81%
22,8%
3,7%
83%
19,3%
11%
100%
Skin flap 
vaginoplasty
Modified McIndoe 
procedures
Vaginoplasty 
without graftsMcIndoe procedure
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Satisfactory intercourse: 
95% [103,108,178]
Intercourse without 
dyspareunia or vaginal 
dryness: 94% 
Satisfactory intercourse 
without partner 
complaints: 86% [99] 
Normal libido and 
orgasm: 100% [176,177]
In 8% [103,178] 
postoperative dilation:
Anatomical success : 
96-100%
Sexual activity: 33-67% 
[103,178] to 100% 
Functional success: 
95-100%
Dilation: 5% (99)
Anatomical   
success: 100%
Sexual activity: 100%
Functional success: 86%
Satisfactory coitus: 89.7%  
[62,64,114,118,181,182, 
185,187-189]
Normal heterosexual 
relationships: 98% [60,180] 
Same FSFI scores 
as controls: 90% 
[118,183,184,190] 
Note: Only in one study  
results were 0% over the 
whole line [186]
In  
[64,114,118,181,186, 187,190], 
50-100% of patients dilated 
for 2-12 months or were 
currently still dilating
Anatomical success:87% 
Sexual activity:92%
Functional success: 82% 
Surgery: 2.8% 
[62,64,183,186,184]
Anatomical success:95%
Sexual activity: 89%
Functional success:92%
Dilation: 1.5% [186]
Anatomical success:NR
Sexual activity: 0%
Functional success: 0%
Satisfactory intercourse 
without difficulties: 90%,    
[103,107,112,114,164,195 
,199,201,202,204-207,209, 
214,216-218,220,222,224, 
227-229] 
Married sex life: 100% [191]
Satisfactory   
sexual activity: 85%  
[193,194,196,197,208,211,212,
215,221,225,226,230,231]
Advised   
postoperative dilation in   
[107,112,114,164,191,195,196, 
199,207,208,214,215,220,222,
224,225,230,231]:
Anatomical success: 97%
Sexual activity:70%
Functional success:93%
No recommended dilation: 
[193,197,201,206,209,213, 
217,221,226-228]:
Anatomical success: 91%
Sexual activity: 73%
Functional success:90%
Satisfactory intercourse 
without dyspareunia: 96%
Satisfaction with non-
coital activities and 
pleasure: 100%  
[232,238]
Satisfying marriage or 
‘very good quality of 
sexual relations’ [74,239]: 
55-100% 
Significant increase 
of penetration and 
satisfaction scores for both 
partners [79,241]: 100%
A tendency of strictures 
could be overcome in 
patients who dilated 
[77,113,232,233], but 
occasional problems  
with disgust to dilator 
[232] and vaginal bleeding 
were reported [235]
Anatomical success: 97%
Sexual activity: 82%
Functional success: 95%
Surgery: 0.4%  
[105,234]
Anatomical succes:100%
Sexual activity:83-100%
Functional success:100%
Dilation: 0.1%  
[242]
The woman had neither 
sexual intercourse nor 
regular use of vaginal 
dilators as advised
Traction 
vaginoplasty
Intestinal 
vaginoplasty
Peritoneal 
vaginoplasty
Vulvavaginoplasty
Definition 
Postoperative 
dilation 
management
Previous 
failed 
vaginal 
recon-
struction
Surgery (peritoneal   
or McIndoe): 10.5% 
[103,107,164,191,194,196 
,199,202,206,207,209,210 
,213,214,216,220,224-226, 
228,229]
Anatomical success: 92%
Sexual activity: 75%
Functional success:90%
Abbreviations: FSFI= Female Sexual Function Index; NR= Not Reported
96% 90% 93% 95%Functional 
success
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Satisfactory   
intercourse
Satisfactory’ [69]
Advised in 
[29,98,112,123],but 25%  
did not dilate properly
Anatomical success: 58% 
Sexual activity: 73%
Functional success: 92% 
Surgery: 7.7% 
[29,120,122,123]
Anatomical success: 85%
Sexual activity:80%
Functional success: 71%
Dilation: 8% [98]
Anatomical success: 78%
Sexual activity:72%
Functional success: 100%
Satisfactory sexual 
intercourse (no dyspareunia), 
without partner complaints 
[99,153] nor differences with  
a control group [138]
‘Normal or successful  
sex life’: 100%    
[134,136,147,149,309]
‘Satisfaction with sexual 
function: 67% -100  
[100,109,146]
Failure to dilate:  
unsatisfactory (anatomical 
and functional) results in most 
[103,108,126,145,150,153], 
except [144]
Most evident in young patients 
[137] and due to psychological 
reasons [150]
40 % reported it was daily 
nuisance [151]
Postoperative dilation  
(min 6 months):   
good results [140,142,143,151]
Long-term use: permanence 
of satisfactory results in > 90%  
of cases [36,136,149]
Contracture yrs after operation 
if no dilator was used in non-
sexually active women [34] 
Surgery: 3.4%   
[115,120,127,129,130,137, 
139,140,151]
Anatomical success: 76%
Sexual activity: 86%
Functional success: 88%
Follow-up: 6.5± 8.5 years
Dilation: 4.6% 
[101,102,126,140,151]
Anatomical success:92%
Sexual activity:96%
Functional success:78%
Follow-up: 12.6 ± 9 years
Pleasurable sexual  
intercourse, without 
dyspareunia and lubrications 
problems, and validated 
questionnaire scores 
comparable to controls 
[159,162]
100% used dilators when   
not sexually active, but those 
who had poor compliance 
had strictures [155,158]
Surgery: 3%   
[54,155,160,164]
Anatomical success: 100%
Sexual activity: 56%
Functional success: 93%
Dilation: 16%  
[54,155,164]
Anatomical success: 100%
Sexual activity: 49%
Functional success: 93%
Satisfactory coitus: 91%  
[41,50,165,166,175]
Adequate erotic sensation: 
100% [165,174] 
Satisfactory sex life  
(for both partners): 71-100%  
[166,168,169,172] 
Married women: 100%  
[173]
Only in two studies reported 
[171,173], in which effect on 
anatomical and functional 
outcome is NR in [144]. 
In [135], vaginal length 
increased from 7cm to 9cm 
in those who dilated, with 
none of the women being 
sexually active
Vaginal narrowing only n 
studies in which patients 
did not seem to dilate 
[165,167,172,174]
Surgery: 2%   
[167,171]
Anatomical success: 95%
Sexual activity: NR
Functional success: NR
Skin flap 
vaginoplasty
Modified McIndoe 
procedures
Vaginoplasty 
without graftsMcIndoe procedure
(Amnion: 98%,  
Interceed: 93%  
Buccal mucosa: 88%)
93% 97% 89,5% 96%
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NR   
(6weeks – 25 years)
Follow-up < 1y  
(6weeks-1 year)  
[108,178], vs ≥ 1y  
(2y- 25 years) [99,311]:
Anatomical success: 
100 vs 98%
Sexual activity:  
33-55% vs 100%
Functional success: 
96% vs 90%
3.6 ±4.5 years  
(1 month- 18 years)
Follow-up < 1y 
[60,64,185,189] vs ≥1 y:
Anatomical success:  
100% vs 89%
Sexual activity: 
81% vs 93%
Functional success:  
96% vs 90%
4.3 ± 2.5years   
(1 month-24 years)
Follow up < 1y 
[193,194,210,212] vs ≥ 1 y:
Anatomical success:  
100% vs 89%
Sexual activity:  
48% vs 67%
Functional success:  
92% vs 87%
1.9±1.5 years   
(6 months-13 years)
Follow up < 1y 
[113,234,235] vs ≥  1 y: 
Anatomical success:  
100% vs 98%
Sexual activity:  
87% vs 95%
Functional success:  
100% (but with vaginal 
dryness)  vs 89% 
Traction 
vaginoplasty
Intestinal 
vaginoplasty
Peritoneal 
vaginoplasty
Vulvavaginoplasty
Mean  
Follow-up 
(years)
and buccal mucosa [55,163,164] 3) Skin flap 
procedures, including myocutaneous / fa-
sciocutaneous flaps [50], pudendal thigh 
flaps [165,166], full thickness skin grafts from 
groins/buttock [167-169], labia minora flaps 
[41,170-174] or a mix of skin flap techniques 
[175] 4) Vulvavaginoplasty (i.e. Williams 
procedure) [99,103,108,176-179] 5) Peritoneal 
vaginoplasty (i.e. Davydov procedure) 
carried out laparatomically [60,62,180-182] or 
laparoscopically [64,114,118,183-190] 6) Bowel 
vaginoplasty with use of sigmoid colon, 
cecum or ileum [103,107,112,114,115,164,191-
226], jejenum [227,228] or rectosigmoid [229-
231] and 7) Traction vaginoplasty, consisting of 
the Vecchietti technique or balloon traction 
[74,77-79,105,113,118,232-243]. Four studies 
[106,110,111,244] reported the outcomes of 
different vaginoplasty procedures combined. 
Seventeen studies also specifically 
mentioned the sexual long term outcomes 
in women without treatment (with or 
without coitus) [81-84,100,110,111,219] or after 
mixed treatment regimens (dilation, surgery, 
coitus or no treatment) [20,84,245-250]. 
Lastly, vaginal dilation studies are reviewed 
[23,74,84,85,93,98,99,101-104,106,107,109-
111,251-263]. 
To assess diagnosis related success rates 
(MRKH vs CAIS ), we included in a separate 
analysis only studies in which the diagnosis of 
the participants was specified as either 46,XX 
MRKH (n=150 studies) or 46,XY disorders of 
testosterone biosynthesis or action (mainly 
CAIS) (n=22 studies) [54,79,82,100,104,110,135,
141,153,155,197,199,203,219,233,241,244,247,249,
254,260,261], including nine studies in which 
there was a mix of 46,XX and 46, XY, but 
differences between the two groups of 
women were separately discussed [54,82,135
,153,155,197,199,233,260].
Tables 3-6 summarize the outcomes of the 
various surgical and non-surgical procedures 
and influencing factors regarding anatomical 
and functional success, clarified for each of 
the studies. 
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1.2 ± 1.0 years  
(2months- 37 years)
Follow-up < 1 y 
[112,119,122] vs ≥1 y:
Anatomical success:  
83% vs 95%
Sexual activity:  
91% vs 81%
Functional success:  
92% vs 88%
4.0 ± 3.4 years   
(1 month-50 years)
Follow-up < 1 y 
[36,104,120,150] vs  ≥ 1y
Anatomical success:   
83% vs 86%
Sexual activity:   
89% vs 90%
Functional success:   
75% vs 88% 
2.3 ±3.7 years   
(1 month – 11 years)
Follow-up < 1y vs ≥ 1y 
[116,159,162,164]
Anatomical success:   
97% vs 76%
Sexual activity:   
73% vs 93%
Functional success:   
94% vs 84% 
1.6 ± 1.6 years   
(2 weeks- 7.8 years)
Follow-up < 1y 
[41,50,174,173] vs ≥ 1y:
Anatomical success:  
97% vs 93%
Sexual activity:  
55% vs 88%
Functional success:  
94% vs 93%
No studies specifically  
reporting the relevance of 
hymen in outcomes
Presence hymen in  
[74,77,99,105 ,114,179,238,242]: 
highly variable results:
Anatomical success:   
81-100%
Functional success:   
55-100% 
Prepuberty  vs puberty in same 
study (all bowel vaginoplasty):
Anatomical success: both 100% 
[198], NR in [211,213]
Complications:   
more common in puberty group  
[198,211,213]
Functional success: unknown vs 0% 
[213] -100% [211], NR in [198]
13-18 years vs >19 years   
(145) (McIndoe procedure)
Anatomical success:   
66.7 % vs 86.5%
Complications (graft infections): 
53% vs 15%
Functional success:   
60% (33% for 13-15 years,   
85% for 16-18 years) vs 71%
Older patients (>30 years):  
more disappointing, possibly 
because of an alteration   
of tissue elasticity [238]  
(Vecchietti procedure)
In ≥ 50% of studies: 
psychological interventions 
recommended, but no 
suggestions as to what type  
or when to deliver
Psychological counseling 
(support group or individual 
counseling) [20,100,102,139, 
151,178,206,217,232,235,239,24
5,246,248] vs no psychological 
counseling:
Anatomical success:   
both 91%
Functional success:   
89% vs 82 %
46,XX MRKH vs 46, XY 
CAIS
Vaginal length before 
surgery: 1.4±1.1 cm  
vs 3.3 ±2.6cm (p= 0.03)
Vaginal length after 
surgery: 9.0 ±1.9 cm  
vs 8.3 ± 2.9 cm
Anatomical success:  
92% vs 95%
Sexual activity:  
81% vs 73%
Functional success: 
90% vs 85%
Skin flap 
vaginoplasty
Modified McIndoe 
procedures
Vaginoplasty 
without graftsMcIndoe procedure
TABLE 4
Other influencing factors on anatomical 
and functional success rates in surgical studies.
Hymen Psychological 
counseling
Timing of treatment Diagnosis
156 888 86%
93% MRKH
7% CAIS or disorders of androgen   
or synthesis
78%
Note: No difference between  
MRKH & CAIS
MRKH:78%
CAIS:77.5%
>6cm: 78% [85,93,98,104,106,110, 
251,254,255,257,262] 
>7cm: 69% [23,260,263] 
>8cm: 33% [84,99,261]
Max 25% contracture of    
the vaginal space: 43% [101]
Not further specified: >90% 
[74,103,256,258]
2% [23,74,253,263]
Urinary complaints: 1%
Pain and bleeding: 0.5% and  
Vaginal prolapse: 0.3%
Note: No differences in frequency or  
type of complications between CAIS   
and MRKH   
4.2 ±3.4 years (0.3 months- 27 years)
Follow-up < 1 year [25, 259] vs ≥ 1 year:
Anatomical success:   
88% vs 85 %
Sexual activity:    
91% vs 81%
Functional success:    
91% vs 85%
96% 
Successful sexual function or satisfaction 
with sex life not further specified: 96% 
[109,254,259,262]
Comfortable coital and orgasmic 
function: 74% (range 0-100%)  
[23,84,85,93,99,101-103,106,251-
253,255,256,260]    
with worst results (<50%) in  
[23,101,106]
Based on standardized questionnaires (FSFI): 
sexual dysfunction in 100% [110]   
to no differences compared to  
controls in 25% [107,258] 
11% [74,98,99,101,255,263]
Reasons:
Motivational problems [23,84,93,98,101,260] 
Poor compliance [23,85,252,262] 
Discomfort, pain (because of lichen 
sclerosis), vaginal prolapse or prior attempt at 
hymenectomy with secondary scar formation 
[23,74,101,256]
Anatomical reasons: Absence of an 
appreciable dimple to begin with [103,256] 
or sturdy perineum [84,99] and multiple 
congenital abnormalities [262]
Practical reasons such as lack of  
privacy [23,260] or travel distance   
to the clinic [106] 
Psychosocial reasons such as no or 
an unstable relationship at the time of 
treatment [84,255,260], cultural or religious 
beliefs [255,262], young age [101], learning 
difficulties [262], interpersonal conflict related 
to the treatment [262] and significant mental 
health problems [255,262]
Not successful despite compliance with 
treatment recommendations [260,263]. 
Cause unclear ( Note:Majority had MRKH,  
and thus likely a shorter vaginal start length)
TABLE 5
Summary of vaginal dilation studies    
[23,74,84,85,93,98,99,101-104,106,107,109-111,251-263].
N patients Sexual activity
Diagnosis
Functional 
success
Anatomical 
success
Definition   
of anatomical  
success
Definition 
functional 
success
Proportion of 
patients with 
complications 
and main 
complications
Mean  
follow-up 
(years)
Failed 
dilation
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TABLE 6
Influencing factors on anatomical and functional     
success rates in vaginal dilation studies.
7.6 (±4.8 months) 
(range 2days- 60 
months)
No association with 
anatomical success  
(R= -0.2, p>0.05)
Dilation ≤ 6m [99,106, 
258-260,263] vs > 6 m 
[23,98,101,256,257]
Anatomical success: 
73% vs 63%
Sexual activity: 
86% vs 73%
Functional success: 
70% vs 57%
Note: dilator treatment 
was stopped after 
maximum 6 months of 
compliance, irrespective 
of results, or because 
no further elongation of 
the vaginal length was 
observed in [98,99,263] 
In 63% of studies
Definition:
Emotional support from sensitive physician,  
not necessarily psychiatric care: [103]
Meeting with succesfully treated   
former patient: [93,253]
Patient and family counseling: [101]
Input from nurse specialist and/or psychologist: 
[23,110,253,257-260,262,263]
Psychodramatic therapy: [254]
Support group meetings: [255]
Not further specified: [106,251,256,261]
Psychological counseling    
vs no psychological counseling:
Minimal amount of months dilating: 3.8 ± 3.2 
months vs 1.4 ± 0.4 months, p<0.05
Anatomical success: 74 % vs  63% p>0.05
Functional success: 70 % vs 77% p>0.05
Successful completion of treatment not dependent 
on psychological counseling [106] and not different 
between inpatients  or outpatients [106] 
The quality of life was high in groups who attended 
counseling and those who did not [270];  however, 
mental health was poor compared to physical health 
[111] and scores for sexual depression, sexual anxiety 
and fear of sexual relations remained high compared 
to groups of non-affected women [111]
No studies compared women who did and did not 
maintain dilation when not being sexually active 
regarding functional or anatomical outcomes.
Only in  two studies [85,260] women without  coitus 
were still dilating at the time of follow-up:vaginal 
length: 6.5-8.5cm 
Note: unclear whether women who used dilators 
had smaller vaginal lengths vs those who were 
sexually active
Possibly, sexual activity further lengthens the vagina 
[111], and a combination of dilators and intercourse 
improves both anatomical and functional success 
rates [84,106,255]
Maintenance dilation recommended:    
2-3 times/week when no regular coitus    
[23,98,101,109,251,254,256,260]
Motive: to avoid shrinkage of vagina
No further dilation recommended [253,262] 
Motive: when embarking in a relationship after 
a substantial absence of dilators or intercourse, 
women very quickly regain their original length, 
eventually after dilating for a short time [262] 
Anatomical success: NR
Functional success: only assessed in small subgroup 
of women, reported in [258], with sexual problems 
(difficulties with maintaining lubrication, pain during 
intercourse)
Frequency of dilation 
periods, not the total 
amount of minutes 
dilating per day (e.g. one 
time for 30 minutes vs 
3 times for 10 minutes) 
positively associated  
with anatomical success 
(R= 0.514, p<0.05). 
Dilation 2-4x day  
[23,85,93,99,101,106, 
252,259,262]  
vs 1x/d [84, 109,251, 
260, 261,263]:
Anatomical success: 
76% vs 49% (p=0.06)
Sexual activity: 
80% vs 91%
Functional success: 
78% vs 84%
Total duration of 
treatment;   
7.6 ±5.4 months  
vs 5.1 ± 0.1 months
Positive association  
with anatomical success 
(R= 0.6, p< 0.05) 
< 18 years 
[23,99,101,109,255,261] 
vs ≥ 18 years  
[85,98,106,251,252,254, 
257-260,262,263]:
Anatomical success: 
47% vs 78% (p<0.05)
Sexual activity:  
77% vs 88%
Functional success: 
78% vs 76%
 
46,XX MRKH vs 46,XY 
CAIS
Start vaginal length: 
3.1 ± 0.5 cm   
vs 4.5 ± 2.1 cm
End vaginal length:  
6.8 ±1.8 cm   
vs 8.2 ±0.8 cm
Anatomical success: 
70% vs 79%
Sexual activity: 
76% vs 42% 
Functional success: 
73% vs 44% 
Positive association 
between start vaginal 
length and end vaginal 
length (R=0.69, p< 0.05)
Start vaginal length not 
significantly correlated 
with anatomical success 
(R=0.61, p> 0.05)  
Larger vaginal start 
length associated with 
shorter duration of 
dilator therapy  
(R= -0.9, p< 0.05) 
Note: unclear how 
previous attempts at 
sexual intercourse might 
have influenced the start 
vaginal length, as this 
information was  
not reported in most 
studies [94] 
Absence (252): 
Anatomical success: NR
Sexual activity:NR
Functional success:92%
Hymen, hymenal 
remnants or 
pseudo-hymen in  
(74,85,99,251,256) 
vs studies in which 
parameter was 
unknown:
Anatomical success: 
68% vs 71%
Sexual activity: 89% 
vs 71%
Functional success: 92% 
vs 67%
Total duration of 
dilation treatment
Psychological counseling
Age at start 
treatment
Maintenance dilation
Hymen
Frequency of 
dilation
Diagnosis
Vaginal length at 
start treatment
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Practice informing Theory 
Establishing the risk/efficacy profile of 
the different surgical and non-surgical 
techniques, we evaluate if vaginal dilation, 
proposed as first line technique is justified on 
an evidenced base. 
Comprehensive synopsis 
of main outcomes 
Anatomical success and complications
Anatomical success, referring to an 
adequately sized vagina, seems to be in most 
studies defined on the basis of two (related) 
parameters. The first is vaginal length, agreed 
upon to be at least 6 cm. The second is an 
absence of complications (and in particular 
contractures affecting vaginal length, or scar 
formation), considered to be associated with 
a cosmetically pleasing result (in the rule 
according to the clinician’s perspective).
Reference values for normal vaginal length 
were previously described to be 7 to 13 cm 
(mean 9.25 ±1.56 cm) [264]. Non-surgical 
vaginal dilation treatment has been shown 
to normalize vaginal length in at least 
75% of women, irrespective of karyotype 
or underlying diagnosis. However, when 
anatomical success was defined as a length of 
≥ 7 cm, vaginoplasty techniques alike yielded 
significantly higher anatomical success rates 
(> 90% vs. 78% after vaginal dilation). 
In contrast, complication rates were 
significantly lower within the vaginal dilation 
series as compared to the published surgical 
series (2% vs. 6-25%). Main complications 
in the vaginal dilation group were urinary 
complaints and infrequent pain and bleeding 
(≤ 1%). Similar complications and rates were 
found with use of traction vaginoplasty 
techniques, with the exception of bladder 
trauma (2%) being more surgery-prone. 
Complications of the majority of surgical 
techniques involving a dissection between 
the rectum and bladder, were vaginal 
strictures, contractures or stenosis (4–9%), 
urinary tract infections (4-7%), vesicovaginal 
or rectovaginal fistulae (1-3%), and rectal or 
bladder perforation (1-4%). In the case of skin 
grafting, extra complications included (partial) 
necrosis of the graft (1- 3.5%) and hair growth 
in the neovagina (1-6%). Persistent discharge 
(2-3%) was only apparent after peritoneal and 
bowel vaginoplasty; in the latter only vaginal 
prolapse was also common (3%). In general, 
reported complications rates were higher in 
studies where previous treatment (surgery 
or dilation) had failed, and even higher after 
surgery as a first line treatment compared to 
after dilation for most main complications 
associated with the respective techniques. 
Functional success
There is more variability regarding the 
definitions of functional success, although 
most seem to include the notion of ‘full genital 
performance during heterosexual intercourse 
as the essence of sexual functioning’ [265]. 
When referring to satisfactory coital function, 
functional success for vaginal dilation 
techniques is at least 74%. This is significantly 
lower as compared to vaginoplasty studies, 
reporting success rates between 90-96%. 
When functional success is defined as 
‘satisfaction with sex’, including non-genital 
sex, differences disappear (93% vs. 96%). 
Overall, in both vaginoplasty and vaginal 
dilation studies, the terms ‘‘active sex life’’ 
or ‘‘satisfied’’ were often not operationally 
defined, so it is left unclear as to what 
was precisely meant by these terms [266]. 
In early reports, as well as reports from 
developmental non-Western countries, it 
was not uncommon to let functional success 
depend on the ability of the woman to 
provide pleasure to the partner. This suggests 
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that outcomes in the form of ‘satisfaction’ 
should not be taken at face value but, 
rather, interpreted critically in the light of 
historical and cultural contexts. Recently 
available standardized questionnaires on 
sexual function, such as the Female Sexual 
Function Index (FSFI) [267] can reliably assess 
female sexual wellbeing and can provide an 
alternative way to compare the functional 
outcomes of different vaginal reconstruction 
options. Table 7 provides an overview of the 
studies with FSFI results. Mean total FSFI scores 
(range 0-36) indicate in general, weaker 
functional scores, after both vaginal dilation 
(25.2 ± 4.5) and vaginoplasty (28.03 ±3.0), 
compared to the standardization population 
(30.2 ± 6.1). Lower scores are evident in four 
of the six subscales: arousal, lubrication, 
orgasm, and pain during intercourse (p<.01), 
with no differences for desire or satisfaction 
with sex life and/or relationship. As sexual 
distress is not assessed in most studies - 
a criterion essential to diagnose a sexual 
dysfunction according to the Diagnostic 
and Statistical Manual of Mental Disorders- 
Text Revision (DSM-IV-TR) , the prevalence 
of sexual dysfunctions remains unclear. No 
differences are found between different 
vaginoplasty methods, but the samples 
are small. Of interest, women who were 
medically treated (surgery or vaginal dilation) 
did not have better indicators of sexual 
wellness or sexual function than those who 
were untreated, suggesting an important role 
of other factors than treatment, affecting 
sexual well-being in these women. Studies 
investigating other quality of life parameters 
suggested that psychological variables such 
as depression symptoms [231,260,268], doubts 
about female identity [196,207,244] and body 
image problems [102] are still prevalent after 
treatment and that neither surgical or non-
surgical options, even if satisfactory, solve all 
problems [107]. It is interesting in this respect, 
that women who had undergone treatment 
still perceive their vagina as abnormal [247]. 
The repercussions of a negative genital 
image on sexual satisfaction have been 
shown in the general population [269]. Stable 
relationships and a good communication 
between partners were further suggested 
to be crucial contributors to overall sexual 
satisfaction, independent of neovaginal 
length or treatment [84,190,270]. As such, the 
importance of vaginal depth for satisfactory 
outcomes and the general relationship 
between anatomical and functional success 
remains difficult to determine [151,240,260,271]. 
With regard to the FSFI evidence, sexual 
problems were not more common in studies 
in which a mean vaginal length of less than 
6.6 cm was reported. However, it is unclear 
from these studies if individual women 
with a smaller vaginal length were sexually 
active and had lower functional outcomes. 
Methodological problems have been noted 
with the FSFI when women report not to be 
sexually active in the last 4 weeks preceding 
the survey [272]. In addition, standard 
instruments, such as the FSFI, might not be 
well-tailored to assess the specific situation 
of women with vaginal hypoplasia, suggesting 
that an improved research methodology 
is needed to fully assess the impact of the 
involved conditions and its management on 
sexual experiences and wellbeing.
Quest for the optimal 
vaginoplasty technique
Based on the currently available evidence, it 
remains difficult to determine the superiority 
of one vaginoplasty technique over the 
other. This is due to problems including 
the heterogeneous group of patients, and 
the unavoidable reporting bias of surgeons 
towards the techniques they are mostly 
experienced in. Another problem relates 
to the lack of concordance in recording 
the long-term outcomes of the different 
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TABLE 7
Female Sexual Function Index values after alternative vaginoplasty techniques, 
vaginal dilation and no treatment in women with vaginal agenesis.
[267] 
131
Control
Control
4.1 (1.1)
5.0 (1.0)
5.5 (0.9)
5.0 (1.2)
5.1 (1.2)
5.5 (1.0)
30.2 (6.1)
NR
NR
9.6 (1.5)
[110] 
9 
46,XY DSD 
No treatment
3.8 (0.6)
4.8 (1.2)
4.8 (0.9)
4.9 (1.0)
4.9 (1.0)
5.0 (0.7)
27.6 (4.8)
55,6
50
8.9 (2.6)
[111] 
10
MRKH 
No treatment
4.9 (1.0) 
5.2 (1.0 
4.9 (1.3) 
5.1 (1.1) 
5.6 (0.4 
NR 
NR 
NR 
NR 
4.8 (2.6)
[110] 
15
MRKH &  
46,XY DSD`
Bowel [n=2], 
Skin grafts [n= 
11], Vecchietti 
[n= 2] 
3.9 (1.2) 
4.3 (1.3) 
3.5 (1.8) 
4.0 (1.3) 
4.5 (1.2) 
4.1 (2.2) 
23.9 (5.7) 
57,1 
62,5 
9.1 (2.7)
[111] 
7
MRKH
Vecchietti [n=4],  
McIndoe [n=1], 
bowel [n= 1] 
and skin flap  
[n= 1]
3.9 (1.3)
4.8 (1.0) 
5.3 (0.7) 
5.0 (0.8) 
5.5 (0.8) 
NR 
NR 
NR 
NR 
7.4 (2.6)
[271] 
18 
MRKH 
Wharton  
3.6 (1.2-6) 
4.5 (2.4-6) 
5.7(1.2-6) 
4.2 (1.2-6) 
5.6 (2.4-6) 
4.8 (0-6) 
28.2 (10.8-36)
NR 
80 
6.3 (4.5-12)
[125] 
7 
MRKH 
Wharton  
4.3 (1.3) 
5.4 (0.5) 
5.1 (1.5) 
4.9 (1.0) 
5.1 (1.5) 
5.1 (1.1) 
29.9 (4.3) 
NR 
NR 
8.3 (7-10)
[114] 
11 
MRKH 
Bowel  
4.2 (0.2) 
4.2 (0.1) 
4.2 (0.1) 
4.1 (0.3) 
4.4 (0.3) 
4.2 (0.3) 
24.8 (1.2) 
NR 
NR 
12.6 (0.4)
[184] 
25 
MRKH 
Davydov 
4.4 (0.9) 
4.4 (1.1) 
4.5 (1.4) 
4.1 (1.3) 
4.6 (1.1) 
4.4 (1.4) 
26.5 (5.6) 
NR 
72 
7.2 (1.5)
[118] 
40 
MRKH 
Vecchietti 
4.2 (0.9) 
4.6 (1) 
4.5 (1.0) 
4.4 (0.9) 
5.2 (1.2) 
5.2 (1.0) 
30.2 (1.0) 
NR 
NR 
7.5 (1.1)
[243] 
23 
MRKH 
Vecchietti 
4.5 (0.7) 
5.9 (0.8) 
4.3 (0.8) 
4.6 (0.9) 
5.2 (0.6) 
4.7 (0.7) 
30.1 (3.8) 
NR 
NR 
8.8 (1.1)
[77] 
27 
MRKH 
Vecchietti 
4.4 (0.8) 
4.8 (0.8) 
5.0 (0.8) 
4.6 (1.0) 
5.4 (0.6) 
5.0 (0.9) 
29.0 (3.2) 
NR 
55 
6
[110] 
8 
46,XY DSD 
Dilation 
2.8 (0.8) 
4.3 (1.1) 
4.8 (1.3) 
4.3 (1.6) 
4.4 (1.0) 
2.4 (2.5) 
21.6 (2.5) 
43 
100 
7.3 (1.3)
[111] 
20 
MRKH 
Dilation 
3.5 (1.2) 
3.6 (1.7) 
4.2 (1.7) 
3.32 (2.0) 
4.0 (2.0) 
NR 
NR 
NR 
NR 
5.1 (2.6)
[107] 
5 
MRKH 
Dilation 
4.7 (1.3) 
5.1 (1.0) 
5.1 (1.1) 
4.8 (0.9) 
5.4 (1.2) 
5.2 (1.1) 
30.3(6.2) 
60 
25 
NR
[258] 
56 
MRKH 
Dilation 
3.7 (1.0) 
4.0 (1.4) 
4.2 (1.4) 
3.9 (1.5) 
4.3 (1.2) 
3.6 (1.7) 
23.7 (4.3) 
NR 
NR 
NR
Ref
Ref
N
N
Diagnosis
Diagnosis
Satisfaction
Satisfaction
Arousal
Arousal
% Sexual 
distress
% Sexual 
distress
Study
Study
Pain
Pain
Lubrication
Lubrication
% FSD
% FSD
Desire
Desire
Total FSFI
Total FSFI
Orgasm
Orgasm
Vaginal 
length (cm)
Vaginal 
length (cm)
Data presented as mean (SD). Used abbreviations: MRKH: Mayer-Rokitansky-Küster-Hauser syndrome, CAIS: Complete Androgen Insensitivity 
Syndrome; DSD: Disorders of Sex Development, FSFI: Female Sexual Function Index (range 0-36, domain scores 0-6),  FSD= Female Sexual 
Dysfunction, Ref= Reference, NR= Not Reported
161[107] 
35 
MRKH 
Bowel  
4.4 (0.9) 
4.7 (0.7) 
5.2 (0.9) 
4.4 (1.1) 
5.4 (0.6) 
3.9 (1.2) 
28.0 (3.1) 
85 
30 
NR
[231] 
45 
MRKH 
Bowel  
NR 
NR 
NR 
NR 
NR 
NR 
28.9  
(11.5-35.7)
NR 
14,8 
13
[207] 
8 
MRKH 
Bowel  
5.0 (0.5) 
4.9 (0.3) 
5.0 (0.9) 
4.7 (0.9) 
5.6 (0.3) 
4.8 (1.0) 
30.0 (3.0) 
NR 
12,5 
NR
[162] 
7 
MRKH 
Oxidized 
cellulose 
NR 
NR 
NR 
NR 
NR 
NR 
32.5 (1.1) 
NR 
NR 
9.6 (2.1)
[159] 
5 
MRKH 
Amnion 
4.9 (1.2) 
5.0 (0.8) 
4.0 (0.7) 
5.5 (1.0) 
5.3 (1.4) 
5.3 (1.8) 
30.0 (6.9) 
NR 
NR 
9.8 (1.7)
[114] 
21 
MRKH 
Davydov 
4.3 (0.1) 
4.2 (0.1) 
4.0 (0.2) 
4.0 (0.3) 
4.5 (0.2) 
4.4 (0.3) 
25.3 (0.5) 
NR 
NR 
11.9 (1.2)
[118] 
40 
MRKH 
Davydov 
4.3 (0.7) 
4.7 (0.8) 
5.1 (0.6) 
5.0 (0.6) 
4.8 (1.5) 
4.7 (1.0) 
31.8 (0.8) 
NR 
NR 
8.5 (1.6)
[186] 
6 
MRKH 
&CAIS  
Davydov 
3.9 (1.2) 
4.0 (1.1) 
4.4 (1.0) 
3.3 (1.6) 
4.0 (1.8) 
1.9 (1.9) 
21.4 (5.3) 
NR 
75 
NR
[190] 
31 
MRKH 
Davydov 
3.8 (0.9) 
4.2 (0.8) 
5.1 (0.6) 
3.8 (1.2) 
4.5 (1.1) 
4.7 (1.2) 
26.1 (4.8) 
NR 
71 
6.3 (1.3)
approaches. A follow-up of less than 1 year 
seemed to be associated with less sexual 
activity and functional success, but the effect 
on anatomical success is unclear. It is possible 
that the severity of dyspareunia or adequate 
lubrication are inversely proportional to the 
time since operation, resulting from the 
progressive epithelization of the neovagina, 
a process that is almost complete after one 
year. Despite significant advances over the 
past decades in surgical techniques and 
improved knowledge of the anatomy and 
innervation of the female genitalia, there is at 
present no evidence that newer techniques 
improve long-term outcomes.
In addition, anatomical (based on vaginal 
length) and functional success (based on 
coital activity) were not significantly lower 
in studies in which previous surgery or 
dilation had failed, although there was a 
trend towards more complications in these 
studies. It could also be that patients in whom 
previous treatment had failed were those with 
more complex inherent anatomical features 
to begin with. As such, it remains unclear if 
previous attempts at vaginal reconstruction 
jeopardize surgical success. 
Moreover, there is a lack of a standardized 
approach in reporting the results of 
postoperative dilation management. In those 
studies that mentioned a proper postoperative 
dilation regimen, anatomical success rates 
were in general higher and contractures 
and strictures (between 5-7%) could be 
overcome, even in bowel vaginoplasty where 
postsurgical dilation is generally said not 
to be necessary. Therefore, maintenance 
dilation seems to have an additive value, 
either with regular dilation or coital activity. 
Nuancing the need for maintenance dilation 
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however, success rates are in general also 
high in studies without postoperative dilation. 
Finally, from the available evidence, it remains 
unclear if age at surgery is related to the 
outcomes or if there exits an optimal time 
window for the most favorable anatomical 
outcomes. The majority of women felt 
however that the appropriate time to undergo 
surgery was in adolescence [206], seeming 
to underline that interventions can only be 
undertaken when the patient is emotionally 
mature and ready to engage in sexual activity 
[103,113,121,145,159] or marriage in some 
cultures [126,158]. It has also been suggested 
that a vagina is not necessary for a young girl 
prior to sexual intercourse [6] and that early 
psychological problems related to regular 
postoperative dilation can be minimized by 
delaying surgery [202].
In sum, the quest for the optimal surgical 
method continues, as no technique is 
completely without failure risk, and some 
have (still) high complication rates. In general, 
however, traction vaginoplasty seems to 
have the highest anatomical (≥6cm, 99%) 
and functional success rates (satisfactory 
coitus, 96%), whereas both split-thickness 
and full-thickness skin graft procedures and 
intestinal and peritoneal procedures have 
the lowest outcomes (83-95% anatomical 
success and 90-93% functional success). 
Traction vaginoplasty also has the lowest 
complication rate, suggesting it to be an 
appropriate surgical technique either as first 
line treatment or after failed vaginal dilation. 
Effectiveness of vaginal
dilation as first-line technique: 
A time-honored practice?
Combining data from published non-surgical 
series allows some important insights into 
relevant factors which may impact on daily 
clinical vaginal dilation practices and on 
decision-making in individual cases.
Anatomical success
Surprisingly, start vaginal length was not 
significantly associated with anatomical 
success. This refutes the claims that success 
can only be achieved in women with an 
existing vaginal dimple of 2-3 cm [99]. For 
this reason, women with CAIS and androgen 
synthesis disorders, who generally have a 
larger starting vaginal length, do not seem 
to have an advantage over women with 
MRKH. Of note, women above 18 years of 
age at the start of treatment had significantly 
higher anatomical success rates, which is 
probably related to motivational reasons. 
Dilation has to be actively managed by the 
patient and a sustained effort is required, 
while progress is slow [273]. Therefore, we 
suggest dilator treatment only in women in 
whom motivation is high, for example when 
being in a current relationship or wanting 
to engage in sexual activity, which has also 
been shown to be an important factor in 
postoperative dilation management. With 
regard to frequency and duration of dilation 
treatment, it becomes clear that the best 
anatomical results were obtained when 
the frequency of dilation periods was high, 
suggesting that regular stretching is more 
beneficent than the actual total time of 
stretching. Total duration of dilator treatment 
seems not to be related to anatomical 
success. Although some, including our own 
research group [93,251,274], suggested that 
the highest gain in vaginal depth was reached 
within 4-6 weeks, and that the gain thereafter 
is minimal, it is unclear from the available data 
if there exists an optimal window for gaining 
length. Unfortunately, despite compliance, 
which can be increased with psychological 
support [257,262], conservative therapy can 
fail [111,263]. No conclusions so far can be 
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drawn on the presence or absence of the 
hymen relating to failure of treatment [275], 
nor whether perineal skin is different from the 
vagina in its elastic characteristics. However, 
failed dilation therapy does not preclude 
anatomical (nor functional) success if 
vaginoplasty afterwards is necessary. Overall, 
complication rates were significantly lower 
within the vaginal dilation groups as compared 
to the different vaginoplasty techniques (2% 
vs. 6-25%), being its major advantage, but 
should be followed-up in the long term as 
well. Displacement of the bladder neck might 
occur during vaginal lengthening, which may 
affect bladder function and cause urinary 
symptoms [263]. Also, the creation of a vagina 
in this fashion does not preclude vaginal 
disease, and cases of vaginal intra-epithelial 
neoplasia and vaginal carcinoma have been 
described [276]. To date fifteen (case) reports 
of vaginal prolapse have been reported 
[74,140,177,277-283] which is still considerably 
less frequent than reported prolapse after 
vaginoplasty (e.g. bowel vaginoplasty: 3%). 
Finally, although no randomized control data 
exist regarding maintenance dilation, the 
available evidence suggests that continued 
dilation is needed to maintain patency in 
periods of coital inactivity.
Functional success
From the available evidence, total duration 
of vaginal dilator treatment might have a 
detrimental effect on sexual activity levels 
and functional success rates, suggesting that 
dilation therapy should perhaps be stopped 
after 6 months of compliance, moreover 
because anatomical success seems thereafter 
not affected. While the reasons for decreased 
functional success are not entirely clear, it is 
possible that the emotionally charged nature 
of the dilation process may make it difficult 
for women to keep separating on the long 
term medical dilation treatment from ‘real 
sex’ - with a possible disgust or withdrawal 
from sexual activities. Especially younger 
women (< 18 years) might be more vulnerable 
to such difficulties, as motivational issues are 
already more prevalent in this age group. This 
does, however, question the possible impact 
of the recommended maintenance dilation 
on psychological grounds. Furthermore, as 
in surgical series, the importance of assessing 
functional success on the long-term is 
confirmed, as there seems to be a decrease 
with a longer follow-up period. Although 
some researchers have suggested that 
psychosexual functioning levels and coping 
abilities improve with time [20,220], others –
including our research group- have indicated 
that women continued to feel far from 
normal in the areas of sexual potency and 
reproduction (i.e. perceived loss of social role 
as potential mother, loss of sense of equality 
with peers), contributing to high emotional 
distress, in different ways and at different 
times [111,274,284]. Continued long term 
follow-up acknowledges the importance 
of developmental-temporal factors to the 
distress. 
Given the physical and psychological 
challenges then of this lifelong condition, 
it is unlikely that these women will 
achieve complete normal sexual function 
[111]- whatever enlargement technique 
is used. Interestingly, however, women 
simultaneously reported relatively high levels 
of sexual difficulties and sexual ‘satisfaction’. 
Problems related to the definition of 
‘satisfaction’ with sex – for whom and 
with what (i.e. intercourse) - were already 
mentioned. In addition, women with MRKH 
or CAIS might have learnt to be ‘satisfied’ 
with barely satisfactory sexual experiences—
that is, the women might have felt that sexual 
difficulties were to be expected and thus that 
they should not be dissatisfied [247]. Although 
this raises concerns about the powerful 
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influence of the current cultural context in 
which (sexual) difference is still taboo, it also 
questions how treatment success should be 
further approached [285]. Moreover, as it was 
shown in therapeutic work that few women 
with vaginal hypoplasia allude to pleasure 
as a reason for wishing to engage in sex but 
rather reasons related to ‘feeling’ and ‘acting’ 
normal through intercourse [286], assuming 
intercourse will be a central therapeutic goal 
for these women is likely to give misleading 
impressions of what constitutes a successful 
treatment outcome [287]. A key message 
here is that - where earlier approaches may 
have considered ‘normative’ functions of 
the genitalia and relative absence of patient 
complaints as indicators of good outcomes-, 
future approaches need to reformulate 
outcome evaluation and specifically raise 
a wider range of psychosexually oriented 
questions [286,287]. A simple questioning on 
sexual ‘satisfaction’ is not a useful measure in 
these diagnostic groups. 
Pitfalls in treatment success
Psychological profile 
and the effect of counseling
In general, an inaccurate evaluation of the 
emotional status before any treatment is 
suggested to lead to a poor result [103,142], 
as it was made clear that most women were 
struggling with body image [102,107], or felt 
anxious, socially unattractive, depressed 
or lacked self-control [115,232,245,246]. 
Psychological interventions, such as 
cognitive behavioral group therapy in these 
women have been shown to be effective in 
reducing anxiety and feelings of depression 
[288-290]. However, despite the expectancy 
that the probability of further positive, 
functional or anatomical, outcomes are 
maximized with psychological counseling, 
this could not be confirmed with the 
current data. The self-esteem, knowledge, 
or interpersonal skills built up in therapy 
or by peer support did not seem to be –
both immediately and on the long-term - 
translated in satisfying sexual relationships 
[273,274,289]. Despite counseling, some 
still felt depressed and extremely insecure 
relating to others [20,245], which is possibly 
also reflected in rather low sexual activity 
rates in any treatment paradigm (85%). 
Findings from our group even showed an 
unexpected increase in emotional difficulties 
after a standardized dilation program 
with input from a clinical psychologist 
[274]. The majority of participants refused 
psychological counseling after a few 
sessions because contact with psychologists 
was said to engender powerful ambivalent 
emotions of abnormality as well as feelings 
of failure in not coping with the condition. 
Contact with peers was said to be motivating 
during treatment, but was further limited 
to discussion of subjects related to the 
shared condition [19,274]. While the move 
to including psychological input in clinical 
teams specializing in disorders of sex 
development (DSD) is significant, it is still 
open to negotiation how the psychologist’s 
role in certain situations allows for 
substantive and worthwhile contribution. It 
is of utmost importance to gain additional 
experience concerning the format of 
acceptable and efficient psychological care 
and how to integrate it in the regular medical 
follow-up [285].
Diagnosis effects
The present review further underlines 
the importance of detailed reporting on 
diagnosis, as there are differential outcomes 
for women with 46, XY disorders of androgen 
action or synthesis (mainly CAIS), and 46, XX 
MRKH. 
165
Although no differences in anatomical out-
comes were found, women with a 46,XY 
karyotype have a significantly larger start 
vaginal depth compared to 46,XX women (e.g. 
[260]). The question arises as to whether this 
is the reason why the majority of women with 
CAIS do not opt for vaginal reconstruction 
interventions. The prevalence of vaginal 
hypoplasia within a CAIS population has not 
extensively been studied. Due to the action of 
fetal testicular antimüllerian hormone on the 
developing müllerian ducts, it is hypothesized 
that CAIS might be associated with 25% to 
33% loss of vaginal length [247]. In this review, 
however, despite a wide range, an average 
loss of 66% was shown in women with CAIS 
who had no treatment or sexual activity yet 
(3.8cm ±2.2 vs. 9.6 ±1.5 cm in non-affected 
women[264], contradicting previous studies 
[100,219,247,249], and perhaps indicating that 
only those CAIS women with the shortest 
start vaginal length and/or who have not 
been sexually active yet seek medical advice. 
After treatment, length of the neovagina is 
not necessarily proportional to satisfactory 
outcomes and this topic should deserve 
more detailed investigation.
In contrast, functional success rates, with all 
reconstruction techniques, were in general 
significantly lower in women with a 46, XY 
karyotype compared to women with 46, XX. A 
high rate of impairment of desire and arousal 
and dyspareunia in women with CAIS has 
been shown before[291], which could be due 
to the complete lack of androgens affecting 
libido and orgasm [100,247] and/or lack of 
androgen imprinting on the brain [291]. Also, 
gonadectomy and the subsequent estrogen 
substitution therapy is sometimes said to 
lead to insufficient vaginal lubrication [263]. 
However, this information is not recorded in 
most studies and it is difficult to surmise how 
it might have impacted upon the results.
Theory informing Practice
What emerges from this overview of selected 
publications is that evidence for both physical 
and psychosocial outcomes in women with 
vaginal hypoplasia remains incomplete and 
uncertain. Some fundamental questions about 
whether for instance treatment harms genital 
sensitivity or produces acceptable cosmetic 
results according to the affected women 
themselves are still disputed [292]. How 
these issues interplay in individual situations 
may perhaps never be resolved definitively 
because the answer will always depend on 
too many variables: the woman’s individual 
anatomy and physiology, the clinician’s skills 
and judgment, the quality of post-operative 
care, the psychosocial resources available 
and their perceived usefulness, relationships 
within the family and the deeply subjective 
nature of satisfaction with sexual sensation 
and function as well as cosmetic outcomes 
[293]. Women must have access to this 
balanced information, in order to fully weigh 
the potential risks and benefits of treatment. 
Furthermore, as the medical literature lacks 
high quality comparative outcome studies, 
no evidence-based treatment guidelines can 
be provided. Despite limitations, with the 
obtained evidence concerning the results of 
current techniques, we are in a position to 
advance thinking and practice in this field in 
various ways.
Recommended treatment algorithm 
in women with vaginal hypoplasia
Figure 2 summarizes the treatment decision 
tree in women with vaginal hypoplasia. 
Because of the physically low complication 
rate and an overall success chance of 75%, 
vaginal dilation treatment (either with or 
without intercourse) as a first line choice 
seems to be justified if women had no 
prior treatment (i.e. reconstructive surgery). 
166
Dilator treatment has not only benefits 
(e.g. preservation of vaginal tissue), but also 
barriers, which should not be minimized 
[273]. Vaginal dilation is time consuming and 
some patients find it distressing. Overall, the 
laparoscopic Vecchietti procedure, becoming 
more and more available in specialized 
centers, is considered an appropriate surgical 
option for the creation of a neovagina in 
patients who are poorly compliant and failed 
dilation therapy, or for those who do not 
want to start with vaginal dilation therapy. 
It is difficult to justify proceeding directly to 
some of the more complex techniques such 
as intestinal vaginoplasty with its associated 
high morbidity and long term side effects. 
These techniques can have a role in complex 
patients with previous extensive abdominal 
surgery, particularly those cases where 
there is significant scarring from previous 
surgery. Choosing the right operation in 
patients who require surgical reconstruction 
is integral to success. Moreover, it should be 
noted that the first attempt at any neovaginal 
reconstruction has the best chance for 
success and every failed attempt leaves its 
traces and should be avoided. Therefore, it 
is crucial to resolve whether the patient has 
the mental resources, including perhaps 
certain personality traits, necessary to cope 
with the management of her condition in an 
effort to optimize therapeutic success [246]. 
Regardless of the vaginal reconstruction 
technique used, patients should be managed 
in specialized centers by a multidisciplinary 
team, where there is adequate emotional and 
psychological support available. Specialist 
units should be able to offer all treatment 
options and also have a duty to provide 
detailed long-term outcome data [17,21].
New ideas from old concepts: 
Vaginal dilation treatment 
in clinical practice
A practical protocol, informed by the literature 
and our own experience, for the management 
of women with vaginal hypoplasia is provided 
Woman with 
vaginal hypoplasia
Intercourse + 
vaginal dilation
Vaginal dilationIntercourse
Failed vaginal
dilation
Laparoscopic
Vecchietti
procedure
Failed
vaginoplasty
Laparoscopic
Davydov
Intestinal
vaginoplasty
No prior treatment
Maintenance dilation
Prior treatment
Figure 2
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in Figure 3 (adapted from [274]). A further 
individual-based approach with skillful eva-
luation and negotiation with the patient can 
help to prevent vaginal dilation treatment 
failure and limited compliance. Figure 4 
illustrates how a vaginal dilation user model- 
based on a health belief model of behavior 
change [294], and on therapeutic interventions 
within a framework of cognitive-behavioral 
psychology and motivational interviewing 
[260,295,296] - would incorporate the in-
fluencing factors identified in this review. It 
provides useful pointers for understanding 
compliance difficulties with vaginal dilation 
and suggests that vaginal dilator use can be 
increased by: 
A accounting for modifying factors 
before and during the course of treatment, 
such as diagnosis adjustment. Women 
may experience a range of symptoms 
consistent with posttraumatic stress disorder. 
Psychological difficulties may act as a barrier 
to dilator treatment, or conversely, the dilator 
treatment may exacerbate pre-existing 
psychological symptoms [262] and must be 
delayed in the presence of psychological 
disorders (e.g. depression) [257]. The further 
timing of treatment should be planned on 
an individual basis as there is considerable 
variation in psychosocial development and 
maturity. High motivation to start with sexual 
activity or a current relationship will benefit 
dilator use. It is suggested not to start dilator 
treatment before the age of 16 years, due to 
motivational issues, which are more prone 
in adolescence [257]. Also, younger women 
may be less familiar with their genitalia [274] 
or might have anxious reactions toward the 
idea of inserting an instrument in the vulvar 
region [257], the more so when dilators 
are perceived as highly sexualized objects 
[297]. For some women, negative genital 
perceptions may also be exaggerated by an 
idealization of ‘normal’, and negative social 
comparisons may raise the anxiety further 
[298]. Ideally, where appropriate, patients 
should be encouraged to access support 
from their personal contexts, as it enhances 
self-management in many chronic diseases 
[299]. However, because of the intimate 
nature of the syndromes, many women 
feel they cannot talk about it with family or 
friends and wish to hear about other patients’ 
experiences. Support groups can provide 
a useful resource for sharing concerns 
or motivation during treatment. Regular 
appointments with a clinical psychologist, 
nurse specialist and/or physiotherapist can 
provide opportunities for addressing other 
implications of the diagnosis, such as its 
effect on fertility or body/genital image and 
for problem-solving practical difficulties 
B providing stronger cues to action, such as 
additional information (e.g. websites, easy-
to-follow instructions boosting patient’s 
confidence to correctly use the dilators), 
and easy dilator provision (e.g. through the 
hospital pharmacy). Also, regular vaginal 
examinations by clinicians and personal 
experience of anatomical and functional 
success can act as confirmation of the 
efficacy of dilators. However, as vaginal 
size in non-sexual situations can be a poor 
predictor of pleasurable intercourse upon 
sexual arousal, clinicians should reduce the 
level of preoccupation with vaginal size solely 
and also emphasize sexual enjoyment.
C emphasizing the benefits (e.g. sexual 
function is possible by achieving greater 
vaginal length) and overcoming the barriers 
(e.g. having a sense that it is not right or 
natural to touch genitals or treatment 
triggers flashbacks to previous traumatic 
experiences such as unsuccessful attempts 
at intercourse) [296].The extent of a positive 
attitude towards treatment (i.e. benefits 
outweighing the barriers) and the perceived 
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Interim appointments 
to measure vaginal 
depth; psychosexual 
support
Figure 3. Treatment protocol. Vaginal examination by a gynecologist is followed by at least one therapy 
session by a clinical psychologist/sexologist to identify any contraindications to using dilators (e.g. 
depression) and maturity of the patient, optimizing the probability of a positive outcome of treatment. 
Potential benefits of dilation as perceived by the patient as well as potential obstacles associated with 
implementing the regime are elicited. The women are encouraged to solve problems around any identified 
difficulty. Once an initial trial of dilation treatment uptake is agreed upon, standardized spoken and  written 
instructions on vaginal dilation are given and patients are shown by a specialized physiotherapist how to 
apply gentle pressure to the vaginal dimple using dilators for 20 minutes daily, 7 days a week . The dilators 
range upward gradually to the size of a man’s fully erect penis. The women are asked to self-monitor their 
practice and associated pain/discomfort ratings in a diary specially designed for this purpose, which includes 
extra information on pelvic floor muscle relaxation, genital anatomy, dilator use and pain relief. Moreover, 
they are given the opportunity to meet with patients who are currently dilating or (successfully) completed 
the program,  as was originally proposed by Ingram [93]. After 6 weeks, the initial trial is evaluated with the 
psychologist and physiotherapist to ensure that the women are still motivated to continue. If not, treatment 
is suspended and reasons for discontinuation explored and discussed in multisciplinary team meetings. 
If the patient decides to discontinue, the laparoscopic Vecchietti procedure is the method of choice for 
further neovaginal creation [74]. If dilator treatment is continued, patients attend for up to five follow-up 
visits at 6–8 weeks apart with the physiotherapist and after 12 weeks with the gynecologist to evaluate 
the anatomical results. Telephone and email contact is available if required. Emotional and psychological 
support from the team clinical psychologist is available as needed before, during or after treatment. 
Treatment is deemed completed when a patient is able to engage in pleasurable sex and/ or coitus with no 
difficulty or if a vaginal dilator can be easily inserted to ≥7cm. At completion of the treatment, women are 
encouraged to maintain dilation two times a week for 20 minutes when not sexually active.
Indication:
urogynecological
examination
Additional sessions 
with psychologist
Delay dilation 
therapy
Visit psychologist:
patient ready for
dilation therapy?
Laparoscopic
Vecchietti
-> Successful?
Other vaginoplasty
technique
(skin flaps/bowel)
Maintenance 
dilation
Follow-up after 1y
Evaluation 
trial session -> 
Continuation 
dilation therapy?
Stop treatment if:
- Sex is pleasurable and/ 
   or coitus is possible
- Dilator of ≥ 7 cm can 
   be inserted
Visit gynecologist/
physiotherapist 
and psychologist:
follow progress
NO
NO
NO
NO
YES
YES
YES
4 WEEKS
3-12 MONTHS
Figure 3
YES 6 WEEKS
Trial session
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efficacy (i.e. personal beliefs of how likely it 
is that dilation will work) will be central to a 
woman’s motivation to repeat the exercises 
regularly [257]. 
D minimizing the perceived threat, such 
as pain during intercourse. Anxiety can 
lead to a higher anticipation of pain, 
thereby exacerbating pain by intensifying 
muscular spasms. Relaxation training and 
psychological pain management techniques 
in the treatment of dyspareunia associated 
with gynecological conditions such as vulvar 
vestibulitis, might be useful [300].
Remaining questions 
and future perspectives
The current review has highlighted the need 
for further investigations in a number of areas. 
First, a fuller awareness of a need to assess 
treatment outcomes (i) both qualitatively and 
quantitatively, with an improved research 
methodology, (ii) including a wider range of 
psychosexual matters, including the quality 
of intimate relationships, and partner-
independent sexual activities and (iii) at various 
developmental time points. Longitudinal 
studies, incorporating a head-to-head 
prospective evaluation of interventions, 
should be undertaken. The majority of 
studies evaluated had a retrospective design, 
and pre-treatment measures were available 
for comparison only in a handful of studies 
[79,114,125,241,260,263]. Comparing pre-and 
post treatment results, specifically in the 
long-term, would provide a more precise 
indication of the effect of any treatment.
Second, reports on the associated anomalies 
have not been the major focus of recent 
papers on vaginal agenesis. No firm 
Figure 4. Determinants of vaginal dilator use.
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conclusions can be drawn about certain 
anatomical prerequisites for treatment 
success (e.g. presence of hymen), and further 
comparative studies between 46, XX women 
and 46, XY women with vaginal hypoplasia in 
different areas are highly valued. For instance, 
the relative contribution of hormonal factors 
in sexual dysfunction, in CAIS vs. MRKH, has 
to be further elucidated.
Third, the possibility of coital dilation 
should be further taken into consideration 
and explained to the patients as one of the 
available therapeutic procedures. The impact 
of further sexual activity post-treatment 
on anatomical outcomes needs further 
investigation, as this could not be confirmed 
in all studies. 
Fourth, additional experience has to be gained 
on how psychological input may impact on 
the processes of diagnosis and treatment. 
Psychotherapy might provide an exploration 
of alternatives to penetrative intercourse. Of 
note, the standard sex therapy for couples 
who experience difficulties with intercourse, 
is to first of all abstain from it. Masters & 
Johnson advised couples to ‘sensate focus’ or 
(re)-discover a range of pleasurable activities 
together [301]. However, the typical advice 
for a woman who has undergone vaginal 
reconstruction is that she must engage in 
regular intercourse or dilate indefinitely. This 
advice may be counter productive for the 
woman and her partner [298].
Finally, the rarity and (vaginal depth) variability 
in patients with vaginal hypoplasia precludes 
the establishment of strict guidelines 
regarding both non-surgical and surgical 
management. To our knowledge, this was the 
first review in which the outcomes of more 
than thirty vaginal dilation treatment studies 
were under scrutiny, compared to outcomes 
of more than 190 surgical studies. The low 
rate of physical complications associated 
with dilator treatment should not lull us 
into prescribing a treatment that may not 
be effective and dilation treatment should 
be further subjected to the same scrutiny 
as any other intervention [273]. Routine 
data collection, driven by patients’ lived 
experiences, is the key marker of care quality 
and should inform service improvement 
strategies. Meanwhile, with proper care, 
might we begin to think of the vagina as 
Oliver Wendell Holmes once viewed the 
mind: ‘Man’s mind, once stretched by a new 
idea, never returns to its original dimensions 
(p.508) [302]. 
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Study question:  Is non- surgical vaginal dilation treatment, according to a standardized protocol 
and delivered by a multidisciplinary team, effective in obtaining and maintaining normal vaginal 
length (≥ 6.5 cm) and psychosexual wellbeing in the long term (>1 year) in women with vaginal 
hypoplasia?
Summary answer: Vaginal dilation treatment normalizes vaginal length in at least 90% of 
women, but psychosexual wellbeing remains compromised one year later.
What is known already: Vaginal dilation treatment has been shown to be a (cost) effective first 
line alternative to vaginal surgery in normalizing vaginal length and improving sexual wellness 
and function. There remains, however, a need for prospective treatment studies, with a long 
term assessment of multiple outcomes.
Study design, size, duration: A prospective, single-centre observational study of women 
with vaginal hypoplasia who were prescribed vaginal dilation treatment, coordinated by a 
multidisciplinary team, between January 2010 and April 2013, is reported. 
Participants/materials, setting, methods: From eighteen women meeting the inclusion 
criteria, sixteen, of whom twelve with Mayer-Rokitansky-Küster-Hauser syndrome and four 
with 46, XY Disorders of Sex Development participated. Mean age at start of treatment was 
18 (± 2.6) years. All women underwent an outpatient vaginal dilation program supervised by 
a clinical psychologist and a physiotherapist. At baseline (T0), at stop of treatment (T1) and at 
1 year follow-up (T2), semi-structured interviews and validated standardized questionnaires 
assessed emotional and sexual wellbeing, including sexual function and distress, self-esteem, 
vaginal perceptions, health related quality of life and behavioral functioning. Gynecological 
examinations evaluated vaginal dimensions. 
Main results and the role of chance: Ten women completed the program (77%), three are still 
in the program and three failed dilation and choose for surgical vaginoplasty. Ninety percent 
of those who finished treatment reached a vaginal length within the normal range (≥ 6.5 cm) 
in 5.8 ± 3.3 months. Seventy percent was sexually active and had pleasurable experiences at 
T1, 57% at T2. The significant decrease in sexual distress at T1 (p<.05), was followed by an 
increase at T2 (p>.05). Depressive mood symptomatology remained high at T1 and T2, related 
to the permanent loss of bodily integrity and fertility. The majority refused further psychological 
counseling after one or two sessions.
Limitations, reasons for caution: Despite the high response rate (89%) and the fact that a series 
of 16 cases is acceptable for rare conditions, the actual number does not allow for robust 
analyses to identify key factors in emotional and sexual wellness with confidence. Importantly, 
a significant proportion was reluctant to fill out the questionnaires, especially at follow-up 
(50%), which makes the quantitative comparisons difficult and might have biased the results.  
Wider implications of the findings: Vaginal dilation with psychophysiological support is 
4.2 
Vaginal dilation treatment in women 
with vaginal hypoplasia: A prospective 
long term intervention study
ABSTRACT
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Introduction
Congenital vaginal agenesis, as is the case in 
Mayer-Rokitansky-Küster-Hauser syndrome 
(MRKH) and Complete Androgen Insensitivity 
Syndrome (CAIS), is uncommon: 1 in 5000 
female births for MRKH [1]; 1 in 13 000 - 40 
000 for CAIS [2]. Therefore, a specialized 
referral center is the optimal environment 
for diagnosis and management by a 
multidisciplinary team [3]. The key focus of 
clinical management is to increase vaginal 
dimensions to permit penetrative sexual 
intercourse. Depending on anatomy and 
operative history, vaginal enlargement may 
be achieved by nonsurgical vaginal dilation 
and by surgical reconstructive techniques [4, 
5]. Progressive pressure to the vaginal dimple 
with vaginal molds of gradually increasing 
length and width, has been used for over 70 
years [6]. As it has been shown to be a (cost) 
effective technique, with few complications 
and no anesthetic and surgical risks [1,3, 
7-9], it is proposed by the American College 
of Obstetricians and Gynecologists as first 
line technique [10]. However, it is a time-
consuming exercise and anatomical success 
seems to be directly related to compliance [1], 
which is said to be low [11]. Factors associated 
with non-adherence include embarrassment, 
anxiety, predicted or actual pain upon dilating, 
fear of damaging the vagina, or insufficient 
information about dilator use [12, 13]. The 
regimen has been described as distasteful 
in interview studies [13], and because of the 
intimate and privative nature of the treatment, 
carries emotional implications [12-14]. The 
usually young, adolescent women have to 
find a way to accommodate the device [14]. 
Moreover, upon receiving the diagnosis of 
MRKH or CAIS, women were introduced to 
the idea of their body as different, with the 
physical manifestation being the absence 
of the womb and vagina. The loss of bodily 
integrity and fertility can be surmised to 
have an impact on identity and body image 
[15, 16]. These factors may also compromise 
relationship outcomes and sexual function. 
Therefore vaginal length measurements 
cannot be used as the single parameter on 
which to quantify treatment success [15].
Given the emotional sequelae of the 
diagnosis and the potential drawbacks of 
vaginal dilation, professional emotional and 
effective in creating a vagina of functional length within an acceptable time period in 90% of 
the patients, which corroborates previous study findings. However, vaginal creation invariably 
connects women to the underlying diagnosis, which remains to have a negative impact on 
emotional wellbeing in the long term. Care providers should  investigate multiple clinical needs 
more thoroughly. In particular, the role of psychological intervention as both a primary and 
adjuvant treatment needs clear evaluation. 
Study funding/competing interest(s): This work was supported by a grant from the Flanders 
Research Foundation (FWO Vlaanderen), Belgium. No competing interests declared.
Key Words. vaginal hypoplasia, vaginal reconstruction, vaginal dilation, vaginoplasty, sexual 
function, Mayer-Rokitansky-Kuster- Hauser syndrome, Complete Androgen Insensitivity 
Syndrome, long term outcome, Disorders of Sex Development
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Maintenance 
dilation
Follow-up after 1y
Stop treatment if:
- sex is pleasurable and/or   
   coitus is possible
- a dilator of 7cm or more  
   can be easily inserted
Intermediate 
appointments for 
measuring vaginal 
depth; psychosexual 
support
Appointment with 
gynecologist/urologist/
physiotherapist and 
psychologist:
evaluation progress
Evaluation trial 
session:
continuation
dilation therapy?
Trial session
Figure 1. Treatment algorithm for vaginal hypoplasia at Ghent University Hospital
psychological support must be planned as 
integral part of the medical care. With such 
an approach, barriers to dilation treatment 
adherence are more likely avoided rendering 
it viable as first line approach [7]. The 
effectiveness of dilator treatment, like any 
other intervention, should be thoroughly 
evaluated, ideally in a prospective study of 
multiple outcomes (e.g. sexuality, quality of 
life and emotional wellbeing), including long- 
term treatment gains. Our aim was to report 
prospectively and both quantitatively as 
well as qualitatively the short and long term 
results (>1 year) of first line dilation treatment 
derived from the original Frank technique [6] 
and delivered by a multidisciplinary team, for 
women with vaginal agenesis and without a 
previous history of vaginal surgery. 
Materials and Methods
Study design and population
This was a prospective, longitudinal, single-
centre study of all women who were 
prescribed vaginal dilation treatment for 
vaginal hypoplasia between January 2010 
and April 2013. Participants followed the 
treatment protocol outlined in Figure 1. At 
baseline (T0), at stop of treatment (T1) and 
Indication:
urogynecological
examination
Additional sessions 
with psychologist
Delay dilation 
therapy
Visit psychologist:
patient ready for
dilation therapy?
Laparoscopic
Vecchietti
YES
YES
NO
NO
NO
YES
6 WEEKS
6 WEEKS
3-12 MONTHS
Figure 1
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at 1 year follow-up (T2), validated stan-
dardized questionnaires on emotional and 
sexual wellbeing were completed, and 
gynecological examinations were performed 
to measure vaginal length. Semi-structured 
interviews included questions about the 
participant’s reaction towards the diagnosis 
and experience of dilator treatment, 
information provision, compliance with 
dilation treatment and frequency of vaginal 
dilation. 
Ethical approval
The institutional ethics committee of Ghent 
University Hospital provided ethical approval 
for this research to proceed (EC 2010/030). A 
written informed consent had been obtained 
at T0 from all participants.
Treatment protocol
The out-patient program was designed 
based on careful exploration of the literature, 
especially motivational and behavioral 
psychology [7,12]. A vaginal examination was 
performed by a single gynecologist and was 
followed by at least one therapy session by 
a clinical psychologist/sexologist to identify 
any contraindications to using dilators (e.g. 
depression) and to evaluate the maturity of 
the patient in order to optimize the probability 
of a positive treatment outcome. Potential 
benefi ts of dilation as perceived by the patient 
as well as potential obstacles associated with 
implementing the regime were elicited. The 
women were encouraged to discuss possible 
problems around any identifi ed diffi  culty. Once 
an initial trial of dilation treatment uptake was 
agreed upon, standardized spoken and written 
instructions on vaginal dilation were given 
and a specialized physiotherapist instructed 
patients on how to apply gentle pressure 
to the vaginal dimple using Feminaform 
(Pelvitec™) dilators for 20 minutes daily, 7 days 
a week (Figure 2). The size of the dilators was 
gradually increased up to the size of a man’s 
fully erect penis. If the vagina reached a length 
of 3 cm, size 2 was used; at 5 cm, size 3 was 
used. The women were asked to self-monitor 
their practice and associated pain/discomfort 
ratings in a diary specially designed for this 
purpose, which included extra information 
on pelvic fl oor muscle relaxation, genital 
anatomy, dilator use and pain relief. The 
participants were given the opportunity to 
Figure 2
Figure 2. Feminaform (Pelvitec™) dilators. The set is available through the hospital pharmacy and with 
discrete packaging. The dilators come in four sizes of increasing width and length (Size 1: diameter 22mm, 
length 85mm; size 2: diameter 27mm, length 105mm; size 3: diameter 32mm, length 135mm; size 4: 
diameter 37mm, length 160mm).
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meet with patients who were currently dilating 
or had (successfully) completed the program, 
as was originally proposed by Ingram [17]. 
After 6 weeks, the initial trial was evaluated 
with the psychologist and physiotherapist to 
ensure that the women were still motivated to 
continue. If not, treatment was suspended and 
reasons for discontinuation were explored, 
and discussed during multidisciplinary team 
meetings. If the patient decided to discontinue, 
the laparoscopic Vecchietti procedure was 
proposed as the method of choice for further 
neovaginal creation [18]. This technique is 
based on stretching of the patient’s own vaginal 
skin by use of a traction device – in a way very 
similar to active vaginal dilation - and has 
been shown to a be relatively safe procedure 
for women without previous vaginal surgery 
[19]. Patients who continued dilator treatment, 
attended for up to five follow-up visits at 6–8 
weeks apart with the physiotherapist and after 
12 weeks with the gynecologist to evaluate 
anatomical results. Telephone and email 
contact was available if required. Emotional 
and psychological support from the team 
clinical psychologist was available as needed, 
before, during or after treatment. Treatment 
was deemed completed when a patient had 
pleasurable sex and/or engaged in coitus 
with no difficulty or if a vaginal dilator size 3 
(width 32 mm; length 135 mm) could be easily 
inserted to ≥7cm. It was predicted that after 3 
months a doubling of the start vaginal length 
could be obtained, and treatment should not 
last longer than 12 months. At completion of 
the treatment, women were encouraged to 
maintain dilation twice a week for 20 minutes 
when not sexually active, at least during the 
first 6 months. 
Outcome variables
Vaginal length. Vaginal length was measured 
by inserting a cotton bud into the vagina; 
the length in centimeters from the posterior 
fourchette to the most proximal part of the 
blind ending vagina was recorded.
Vaginal perceptions. In order to establish 
whether the objective anatomical change 
was associated with changes in self-
perceptions, patients were asked to report 
how they perceived their vagina by choosing 
from the following six statements: 1) My 
vagina is more or less normal 2) I do not 
know or I am not sure. 3) My vagina is tiny or 
non-existent 4) My vagina is small (short or 
narrow) 5) A sexual partner would notice it is 
different from other women 6) I would like a 
bigger vagina (longer or wider)[7].
Sexual dysfunction and distress. Sexual 
function was assessed by the Female 
Sexual Function Index (FSFI) questionnaire 
[20] (Dutch translation with excellent 
psychometric properties) [21]. This short 19-
item questionnaire assesses adult female 
sexual quality of life in the 4-week period 
before completing the survey and its score 
is unbiased regarding age, education, and 
economic status. The items are assigned 
to six separate domains of female sexual 
function: desire, arousal, orgasm, pain during 
intercourse, vaginal lubrication, and global 
sexual and relationship satisfaction. All items 
in the FSFI have a five-point basic response 
scale (1 to 5) denoting variations in frequency, 
intensity or degree of satisfaction. Sexual 
domain scores have a scale score 0-6. Higher 
scores indicate more normal sexual function. 
Sexual distress was assessed by the Female 
Sexual Distress Scale-Revised (FSDS-R) [22], 
validated for the Dutch-speaking population 
[21]. This is a self-administered questionnaire 
consisting of 13 items that relate to different 
aspects of sexual distress. Every item requires 
an answer that is then rated as 0–4 (never [0], 
rarely [1], occasionally [2], frequently [3], or 
always [4]). The total score, ranging from 0 
to 52, provides a measure of sexual distress, 
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in which the higher the score, the higher the 
level of sexual distress. 
Health related quality of life. The TNO-AZL 
Questionnaire for Adult’s Health-Related 
Quality of Life (or TAAQOL) assessed the 
occurrence of particular functional problems 
on 10 scales (cognition, sleep, pain, social 
contacts, daily activities, sex, vitality, 
happiness, depressive mood and anger 
mood) and the degree to which the patient 
was actually emotionally bothered by that 
problem during the last month (1 very much 
bothered - 4 not at all bothered). Scores for 
each scale are between 0-100, with higher 
scores indicating a higher occurrence of 
problems [23].
Behavioral functioning. The Youth Self - 
Report (ages 11-18) and Adult Self-Report 
(ages 18–59) present participants with 
statements that relate to emotional and 
behavioral problems and competencies, 
using a 3-point response format to establish 
the frequency of problem behaviors (0-Not 
True, 1-Somewhat or Sometimes True, 2-Very 
True or Often True) [24]. The YSR and ASR 
produce an internalizing and externalizing 
behavior problem score and total problem 
score. Externalizing behavior problems—
behaviors characterized by an undercontrol 
of emotions—include difficulties with inter-
personal relationships and rule breaking. 
Internalizing behavior problems—defined as 
an overcontrol of emotions—include social 
withdrawal, feelings of worthlessness or 
inferiority [24] Raw scores are transformed 
to T-scores, with a mean of 50 and standard 
deviation of 10. Problems are clinically 
relevant with T scores > 65.
Patient population and sexual activity.
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MRKH
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3.0
6.0
3.0
3.0
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9.0
5.0
3.0
No
No
Yes
Yes
No
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No
Yes
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Yes
Yes
Yes
No
Yes
No
Yes
No*
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Yes
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Yes
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Yes
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No
Yes
Finished  dilation
Finished  dilation
Finished dilation
Finished dilation
Finished dilation
Finished dilation
Finished dilation
Finished dilation
Finished dilation
Finished dilation
Dilation in progress
Dilation in progress
Dilation in progress
Stopped dilation + Vecchietti
Stopped dilation + Vecchietti
Stopped dilation + 
Sigmoid vaginoplasty
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Diagnosis
Age at 
start 
dilation 
(years)
Pre 
treatment 
(T0)
SEXUAL ACTIVITY
Total 
duration 
of dilation 
treatment
(months)
Post  
Treatment 
(T1)
Status
Partner 
at start 
dilation
Nr
Abbreviations: MRKH= Mayer-Rokitansky-Küster-Hauser syndrome, CAIS= Complete Androgen Insensitivity Syndrome,  5αRD= 5α Reductase 
Deficiency,  TBC= To Be Continued, could not be evaluated yet, NR= not reported, * did not fill in (all) questionnaires, 1 She had already  dilated 
before during 3 months in another hospital,  but was unhappy about the lack of psychological counseling during treatment. 
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Body image. An adapted version of a 
body image scale [25] was used to assess 
satisfaction with 32 sex-specific and non sex-
specific body characteristics on a five-point 
basic response scale (1 to 5). We determined 
satisfaction regarding the genital area (4 
aspects: vagina, clitoris, labiae, pubic hair) 
and total body image (28 aspects e.g. arms, 
legs, nose). Higher scores denote more 
dissatisfaction.
 
Self esteem. The Rosenberg Self-Esteem 
Scale [26], with a validated Dutch translation 
[27] is a 10-question scale, designed to 
represent a continuum of self-worth 
statements. All items are coded on a four-
point scale ranging from 0 (strongly disagree) 
to 3 (strongly agree). Total scores range from 
0 up to 30, with higher scores indicating a 
higher global self-esteem. 
Statistical analysis
The qualitative data were analyzed using 
thematic analysis, defined as a method for 
identifying, analyzing and reporting themes 
within data [28]. Quantitative statistical 
analyses were performed using SPSS version 
20.0 (SPSS Inc., Chicago, IL). Non-parametric 
Wilcoxon signed-rank tests were conducted 
with a Bonferroni correction applied, for 
comparing mean rank scores for emotional 
and sexual wellbeing at T0, T1 and T2. Non-
parametric effect size (ES) estimates and 95% 
confidence intervals (CI) were calculated [29]. 
Mann-Whitney U-tests were used to assess 
differences in anatomical success when 
controlling for frequency of dilation (≤4 or >4 
times a week), sexual activity during dilation 
program (yes or no) and karyotype (46, XY 
or 46, XX).Associations between variables 
were sought using Spearman correlation 
coefficients. P < .05 was considered 
statistically significant. Two-tailed statistical 
tests were chosen to reduce the risk of type 
I errors.
Results
Of the 18 women approached, 16 agreed 
to participate. Two women were reluctant 
to discuss this sensitive issue, but both did 
start with the dilation program. One woman 
with CAIS (aged 19 years) stopped after a few 
sessions already as she reported satisfactory 
coitus with her partner (start vaginal length 
4.5 cm, last measure 6 cm). The other 
woman with MRKH (aged 17 years) obtained 
an increase of 4cm (from 2 to 6cm) after 5 
months and shows little interest in sexual 
activity and relationships. The characteristics 
of the participants are displayed in Table 1. 
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Ten women completed the program, 
three women are currently still following 
the dilation program, and three women 
stopped dilation treatment and underwent a 
vaginoplasty procedure. 
Attitudes towards vaginal dilator 
use before and after dilation treatment
Table 2 summarizes the benefits and 
disadvantages of dilation treatment as 
mentioned by the participants. Before start, 
they demonstrated good knowledge on the 
purpose of using vaginal dilators, i.e. to have 
normal/pain free intercourse, and to possibly 
avoid surgery and scars (i.e. implying visibility 
of the condition). After treatment, women 
included also advantages of connectedness 
to the body through dilation and feeling better 
as a woman, but the majority reported that it 
was an unpleasant reminder of abnormality. 
Interestingly, only half of the women with 
partner told them about the treatment.
Vaginal dilation frequency, 
vaginal size and total duration of therapy
With the given instructions and extra 
information (i.e. pelvic floor exercises, 
examine genitals with mirror), all of the 
women felt confident enough to continue 
with dilator treatment beyond the trial period.
Ten women successfully completed the 
program, and 90% (n=9) achieved a value 
within the normal range (6.5-12.5 cm) [30] 
(Table 3). All women started to dilate as 
recommended (15 to 20 minutes daily, 7 days 
a week), but after 1 to 3 months the reported 
frequency decreased significantly, ranging 
from 3 to 4 days a week to once a week in 
5 out of 10 women. Reported motives were: 
time and effort constraints (e.g. no dilation 
during certain time periods such as exams 
(n=5), privacy reasons (i.e. shared student 
housing) (n=2) and less perceived vaginal 
increase (n=1). Those who dilated frequently 
(> 4 days a week), had a significantly larger 
end vaginal length (p=.034) and a non 
significant shorter total duration of dilation 
therapy (p=.459) (Table 3). There was no 
significant correlation between start or end 
vaginal length and duration of treatment 
(Rs= -.44, p=.204 and Rs=-0.14, p=.69 
respectively) nor between start and end 
TABLE 2
Benefits and disadvantages of 
dilation treatment endorsed 
by participants.
13/13
3/13
 
3/13
 
2/13
2/13
1/13
8/13
3/10
3/10
1/10
 
8/10
4/10
4/10
2/10
2/10
2/10
3/10
1/10
1/10
Before treatment
Benefits of dilation
Being able to have normal/pain free   
sex, whenever I want
You are in control (of the pain) 
Better than surgery (e.g. no scars,   
no possible loss of sensation) 
Disadvantages of dilation
Feel abnormal 
Pain/discomfort 
Afraid of association of sex with dilation  
After treatment*
Benefits of dilation
Enough vaginal length to have sex
Being more connected with your   
own body through dilation
You achieve something yourself 
Feel better as woman 
Disadvantages of dilation
Unpleasant reminder of something  
preferably forgotten: e.g. ‘It (dilation)   
reminds me of being abnormal’ 
Chore/boring 
Discomfort/pain 
Fear of pushing too hard or hurting myself   
Too slow progress 
Privacy/discretion needed
Disadvantages of not dilating 
Lose any progress already made   
and feeling guilty of not doing it 
Won’t be able to have ‘normal’ sex 
Have to have surgery 
 Number 
of participants
*Not including the three women who are currently still in the program
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TABLE 3 Vaginal size, frequency of dilation and total duration of dilation treatment.
Dilation only (n=10)
Frequency of dilation ≤ 4d/w (n=5)
 > 4d/w (n=5)
Intercourse during treatment*  Yes (n=4)
  
 No (n=5)
Dilation + Surgery (n=3)      ≤ 4d/w (n=3)                                    
2.7 ± 1.2
2.7 ± 1.3
2.7 ± 1.3
2.1 ± 0.9
2.8 ± 1.2
3.5 ± 1.3
7.7 ± 0.8
7.2 ± 0.4
8.2 ± 0.8
7.6 ± 0.3
7.5 ± 0.9
4.8 ± 0.7
5.8 ± 3.3
6.7 ± 4.4
4.9 ± 1.8
5.9 ± 2.2
6.3 ± 4.3
5.7 ± 3.1
Vaginal length 
before dilation (cm)
Vaginal length 
after dilation (cm)
Total duration of 
dilation treatment 
(months)
Abbreviations: d= days, w= week,*Not reported in n=1
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Figure 2. Vaginal length according to duration of treatment. Women who did not complete the treatment 
program are shown with dotted lines. The normal vaginal length reference range, in grey, is derived from [30]
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vaginal length (Rs=0.06, p=.86). Although 
not significant, women with 46, XX MRKH
(n=12) had on average a smaller start vaginal 
length compared to women with 46, XY DSD 
(n=4) (2.5±1.0 cm vs. 3.6 ± 1.5 cm, p=.159). 
Three participants (nr 14-16) stopped with 
dilator therapy because of too little perceived 
progress (n=3), pain (n=2) and negative 
confrontation with the condition (n=3). At 
stop they had gained significantly less vaginal 
length (p=.009) (Table 3), although they had 
a comparable start vaginal length and dilated 
during a comparable period, but with a lower 
frequency, especially towards the end (<once 
a week). A decrease in vaginal length could 
be observed (Figure 3). These women were 
on average younger (16.3± 2.3 years vs. 18.4 
± 2.6 years), although not significantly (p= 
.244). After surgery, they reached a significant 
longer end vaginal length (10.3 ±2.1 cm) 
compared to the women after dilation 
therapy only (7.7 ± 0.8 cm, p=.029). 
Maintenance dilation 
In women who completed the program, only 
two women (nr 1, 7) continued to dilate during 
the first 6 months after stop (once a week), 
especially before having sexual intercourse 
because they were afraid it would not ‘work’. 
Only one woman (nr 7) dilated at the time of 
follow-up (approximately 4 times a month 
for 10 minutes), because she felt that she lost 
vaginal depth when not being sexually active 
and because she wanted to gain additional 
depth. She had a significantly larger vaginal 
length (and seemed to have gained extra 
length; Figure 3) at follow-up (11cm vs. 6.5 
cm (6.5-7cm, p<.05) compared to those who 
did not dilate at follow-up. Reasons for non-
dilation in the other women included regular 
sexual intercourse (on average 2 times a 
week, n=2), not wanting to do it anymore 
even when not sexually active (n=1), negative 
confrontation with diagnosis (n=1), and no 
perceived loss of vaginal depth (n=2).
Women, who had surgery, wore a vaginal 
prosthesis day and night during the first 
3 months after surgery. For the following 
3-6 months, they were advised to wear the 
prosthesis only at night and at least 4 hours 
during the day. One woman (nr 14) wore the 
prosthesis more as she was afraid to lose 
vaginal length; another (nr 15) did not dilate 
and lost 2 cm of vaginal length. The third 
women (nr 16) dilated as prescribed. After 6 
months, 2 out of three were still dilating on 
average once a week for 20 minutes. None 
of the two women of whom follow-up was 
available were dilating after 1 year. 
Complications
One participant (nr 12) had started to 
dilate the urethra, but this was noticed at 
gynecological checkup after 6 weeks and 
had no further consequences. No other 
complications were seen in the women who 
finished the program. One of the women 
with the Vecchietti procedure (nr 15) suffered 
from continuous cystitis in the first three 
months after surgery, and was operated for 
a vesicovaginal fistula a year later. No other 
complications were reported. 
“We live in the 21st century, 
everything needs to be quick and 
deliver quick results. Dilation is a 
long process, but only on 
an anatomical level, not 
psychologically. You, yourself, 
bring things in movement, you 
learn a lot about yourself “
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Vaginal perceptions 
Improvement was reported for most of the 
vaginal perception items following treatment, 
in particular, a significantly higher proportion 
of women felt that their vagina was no longer 
tiny or non-existent after dilation therapy 
(p=.002) and at follow-up (p=.008).However, 
more than half of the women considered 
their vagina still small and would like to 
have a larger vagina, independent of type of 
treatment (Figure 4). 
Sexual activity
Forty percent of women (4/10) who finished 
the program successfully had had sexual 
experiences before treatment, but none 
of them had had sexual intercourse yet 
(Table 1). Seventy percent was sexually 
active after dilation treatment and 80% had 
had pleasurable intercourse, although not 
completely pain free. The women who had 
intercourse during the dilation program 
(towards the end) (n=4) (nr2, 4, 5, 9) did 
not have significantly larger end vaginal 
lengths compared to the women who were 
not sexually active during the program, nor 
had a significant shorter duration of dilation 
therapy (p>.05) (Table 3). Fifty-seven percent 
(4/7 who were eligible for follow-up) were 
sexually active (including intercourse) at 
follow-up and vaginal length in all was >6.5 
cm. Two women (nr 1, 6) reported no interest 
in sex nor at stop, nor at follow-up. The first 
because her partner broke up the relationship 
during treatment and she still felt afraid to 
open up to new partners; the second felt she 
was still too young (20 years). 
Two out of three women (67%) who had 
surgery had intercourse 6 months after 
surgery and/or at follow-up, which was 
Figure 4
A sexual partner would notice 
it is different from other women
VAGINAL DILATION 
ONLY GROUP
VAGINAL DILATION FOLLOWED 
BY SURGERY GROUP
I would like a bigger vagina 
(longer and wider)
My vagina is small 
(short or narrow)
My vagina is  normal
My vagina is tiny or non -existent
I don't know or I am not sure
0% 100% 0%
Pre            Post            Follow-up
Figure 4. Vaginal perceptions. Responses (i.e. percentage of affirmative answers) in women who finished 
the dilation program on the left and women who had surgery on the right, before  and after the treatment 
program and at 1year follow-up (only in women who finished the dilation program) 
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TABLE 4
pleasurable only in one woman. The other 
woman reported subjectively more difficulties 
reaching orgasm compared to before the 
operation. 
Sexual and emotional wellbeing 
Table 4 summarizes the questionnaire results. 
Only 5 participants of those who finished the 
vaginal dilation program, wanted to complete 
(some) questionnaires at 1 year follow-up. 
Reasons given by the other women included 
not wanting to be confronted again with 
the diagnosis and associated infertility issue 
(n=2), and emotional problems related to the 
recent passing of the mother (n=1).
There was a significant reduction in reported 
sexual distress after dilation therapy (p=.049, 
medium ES), but this difference disappeared at 
follow-up (p>.05). There were no statistically 
significant differences in sexual function 
domains, self-esteem, genital image, body 
image or behavioral functioning, before and 
after dilation therapy, despite some medium 
effects of dilator treatment on lowering 
internalizing and total problem behavior 
(not in clinical range). Regarding quality of 
life, a significant increase in occurrence of 
depressive moods after dilation therapy was 
found (p=.026, large ES), decreasing again 
at follow-up (p>.05) (Table 4).  Within the 
surgery group, differences before and after 
Median scores and ranges for sexual functioning and distress, behavioral functioning, 
self-esteem, genital and body image and health related quality of life in women who 
successfully completed the vaginal dilation program.
Sexual functioning
Sexual distress
Desire
Arousal
Lubrication
Orgasm
Satisfaction
Genital image
Body image
Self-esteem
Behavioral functioning
Internalizing behavior
Externalizing behavior
Total problem behavior
Health related QoL
Cognitive functioning 
Sleep problems 
Pain 
Social problems 
Daily activities 
Sexual problems 
Vitality 
Positivity 
Depressive moods
Anger moods
22.5 (1- 41), N=8
3.6 (2.4-4.8), N=6
5.0 (3.3-5.1), N=6
5.4 (3.6-6.0), N=6
4.8 (1.2- 6.0), N=6
5.6 (4.8-6.0), N=6
2.8 (2.3- 3.8), N=8
2.8 (1.9 – 3.6), N=8
19 (12-22), N=8
57 (36-90), N=8
47.3(38– 63), N=8
52.5 (30 – 67), N=8
68.8 (43.8 – 100), N=8
81.3(50-100), N=8
96.9 (81.3– 100),  N=8
100 (75-100), N=8
93.8 (31.3 -100), N=8
100 (62.5– 100), N=8
54.2 (41.7– 100), N=8
66.7 (50-100), N=8
70.8 (41.7- 91.7), N=8
83.3(66.7- 100), N=8
14 (0- 25), N=8
4.2 (3.6- 5.4), N=6
5.1 (4.8-6), N=6
5.7 (5.1- 6), N=6
5.4 (2.4-6), N=6
5.6 (4.8-6), N=6
2.8 (1.8- 4.3), N=8
2.7 (1.1 – 3.7), N=8
19 .5 (13-23) ,N=8
49.5 (38-71), N=8
47 (34-63), N=8
46 (30-66), N=8
81.3 (43.8-100), N=7
75 (25-100), N=7
87.5 (75-100, N=7
100 (81.3 -100), N=7
87.5 (31.3-100), N=7
100 (50-100), N=7
66.7 (58.3-91.7), N=7
66.7 (58.3- 100), N=7
75 (66.7-91.7), N=7
88.9 (66.7-100), N=7
32 (2-39), N=4
3.6 (3.6-4.2), N=3
5.1 (4.5- 6.0), N=3
5.1 (4.2- 6.0), N=3
5.6 (5.2- 6.0), N=3
5.6 (2.4- 5.6), N=3
2.9 (2.3- 3.0), N=4
2.9 (2.1-3.6), N=4
18 (14-19), N=4
55.5 (45-64), N=4
53.5 (41-63), N=4
56 (44-57), N=4
93.8 (31.3- 100), N=5
75 (43.8 – 100), N=5
87.5 (75-100), N=5
100 (50-100), N=5
100 (56.3- 100), N=5
81.3 (0-100, N=5
66.7 (33.3-100), N=5
66.7 (25- 83.3), N=5
66.7 (33.3- 91.7), N=5
77.8 (66.7-100), N=5
Pre (T0) Post (T1) Follow-up (T2)
Note: The effects of therapy were tested using Wilcoxon Signed Ranks Test ), *p<.05; ES= Effect size. To calculate the effect size for nonparametric 
tests, the formula r= Z/√N  , with Z the value obtained from the Wilcoxon test, and N the sample size. 95% CI (Confidence intervals) = ES -1.96se to ES 
+ 1.96se, with asymptotic standard error se= 1/ √(n-3)  [29]. Below 0.1 is a small effect, between 0.1 and 0.3 a medium effect and above 0.50 a large 
effect Self-Esteem (Total score: 0-30); Sexual Distress (Total score 0-52); sexual function domains (desire, arousal, lubrication, orgasm, satisfaction, 
scale 0-6) only in women who were sexually active, Health related Quality of Life domains (0-100); behavioral functioning, T-scores, M= 50, SD= 
10); Genital and body image (scale 1-5). 
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surgery could not be calculated, because 
of the small sample sizes and missing 
data. None of them wanted to complete 
questionnaires at follow-up, for reasons 
of severe depression because of familial 
problems (n=1) and desire of closure (n=2). 
Discussion
The present study demonstrates that in the 
majority of women with vaginal agenesis 
(77%, 10/13) vaginal dilation therapy, following 
a strict protocol and with continuous 
psychophysiological support, can effectively 
create a vagina within normal ranges (6.5- 
13cm) [30,31] in a period of approximately 6 
months, which corroborates previous study 
findings [1,3,7,17,32]. If the frequency of dilation 
was higher, the total duration of therapy was 
shorter and vaginal end length was higher, 
irrespective of sexual activity during the 
program [1]. Successful dilation could also 
be achieved in patients with a shorter start 
vaginal length, which refutes the claim by 
some groups that a vaginal dimple of 3-4 
cm is needed [33, 34]. In all but 3 women, of 
-0.49
-0.41
0.00
-0.14
-0.10
-0.11
-0.02
0.00
-0.19
-0.43
-0.29
-0.45
-0.34
-0.08
-0.41
0.00
-0.13
-0.11
-0.23
-0.07
-0.60
-0.14
-0.26
-0.47
0.00
-0.12
0.00
-0.26
-0.26
-0.13
0.00
0.00
0.00
0.00
0.00
-0.26
-0.12
-0.32
0.00
-0.20
-0.17
-0.52
-0.46
0.00
-0.13
-0.38
-0.34
-0.36
0.00
-0.33
-0.19
-0.26
0.00
-0.22
0.00
0.00
-0.12
-0.12
-0.42
-0.14
-0.14
-0.41
0.00
-0.47
-0.04
-0.32
-1.03; 0.05
-0.95; 0.13
-0.54; 0.54
-0.68; 0.40
-0.64; 0.44
-0.76; 0.54
-0.56; 0.52
-0.54; 0.54
-0.73; 0.35
-1.02; 0.16
-0.88; 0.30
-1.04; 0.14
-0.88; 0.20
-0.62; 0.46
-0.95; 0.13
-0.54; 0.54
-0.67; 0.41
-0.65; 0.43
-0.82; 0.36
-0.66; 0.52
-1.19; -0.01
-0.73; 0.45
-1.14; 0.62
-1.35; 0.41
-0.74; 0.74
-0.86; 0.62
-0.74; 0.74
-1.14; 0.62
-1.14; 0.62
-1.01; 0.75
-0.88; 0.88
-1.1; 1.1
-1.1; 1.1
-1.1; 1.1
-0.74; 0.74
-1.00; 0.48
-0.86; 0.62
-1.1; 0.42
-0.74; 0.74
-1.08; 0.88
-0.91; 0.57
-1.26; 0.22
-1.2; 0.31
-0.74; 0.74
-1.01; 0.75
-1.26; 0.50
-1.08; 0.4
-1.1; 0.38
-0.74; 0.74
-1.43; 0.77
-1.07; 0.69
-1.14; 0.62
-0.88; 0.88
-1.32; 0.88
-1.1; 1.1
-1.1; 1.1
-0.86; 0.62
-0.86; 0.62
-1.16; 0.32
-0.88; 0.60
-0.88; 0.60
-1.29; 0.47
-0.74; 0.74
-1.21; 0.27
-0.78; 0.70
-1.1; 0.42
0.049*
0.10
1.00
0.59
0.69
0.72
0.93
1.00
0.45
0.11
0.27
0.09
0.18
0.73
0.10
1.00
0.60
0.66
0.40
0.79
0.026*
0.59
0.47
0.18
1.00
0.72
0.00
0.47
0.46
0.72
1.00
1.00
1.00
1.00
1.00
0.42
0.71
0.32
1.00
0.58
0.58
0.10
0.14
1.00
0.72
0.29
0.29
0.16
1.00
0.41
0.59
0.47
1.00
0.59
1.00
1.00
0.72
0.71
0.18
0.66
0.66
0.66
1.00
0.14
0.89
0.32
ES 
T0-T1
ES 
T1-T2
ES 
T0-T2
95% CI 95% CI 95% CIP P P
“Those girls opting for an 
operation, they give up. 
They don't deal well with 
what they have, they just want 
to get it over with.  But with
 all respect, if they can't 
do it, they can't. “
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whom 2 underwent surgery afterwards, at 
least a doubling of the start vaginal length 
was reached within the first 2 to 3 months. 
The increase in vaginal length thereafter was 
much smaller (mean 1.5 cm, range 0.5- 2.5 
cm). This might be due to the decreased 
dilation frequency and motivational issues 
after 3 months, but further studies need to 
elucidate if there exists an optimal window 
for anatomical success and if women need 
to generate more pressure thereafter. The 
three women who did not succeed, had 
gained significantly less depth at treatment 
stop, despite the same start vaginal length 
and although they dilated for a comparable 
period of time, with the same frequency. 
These women mentioned pain as an obstacle 
and it is possible that they had a more sturdy 
dimple or fibrotic vaginal top [35]. From a 
psychological viewpoint, maturity and age at 
treatment might have influenced the results. 
They were on average younger and it has 
been shown that patients younger than 18 
years had a statistically significant dilation 
failure rate [32]. In addition, these women 
mentioned vaginal dilation confronting 
them negatively with the diagnosis and with 
being different from peers at an age where 
they wanted to fit in, although in general 
the majority of women reported that dilator 
treatment was a significant reminder of 
abnormality (80%). It was clear that the 
women, who successfully finished dilation 
therapy, accepted the dilator use as part 
of their normal routine. When motivation 
decreased, dilator use was prompted both 
by repeating to themselves the reasons for 
doing it (e.g. to have normal sex) and by 
the intermediate gynecological checkups in 
which they felt sometimes guilty if they had 
not ‘done well’ [14], suggesting that these are 
valuable in adherence with dilator treatment. 
Although ‘normal vagina size’ was not an 
unreasonable goal of treatment, it did not 
necessarily lead to ‘normal perception of 
the vagina’ and even after treatment, the 
wish for a larger vagina pertained, even with 
positive sexual experiences and a marked 
decrease in sexual distress [7, 12]. The women 
put a great deal of emphasis on genital 
underdevelopment as the major barrier to 
having a sexual relationship. However, post 
treatment, psychological barriers to engage 
in sexual activity and sexual enjoyment were 
at least as great as the (perceived) physical 
ones. Women described only having sex with 
partners whom they trusted not to ridicule 
their genital abnormality, if they would find 
out.
By taking both a quantitative and qualitative 
long-term approach, it became clear 
that, despite the appearance of outward 
‘normality’ through treatment, participants 
continued to feel far from normal in the 
areas of sexual potency and reproduction 
[36]. Especially the non-genital aspects of the 
condition (i.e. perceived loss of social role as 
potential mother, loss of a sense of normality 
and equality with peers) contributed to high 
emotional distress, in different ways and at 
different times [16]. Continued long term 
follow-up of these women acknowledges 
the importance of these developmental-
temporal factors to the distress [16].
It seems that the medical and the psychological 
management of vaginal hypoplasia cannot 
“I still have the feeling 
that I am not complete, 
that I am not normal. 
I also do not have a vagina, 
it is just a hole that I've created. 
Because through a vagina, you 
can have children. “
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be separated. Recognition of emotional 
problems during dilation treatment has the 
advantage of signaling to the patient the 
need to come to terms with the diagnosis [7]. 
However, only two participants highlighted 
that the input of a clinical psychologist was of 
extra value. All other women refused further 
psychological counseling after two sessions, 
even when experiencing considerable 
emotional difficulties, which was also 
apparent in the unexpected finding of an 
increase in depressive symptoms and no 
improvement in self-esteem after treatment 
[37]. Vagina creation invariably connects 
them to the diagnosis [15], and previous 
qualitative studies did identify both positive 
and negative psychological responses 
following a diagnosis of vaginal agenesis [38], 
even several years later [37]. 
Some mentioned that the involvement 
with a psychologist was likely to generate 
powerful ambivalent emotional reactions of 
abnormality as well as feelings of failure in 
not coping with the condition. Two women 
who had contact with each other during 
treatment, suggested that it increased 
motivation during dilator therapy, but further 
contact could only be limited to discussion 
of subjects related to the shared condition, 
because they had nothing else in common 
[39]. These disappointing outcomes related 
to psychological counseling substantiate 
the need of re-evaluating the role and/or 
form of professional psychological support 
within dilator treatment. Adjusting to a 
diagnosis of MRKH or CAIS is a traumatic 
process for these women and may give 
rise to the development of depressive and 
negative self-beliefs. Treatment itself may 
serve to perpetuate or strengthen these 
feelings and beliefs, which they want to 
avoid. Paradoxically, the challenge consists 
in exposing women as much as possible to 
exposure based- behavior psychological 
interventions, which involves as such the 
exposure of the patient to the feared context 
without any danger, in order to overcome 
their related anxiety, depression and anger 
[40]. Letting women engage with the trauma, 
rather than avoiding it, with interventions 
centering on maladaptive cognitive and 
behavioral strategies (e.g. such as avoidance 
of intimacy) has shown to be effective [41]. 
The aim of psychological support should 
be to reduce patients’ sense of isolation and 
alienation, and engender positive feelings, 
as well as help them to develop skills to 
negotiate within an environment that is 
generally ill equipped to deal with taboo, 
psychological and sexual diversity [36, 42].
An important limitation of this study is its 
small sample size. Although the response 
rate was high (89%) and a series of 16 cases is 
acceptable for rare conditions like MRKH and 
CAIS, the actual number did not lend itself 
to robust analyses that would enable us to 
identify key factors in emotional and sexual 
wellness with confidence. Many women 
were reluctant to fill out the questionnaires, 
especially at follow-up, which makes the 
quantitative comparisons difficult and 
might have biased the results. Second, it is 
not possible from this study to determine 
whether the efficacy of vaginal dilation 
treatment or related psychosexual issues 
“Psychologists precisely 
give you the feeling that 
there is something wrong with you, 
that you are different. 
You just want to feel normal 
and be treated as normal 
as possible. “
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differ between 46, XY and 46, XX women 
with vaginal hypoplasia. Lastly, relationships 
between physical and psychological and 
sexual parameters remain complex and 
require further exploration. Longer vaginal 
length at follow-up was rather associated 
with treatment than with being sexually 
active, which contradicts previous studies 
[1,3,15]. Conversely, the vagina was shorter 
in women who had never been or had not 
recently been sexually active, which supports 
the hypothesis that dilation is needed to 
maintain patency in periods of coital inactivity.
This study also has some strengths. We chose 
well-validated and widely used outcome 
measures to allow comparability with 
previous studies. Perhaps the main strength 
of this study is that it adds to the limited 
knowledge of psychological functioning and 
the associated treatment issues in women 
with vaginal hypoplasia. To our knowledge 
this is the first prospective study objectively 
assessing multiple outcomes after vaginal 
dilation treatment, also on the long-term. 
At completion of treatment, anatomical 
changes are positively associated with 
(psycho)sexual outcomes; however the 
long –term outcomes regarding emotional 
and sexual wellbeing are less optimistic than 
previously hoped for. 
Conclusion
The management of women with vaginal 
agenesis can be entirely nonsurgical 
in the majority of cases, without major 
complications. We have shown that 
vaginal dilator treatment increases vaginal 
dimensions within the normal range and 
that anatomical changes were associated 
with better psychosexual outcomes, at least 
immediately after treatment. Therefore, 
dilator therapy should remain the cornerstone 
of neovaginal reconstruction treatment. 
However, women’s compliance with vaginal 
dilator therapy is influenced by a variety of 
psychosocial factors, including attitudes 
towards the dilator, values, beliefs, emotional 
adjustment to the diagnosis and motivations. 
The role of psychological interventions as 
well as peer support as both a primary and 
adjuvant treatment needs clear evaluation. 
Above all, the results of this study emphasize 
a need to look harder at the challenges of 
living with vaginal hypoplasia syndromes 
and care providers may need to investigate 
multiple clinical needs more thoroughly.
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CHAPTER 5
Towards a new 
treatment strategy in 
men with DSD and 
micropenis  
As long as men continue to equate penis 
size with masculinity,  they will continue to 
feel unnecessary sexual anxiety. 
Christopher Kilmartin
Based on:
Callens, N., De Cuypere, G., Van Hoecke, E., T’Sjoen, G., Monstrey, S., Cools, M.*, Hoebeke, P.* 
Sexual Quality of Life after Hormonal and Surgical Treatment, including Phalloplasty, in Men with 
Micropenis: A Review. J Sex Med, 2013, in press.
Callens, N. De Cuypere, G., T’Sjoen, G., Monstrey, S., Lumen, N., Van Laecke, E., Hoebeke, P.* & Cools, 
M.* Sexual Quality of Life after Total Phalloplasty in Men with Penile Deficiency. 2013, submitted. 
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Introduction. The term micropenis encompasses a range of congenital and acquired conditions 
that result in an abnormally short penis. Small penis size may persist into adulthood, becoming 
a major cause of dissatisfaction.
Aim. To review the literature pertaining to the effects of hormonal and surgical treatment on 
psychosexual functioning and quality of life (QoL) in individuals with micropenis who were 
raised male.
Main Outcome Measures. Long-term psychosexual and QoL outcomes after hormonal and 
surgical treatment, including phalloplasty.
Methods. PubMed search for relevant publications (1955–2012) on the role of hormonal and 
surgical treatment in sexual QoL in adult men with micropenis.
Results. Multiple variations in the etiology of micropenis make it difficult to draw firm 
conclusions that fit all of the patients within this disparate population. However, the literature 
review supports the conclusions that (i) male gender assignment is preferable for most 46,XY 
infants with congenital micropenis because of the likelihood of male gender development and 
genitosexual function; (ii) small penis size persisting into adulthood and dissatisfaction with
genital appearance jeopardize sexual QoL; (iii) there is no known intervention, apart from 
phalloplasty, to guarantee that the penis will become normal in size; (iv) early data suggest 
that the phalloplasty technique considered the gold standard for gender reassignment in 
the transgender population can also be transferred to 46,XY patients with micropenis; (v) 
psychological support should be an integral part of management in order to alleviate the 
distress and impairment of QoL experienced by these individuals.
Conclusions. Further publication of series with large numbers and longer follow-up is needed. 
Specific outcome kits should be designed to measure more precisely patients’ degrees of 
satisfaction with cosmetic, anatomical, and functional variables. Only if health-care professionals 
fully appreciate the impact of this condition can optimal care be provided.
5.1 
Sexual Quality of Life after Hormonal 
and Surgical Treatment, Including 
Phalloplasty, in Men with Micropenis:
A Review
ABSTRACT
Key Words. Disorder of Sex Development; Micropenis; Male Genitoplasty; Phalloplasty; 
Reconstructive Penile Surgery; Hormonal Treatment; Sexuality; Quality of Life; Review
Introduction
The term micropenis encompasses a range 
of congenital and acquired conditions that
result in an abnormally short penis with a 
stretched length of more than 2.5 SD below 
the mean for age and with a urethral meatus at 
the tip of the glans penis, i.e., no hypospadias 
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[1–3]. Stretched penile length varies from a 
mean of 3.5 ± 0.4 cm at birth [4,5] to 12.4 ± 2.7 
cm in adults (range 7–18 cm) [6,7] (Table 1). A 
penis with a stretched length of <2.5 cm in 
term infants and <7 cm in (Caucasian) adults 
is by definition a micropenis. Hormonal 
abnormalities after 12 weeks of gestation can 
lead to micropenis, either isolated or together 
with other members of the broad diagnostic 
category of disorders of sex development 
(DSD) [2]. DSD refers to all conditions in 
which the development of the chromosomal, 
anatomical, or gonadal sex is atypical [8].
The causes of congenital micropenis (also 
called true micropenis) can be divided into 
three broad groups: hypogonadotropic 
hypogonadism (pituitary/hypothalamic fail-
ure), hypergonadotropic hypogonadism 
(primary testicular failure), and idiopathic 
(associated with a functional hypothalamus–
pituitary–testicular axis). (For a full overview, 
see [3] and [9].) An isolated micropenis seems 
to occur more commonly with gonadotropin 
deficiency, whereas micropenis associated 
with a lack of testosterone (first group) is 
often accompanied by hypospadias and/
or undescended testes, suggesting normal 
placental human chorionic gonadotropin 
(HCG)-induced testosterone levels during 
the period of organogenesis [2]. Causes of 
acquired micropenis include trauma, surgery, 
infection, and genital cancer.
Controversially, feminization of the small 
phallus was long considered the ultimate 
alternative in the penile deficient patient 
[10–12]. The rationale behind this attitude 
was that it was considered more feasible 
to create a penetrative conduit than a 
penetrating organ and that humans were 
considered psychosexually neutral at birth 
[13]. Neurological damage caused by phallic 
reduction, neovaginal inadequacy, and 
subsequent (gender) identity crises were 
reported [8,13]. Moreover, as was shown 
in a review by Meyer-Bahlburg et al. and a 
study by Reiner, female gender assignment 
of 46,XY infants and young children with a 
medical condition involving severe genital 
abnormalities of nonhormonal origin 
(including penile agenesis, cloacal and 
classical exstrophy of the bladder, and penile 
ablation) carries a risk of later patient-initiated
gender change to male that is considerably 
higher than the risk of patient-initiated 
gender change to female in male-raised 
patients [14,15]. The disastrous physical and 
psychological effects of this practice led 
many pediatric urologists to revise their 
recommendations.
If there is an adequate volume of erectile 
tissue and normal androgen responsiveness, 
primary treatment revolves around 
exogenous testosterone administration 
or HCG treatment to increase penile 
length [3]. Although good responses are 
typically seen in early childhood [16–19], the 
impact on ultimate penile length remains 
unknown [3]. There may also be differences 
in pathophysiological aspects of penile 
development and response to treatment 
between patients with micropenis as an 
isolated condition and patients with defects 
Stretched penile length   
(in centimeters) by age.TABLE 1
Age Mean ± SD
*Source: Feldman and Smith [4], †Source: Schonfeld and Beebe 
[5], ‡Source: Wessells et al. [6], SD = standard deviation
Newborn (30 weeks)*  2.5 ± 0.4
Newborn (term)*  3.5 ± 0.4
0 to 5 months†   3.9 ± 0.8
6 to 12 months†   4.3 ± 0.8
1 to 2 years†   4.7 ± 0.8
2 to 3 years†   5.1 ± 0.9
3 to 4 years†   5.5 ± 0.9
5 to 6 years†   6.0 ± 0.9
10 to 11 years†  6.4 ± 1.1
Adult‡  12.4 ± 2.7
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in the organogenesis of the male genital 
system (e.g., hypospadias, cryptorchidism) 
[19]. Moreover, it is not known whether 
prepubertal hormonal treatment can 
influence both somatic growth and pubertal 
penile growth, including penile shaft and skin 
enlargement, sufficiently to facilitate better 
surgical results [20]. No data are available 
on long-term effects of early testosterone 
treatment, such as negative impact on final 
height or inappropriate maturation of germ 
cells during childhood.
In general, surgical treatment should achieve
the major goals of (i) correction of chordee 
and straightening of the penis such that 
full painless erection enabling satisfactory 
penetration can be achieved (with or without 
prosthesis); (ii) urethroplasty enabling func-
tional micturition (including urination from 
the standing position); (iii) reconstruction 
of the tissues forming the ventral surface of 
the glans (glanuloplasty, repair of division of 
the corpus spongiosum and skin); and (iv) 
reconstruction of the scrotum and orchiopexy 
[21]. Developments in total phalloplasty 
procedures using pedicled or free tissue flaps 
(and combined with insertion of an inflatable 
penile prosthesis) seem promising but can 
still be associated with repeated surgical 
interventions and high rates of complications 
(such as urethral strictures or fistula 
formation), even in the most experienced of 
hands [2,3,22–26]. The questions remain as to 
whether male genitoplasty, with or without 
hormonal treatment, can replicate the 
complexity of penile anatomy and function 
and whether conducting phalloplasty 
procedures improves physical and sexual 
outcomes compared with genital surgery 
without phalloplasty. Because case numbers 
are in general low and many patients are lost 
to follow-up, there are extremely few reports 
of the outcome after surgery.
Aims
This review considers the impact and 
outcomes of both etiology and treatment of 
penile insufficiency in individuals raised male. 
We aimed (i) to summarize the literature 
on surgical, hormonal, and psychosexual 
outcomes in males with congenital or 
acquired micropenis; (ii) to identify existing 
gaps in our knowledge regarding the 
psychological impact of this condition on 
Quality of Life (QoL) outcomes; and (iii) to 
offer suggestions for future research and 
clinical practice.
Methods
A systematic search of the databases PubMed 
and Web of Science was conducted for the 
period between 1955 (the year that John 
Money published his now classic work on 
hermaphroditism, currently referred to as 
DSD [8]) and 2012. The following keywords 
were used: micropenis, disorder of sex 
development, intersex, masculinizing/ male 
genitoplasty, male pseudohermaphroditism,
phalloplasty, ambiguous genitalia, perineo-
scrotal hypospadias, psychological outcomes, 
hormonal treatment, testosterone, genital 
appearance, sexual functioning, surgical 
outcome. Only English manuscripts and 
those translated into English that provided 
data on various aspects of sexuality in 
46,XY patients with congenital or acquired 
micropenis, either isolated or in the context 
of a DSD, who were sex-assigned as males 
were included. Studies solely including 
patients with hypospadias repair but without 
genital ambiguity and studies involving solely
patients with cloacal exstrophy or aphallia 
were not the focus of this review (see [14] for 
an overview). Additionally, this article did not 
address men complaining of a small penis 
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despite an actually normal size and opting for 
penile augmentation procedures, as they are 
managed differently [7].
Results
The literature search yielded 29 studies 
from the years 1974–2012 examining 
aspects of treatment and sexuality in 46,XY 
individuals with micropenis who were sex-
assigned as male [17–20,27–51] (see Table 
2A). The majority of patients examined had 
undergone corrective surgery, although 
three of the studies gave no information on 
whether and in what way surgery had been 
done [32,37,39]. Tables 2B and 2C provide 
information on the functional outcomes 
grouped according to etiology in the study 
population (no DSD, underlying DSD, or 
both etiologies), testosterone treatment 
in infancy and/or childhood (yes, no, or 
unknown), and type of surgical treatment 
(no surgery, male genitoplasty procedures 
excluding phalloplasty, or phalloplasty). 
Reliable information on childhood 
hormonal treatment to stimulate penile 
growth or on hormone substitution therapy 
in adolescence or adulthood was included in 
half of the studies. Only a minority of studies 
included comparison data. The studies 
differ from each other substantially in both 
number and type of investigated variables. 
Standardized or partly standardized 
instruments for data assessment were 
only used in nine studies [31,33,34,38–
40,43,49,50]. Therefore, a meta-analysis 
calculating the effect sizes of previous 
results was not possible. In the following 
sections, the findings are summarized 
according to the investigated variables.
TABLE 2A
Overview of diagnostic and treatment details in postpubertal individuals  
with congenital micropenis or acquired penile insufficiency.
Mean 25 years (range 14–39)
   
  
 
22–31 years
   
   
  
31–48 years
17–43 years
   
   
3 adolescents, 2 adults
   
   
   
   
  
7 children, 4 adolescents, 5 
adults (range 18–24 years)
   
   
  
17.7–36.6 years
PAIS (8)
    
   
 
Hypogonadotropic hypogonadism (3), 
adiposogenital dystrophy (2), primary 
hypogonadism (1), idiopathic (1), Robinow’s 
syndrome (1), atrophic testes (1)
CAH (2), anorchia (1)
Hypogonadotropic hypogonadism (4), idiopathic 
(3), mixed GD (3), MPH (2)
    
17βHSD3 deficiency
    
    
    
    
   
 
Posttraumatic amputation, developmental 
anomalies, micropenis or circumcision accident 
(NR)
    
    
Perineoscrotal hypospadias with undescended 
testes and micropenis: 46,XY (12), 45,X/ 46,XY (6), 
46,XX (1)
8
 
 
 
9
 
 
 
3
12
 
 
5
 
 
 
 
 
16
 
 
 
 
19
Money & Ogunro, 1974 [27]
   
  
 
Money et al., 1984 & 1985 [28,51]
   
   
   
Van Seters & Slob, 1988 [29]
Reilly & Woodhouse, 1989 [18]
   
   
Farkas & Rosler, 1993 [20]
   
   
   
   
   
Gilbert et al., 1993 [30]
   
   
   
   
Miller & Grant, 1997 [31]
Study Nr Age Diagnosis (n)
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Anatomical Outcomes
Penile Length After Hormonal  
Treatment in Childhood and Adulthood
In 11 studies, males with micropenis, either 
true [17,18,28,33,36,38,51] or in association 
with a DSD [18–20,29,36,40,49], were or had 
been treated with HCG, testosterone cream 
applied to the genitalia, and/or intramuscular 
injections of testosterone enanthate in 
infancy and/or childhood.
Within the true micropenis group, the re-
ported immediate effect on penile size in 
infancy and/or childhood was significant in 
all but one study [36], but only in half of the 
studies did stretched penile length (SPL) also 
fall within the normal range in adulthood, 
following hormone replacement therapy 
(HRT) beginning at the age of puberty 
[17,33,38]. In one study [33], the adult penile 
lengths of three men treated in childhood 
showed a trend toward longer final length 
compared with those men whose treatment 
was initiated later in development, suggesting 
the value of early diagnosis and treatment, at 
least in this group. The prognosis for adult SPL 
seemed to be better in Kallmann’s syndrome 
compared with the other etiologies of true 
micropenis.
Within the DSD group, results were more 
varied. Despite a significant increase of penile
length in childhood in two studies [18,19] 
(but not in two others [36,40]), the penile 
length remained significantly shorter than 
the reference values for young adults after 
HRT and surgical correction. It seems 
that testosterone treatment in childhood 
accelerates penile growth but does not 
increase the size of the penis beyond its 
Hypospadias (8), cryptorchidism 
(2), clitoris-sized phallus (4)
  
 
Inadequate testis function (6)
   
   
  
 
Hypospadias (3)
Hypospadias 
(5),underdeveloped scrotum (3), 
small (3) or absent testes (1)
Chordee (5), cryptorchidism (4)
  
   
   
   
   
   
NR
   
   
   
  
Hypospadias (19)
Abdominal skin graft (1) 
   
  
 
Skin graft, not specified (1)
   
   
  
 
NR (1)
No
   
  
 
No
   
   
   
   
  
 
Forearm fasciocutaneous 
free flap (16)
   
   
   
No
Hypospadias repair (5)
   
  
 
Z-plasty (9)*
   
   
   
 
Prosthetic testis (1)
Hypospadias repair (5)
   
   
 
Chordee release, penile 
lengthening,† and dorsal skin 
mobilisation to penile ventrum 
as preparation for second-stage 
hypospadias repair (Duplay or 
modified Denis Browne-type) (5)
NR
   
   
   
   
 
Staged hypospadias repair (19) 
Not erectile and insensititive 
after phalloplasty, hypospadias 
repair failed (2)
Not erectile after  
phalloplasty (1)
   
  
 
Phalloplasty failed (1)
NR
   
  
 
NR‡
   
   
   
   
  
 
Total flap failure (1), urethral 
fistula (5), urethral strictures (3), 
meatal stenosis (1); redo surgery 
because of complications in 7 
and esthetic reasons in 4
Persistent abnormalities of 
micturition and spraying (13)
Other genital features of
defective virilization (n)
Other masculinizing
genitoplasty (n)
Phalloplasty (n) Complications (n)
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TABLE 2A
Overview of diagnostic and treatment details in postpubertal individuals  
with congenital micropenis or acquired penile insufficiency.
Mean 38 years (range 21–54)
   
  
 
Mean 34 years (range 20–54)
   
   
   
Mean 22.2 years (range 20–26)
   
  
Mean 23 years (range 18–30)
   
   
   
Mean 35 years (range 22–52)
   
Mean 22 years (range 18–32)
   
Mean 25 years (range 18–32)
   
   
Mean 24 years (range 16–43)
   
   
   
Mean 12 years (range 10–15)
   
Mean 20.7 years (range 14–38)
   
   
   
Mean 21.4 years (range 19–26)
   
   
   
15–42 years
   
   
Mean ≥15.3 years after surgery in 
childhood or infancy
Mean 21.0 ± 3.6 years
Mean 28 years (range 5–52)
  
 
Hypogonadotropic hypogonadism (6), panhypo-
pituitarism (2), hypergonadotropic hypogonadism 
(2), idiopathic (1)
PAIS (5), partial GD, (7), unspecified intersex (9)
    
    
    
Penile amputation (8), congenital micropenis (4),
penile gunshot wounds (4), traffic accident (2)
    
PAIS (5), multiple hormonal effects (4), hypo-
gonadotropic hypogonadism (2), idiopathic 
micropenis (9)
   
 
Unspecified with ambiguous genitalia (21), 
micropenis (11)
Hypogonadotropic hypogonadism (11), primary
testicular failure (3), idiopathic (8)
Mixed GD (1), CAH (1), PAIS (2), severe hypospadias 
(11), 5αRD deficiency (1), bifid urethra and ectopic 
urethra (1)
PAIS
    
    
    
Failed epispadias repair (4), micropenis (3), 
intersexuality (1)
Testicular dysgenesis (2), true hermaphroditism 
(6), 5αRD2 deficiency (1), PAIS (7), MPH (9)
    
    
Partial GD (6), mixed GD (4)
    
    
    
Bladder exstrophy (3), crippled penis (1), shriveled 
penis (1), penile amputation (2)
    
46,XY DSD (AR pathway problem) (8)
   
Ovotesticular DSD (3), 45,XO/ 46,XY mixed GD (4), 
46,XX testicular DSD (4), AIS (1)
Iatrogenic trauma (20), traffic accidents 
(11), burns (3), self-amputation (2), ritual 
circumcision (2), penile fracture (2), gunshot 
trauma (2), electrocution (1)  
 
13
 
 
21
 
 
 
18
 
 
20
 
 
 
32
 
22
 
17
 
 
15
 
 
 
8
 
25
 
 
 
10
 
 
 
7
 
 
8
 
12
 
 
43 
 
 
 
 
 
Wisniewski et al., 2001 [33]
   
  
 
Migeon et al., 2002 [34]  
   
  
 
Sengezer et al., 2004 [35]
   
  
Husmann, 2004 [36]
   
   
  
 
Meyer-Bahlburg et al., 2004 [37]
   
Lee & Houk, 2004 [38]
   
Warne et al., 2005 [39]
   
   
Bouvattier et al., 2006 [40]
   
   
   
Djordjevic et al., 2006 [41]
   
Nihoul-Fékété et al., 2006 [42]
   
   
   
Szarras-Czapnik et al., 2007 [43]
   
   
   
Lumen et al., 2008 [44]
   
   
Schwentner et al., 2008 [45]
   
Kojima et al., 2009 [46]
Perovic et al., 2009 [47]
   
   
   
  
 
Study Nr Age Diagnosis (n)
18–27 years
 
Mean 34 years (range 22–47)
  
Mean 38 years (range 21–54)
Fetal and postnatal gonadotropin deficiency (5), 
hypogonadotropic hypogonadism (3)
Hypogonadotropic hypogonadism (1), PAIS (1), 
CAH (1), MPH (1)
Hypogonadotropic hypogonadism (6), panhypo-
pituitarism (2), hypergonadotropic hypogonadism 
(2), idiopathic (1)
8
 
4
 
13
Bin-Abbas et al., 1999 [17]
   
Schober, 2001 [32]
  
 
Wisniewski et al., 2001 [33]
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Small testes and poor quality 
of corpora (6); mean pubic hair 
Tanner stage 3.6 (range 1–5)
Hypospadias (21); mean pubic
hair Tanner stage 4.1 (range 
3–5)  
 
NR
  
Undervirilization based on 
genital and pubertal hair de-
velopment (Tanner stage 1
(15) and 2 (5))
Hypospadias (21)
   
NR
  
Hypospadias (at least 11)
   
   
Cryptorchidism (bilateral 6,
unilateral 5), hypospadias (15), 
severe undervirilization (EMS 
< 5, 15)
NR
  
Hypospadias and chordee (25),
undervirilization (PAIS, 5; true
hermaphroditism, 1; testicular
dysgenesis, 1)
Hypospadias (7), an abnormal
testis on one side and a streak 
gonad on the other side (4), or 
bilateral dysgenetic testes (6)
NR
   
  
 
Hypospadias (8), cryptorchidism
(8)
Hypospadias (12), 
cryptorchidism (5)
NR
No
   
  
 
No
   
   
  
 
Free sensate osteocutaneous 
fibula flaps (18)
No
   
   
   
NR
   
No
   
NR
   
   
No
   
  
  
Musculocutaneous
latissimus dorsi free flap (8)
No
   
   
   
No
   
   
  
Radial forearm free flap (6), 
anterolateral thigh flap (1), 
inflatable penile prosthesis (4)
No
   
No
  
Redistribution of remaining 
penile skin and scrotal flaps 
(35), variety of surgical 
techniques (8)§ 
   
 
Prosthetic testis (3)
   
  
 
Chordee release, staged
hypospadias repair, prosthetic
testes, removal of müllerian
remnants, orchiopexy (17)
NR  
 
Release of suspensory ligament
and injection of autologous fat (5)
   
   
NR (at least 16, not specified)
   
None
   
NR
   
  
Hypospadias repair (15)
   
   
   
Inflatable penile prosthesis (2)
  
Correction of penile curvature,
hypospadias repair (25)
   
   
Hypospadias repair, removal of
müllerian remnants, penile re-
construction (not specified) (10)
  
 
NR
   
   
Hypospadias repair (8)
  
Hypospadias repair (12)
   
   
NR
NA
   
  
 
Fistulae, strictures, urinary tract
infections, urethral dilations,
testicular pain, hair growth in
urethra (NR)
Flap failure (1), persistent
urethral stricture (1)
Dissatisfied with “lumpiness” of
penile shaft (5)
   
   
NR
   
NA
   
NR
   
   
NR
   
   
  
Urethral fistula with redo
operation (3)
Perineal or penile fistula (4),
penile deformity (1)
   
   
NR
   
   
  
Urinary stricture and/or fistula (2), 
removal of penile prosthesis (2)
   
NR
   
NR
   
Infection after implantation of
penile prosthesis (1), protrusion of 
a semirigid prosthesis (1), urethral
stenosis (1), urethral fistulae (2), 
partial skin flap necrosis (2); redo 
surgery (5)
 
Other genital features of
defective virilization (n)
Other masculinizing
genitoplasty (n)
Phalloplasty (n) Complications (n)
Small testes (8)
   
NR
Small testes and poor quality 
of corpora (6); mean pubic hair 
Tanner stage 3.6 (range 1–5)
No  
 
No
No
No  
 
NR, but most had “surgical 
alteration”
Prosthetic testis (3)
NA
  
 
NR
NA
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TABLE 2A
Overview of diagnostic and treatment details in postpubertal individuals  
with congenital micropenis or acquired penile insufficiency.
“predetermined” length [20,46,49]. Persistent 
microphallus was most often diagnosed in 
patients with partial androgen insensitivity 
syndrome (PAIS), where little or no SPL gain 
was noticed, irrespective of HRT [27,40,42,49].
Surgical Outcomes and Genital  
Appearance After Phalloplasty or 
Masculinizing Genitoplasty
The use of male genitoplasty techniques 
in combination with one another and the 
differences between cases (e.g., degree 
of hypospadias, amount of erectile tissue 
present) make direct comparison of 
surgical results difficult (Table 2A). The first 
phalloplasty procedures (with a nonspecified 
skin graft) performed in patients with 
congenital micropenis yielded no anatomical 
success [27–29]. Later studies in patients with 
both congenital and acquired micropenis 
showed more encouraging results, although 
complications were reported in 28% of cases 
(26/92), ranging from flap failure (n = 4) and 
problems with the penile prosthesis (n = 4) 
to urethral fistulae, stricture, or stenosis (n = 
18). A redo operation was necessary in 27% of 
the cases (25/92) [30,35,41,44,47]. Complication 
and resurgery rates were relatively higher after 
use of forearm free flaps and latissimus dorsi 
flaps (29–44%) compared with use of fibula 
flaps (11%) (Table 2A), although it is difficult 
to compare the main phalloplasty techniques 
used, as patient samples were diagnostically 
diverse and treatment was adjusted according 
to the involved penile pathology and the 
type and extent of injury. Almost 100% of 
men reported the ability to void in a standing 
Study Nr Age Diagnosis (n)
Mean 19.3 years (range 15–25)
   
   
   
   
   
   
Mean 22 years (>18 years, n = 38)
   
   
   
   
Mean 17.6 years (range 14.5–20.8)
   
   
   
   
  
 
Mean 19.5 years (range 18–50)
MPH (43), mixed GD (3), true hermaphrodite (7), 
CAH (7)
    
    
    
    
    
46,XY/45,X mosaicism (8), partial GD (4), Frasier
syndrome (1), 17βHSD3 deficiency (3), 3βHSD2
deficiency (1), 5αRD2 deficiency (10), PAIS (6),
undetermined 46,XY DSD (19), ovotesticular 
dysgenesis (4), CAH (3)
Partial GD (7), 5αRD2 deficiency (2), PAIS (1),
undefined 46,XY DSD (9)
    
    
    
   
 
Mixed or partial GD (3), penoscrotal hypospadias 
(3), penile hypospadias and micropenis (1), 
epispadias (1), 46,XY hermaphroditism (1), 
unclassified (1)
60
 
 
 
 
 
 
 
59
 
 
 
 
 
19
 
 
 
 
 
 
10
Gupta et al., 2010 [48]
   
   
   
   
   
Sircili et al., 2010 [49]
   
   
   
   
  
 
Blanc et al., 2011 [19]
   
   
   
   
  
 
Kohler et al., 2012 [50]
*Z-plasty to release the body of the micropenis from being entrapped behind adhesions and phimosis of an excessively redundant preputial 
formation, †Dissection of fibrous tissue from the ventrum of the phallus extending down in between the crura of the corpora cavernosa and 
dissection of the suspensory ligament on the dorsal aspect of the penis ‡In total population of 16 patients, including 11 children: distal meatal 
stenosis (n = 2), breakdown of neourethra (n = 1), fistulae (n = 3), §Treatment according to the involved penile entity, type and extent of injury. 
For a full overview, see Perovic et al. [47]. SPL = stretched penile length; DSD = disorders of sex development; HRT = hormone replacement 
therapy (testosterone); PAIS = partial androgen insensitivity syndrome; CAH = congenital adrenal hyperplasia; GD = gonadal dysgenesis; 5αRD2 
= 5-alpha reductase 2; 17βHSD3 = 17-beta hydroxysteroid dehydrogenase 3; 3-βHSD2 = 3-βhydroxysteroid dehydrogenase 2; MPH = male 
pseudohermaphroditism; NR = not recorded
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position with a sufficient urine caliber 
[30,35,44,47]. Cosmetic appearance was judged 
to be satisfying in more than 85% of cases 
(63/74) [30,41,44,47]. Reasons for dissatisfaction 
included scarring [41,44] and color mismatch 
problems with scrotal skin and the skin of the 
penile stump [35], making redo surgery for 
esthetic reasons necessary in some cases [30].
Male genitoplasty procedures other than 
phalloplasty mainly involved (staged) 
hypospadias repair, chordee correction, and/
or penile lengthening (i.e., excision of the 
pubic fat pad and division of the suspensory 
ligament) [18–20,31,34,36,40,43,45,46,48–50]. 
Table 2A summarizes the specific techniques 
used, but only a minority of studies included 
further details of the performed procedures. 
Frequently reported complications (in 
55%) were urethral fistulae and/or stenosis, 
micturition problems, and hair growth in the 
urethra causing obstruction and infection 
[19,31,42,48–50]. The majority of men reported 
urinating from a standing position [20,49], but 
11% to 47% complained of spraying during 
micturition [19,31], postvoid dribbling, or a 
need to “milk” the urethra after voiding [49]. 
Dissatisfaction with genital appearance and 
penile size was found in 45% of patients 
who underwent these procedures and was 
thus markedly higher compared with the 
dissatisfaction rate of 15% after phalloplasty 
(P < .01) [19,20,31,34,36,37,42,43,45,48–50]. Inte-
restingly, dissatisfaction was significantly 
higher (81%, 39/48) in men who did not 
undergo any masculinizing genitoplasty 
procedure [28,33,36,38] (P < .01 by Fisher’s 
exact test). In three studies, a third to half of 
the patients were teased by peers or received 
comments on the appearance of their genitals, 
irrespective of surgery or type of surgery 
[18,28,48].
Other genital features of
defective virilization (n)
Other masculinizing
genitoplasty (n)
Phalloplasty (n) Complications (n)
Hypospadias (at least 6)
   
   
   
   
   
  
Microphallus (44), bifid scrotum
(43), penoscrotal transposition
(23)
   
   
 
Hypospadias (19), crypto-
rchidism (5), bifid scrotum (10), 
impaired testicular function (14
   
   
  
Hypospadias (10), severe 
underandrogenization (7)
No
   
   
   
   
   
   
No
   
   
   
   
No
   
   
   
   
   
No
Not specified (60)
   
   
   
   
   
   
Hypospadias repair (modified
Denis-Browne) (59)
   
   
   
Hypospadias repair (19)
   
   
   
   
  
Hypospadias repair (10)
Scrotum diverticulum (1), 
proximal penile diverticulum (1), 
urethral stricture (2), hair in the 
urethra causing obstruction and 
infection (3), residual chordee 
correction (3), distal urethroplasty 
(4), urethral fistula (21)
Urethral fistula (30), urethral
stenosis (13)
   
   
  
Urethral fistula (9), urethral
stenosis (3); additional
procedures for penoscrotal
transposition (3), buried penis
(1), and recurrent ventral
curvature (1)
Complications (5), resurgery (3)
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Psychological Outcomes
Sexual Experiences and Sexual Activity
The majority of studies did not use validated 
instruments. Likewise, it remained unclear in 
some studies whether only coital sexual activ-
ity was included in the assessment or whether 
noncoital activities (e.g., masturbation) were 
included as well. Overall, literature data 
suggest that at least three-quarters of 46,XY 
males with DSD including micropenis were 
sexually active or had at one time engaged 
in sexual activity. At least 50% (up to 100%) 
were satisfied with their sex life at the time 
of investigation, including both men with a 
history of genital surgery and those without 
[29,32,34,37,45].
Firm conclusions on the effect of surgery 
cannot be drawn, as in almost all studies, 
either patients had already undergone surgical 
alteration or it was not specified to what 
extent surgery affected eventual functional 
outcomes [18,27,36]. The first phalloplasty 
TABLE 2B
Hormonal, anatomical, and psychosexual outcomes in men with micropenis 
who received androgen treatment in infancy and/or childhood.
Surgical treatment
and etiology
Dissatisfaction with 
genital appearance, n (%)
Normal
 SPL,
n (%)*
Number
of cases
HRT, 
n (%)†
Sexuality, n (%)
No surgery
Non-DSD etiology       
    Wisniewski et al., 2001 [33]‡  3  3 (100)  1 (33)  Erection and ejaculation, 3 (100) 3 (100)
    Bin-Abbas et al., 1999 [17]  8  8 (100)  NR  Intercourse, 6 (75)  8 (100)
    Lee & Houk, 2004 [38]§  20  14 (70)  9/12 who completed  Intercourse, 8/12 who completed  14 (70) 
   questionnaires reported  questionnaires(67); masturbation,    
   (75)¶ 20 (100)  
    Money et al., 1984 & 1985 [28,51] 4  0 (0)  3 (75) Intercourse,  0 (0); masturbation,2 (50) 2 (50)
DSD etiology,            
    Van Seters & Slob 1988 [29]  2 0 (0) 0 (0)  Orgasm and satisfaction with  2 (100) 
    sex life, 2 (100) 
Both DSD and non-DSD etiologies             
    Husmann, 2004 [36]  15  2/20 (10)††  15 (100)  Sexually active, 12/20 (60); NR 
    Intercourse, 8/20 (40)††
    Reilly & Woodhouse, 1989 [18]  7  0 (0)  6/12 (50)††  Intercourse, 9/12 (75); erection 7 (100) 
    and orgasm, 12/12 (100)††
Surgery (without phalloplasty)
Non-DSD etiology       
    Money et al., 1984 & 1985 [28,51] 1  1 (100)  1 (100)  Masturbation, 1 (100)  Not  
     needed
DSD etiology       
    Blanc et al., 2011 [19]  19  1 (5)  2 (11)  NR  8 (42)
    Farkas & Rosler, 1993 [20]  5  5 (100)  3 (60)  Intercourse, 1 (20); erection and Not  
    ejaculation, 2 (40) needed
Sircili et al., 2010 [49]¶  38  36 (95)  3 (8)  Sexually active, 33 (87); sexual  NR 
    intercourse, 21 (55)
Bouvattier et al., 2006 [40]**  15  0 (0)  NR  Intercourse, 0 (0); masturbation,5 (33);  4 (27) 
    avoidance and non-communication,    
    15 (100); dissatisfaction with sexual   
    acts, 13 (87)
Both DSD and non-DSD etiologies       
    Husmann, 2004 [36]  5  2/20 (10)††  5 (100)  Sexually active, 12/20 (60); NR 
    intercourse, 8/20 (40)††
    Reilly & Woodhouse, 1989 [18] 5  0 (0)  6/12 (50)¶  Intercourse, 9/12 (75); erection  5 (100) 
    and orgasm, 12/12 (100)††
Androgen treatment consisted of treatment with human chorionic gonadotropin, testosterone cream applied to the genitalia, and/or 
intramuscular injections of testosterone enanthate, *SPL within 2 SD of mean for age in adultood,  †Only HRT-compliant patients were included
‡Used the Sexual Behavior Assessment Schedule–Adult to obtain information on sexual orientation, §Used the Social Adjustment Self-Report 
Questionnaire and Hopkins Symptoms Checklist, ¶Used the International Index of Erectile Function,  **Used the Simplified International Index 
of Erectile Dysfunction and Golombok–Rust Inventory of Sexual Satisfaction, ††Results reported for total patient population, as results were 
not separately discussed for men who underwent surgery and those who did not, SPL = stretched penile length; HRT = hormone replacement 
therapy; NR = not recorded
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TABLE 2C
Hormonal, anatomical and psychosexual outcomes in men with micropenis not 
known to have received androgen treatment in infancy and/or childhood.
Dissatisfaction with
genital ap-
pearance, n (%)
Normal
 SPL, n (%)*
Number
of cases
HRT, 
n (%)†
Sexuality, n (%)
No surgery
Non-DSD etiology                  
    Wisniewski et al., 2001 [33]‡  10  5 (50)§§ 2 (50),  Good to fair erection and ejaculation, 10 (100)  7 (70) 
   all with     
   micropenis
    Lee & Houk, 2004 [38]§  2  0 (0)  NR No intercourse but other  NR 
    sexual activities, 2 (100)¶¶
    Money et al., 1984 & 1985  3  3 (100)  2 (67)  Masturbation, 1 (33)  0 (0); not  
    [28,51]      needed in†††
DSD etiology       
    Migeon et al., 2002 [34]¶  4  2/3 who partici- NR Somewhat to totally inadequate sexual 5 (24)¶¶ 
  pated in urological  function, 3 (75); erection 4 (100)   
  exam (67)
    Money & Ogunro, 1974 [27] 2  0 (0)  NR  Sexually active with genital contact, 5 (71)¶¶  3 (38)¶¶
Surgery (without phalloplasty)
DSD etiology       
    Migeon et al., 2002 [34]¶  17  8/15 who partici- NR  Somewhat to totally inadequate sexual  5 (24%)¶¶  
  pated in urological  function, 12 (71); erection, 17 (100)   
  exam (53)
    Money & Ogunro, 1974 [27]  5  0 (0)  NR  Sexually active with genital contact, 5 (71)¶¶  3 (38)¶¶
    Kojima et al., 2009 [46]  12  0 (0)  NR  Intercourse, 4 (40); masturbation, 9 (90);  3 (25) 
    ejaculation problems, 5/7 (71)‡‡‡
    Miller & Grant, 1997 [31]**  19  NR  6 (32)  Intercourse, 12 (63); erection and orgasm,  NR 
    15 (79); ejaculation, 7 (37) 
    Nihoul-Fékété et al., 2006  25  18 (72), all except  13 (52)  NR NR 
    [42]  PAIS 
    Szarras-Czapnik et al.,2007 10  NR  3 (30)  Intercourse, 7 (70); erection and  7 (70) 
    [43]††    ejaculation, 10 (100) 
    Schwentner et al., 2008 [45]  8  NR  0 (0)  Satisfactory sexual function, 8 (100)  NR
    Gupta et al., 2010 [48]  60  NR  44 (73) Erection, 53 (88); ejaculation, 44 (73)  37 (62)
    Kohler et al., 2012 [50]‡‡  10  NR  5 (50)  Erection, 9 (90); ejaculation, 5 (50),  3 (30) 
    genital arousal, 7 (70); fear of sexual contact    
    and initiating sexual contact, 4 (40)
Phalloplasty
Non-DSD etiology       
    Money et al., 1984 & 1985   1  1 (100)  1 (100)  Hypoactive masturbation, 0 (0)  0 (0) 
    [28,51]
    Perovic et al., 2009 [47]  43  43 (100)  2 (5)  Intercourse, 35 (81)  NR
DSD etiology        
    Van Seters & Slob, 1988 [29]  1  0 (0)***  0 (0)  Satisfied with sex life, no intercourse,  1 (100) 
    premature ejaculation and fear regarding    
    sexual performance, 1 (100)
    Money & Ogunro, 1974 [27]  1  1 (100)  NR  Intercourse, 0 (0)  NR
Both DSD and non-DSD etiologies       
    Gilbert et al., 1993 [30]  16  16 (100)  NR  Erogenous sensibility and masturbation,  NR 
    5/5 adults (100) 
    Sengezer et al., 2004 [35]  18  18 (100)  NR  Intercourse, 18 (100)  NR
    Djordjevic et al., 2006 [41] 8  8 (100) 4 (50)  NA (still in adolescence)  NR
    Lumen et al., 2008 [44]  7  7 (100)  1 (14)  Neophallus sensitivity, 5/6 (83)§§§; sexually  NR 
    active with orgasm, 2/4 with erection    
    prosthesis (50)
*SPL within 2 SD of mean for age in adulthood, †Only HRT-compliant patients were included, ‡Used the Sexual Behavior Assessment Schedule–
Adult to obtain information on sexual orientation, §Used the Social Adjustment Self-Report Questionnaire and Hopkins Symptoms Checklist
¶Used the Kinsey Scale to obtain information on sexual orientation, **Used the Case Western Reserve University Sexual Function Questionnaire, 
Spielberger Anxiety Questionnaire, Goldberg General Health Questionnaire, and Beck Depression Inventory, ††Used the Gender Identity Index 
analyzed according to Bem’s gender schema theory, together with three projective tests: the Human Figure Drawing test, Three Wishes Test, 
and Rorschach test, ‡‡Used the ZUF-8 questionnaire measuring patient satisfaction, §§Three men not compliant with HRT had micropenis 
,¶¶Results reported for total patient population, as results were not separately discussed for men who underwent surgery and those who did 
not, ***Phalloplasty failed, †††One man with Robinow syndrome and one with adiposogenital dystrophy (familial agonadism) had adequate 
male hormonal function of their own testes, ‡‡‡Sexual activity was only assessed in n = 10; 7 (70%) had experienced ejaculation, and 5 of these 
7 patients had ejaculation problems, including dribbling, retained, or delayed ejaculation, §§§Genital sensitivity was only assessed in n = 6, as 
one man had only recently been operated. The five men who underwent radial forearm free flap phalloplasty all experienced sensitivity, the 
one man with anterolateral thigh flap phalloplasty did not, SPL = stretched penile length; HRT = hormone replacement therapy; NR = not 
recorded; NA = not applicable
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procedures performed yielded no functional 
(or anatomical) success [27–29], but those 
performed later in patients with penile 
deficiency (both DSD-related and idiopathic 
micropenis) showed good results [30,44,47], 
with erogenous sensitivity present in the 
neophallus [30,35,44].
Data are inconclusive regarding the age at 
first dating or sexual contact [18,29,31,32,38], 
as only one study included control data [38]. 
Warne et al. reported that men with DSD in 
general were less sexually active than men 
with diabetes mellitus or Hirschsprung’s 
disease, although sexual interest was similar 
in both groups [39]. In men with PAIS, sexual 
satisfaction and function were seriously 
impaired, and in comparison with a norm 
sample, lower sexual interest was found [40]. 
Despite obvious anatomical limitations, the 
mechanisms of sexual dysfunction in PAIS 
remain unclear. It is not known whether the 
deficient sexual function is the result of an 
abnormal phallus and androgen resistance or 
just of an abnormal phallus [40].
Many studies showed that men with 
micropenis can experience sexual pleasure 
and orgasm [18,27,29,33,34,43,45,49]. How-
ever, problems with erection and/or with 
precocious or no ejaculation [18,31,46,48–50] 
and compromised penetrative ability are 
often reported [18,20,27–29, 36,40,46].
Whether or not a correlation exists between 
small penile length and dysfunctional 
penetrative intercourse remains unclear. 
Penile length was not associated with 
satisfactory or unsatisfactory sexual activity 
in the study by Sircili et al. [49]. On the other 
hand, having a micropenis was associated 
with absence of sexual intercourse in some 
studies [27–29,40], but not in others [18,46]. In 
men with a history of micropenis but with an 
adult SPL within normal range, only around 
three-quarters reported having satisfactory 
(but not ideal) intercourse [17,38]. In general, 
having a micropenis has a major negative 
impact upon sexual self-confidence [40,48,50]. 
Reasons for compromised penetrative ability 
other than SPL can include dissatisfaction 
with genital appearance and/or postoperative 
complications. Also, perceived penile short-
ness or inadequacy may lead to social or 
sexual avoidance in some men with a history 
of micropenis and normal adult SPL [36,38,49].
Quality of Life Outcomes: Psychopathology 
and Psychosocial Adjustment
Men with DSD do not have more difficulties 
regarding psychosocial well-being (depres-
sion, anxiety, physical and mental health) 
as compared with a control group of men 
with Hirschsprung’s disease [39] and have no 
increased psychiatric morbidity [38]. However, 
other research shows that these men face 
more specific QoL concerns, such as poor 
body image and fear of sexual rejection 
and sexual inadequacy [31,36,38]. Additional 
features of concern are dissatisfaction with 
the amount of facial hair, dissatisfaction with 
small testes, and the problem of infertility 
[48]. Hence, social adjustment and adaptation 
[18,31,48] and interpersonal interactions 
[34,40,42] are frequently impaired.
The effect of male genitoplasty on psy-
chological well-being could not be 
estimated, as in the majority of studies it 
was not mentioned. Two studies report 
a boost in self-esteem after phalloplasty 
[41,44], possibly related to the increase 
in phallic length. On the other hand, 
psychosocial and psychosexual adjustment, 
as well as satisfaction with surgical results, 
may also have been influenced by the 
long-term psychological support these 
patients received. Parental counseling in 
children [18] and an encouraging partner 
217
attitude [29] have been associated with 
better outcomes. Future studies should 
further investigate the impact of parents, 
siblings, partners, and spouses on long-term 
psychosexual development in this group.
Satisfaction with Gender of   
Rearing and Male Gender Role
The majority of men with micropenis were 
satisfied with their male gender of rearing. 
Among studies covered by this specific 
overview, there was only one report of a case 
(with unclear etiological diagnosis) of patient-
initiated legal gender change to female [34]. 
Gender dysphoria and dissatisfaction with 
gender of rearing were expressed by 7.7% 
of men in one study [33] and 21% to 24% in 
two others [34,37]. More specifically, 16% 
(4/25) talked about having an “intersexual” 
gender identity, not a male gender identity 
[32,34], corroborating the findings in Gupta et 
al.’s study that five out of 60 men (8%) had 
mixed feelings about their male gender role 
[48]. Interestingly, these feelings were only 
expressed by men with an underlying DSD, 
not in those with a true micropenis condition.
Sexual Orientation
When applied to individuals with a DSD, the 
concept of sexual orientation means that 
individuals who identify as heterosexual feel 
sexually attracted to persons who fulfill the 
opposite gender role [52]. Most studies suggest 
that 46,XY persons with DSD and micropenis 
are primarily or exclusively heterosexually 
oriented [17,18,27,29,33,34,36,38,40,43,46,48-50]; 
homo- or bi-sexuality is reported in 5–15% 
[33,34,36,38]. Only in the studies by Schober 
and Money et al. was the nonheterosexuality 
rate significantly higher (around 30%) [28,32]. 
Most studies with a mixed population did not 
separate data according to diagnostic groups 
for evaluation.
Discussion
Individuals with conditions associated with 
micropenis differ from other groups on 
important counts. Compared with “healthy 
normals,” they differ in having a chronic 
medical condition. Compared with other 
medical populations, they differ in bodily 
presentation and attendant experiences [53]. 
It is generally conceivable that psychosocial 
aspects related to their medical history can 
have a negative effect on sexual QoL. These 
can include compromised self-esteem 
and impaired psychological well-being in 
addition to social and sexual anxieties, social 
stigmatization, anxiety about the inability 
to conceive, and traumatic treatment 
experiences [52,54]. However, it is difficult to
determine how far physical, psychological, 
and social aspects influence sexual behavior 
and experience because the various 
interacting factors cannot be examined 
separately [52]. Figure 1 illustrates a dynamic 
and interactive model of sexual QoL, affected 
by several factors including desire, situations, 
and sexual ability [54,55].
Sexual function (e.g., erection, orgasm)
Sexual ability 
(self-efficacy)
Sexual
satisfaction
Relationship
satisfaction
Overall
satisfaction
Figure 1. An interactive and dynamic model of 
sexual quality of life (adapted from [54,55])
Figure 1
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In relation to all investigated aspects of sexual
QoL, the results of the studies reviewed 
are inconsistent and show great variability. 
However, they do suggest that 46,XY persons 
with DSD and micropenis tend to identify 
as heterosexual, that they have more sexual 
dysfunctions, and that they are less satisfied 
with their sex lives, their sexual function, 
and the appearance of their genitalia as 
compared with norm samples. It has been 
found that men’s global satisfaction with 
their genitals (e.g., size, shape, coloration, 
testicles) is directly linked to increased body 
satisfaction [56] and sexual functioning 
[57]. In 46,XY patients with DSD-related 
micropenis, it is not only genital appearance 
but also overall physical development—
such as body development and eventual 
breast growth, as is the case in PAIS—that 
can lead to a negative body image and 
impaired social interactions. Their having 
atypical genitals, frequently not suitable for 
heterosexual intercourse, can lead to fears of 
not meeting sexual partners’ needs or fears 
of rejection [52]. The current cultural context 
(including the studies reviewed) reflects the 
continued dominance of the so-called “coital 
imperative” in heterosex, where coitus is seen 
as “normal” and “natural” and where other 
forms of sexual activity are not seen as “real 
sex” [53]. Interestingly, some men reported a 
mutually sexually satisfying sex life with their 
partners, although no partner corroboration 
was sought. These men were reported to 
be able to de-emphasize the importance of 
intercourse, to have found alternative ways 
to reach orgasm, and to be able to meet the 
sexual needs of their partners [29,53].
Micropenis associated with hypogonado-
tropic hypogonadism seems to have a 
better prognosis with regard to hormone 
treatment response and adult penile size as 
compared with DSD-related micropenis. 
This probably reflects a difference in 
embryological pathophysiology, with dis-
turbed organogenesis of the penis only in the 
latter group. To our knowledge, no outcome 
studies exist comparing individuals affected 
by these two conditions.
It is a matter of concern that, even after 
hormonal treatment in childhood and/
or during puberty, small penis size persists 
into adulthood, especially in DSD-related 
micropenis, becoming a major cause of 
dissatisfaction [19,34,36,49]. Excessive worries 
about penis size have been found to contribute 
to poor self-esteem [57]. A micropenis is 
defined as a SPL > 2.5 SDs below the mean 
length for age and ethnic background or, in 
adulthood, a SPL < 7 cm in Caucasians [58]. 
However, it remains to be clarified if this 
also represents a cutoff for psychosexual 
functioning. Our group found that men who 
reported not being able to have penetrative 
intercourse indeed had a mean penile length 
< 7 cm [59]. It is unclear, however, if other 
psychosexual or QoL parameters were also 
negatively affected in this subgroup of men. 
Therefore, determining the cutoff SPL at 
which phalloplasty can be proposed as a 
viable option is highly challenging [46].
It seems that male genitoplasty—with or 
without hormonal treatment—can improve 
satisfaction with genital appearance and 
penile size, although the effect of surgery on 
length is often minimal, in the range of 1–3 
cm [60,61]. Also, the gradual improvement in 
complex hypospadias repair during the last 
30 years does not seem to have been directly 
translated to better (or worse) psychosexual 
outcomes. Repeated surgical procedures 
and complications are of particular 
concern because of associated scarring 
and loss of tissue as well as the presumable 
negative impact on sexual function. Phallus 
reconstruction by phalloplasty seems to 
lead to higher satisfaction with the surgical 
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result (including a larger SPL and fewer 
problems with voiding in a standing position) 
compared with genital surgery without 
phalloplasty. However, further publication 
of series with large numbers and longer 
follow-up is needed to evaluate if and to 
what extent phalloplasty improves physical 
and sexual outcomes. The early data here 
suggest that complete phalloplasty, today still 
mostly used for gender reassignment in the 
transgender population, opens new horizons 
for the treatment of 46,XY DSD patients with 
micropenis.
A high incidence of psychological health and
sexual concerns among micropenis patients, 
combined with the patients’ perception that 
their micropenis has negatively affected their 
QoL, indicates that psychological counseling 
should be recommended routinely in 
the treatment of these patients [9,36] and 
should aim at minimizing stigmatization and 
achieving greater self-acceptance as well as 
social acceptance of their condition. Doing 
a thorough job of educating and counseling 
is paramount, and the role of the parents 
cannot be overemphasized. Clinicians 
should be encouraged to participate in 
providing the patient with a progressive, age-
appropriate explanation of the diagnosis, 
pathophysiology, and potential for fertility 
from childhood through adolescence. 
It may be that long-term psychological 
support is of equal or superior importance 
to the anatomical result [12]. However, in 
our experience, many patients, especially at 
adolescent age, refuse further counseling, 
and research and other initiatives focusing on 
how to reach this group are highly needed.
Limitations and Future
The generalizability of previous results 
is compromised by the limited number 
of studies, the small and diagnostically 
heterogeneous samples, and differences 
in cultural and societal backgrounds. Most 
studies focus too strongly on heterosexual 
penetrative function. Qualitative and 
psychological aspects of sexual experience, 
including partner perspectives, should be 
investigated as well. For example, it has been 
shown that within the general population, 
the percentage of women who are satisfied 
with their partner’s penis size is much higher 
than the percentage of men who are satisfied 
with their own penis size [56,62]. Both the 
treatment history of the study participants 
(e.g., hormone treatment, age at time of 
surgery) and the operationalization of 
variables were insufficiently documented 
in most of the studies. Sexuality and 
adjustment of individuals with DSD have 
rarely been studied in detail because of the 
lack of specifically designed instruments 
accounting for the unique qualities of 
these people. In the effort to understand 
and better appreciate the DSD condition, 
there is need for a DSD-specific outcome-
reporting kit that includes standardized 
questionnaires and discriminating scales to 
measure more precisely patients’ degrees 
of satisfaction with regard to cosmetic, 
anatomical, and functional variables [12]. 
QoL research will provide vital information 
about the appropriate age for medical/
surgical intervention and the utility of 
various approaches, including psychological 
counseling, for clinical management.
Conclusion and Recommendations
First, according to the available data, the 
majority of adult male-raised patients with 
micropenis are satisfied with their childhood 
gender assignment and can achieve male 
sexual function. However, dissatisfaction 
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with sexual quality of life, dissatisfaction with 
cosmetic appearance, and stigmatization are 
reported.
Second, there is a lack of systematic studies 
of the impact of (different) hormone 
replacement therapy protocols on adult 
penile length and psychological outcomes, 
as well as of their long-term safety.
Third, the effect of male genitoplasty on 
penile length is often minimal and is, for 
most patients with micropenis, not enough 
to improve genital image and sexual quality 
of life.
Fourth, phalloplasty may improve outcomes,
but patient expectations need to be 
realistic. A balanced discussion, including 
multidisciplinary and psychological support 
for patients, is important in order to achieve 
appropriate treatment decisions.
Fifth, reporting long-term outcomes into 
adulthood is essential to appreciate the global
effect of the decisions made. Methodologies 
of treatments should be rigorously 
documented in future research, following 
the principles of evidence-based medicine. 
Equally importantly, it should be assessed 
how important surgical sex adjustment is in 
comparison with other factors that influence 
the psychosexual development of men with 
micropenis.
In conclusion, a structured counseling 
protocol and guidelines for the indications of 
phalloplastic surgery in men with micropenis 
(and 46,XY DSD) should be developed.
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Background. Total phallic reconstruction, currently the gold standard in female- to- male 
transgender patients, has a  potential indication for men with penile deficiency who are 
dissatisfied with their genital appearance or have unsatisfactory intercourse. 
Objective. To report long-term follow – up of phalloplasty in men with penile deficiency 
Design, settings, and participants. Sexual Quality of Life (QoL) was assessed in 10 men (aged 
20 - 43 years) at least one year after phalloplasty in a single institution (80% radial forearm 
free flap, 20% anterolateral thigh flap).  In all but one an erectile prosthesis was implanted on 
average one year after phallic reconstruction. 
Outcome measurements and statistical analysis. Neophallus sensation, complications and 
genital appraisal were recorded. Sexual Qol outcomes were compared to those of men with 
hypospadias repair (n=73)  and control men (n=50). 
Results and limitations. After phalloplasty (mean 36.9 months, 14-92 months), all men were 
sexually active (80% intercourse, 100% masturbation with orgasm and ejaculation). However, 
75% indicated to be inhibited in seeking sexual contacts, compared to 40% of hypospadias 
patients (p<.05) and 11% of controls (p<.01). Although 90% were satisfied with the final surgical 
result, dissatisfaction with some aspects of genital appearance was present in 50%. Erogenous 
neophallus sensitivity was said to be less than previously hoped for. Six men developed urinary 
complications (urethral stricture and/or fistula) and one man underwent revision of the erectile 
implant because of dysfunction. Nevertheless, all indicated they would choose again for 
phalloplasty if necessary. 
Conclusions. Total phalloplasty opens new horizons for the treatment of men with penile 
deficiency, but limitations of the technique should be emphasized prior to surgery. Psychological 
support should be an integral part of the management in alleviating the impairment of sexual 
QoL. Publication of series with large numbers and longer follow-up is needed.
5.2 
Sexual Quality of Life after 
Total Phalloplasty in Men with 
Penile Deficiency
ABSTRACT
Key Words. Disorder of sex development; micropenis; penile deficiency;  phalloplasty, psy-
chosexual functioning; reconstructive penile surgery
Introduction
Until the late 20th century, surgical 
construction of a cosmetic and functional 
penis was not feasible and traditional clinical 
management of male neonates with severe 
phallic inadequacy (i.e. stretched penile 
length < 2.5 cm) included social and surgical 
female sex assignment, acknowledging 
the importance of normal penile cosmesis 
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and function for male social integration 
and sexuality [1,2]. (Gender) identity crises 
and reported neovaginal inadequacy in 
female-raised 46, XY men [3,4], as well as 
improvements in the understanding of 
the phallic nerve supply [5] together with 
refinements in surgical techniques [6,7] 
led reconstructive surgeons to revise the 
indications [8-10]. 
However, total phallic reconstruction 
is rarely performed today in males with 
penile deficiency, despite its widespread 
and successful use in the transgender 
population [11,12]. Small series have reported 
cosmetically acceptable and sensate neo-
phalli with incorporation of a neourethra 
to allow voiding in a standing position and 
with enough bulk to allow the insertion of 
a penile prosthesis for pleasurable sexual 
intercourse [13-19]. However, the absence 
of control groups or norms, the use of non-
validated measures, particularly with respect 
to psychosexual outcome, unclear protocols 
and indications (e.g. age of patient, penile 
length, specific diagnosis) and the premature 
reporting of results limit the conclusions 
that can be drawn [8]. Our experience with 
phalloplasty in ten adult men with penile 
deficiency and their long term sexual quality 
of life (QoL) (≥ 1 year postsurgery) is reported 
here.
Patients and Methods
Patients and procedure
This was a retrospective monocentric study 
of patients aged 18 and older who underwent 
phalloplasty for penile deficiency between 
March 2004 and November 2011 (Table 1). 
Approval was granted by the Medical Ethical 
TABLE 1 Age and medical characteristics of non-responders and participants.
Characteristic
Participants  
(n=10)
Non-responders  
(n= 8)
P-value
Mean age (range)
Diagnosis
 46, XY DSD and micropenis
 Bladder or cloacal exstrophy
 Trauma or penile amputation
 Idiopathic micropenis
Type of phalloplasty
 RFA
 ALT
Complications 
 None
 Urethral stricture and/or  fistula 
 Urethral stenosis 
 Infection (urinary infection, infected seroma or haematoma)
 Pilonidal sinus
 Erectile implant
 Removal of erectile implant 
28.2 (20-43)
3
5
2
0
8
2
30% (n=3)
40% (n=4)
10% (n=1)
20% (n=2)
0% (n=0)
 9
10% (n=1)
31.9 (20-49)
1
3
3
1
6 
2
37.5% (n=3)
37.5% (n=3)
0% (n=0)
12.5% (n=1)
12.5% (n=1)
7
43% (n=3)
0.53‡
0.47†
0.80†
0.68†
0.15†
Used abbreviations: DSD= Disorders of Sex Development,; RFA= Radial Forearm Free Flap; ALT= Anterolateral Thigh Flap; No statistical 
differences between the two groups were found. ‡Mann–Whitney U-test for continuous variables; †χ2-test  for categorical variables. In case 
that >20% of the cells showed an expected frequency <5, Cramer’s V was applied V=√χ²/(n (k-1)), with χ²= Pearson Chi square value, n=number 
of observations, k=the smallest value of the number of  columns or rows of table
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Commission of the Ghent University Hospital 
(Trial number EC2011/466) and written 
informed consent was obtained from all 
participants. They were off ered a urological 
examination and sexual QoL was assessed by 
means of a standardized personal interview-
conducted by a psychologist previously 
not involved in the care of these men - and 
previously used in 73 men with hypospadias 
repair and 50 controls who were treated 
for isolated inguinal hernia by the group of 
Mureau et al [20]. As the same methodology 
was used and no diff erences were found in 
terms of sociodemographic  participants’ 
characteristics, this study was used for 
comparison with our results [20]. 
Surgical techniques
Our method of choice for penile recon-
struction was the modifi ed technique 
of Radial Forearm Free Flap (RFA) [7], 
described in detail before [21,22] (Figure 
1). When vascular anatomy was uncertain, 
like in cloacal exstrophy, a free fl ap was 
contraindicated and a pedicled Anterolateral 
Thigh Flap (ALT) was used [21,22]. Phalloplasty 
involves the following steps: 1) creation of 
the phallus with a competent neourethra and 
microvascular transfer to the recipient site, 
2) anastomosis of the native urethra to the 
phallic urethra when applicable, 3) sculpture 
of the glans using the Norfolk technique [12] 
4) connection of a nerve of the fl ap to any 
dorsal penile nerve that can be identifi ed and 
5) incorporation of residual genital sensitive 
tissue at the base of the phallus (e.g. native 
glans penis). The second procedure consists 
of insertion of infl atable Ambicor™ or semi 
rigid Spectra™ penile prostheses with one 
or two cylinders (American Medical Systems, 
Minnetonka, Minnesota) on average 1 year 
after phalloplasty. When possible, the base 
Figure 1. Radial forearm free fl ap phalloplasty
Figure 1
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of the cylinder (Figure 2) was fi xed in the 
remnants of the corpora cavernosa. If not, the 
cylinder was attached to the ramus inferior 
ossis pubis with a non-resorbable suture. 
Results
Patient group
Ten of the 18 invited men participated 
(response rate: 56%). The remaining eight 
either declined participation, or could not 
be reached (by phone, e-mail, or post mail). 
Non-responders and participants did not 
signifi cantly diff er in the medical variables 
(Table 1). However, in the early postoperative 
period two major complications were only 
seen in the non-responders: one patient 
developed a pulmonary embolism and 
was treated with a therapeutic dose of 
low-molecular-weight heparin. Another 
developed severe hematuria with clotting 
and obstruction of the urinary catheters 
which was treated conservatively.
TABLE 2 Participants’ characteristics.
Patient Indications
Follow-up 
(mo)
Type of 
phalloplasty
Erectile 
prosthesisa
Complications
43
31
25
43
20
22
22
20
32
24
17
92
20
47
14
63
35
33
24
24
RFA
RFA
RFA
ALT
RFA
ALT
RFA
RFA
RFA
RFA
Penile amputation
— squamous cell carcinoma in situ
Shriveled penis 
– bladder exstrophy
Micropenis 
— 17, 20 lyase defi ciency
Penile necrosis
— embolisation for priapism
Shriveled penis
– bladder exstrophy
Shriveled penis 
– cloacal exstrophy
Shriveled penis 
– bladder exstrophy
Shriveled penis 
– bladder exstrophy
Micropenis 
—partial androgen insensitivity syndrome
Micropenis
— partial androgen insensitivity syndrome
(Transient) 
urethral fi stula
None
(Transient) urethral 
fi stula and stricture
Urethral fi stula and 
stricture
Urinary infection
None
Urethral stenosis, fi stula,hair 
incrustation in neo urethra
None
Urethral stricture 
and fi stula
Infected haematoma, 
(transient) fi stula
AMS Spectra™, 
1 cylinder, 12 cm
AMS Ambicor™, 
2 cylinders*, 14cm
No
AMS Ambicor™, 
2 cylinders, 18cm
AMS Ambicor™, 
2 cylinders, 14cm
AMS Ambicor™,
 1 cylinder, 16cm
AMS Ambicor™, 
1 cylinder, 14 cm
AMS Ambicor™, 
1 cylinder, 14cm
AMS Spectra™, 
1 cylinder, 12cm
AMS Spectra™, 
1 cylinder, 12cm
1
2
3
4
5
6
7
8
9
10
*Revision prosthesis because of aneurysmal swelling. Abbreviations: RFA= Radial forearm free fl ap; ALT= Anterolateral Thigh Flap; AMS= 
American Medical Systems, yr= year; mo= months, a The decision on the number of cylinders implanted was made at the beginning of surgery 
based on the girth of the phallus and the possibility of dilating two pockets without damaging the urethra. With the observation of unesthetic 
outcomes due to asymmetry in the fi nal position of the cylinders, the two-cylinder option was no longer proposed to the patients.
Age at 
follow-
up (yr)
Figure 2. Penile prosthesis
Figure 2
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Surgical procedures and  
satisfaction with surgical result
Main features of the ten participants (mean 
age 28.2 years, range 20-43 years) are 
presented in Table 2. All were older than 16 
years at the time of surgery. Mean follow- up 
after phalloplasty was 36.9 months (range 
14–92 months). All but two patients (nr 1, 
4) underwent multiple penile and urethral 
reconstructions in early childhood and had 
a stretched penile length of < 6 cm. One 
patient with cloacal exstrophy (nr 6) and one 
patient who underwent penile amputation 
because of penile necrosis after persistent 
priapism treated with an unsuccessful 
cavernosal- femoral shunt and later with 
embolization of the pudendal artery (nr 4) 
were not good candidates for RFA as pelvic 
anatomy and vasculature were uncertain. 
In all but three patients (nr 1,3 and 4), there 
was sufficient penile and/or cavernosal tissue 
to be incorporated at the base of the newly 
reconstructed phallus. Flap survival was 
noticed in all patients, and there were no 
complications concerning the donor area. All 
patients were satisfied to highly satisfied with 
the global surgical result (Table 3) and none 
of the patients regretted surgery. Emptying 
of the bladder was done transurethrally in 
five patients and by catheterization through 
continent diversion in five patients with 
bladder or cloacal exstrophy . Three of these 
patients requested a urethral reconstruction 
for ejaculation, the other two preferred to 
keep their ejaculatory opening at the ventral 
aspect of the scrotum. 
All five patients in whom urethra was 
constructed, developed a fistula at the 
anastomosis of the neo-urethra to the native 
urethra, of whom three also developed a 
urethral stricture. Only two patients needed 
a secondary procedure for closure of the 
persistent fistula; in one of them (a patient with 
a concomitant urethral stricture) a two-stage 
urethroplasty was performed. All patients 
without continent diversion, except two 
waiting for a revision for the urethral stricture, 
could void normally in a standing position. 
TABLE 3
Satisfaction with surgical result and possibilities 
of penile prosthesis during sexual activity.
Phalloplasty (10) Hypospadias surgery (73)a
Mean ± SD (N)
Satisfaction with surgical result (1 to 7) 6.3 ± 0.9 (10)b 5.3 ± 1.4 (57) 4.8 ± 1.6 (16)
Satisfaction with quality of erection during sexual activity (0 to 10) 7.3 ± 3.4 (9)c -  -
Motives for dissatisfaction with penile prosthesis (total N=6)
 1) Problems with rigidity: 50% (n=3)
 2) Having to (de)activate the penile prosthesis interferes with the natural flow of sex: 17% (n=1)
 3) Occasionally  painful pressure of prosthesis in groin area or lower abdomen during intercourse: 83% (n=5)
 4) No control over activation of penile prosthesis: 17%  (n=1)
Distal
hypospadias 
(57)
Proximal 
hypospadias 
(16)
a Data from [20], b significant differences between phalloplasty and hypospadias groups (0.8 [0.4 – 1.1] 95% CI < Cohen d  Effect size < 1.1 [0.6 
– 1.6] 95% CI), p< .01, c Not including the man without penile prosthesis, who was dissatisfied with the quality of erections (score 2/10); Note: 
more motives per subject are possible, no differences in satisfaction were found between men with one or two cylinders implanted
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A penile prosthesis was implanted in nine 
patients on average 16.8 months (range 10-
25 months) after the phalloplasty procedure 
(Table 2). One man underwent a revision of 
the prosthesis because of malfunction based 
on an aneurysmal swelling of one of the 
cylinders (nr 2) after 5.8 years. The majority 
of patients were satisfied with the possibilities 
of the penile prosthesis for sexual activity, 
although problems with the devices were 
reported, independent of the number of 
cylinders implanted (Table 3). 
In three men with a 46, XY disorder of sex 
development condition (DSD), a defeminizing 
gynecomastia surgery (Mean: 14 years (range 
12-16 years) was additionally performed. In 
four patients a unilateral testis prosthesis was 
implanted (left side: nr 3, 5; right side: nr 9, 
10).
Psychosexual outcomes
Sexual adjustment. There were no differences 
in mean ages at which sexual milestones were 
reached (small to moderate effect sizes, Table 
4). 12.5% (1/8) of men with congenital penile 
deficiency had not yet experienced sexual 
intercourse after surgery, versus 20.5% of the 
hypospadias group and 12% of the comparison 
men (p> .05). Four of the seven men who 
had experience with intercourse, had already 
(tried) intercourse before phalloplasty, but 
reported an improvement after surgery. Four 
men had a satisfactory stable relationship, in 
which communication about sexuality was 
present. Although inhibition in sexuality with 
their present partner had diminished, three 
out of four indicated that this might return 
with a possible new future partner. In three 
out of four men without a partner, even with 
sexual (coitus) experience, inhibition and 
fear of sexual rejection were highly present, 
compared to 40% of hypospadiac patients 
(p< .05) and 11% of controls (p< .01). Reported 
motives were related to the fear of ‘technical’ 
failure (n=2), reaction of the potential partner 
on the prosthesis (n=2) or not knowing how 
to use it in a sexual situation (n=1). One 
man is currently following psychotherapy 
to overcome these barriers , another had 
TABLE 4
Mean ages in years of adult phalloplasty patients, hypospadias patients 
and comparison subjects at which sexual milestones were reached. 
Mean ± SD Effect size Cohen’s d [95% CI]‡
N
Age at interview
First time in love
First time masturbation
First time dating
First time French kissing
First time undressed 
necking and genital 
fondling
First time sexual 
intercourse
8b
24.5 ± 4.7
11.8 ± 1.8
12.5 ± 2.1
14.6 ± 1.8
15.1 ± 2.6
16.4 ± 5.5c
18.7 ± 2.4c
73
25.6 ± 5.7
14.0 ± 3.7
13.9 ± 2.0
15.3 ± 2.2
14.8 ± 2.7
17.0 ± 2.5
17.9 ± 2.3
50
25.3 ± 3.7
12.6 ± 3.4
13.4 ± 1.7
15.0 ± 2.6 
15.1 ± 2.8
16.8 ± 2.7
17.3 ± 2.6
-0.6 [-1.6; 0.1]
-0.7 [-1.1; -0.3]
-0.3 [-0.8; 0.1]
0.1 [-0.5; 0.7]
-0.2 [-0.9; 0.4]
0.4 [-0.2; 0.9]
-0.3 [-1;1; 0.6]
-0.5 [-1.0; -0.1]
-0.2 [-0.8; 0.5]
0.0 [-0.7; 0.7]
-0.1 [-0.9; 0.7]
0.6 [-0.1; 1.2]
‡ Effect sizes (ES) of mean differences according to Cohen (1988) were computed, using pooled standard deviations of the two groups (Cohen's 
d = M1 - M2 / sd pooled, where sd pooled = [(sd1²+ sd2²) / 2]. An ES of 0.2 is considered to be small, an ES of 0.5 to be moderate,and an ES of 
0.8 to be large.95% confidence intervals are reported. A positive ES reflects a higher score in the phalloplasty group, whereas a negative score 
reflects a higher score in the hypospadias group or comparison group. a Data from [20], b Not including the two men with acquired penile 
deficiency as adults, c  one man (aged 20 years) did not have had sexual experience yet  
Phalloplasty vs  
hypospadias
Phalloplasty vs 
comparison
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extensive psychological support in the 
past, more related to problems associated 
with his specific DSD condition (e.g. young 
appearance, no masculine hair growth). 
Although offered, all others were reluctant to 
seek psychological advice for problems. Both 
men with acquired penile deficiency in early 
adulthood suffered from depression and 
loss of sexual self-esteem after the trauma. 
One man divorced and did not have coitus 
experience yet after surgery, causing great 
distress for which he is treated with anti-
depressants.
Sexual behavior and functioning. In general, 
no significant group differences between the 
phalloplasty patients and the hypospadias or 
control groups were found with regard to 
frequency of sexual activity with a partner, 
masturbation frequency or sexual desire 
(Table 5). Accordingly, effect sizes were small 
to moderate. 100% of men had experienced 
orgasm with ejaculation; in 8/10 through 
intercourse, in 2/10 exclusively through 
masturbation. None of the men had a 
penile curvature causing difficulties during 
intercourse. In two men painful bladder 
cramps after ejaculation were reported, 
causing no distress. One man complained 
of precocious ejaculation, which he thought 
was of psychological origin and for which he 
had sought professional advice.
Genital sensitivity. In the seven patients in 
whom there was sufficient penile and/or 
cavernosal tissue to be incorporated at the 
base of the newly reconstructed phallus, 
sensitivity to sexual touch was reported to 
be better at the base of the phallus (M= 7.6, 
sd= 0.5), compared to the top (M= 3.7,sd= 
0.6) (Wilcoxon p<.05). The three other men 
(nr 1, 3 and 4) indicated to have little penile 
sensitivity; in one man (nr 3) the skin between 
scrotum and anus and base of scrotum 
was however highly orgasm sensitive. No 
significant correlation was found between 
follow-up time after phalloplasty and 
sensitivity scores.
TABLE 5
Sexual behavior and sexual functioning of adult phalloplasty patients, 
hypospadias patients and comparison subjects.
Mean ± SD Effect size Cohen’s d [95% CI ]c
Sexual activity with a 
partner/month
Masturbation  
frequency/month
Sexual desire (0 to 100)b
8.3 ± 4.5 (4)
5.7 ± 8.0 (10)
79.5 ± 20.8 (10)
7.6 ± 7.4  (58)
6.8 ± 6.9 (66)
64.9 ± 20.2 (73)
6.8 ±  6.3 (44)
5.0 ± 5.3 (47)
69.7 ± 21.7 (47)
0.1[-1.7; 1.8]
-0.2 [-1.7; 1.4]
0.7 [-3.6; 5.0]
0.3 [-1.5; 1.9]
0.1 [-1.4; 1.6]
0.5 [-5.0; 6.0]
a Data from [20]; b visual analog scale; c In order to be able to compare the results across different studies, effect sizes (ES) for group differences 
according to Cohen (1988) with 95% confidence intervals were calculated. A positive ES reflects a higher score in the phalloplasty group, 
whereas a negative score reflects a higher score in the hypospadias group or comparison group.
Phalloplasty vs  
hypospadias
Phalloplasty vs 
comparison
“I was always
this strong man . 
Now I feel so 
vulnerable .“
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Genital appraisal. Phalloplasty (as well as 
hypospadias) patients reported on average 
a more negative genital appraisal than the 
comparison men (large effect sizes, Table 6). 
Approximately twice as many of the former 
groups considered the penile appearance to 
be different from that of other men and tended 
to be dissatisfied with the penile appearance. 
The main spontaneously reported motives 
for dissatisfaction in the phalloplasty patients 
were a small penis size (n=2, 20%) and/ or 
artificial look (e.g. color difference) (n=5, 50%). 
In both the hypospadias and comparison 
groups, the main motive for dissatisfaction 
was penile size, respectively 11.1% and 8%. 
It appeared that more hypospadias patients 
than phalloplasty or comparison subjects 
considered the flaccid penis to be too small. 
However, these percentages diminished 
significantly for penile size during erection 
in the hypospadias and comparison subjects 
(p<.05 for both), but not in the phalloplasty 
group. Moreover, twice as many phalloplasty 
patients reported difficulties with undressing 
publicly (e.g. after sports, sauna) compared to 
hypospadias and control men (moderate to 
large effect size, Table 6). Self-consciousness 
about the penis, including potential questions 
about scars, were the main motive, compared 
to prudishness reported by most controls. 
None of the men have received any negative 
reactions or comments on penile appearance 
from others, including sexual partners.
Discussion
It is reassuring that the majority of adult 
men with penile deficiency who underwent 
phalloplasty experience relatively normal 
sexual adjustment and lead an adult sex life 
that does not differ greatly from men with 
normal genitalia or men who underwent 
hypospadias repair in childhood [20]. These 
results corroborate previous findings at long- 
term follow- up (>1 year post surgery) [15, 
16]. However, a higher percentage of these 
men (50%) were dissatisfied with certain 
aspects of genital appearance compared to 
other studies after phalloplasty (5-14%)[14, 
16] and hypospadias correction (25%) [20]. 
TABLE 6 Genital appraisal and problems with undressing in public. 
Genital appraisal (0 to 4)
1.Penile appearance 
   different  as other men
2.Dissatisfaction with 
   penile appearance
3.Dissatisfied with penile   
    length in flaccid state
4.Dissatisfied with penile     
   length in erect state
Problems with undressing 
in public
2.2 ± 1.5 (10)
80% (10)
50% (10)
20% (10)
22% (9b)
60% (10)
2.4 ± 1.1 (73)
84.7% (73)
25% (73)
38.4% (73)
13.7% (73)
32.9% (73)
3.2 ± 0.8 (15)
40% (50)
12% (50)
20% (50)
4% (50)
22% (11)
-0.2 [-0.4, 0.1]c
-0.2[-1.1; 0.7]d
0.6 [-0.1; 1.4]d
-0.4 [-1.3; 0.5]d
0.3[-0.6; 1.3]d
0.6 [-0.1; 1.4]d
-0.9 [-1.3, -0.5]c
1.0 [0.1; 1.9]d
1.1 [0.3; 1.9]d
0.0 [-0.9; 0.9]d
1.1 [-0.1, 2.2]d
0.9 [0.1; 1.7]
Note: A genital appraisal score (mean ± sd (N ) was computed by adding the answers to the 4 questions, with a score of 1 attributed to answers 
marked ‘yes’. The genital appraisal score varied from 0 (very negative) to 4 (very positive). Percentages represent the proportion of participants 
endorsing a positive answer on the specific genital appraisal items or have problems with undressing in public; ES= Effect size [95% confidence 
intervals], a Data from [20]; b Not including the man without penile prosthesis as he could not have erections; c Effect size calculated according 
to Cohen (1988) ; d Effect size calculated according to Hasselblad and Hedges (1995) due to dichotomous outcomes. A positive ES reflects 
a higher score in the phalloplasty group, whereas a negative score reflects a higher score in the hypospadias group or comparison group.
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Genital appraisal satisfaction did thus not 
exclusively rely on the surgical outcome, 
as 90% of men were highly satisfied, but 
also seemed to be related to psychological 
factors and expectations, as is illustrated by 
poor satisfaction scores in the two men who 
had traumatic penis loss as compared to men 
with congenital micropenis and which also 
corroborates findings within the transgender 
population [11].
The majority of men described how they felt 
sex to be impossible before treatment i.e. that 
their genitals were structurally inadequate 
to sustain the mechanics of penetrative 
intercourse. However, post-treatment, they 
were surprised to learn that having the ‘right 
equipment’ allowing intercourse was only 
part of the story. Three quarters of the men 
still felt inhibited in seeking sexual contacts, 
even with sexual experience. Psychological 
barriers to getting involved in sexual activity 
were experienced to be at least as great as 
the physical ones and the cost of being 
found out by potential partners to be less 
than ‘normal’ men was imagined to be high 
[23]. Therefore, we advocate the importance 
of early and continued counseling as a 
standard practice, since most seem reluctant 
to seek psychological support on their own 
initiative, even when they are experiencing 
considerable difficulties. 
The major drawbacks of phalloplasty are the 
high urethral complication rate (stricture 
and/or fistula) and the problems with the 
penile stiffeners, comparable to the rate 
experienced in transsexual phalloplasty 
[22,24]. 
Obtaining sufficient rigidity to allow 
penetration is extremely difficult because 
there is no good substitute for the unique 
erectile tissue of the penis [24]. The 
anastomosis between the fixed and phallic 
part of the urethra is the most important 
stricture location and prone to fistulation in 
the early postoperative period. These fistulas 
often close spontaneously, but sometimes, 
due to excessive scarring, can lead to 
stricture formation [31]. A broad variety of 
techniques – based on the general principles 
of wound healing and tissue transfer- is 
needed to handle each type of stricture (for 
an overview, see [31], but recurrence remains 
frequent (41%). Moreover, as loss of penile 
tissue is a dreaded complication of bladder 
or cloacal exstrophy repair and the majority 
of the study sample had a multiplicity of 
previous penile reconstructions in childhood, 
complications and psychosexual outcomes 
are  possibly worsened Moreover, genital 
sensitivity was said to be less than hoped for 
in all men, especially at the dorsal locations 
the neophallus, compared to the base where 
incorporation of penile or cavernosal tissue still 
provided erogenous sensation in 70% of men. 
“The thing is, 
when you get out of 
the hospital, you feel 
liking having something 
that is not yours.“
“. . .And even if you 
want to kiss her, you don't 
do it, because maybe 
while she kisses you, she can 
feel that you don't have a penis. 
This is so stupid, but it is in
your head the whole time.“
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This cross-sectional study bears an 
exploratory character and is not without 
limitations. We compared our data with 
those from a different historical and cultural 
study cohort, as control,  which is a possible 
threat to the internal validity. A contemporary 
and representative control group would be 
more meaningful, in particular as the sample 
consisted primarily of white, heterosexual 
men, which limits the external validity of the 
findings. The return-rate was rather low, and 
although the non-responders did not differ 
regarding additional surgical procedures 
or complications, nor demographics, the 
results might be biased. The small size 
caused low statistical power and restricted 
statistical analytic options. In addition, an 
improved research methodology is needed. 
As standardized psychometric sexual Qol 
instruments designed for a normative 
sample are not always able to detect the 
specific distresses experienced by affected 
individuals, in the present study a personal 
interview was deemed more valuable. 
Likewise, methodological differences might 
explain the higher genital sensitivity problem 
rate, as self perceived sensation regarding 
sexual stimulation (by self or partner) was 
assessed instead of vibratory or thermal 
psychophysiological  thresholds [14]. Further 
follow-up of genital sensitivity outcomes is 
essential as sensation at the top of the phallus 
might improve with time. Moreover, long-
term function of the erectile devices remains 
uncertain, as they are designed for men with 
erectile dysfunction, who are older and less 
sexually active than men within this specific 
population [14]. Prospective multicenter 
studies with larger numbers, recruited from 
several sources (i.e. clinic and support 
groups)  and control groups are necessary 
to fully understand the factors that may 
influence long-term sexual outcome, such 
as specific coping mechanisms or family 
background and attitude of patients’ parents 
or partners towards the penile condition 
[25]. A structured counseling protocol and 
guidelines for the indications of phalloplasty 
in these men, including penile deficiency 
within the broader diagnostic category 
of DSD conditions, should be developed. 
More specifically, a penile length of less 
than 6 to 7 cm seems to represent a cut-
off for satisfactory intercourse [20,26], but 
suggesting a cut-off for phalloplasty remains 
highly challenging.
 
Despite the shortcomings of this study, we 
are encouraged by our initial experience 
with RFA in this challenging population, 
including boys with 46,XY DSD and severe 
undervirilization. Penile (re)construction 
may require, however,  multiple steps, and 
satisfaction and resumption of intimacy and 
sexual identity is more complex than just 
creating a phallus. As dissatisfaction with 
genital appearance or size, and fear of sexual 
rejection leading to great psychosexual 
distress have been reported before in studies 
with boys [25] and men with atypical genital 
development [23,27-30], we recommend that 
from childhood onwards patients should be 
given opportunities to develop coping skills 
and a more positive genital (and self) image. 
These may ultimately lead to improved 
sexual quality of life for men recovering from 
phalloplasty.
Conclusion
Penile reconstruction is a matter of concern 
as severe penile insufficiency might jeo-
pardize sexual satisfaction. The results of 
this series concur with others in that the 
microsurgical radial artery–based forearm 
free flap phalloplasty technique provides the 
patient with an excellent result. However, 
patients must be fully informed about 
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“I have to 
accept my new self, 
my limitations 
 and personality. “
possible limitations and complications of the 
technique, as to have realistic expectations. 
In order to guarantee a comprehensive 
treatment concept, continued follow-up and 
the incorporation of psychological factors 
may be equally important.
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CHAPTER 6
General 
discussion
Virginia Braun
238
Even our “parts” are 
(much) more than 
the sum of their parts. 
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Westerners live in societies premised on two widespread, and linked, assumptions related to 
gender(ed) identity [1]. The first is that humans are discretely sexed into two categories [2], 
with fundamental assumptions about gender or sex differences - as can be seen in the current 
popularity of evolutionary psychology, and in the enormous success of pop-psych books like 
‘Men are from Mars, Women are from Venus’ [3]. The second is that gendered identities map 
onto biological bodies, such that genitals are a crucial part of difference and identity [1]. Socio-
culturally, “everyone knows that women and men are very basically distinguished by their 
genitals, so that a female is a person with a vagina; a male is a person with a penis”[4] (p. 113). At 
birth – or before – we are often assigned a sex simply on the basis of a visual inspection of our 
genitals. Psychosexual (gender) identity is assumed to develop based on this genital difference. 
Freud for instance, based his theories on the ‘absolute salience of the genitalia’ with penis 
presence or absence as key component [1,5,6]. The link between genitals and gendered identity, 
then, seems to constitute a basic, everyday, taken-for granted commonsense, in society, 
medical practice, and psychology. These assumptions also come into play for individuals with 
a DSD, who do not have discretely “sexed” genitals, and for transgender individuals, whose 
gendered identity does not ‘match’ their body (e.g.,[7]).
The historical importance attributed to outward and easily checked appearance and the later 
development of surgical techniques for altering genitals, contributed to a shift from gonads 
to genitals as the signifier of gender, and the modern centrality of genital surgery in the 
demarcation of the two sexes [4, 8-11]. Within the standard pediatric practice of sex assignment 
and genital surgery for infants with ambiguous genitalia, considerations for the male or female 
sex differed. For sex-assigned males, potential of sexual function (erectile and penetrative 
potential of the phallus) was a major consideration; in the case of chromosomal females, fertility 
(the presence of womb and ovaries) was deemed most important [10, 12]1. Joan Hampson 
wrote in 1955: ‘If the external genitalia cannot possibly under any conceivable circumstances 
be surgically reconstructed for functioning in one sex, then the other sex should be assigned 
and subsequent medical and surgical efforts should be directed towards securing hormonal 
as well as morphological congruity with the assigned sex’ (p.271) [13]. Although the Money and 
Hampson protocols ostensibly sought to avoid a change of sex, their emphasis on sculpting 
genitalia made surgical sex assignment in infancy common [14]. This also meant that where 
genital ambiguity was pronounced, surgeons traditionally recommended female assignment, 
because it was easier to create a ‘functional’ vagina (i.e. capable of receiving a penis) than a 
‘functional’ penis (i.e. capable of erection and penetration) [10]2. Following the sex assignment 
(and surgery), parents were advised to raise the child without ambiguity, which might include 
having to withhold information from the child (and adult) [15-17]. 
These practices have been challenged, not least through the ‘coming of age’ of those who 
had such interventions as children and, as adults, have spoken negatively on their experiences 
6.1 Genital treatment practices in context
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[10,12,18-23]. Drawing energy from other social movements, such as women’s rights, civil 
rights and gay liberation, as well as through the rapid expansion of the Internet – with the 
development of anonymous online discussion forums- the efforts of DSD activists were 
facilitated in objecting against the timing and necessity of genital surgeries, the presumption 
of heterosexuality in treatment recommendations and the authority of science and medicine 
in general [14]. Although there are still disagreements on the desirability of sex assignment 
at birth, there is general agreement among those seeking changes in practice – translated 
into consensus statements [24,25] - on the need to involve parents fully in decision making; 
to foster more open communication among parents, children and professionals; to provide 
psychosocial care as an integral part of management; to stop viewing the birth of an infant 
with ambiguous genitalia as an ‘emergency’ (unless glucocorticoid treatment and surgery is 
medically necessary to prevent salt-wasting crises or urinary obstruction such as in CAH) and as 
far as possible delay genital and gonadal surgery until the person can give informed consent [10, 
12,26]. In essence, the DSD reform movement is a human rights movement - like the civil rights 
movement against racism and the women’s right movement against sexism – and is founded 
on the assumption that people with DSD should not be oppressed because their bodies simply 
do not fit social norms [27].
The aims of this dissertation were to comprehensively review some of the complexities and 
factors relating to the process and outcome of (mostly) non-consensual genital treatment 
in women with CAH and men with DSD in childhood (Chapter 2) and consensual genital 
treatment practices for adolescent and adult women with an absent vagina and adult men with 
micropenis (Chapter 2,4,5). The study of adult choices for genital reconstruction, either surgical 
or non-surgical, is important, because it addresses cultural imperatives also underlying infant 
1 The asymmetric- or should we say sexist- way femininity and masculinity is treated is problematic. For instance, physicians have 
done far more to preserve the reproductive potential of children born with ovaries than with testes. While genetically male patients 
often have infertile testes, some men with micropenis may be able to father children if allowed to retain their testes [11].
2 What are the limits of acceptability in terms of clitorises and penises? Clitorises are frequently being considered too big in children 
if they exceed one centimeter in length. Penises are considered too small if the stretched penile length is less than 2.5 centimeters 
[11]; Most notably, the Intersex Society of North America produced ‘phall-o-meters’, intended to expose the arbitrary measures 
used for genital inadequacy 
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sex assignment, such as the female-male dichotomy and assumptions about what genitals are 
‘for’ [10]. In addition, studies that show outcomes of genital treatment to be problematic, raise 
questions about the information patients receive, the decision-making process and criteria for 
‘success’ [10,28]. Therefore, we were concerned with the lived experiences of women and men 
with DSD, focusing on decision-making (e.g. perceived advantages and disadvantages of the 
procedures, expectations), the experience of both widely adopted as well as newer genital 
treatment practices and perceived outcomes, particularly in relation to self-perception, forming 
intimate relationships and sexual activities. 
Feminizing genitoplasty for ambiguous genitalia usually comprises clitoral surgery, vaginoplasty 
and labial refashioning, generally performed within the first year of life. Clitoral surgery can also 
be performed without concomitant vaginal surgery and is purely cosmetic, with the objective 
of reducing clitoral size. Vaginoplasty as part of the feminizing genitoplasty is most commonly 
performed for women with congenital adrenal hyperplasia (CAH). In this condition, the internal 
genital anatomy is normal and a uterus is present with the potential for menstruation. The 
vagina is fused with the urethra resulting in a single opening on the perineum (i.e. high or 
low confluence of the vagina). The aim of surgery is to create the lower vagina to avoid 
urinary infections in severe cases of virilization, to allow menstrual flow, and intercourse [29]. 
In addition, female assigned patients with XY, DSD and virilized genitalia (such as in partial 
androgen insensitivity syndrome, PAIS) may also warrant feminizing genitoplasty.
In Chapter 2, it was shown that women with CAH were less likely to have experienced sexual 
intercourse with male partners and were more likely to report pain with intercourse, as well as 
experience considerable anxiety about sex, which corroborates previous study findings [19,30-
36]. Overall sexual function scores were poor when compared to the standard female (control) 
population. It is clearly possible that the genital abnormalities and their surgical correction 
may have resulted in physical difficulties during intercourse for women with CAH, problems 
connected for instance with penetration, insufficiently large vaginal introitus, lubrication, residual 
pain from tissue repair and reduced clitoral sensitivity [36]. CAH women who had experienced 
sexual intercourse, attributed problems with penetration to their genital anatomy (i.e. tightness 
or shortness of the vagina), embarrassment of their body or that they were not ready for it (yet). 
Failure of penetration, or anxiety about penetration, had resulted in the complete avoidance 
6.2 
Exitus acta probat (Ovidius) : 
the end justifies the means? 
6.2.1 What means?
6.2.1.1 Treatment for ambiguous genitalia 
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in some. Lubrication of the vagina is an essential factor in the ease of penetration and is also 
believed to be an indicator of arousal. Arousal, and therefore lubrication, can be inhibited by 
anxiety [37]. Women with CAH did report significantly more problems with lubrication and 
arousal compared to non-affected women, reinforcing the pain and difficulties they experience 
and possible reinforcing concerns about normality of the genitalia and confirmation of ‘not 
being like the other women’[36]. It is clear that besides physical, also social and psychological 
factors may be important (Figure 1). ‘Will it work, will it not work?[…] I know I have to relax, but 
I just tense up, making it even more painful. Moreover, there was a general attitude in the CAH 
group that nothing could be done and that there was no one to go to for help, consequently 
removing self decision-making processes and future initiatives for change, including options 
to improve their sexual situation (e.g. use of lubricants, seeing a sexologist). Similar findings 
were reported before, in which women with CAH held the view that their sexual problems 
were entirely a result of CAH and their failure to consider methods of alleviation, some women 
believing that ‘the right man would somehow make everything right’ [36,38].
In considering the relationship between the physical problems or sexual difficulties, surgery and 
the level of masculinization, a number of factors need to be taken into account. The sample is 
small and includes a number of women who have not had sexual experience. The fact that some 
aspects of surgery were similar for women across levels of abnormality makes any relationship 
between levels of masculinization and sexual problems difficult to examine [36]. In contrast, 
cosmetic appearance was associated with the degree of virilization at birth, in that women with 
the more severe forms of CAH had worse cosmetic outcomes. Previous studies showed greater 
stenosis and a more narrow vagina correlating with more prenatal virilization, with patients in 
the null genotype group having more surgical complications, fistulae and strictures compared 
Figure 1. Interaction of psycho-physiological contributory factors to sexual difficulties 
(adapted from [39])
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to the I2splice group [31,40,41]. In Chapter 2 ,it is shown that the impact of the severity of 
virilization on cosmetic outcome increases with increasing number of surgeries performed and 
with the age at first surgery. Because most of the participants (80%) had the more severe form, 
and more extensive surgery at a younger age, it remains difficult to determine if early feminizing 
surgery had a detrimental effect on cosmetic outcome and if delaying it might have led to better 
outcomes. Also, cosmetic results were still variably evaluated by these women, who tended to 
be only somewhat more critical than the physicians (25% vs 21% rated cosmetic outcome as 
insufficient). To our knowledge, this is the first study reporting the correlation between severity 
of virilization at birth, the extensiveness of surgery and age at surgery, and cosmetic satisfaction 
with surgery in CAH, from both a patient and clinician perspective. It is important to try and 
obtain prospective outcome data. Controlled observational studies are currently not available 
to document whether genital surgery prevents adverse psychosocial consequences. Parents 
and patients do need to be informed extensively about the multiple aspects that contribute 
to outcome after feminizing surgery and of the fair chance that reoperation is necessary in 
adolescence (54%), despite a planned ‘one-stage’ procedure. Vaginal strictures were common 
(22%). Although the percentages were in general lower, it confirms previous study findings of 
high rates (40–100%) of introital stenosis and frequent requirements for repeat reconstructive 
surgery in adolescence before tampon use or intercourse [20,42,43]. Adjunctive treatments to 
prevent stenosis such as vaginal dilators may be helpful, but cannot be used in the young child 
[44]. The atypical urinary tract formation, possibly modified again by reconstructive procedures 
[45], was associated with urinary difficulties in 21% of women. 
Most of the clitoroplasty procedures performed in the participants comprised a reduction of 
the clitoris with preservation of the neurovascular bundle and glans. The effect of these nerve-
sparing procedures on sexual function and in essence, orgasm, remains however unclear. No 
significant differences could be found with a control group of non-affected women, although 
orgasm scores were in general lower. In the two women with clitorectomy, in contrast, sexuality 
was highly impaired. 
Concern about the impact of childhood clitoral surgery on future sexual function is of surprisingly 
recent origin. Pediatric surgeons in the past have been confident that extensive surgery to the 
clitoris would not have an impact on sexual sensation [46]3; however adult patient support 
groups have raised awareness of potential difficulties as a result of clitoral surgery, triggering 
further neurological research, with varying conclusions [19,50,51]. Recent work on the anatomy 
of the clitoris has shown it to be more extensive than previously thought, extending behind the 
pubic bone to reach the anterior vagina [52,53]. Further examination of the innervation of the 
clitoris has demonstrated nerves surrounding the tunica with multiple perforating branches 
entering the dorsal aspect of the corporeal body and glans [54,55]. Thus any incision to the 
clitoral glans, corpora or hood may damage the innervation [44] and repeated clitoral surgery 
3 One of the first studies was again conducted by Money and the Hampsons, declaring that : ‘clitoral amputation in patients living as 
girls does not, so far our evidence goes, destroy erotic sensitivity and responsiveness, provided the vagina is well developed’ (p.334) 
[47]. They surveyed a dozen women about their sexual sensation following the surgery and none of them reported a loss of orgasm. 
In fact all twelve were ‘unanimous in expressing intense satisfaction at having a feminine genital morphology after the operation’ (p. 
295) [48], Money further declared that ‘in the female as well as the male it is remarkable how much erotic tissue can be removed 
without loss of erotic pleasure and the capacity to reach a sexual climax’ (p.93) [49]. 
244
may be more damaging to sexual function than a single procedure [20]. Recent studies have 
been unable to find any significant difference when comparing outcomes of clitorectomy and 
clitoral reduction despite the assumption that nerve preservation is essential [19]. However, 
caution regarding clitoral surgery is advised for preventing possible difficulties, as it was shown 
(Chapter 3) that the clitoris is the most erotically important perceived sensory organ contributing 
to female orgasm. Moreover, women might accept a larger clitoris than is considered to be 
‘normal’ by clinicians, with perceptions of clinicians and women not always aligning (Chapter 
2, 3). Definitions of genital ‘normality’ in practice also appear to vary among clinicians, making 
decisions on where to put the boundaries on ‘acceptable’ levels of anatomical variation highly 
challenging [11].
Lastly, with regard to the purpose of surgery, there is a long-held assumption that early 
surgical alteration of anomalous genitalia- such as an enlarged clitoris being visible- is first 
of all necessary for the sake of facilitating parental bonding and coping4. However, measures 
of parent’s stress do not necessarily correlate with the degree of the child’s genital atypicality 
[57] and uncertainty about diagnosis and prognosis have been found to elicit greater distress 
than physical sex ambiguity [58,59]. Second, clinical management assumes that normalizing the 
genital appearance will also influence psychosexual development of the child, although the 
extent to which gender development arises out of genital anatomy is far from clear, despite 
popular psychoanalytic theories [5,29]. There is a dearth of evidence that early ‘feminizing’ 
surgery is associated with a ’female’ gender identity. The latter is generally preserved among 
CAH girls, despite the presence of atypical genitalia and anecdotal reports of gender dysphoria 
[60]. Of course, choosing to defer surgery and leaving the genitalia unaltered, remains a difficult 
decision, and psychological wellbeing in affected individuals might be at risk. This notion 
finds also support by some studies indicating a preference for early surgery by patients [34, 
40,61]. However, psychological research suggests that children raised with a visible atypicality 
are not necessarily distressed by that atypicality, but more by the pressure to conform - with 
interventions to appear more typical being a manifestation of that social pressure [62]. The 
value of training in coping and stress strategies, as well as negotiation skills (e.g. for not going 
ahead with surgery) is pointed out here [63], for both patients and parents alike. Finally, in 
contemplating the avoidance of early genital surgery, one must also consider that no studies 
have been conducted to demonstrate that potential adverse psychosocial consequences of 
gender-incongruent genital appearance can be ameliorated by psychological counseling or 
psychotherapy, making this an important area of future research [64]. 
4 One problem with performing surgery to allay parental anxiety is that the surgery cannot destigmatize the condition; it can only 
reshape the genitals. Moreover, some parents may regard surgery as a panacea for a variety of concerns – such as fears about 
homosexuality or a girl’s XY chromosomal type – that have very little to do with the child’s genital configuration and that often 
persist despite genital surgery. It is important that clinicians explicitly address misconceptions during decision-making so that 
parents base their decision on the actual benefit of the proposed intervention to the child [56]. 
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Vaginoplasty or vaginal dilation are very different processes. From a woman’s point of view, 
surgery is swift and carried out by experts, whilst dilation requires her active management – she 
would need to remain motivated despite sometimes slow progress, pain and in some situations 
for an imaginary relationship [28]. It is reasonable to expect many more women to opt for 
surgery. However, this is not the ‘quick fix’ as they imagined it to be. From our comparative 
retrospective study in women with vaginal hypoplasia (Chapter 2) it became clear that surgery 
was not viewed as straight forward, especially regarding the complications and resulting scars, 
reminding them daily of what had happened, and reflected in the lower satisfaction scores 
regarding genital and total body image. They also struggled with the postoperative dilation 
regime. As such, for many women, the choice is maybe not so much surgery or dilation, but 
dilation with surgery or dilation without surgery. Some women mentioned (Chapter 2,4) that 
an operation gave them a ‘head start’, so that they only needed to maintain the vaginal volume 
already created. However, many women did not comply with postoperative dilation treatment, 
which made future treatment options for them narrower [28].
In many situations then, vaginal dilation is a safer first line approach, precisely because it carries 
fewer risks (including significantly less lubrication problems, Chapter 2), is reversible and does 
not compromise future treatment options (Chapter 4). In more than 75% of the women it can 
normalize vaginal length within normal ranges (6.5-13 cm) and successful sexual function is 
reported – although most studies solely focused on satisfactory coitus, which is problematic 
given the preoccupation with intercourse and its connotations in women with vaginal hypo-
plasia (see infra). That said, dilation therapy alone is not particularly rosy as an option, and 
there are important psychological issues to be addressed, which is also reflected in the high 
failure rates of women (40%) who tried dilation therapy first before proceeding to vaginoplasty 
(Chapter 2).
Anatomical changes must be accompanied by psychological changes if women with vaginal 
hypoplasia are to fulfill some of the aspirations underpinning their decision to take up vaginal 
reconstruction. The motivation for reconstruction is often based on the desire for women to 
appear and feel ‘normal’, not only in terms of sexual anatomy, but also in terms of sexual activity 
and experiences (see infra) [28]. The psychological distress associated with vaginal hypoplasia 
has been shown to be a barrier for positive experiences of sexual intimacy (Chapter 2,4). 
Although there was an absence of psychiatric morbidity, this cannot be equated with positive 
adjustment. Whilst women were ‘functioning’ well on the whole (keeping up with day to day 
activities), and did not present major mental health problems, they were deeply concerned 
about certain aspects and implications of their condition, especially regarding infertility and 
how and when to communicate this to others. These results corroborate previous studies 
making use of qualitative in-depth interviews [10,36,65-67]. 
What is of major concern, is the perceived usefulness and the avoidance of psychological 
support. Avoidance effectively removes opportunities for learning skills to negotiate within cer-
tain social or sexual situations, such as disclosure of the condition to a potential partner, which 
6.2.1.2  Treatment for an absent or short vagina 
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is viewed as the most daunting task for those women not in relationships. It was frequently 
mentioned as a reason for not seeking relationships. One of the positive outcomes of the 
consensus meeting in Chicago, was making the full diagnostic and treatment knowledge 
available to women, making decisions about treatment, but also about disclosure now ‘their’ 
responsibility [28]. However, many women still feel that they are not in control of these decisions. 
There is a dearth of tools to prepare women - with a DSD condition in general - to become fully 
involved in decision-making processes on (disclosure of) their condition (treatment and non-
treatment related) and to reduce the likelihood of future worries and regret. ‘Right’ decisions 
in this field are not that obvious and are for every woman different. An outline of possible 
psychological approaches is provided later in this thesis. Based on experience built up over 
the years and informed by a review of the literature (Chapter 4), a theory-based model of 
dilator treatment and strategies to facilitate compliance were also developed, in order to inform 
individualized clinical management and further research (see infra).
Many patients with a micropenis (stretched penile length (SPL) <2.5cm at birth) receive 
androgens in infancy/childhood, as first-line medical treatment. Such treatment has in 65-71% 
of boys an immediate effect on SPL in childhood (Chapter 5). However, only 40% has a normal 
SPL in adulthood following HRT at puberty, most likely due to the existence of a ‘masculinization 
window’ during fetal life or in early infancy. Boys with a true micropenis condition seem to have 
a better prognosis than boys with a micropenis as part of the broader category of DSD, but in 
general, a child with a micropenis will become an adult with a micropenis [68]. Attention has, 
therefore, shifted to the effects of masculinizing surgery, on two levels. A first level relates to 
the severe hypospadias most men with a DSD condition and micropenis suffer from, further 
optically shortening the penis as the genital tubercle is bent; a second level relates to penile 
enlargement techniques, including phalloplasty. 
As in feminizing genitoplasty, issues around the ideal timing of hypospadias repair have 
also been raised, yet not with the same intensity [69]. Based on recent reports, it seems that 
patients with a specific DSD diagnosis do not have worse outcomes from surgery than their 
counterparts without a specific diagnosis [70]. Most surgeons still follow the recommendation 
of the American Academy of Pediatrics, according to which hypospadias repair should take 
place between 6 and 12 months of age [71]. However, quality of the evidence for such an 
approach is limited and will likely be challenged until there is additional strict scientific data in 
support of it (for an overview, see [69,72]).
In a first study (Chapter 2), it was shown that men with DSD, all of whom had (recurrent) 
hypospadias repair in childhood, were significantly less satisfied with their penile appearance 
than non-affected men. The majority of studies have found that patients with hypospadias 
repair still report at least some degree of genital dissatisfaction (for a review see [72]). Sixty 
percent indicated that a negative genital appearance had influenced their sexual development, 
confirmed by a review of the literature (Chapter 5), in which it was clear that a deviant and 
6.2.1.3 Treatment for micropenis
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small(er) penis can be central to the experience of psychological distress and might jeopardize 
wellbeing. Retrospective investigations of adults who had suffered from hypospadias in their 
youth also showed that the men who had ever had to endure hurtful comments about the 
visual aspect of their penis experienced their genitals less 'positively' than those who had never 
had any comments [73]. In addition, data in non-clinical populations suggest that men with a 
more positive genital image have less sexual anxiety, and have greater self-esteem [74,75]. Both 
excessive worry about penis size and inflated perceived importance of penis size, have been 
found to contribute to poor self-esteem [76] and negative psychosocial outcomes [77]. Of note, 
for most of the participating men described, having a smaller than average penis was not the 
only difference. Studies examining sexual experiences, wellbeing and quality of life suggested 
that, where puberty is delayed or disturbed as is the case for instance in PAIS, appearance 
factors such as absent facial hair and gynecomastia were also important factors –perhaps the 
most important- organizing social interactions in adolescence [78]. Such appearance factors 
prevented the young men to ‘pass’ in their social world [78]. 
Interestingly, a small penile size was mentioned to be sexually disruptive in only 30% of men 
with DSD (Chapter 2)(as in e.g. [79]). They reported on average more sexual difficulties than 
men without DSD, but only significantly regarding frequency of desire to have sex, problems 
with firmness of the erection and reduced or weak ejaculation. However, they seemed not 
to be distressed about these problems. This is in line with other studies, in which most 46,XY 
DSD males expressed high dissatisfaction with the cosmetic result of genital surgery, but not 
necessarily with the functional surgical result [23]. This suggests that cosmetic aspects of 
surgery should not be underestimated. When assessing the relationship between satisfactory 
intercourse and penile size, men who reported to be able to achieve penetration had a 
significantly larger size (7.9 cm vs. 4.9 cm) (Chapter 2). Thus, a penile length of more than 6 to 
7 cm seems to constitute a premise for successful sexual contact [73]. Interestingly, previous 
authors briefly described a few men with micropenis who reported a mutually satisfying sex 
life (but with difficult intercourse) with their heterosexual partners [80, 81], albeit the authors 
had not sought partner corroboration. The men were said to de-emphasize the importance of 
intercourse and had found alternative ways for themselves and their partners to reach orgasm. 
Does size really matter? Matter for what or for whom? (see infra)
Traditional penile lengthening procedures, such as penile extenders, can only elongate the 
penis by an average of 1.5 – 2.5 cm [82]. It would be a sign of hubris to propose phalloplasty 
– currently the only treatment being able to restore penile length within normal sizes – as a 
panacea. It is not. Radial forearm phalloplasty, the gold standard in transgender surgery, might 
be transferred to patients with a micropenis, and the first results seem promising, both regarding 
sexual function and cosmetic outcome (Chapter 5); however, there are complications and 
without full preoperative workups assessing patients’ expectations and reasons for undergoing 
surgery, patients will still struggle with self-image/penile image and with psychological barriers 
for engaging in sexual activity. 
Again, most patients refused to seek advice. I didn’t want to know a thing, I just wanted to have 
my penis and leave this hospital. The difficulty with suggesting a visit to the psychologist is that 
such a visit is only regarded as an 'examination'; the patient denies any (psychological) concern 
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or problem, personal or in his relationship, but simply has the problem of having a small penis, 
which needs to be ‘fixed’ [83]5. Alternatively, patients might experience the visit to a psychologist 
as an extra threat, if admitting to struggle with emotional difficulties means that the surgery 
-which they have been waiting for, for a long time- might be possibly delayed or canceled. 
To operate on such cases nevertheless implies an attempt to solve an emotional problem 
with a scalpel [83]. A possible approach for the psychosocial management of penile deficiency 
conditions is formulated later in this thesis. Obviously, honesty and openness, especially about 
the possible disadvantageous consequences (e.g. urethral complications and fistulae, low 
genital sensitivity, scars), are essential ingredients in the informed consent process6. “We must 
know when to appropriately perform or withhold surgery. Our ethical duty as surgeons is to 
do no harm and to serve the best interests of our patient. Sometimes, this means admitting 
that a ‘perfect’ solution may not be attainable” [84]. Even improved surgical techniques and 
technologies cannot eliminate ethical dilemma’s surrounding treatment [11]. 
It is important to further appreciate the reasons for the level of preoccupation with certain 
issues regarding genital treatment and its 'success', among men and women with DSD, reasons 
that are understandable given our social context.
First, women and men who seek or undergo genital reconstruction are, consciously or 
unconsciously, driven by gendered aspirations [28]. They want to feel (more) like a ‘normal’ 
female or male by having a vagina or by having a penis [10];
5 It is not self-evident that a psychological problem should be handled medically or surgically. We do not attempt to solve the 
problems many dark-skinned children will face by lightening their skin [11]. Similarly, Cheryl Chase suggested: ‘when a baby is born 
with a severely disfigured but largely functional arm, ought we quickly remove the arm and replace it with a possibly functional 
prosthetic so that the parents and the child experience less psychological trauma?’ Genitals are more psychically charged than 
arms, but also more easily and more often kept privative, whatever their state [11].
6 In fact, others authors have shown that disclosure to parents can make a difference, ‘as the well-informed and open parents 
produced more confident and better adjusted boys’ [81], although they were not considered ‘typical’ in their sex lives (i.e. more 
experimental attitudes to sexual positions and methods) [11].
6.2.2 What end results?
6.2.2.1 Becoming ‘normal’ and doing ‘normal’ through ‘sex’
“You just want to hear you are equal. Equal means 
that you are like the others. Not worse. Also not 
different. Also not better. Just equal. “ 
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However, such as in the case of many women with MRKH or CAIS, it was also shown that the 
vagina was just considered ‘a hole’, and not a ‘real’ vagina, and by implication, they were still 
not ‘real women’, because their fertility issues remained unchanged. The vagina as a symbol of 
reproduction and core of womanhood –amongst other sociocultural representations - have 
been reported before in detail [1,85]. In men’s culture, the (erect) penis has been the ultimate 
symbol of masculine qualities, such as strength, endurance, bravery, potency, and power [86].
Precisely because of this symbolism, men are likely to feel insecure and even embarrassed if 
their penis is below average size.
Ironically, there was an intense preoccupation with ‘successful’ penetration, which invariably 
meant that the partner ‘couldn’t tell the difference’ and for many becoming a real obstacle in 
optimal sexuality outcomes. For men, it was simply the ability of being able to penetrate, for 
women the ability to accommodate a penis without too much discomfort or pain, which was 
also apparent in the criteria for success in for instance most vaginal reconstruction outcome 
7 L-M Liao, Workshop Disorders of Sex Development, 14-15 October 2011, Bologna
6.2.2.2 The coital imperative: the vagina as 
the ‘docking station’ for the penis.7 
“[By having intercourse]you want to know how
it is to be normal, like someone sitting in a wheelchair wanting 
to know how it feels to walk. Maybe this is more what counts, 
rather than it [intercourse] being necessary.“ 
“Penetration is important for my male image, 
that I can do it as a man. “ 
“I already don' t have a uterus, so I would be a   
 total freak show if I wouldn' t have a vagina too. “ 
Second, reconstruction is not chosen just to possess a body part. Rather, genital treatment 
enables them also to act like normal women and men, because they now can have ‘normal sex’. 
The act of penetration was seen by both women and men as essential in allowing them to be 
or feel like a real woman or man, suggesting the conflation of (hetero)sex and intercourse [87].
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studies (Chapter 4) (e.g. ‘normal’ sexual function, satisfactory intercourse). The excessive 
preoccupation with intercourse has encouraged many to undervalue other forms of sexual 
expression, in line with many magazines as well as orthodox sex therapy manuals, referring to 
non-penetrative sexual activities as ‘foreplay’, never as sex [28]. 
This raises further interesting questions as to what or whom the reconstruction is for. Although 
the women and men in this thesis conveyed the impression that although they expected to gain 
psychologically from genital treatment themselves, these procedures were also undertaken 
for (imaginary future) partners, who, as it was assumed, would not want a relationship without 
intercourse [10]. Just as hardly any individual spontaneously allude to pleasure as the reason 
of sexual expression. As one woman commented 'Penetration is no party. But I guess a lot 
of women have that feeling?', justifying in a way the discomfort she experienced during 
intercourse.
It is clear that defining 'success’ is not a sinecure and that many scenarios common in clinical 
practice pose a challenge [28]. For instance, if a woman is deemed physically capable of vaginal 
intercourse, but has never done so, is she then considered a success? Or when she does 
engage in sexual intercourse, but experiences no sexual pleasure, does she represents then 
a successful case? Or what to think about success in the case of a woman with CAH who 
was really unhappy with the cosmetic result, although she could have sexual intercourse? Or 
another scenario where a man is having sexual intercourse but with precocious ejaculation and 
with discomfort, could he count as success?
Masters and Johnson, the grandparents of modern sex therapy, advised couples not to have 
intercourse in the first place, when this was a source of anxiety and difficulty [88]. The ‘ban’ 
on intercourse was suggested to remove the pressure and a sense of ‘failure’ and lead to a 
re-discovering of a range of non-coital and non-genital sexual activities together. One of the 
participants even suggested the importance of the latter and to ‘sensate focus’8: “as a man, 
you have the feeling that everything has to do with your penis. It’s not. It’s also about kissing 
and touching and hugging." Instead, typical advice for instance for women who underwent 
vaginal dilation or surgery is that they must engage in regular intercourse or dilate indefinitely. 
The effects of this on the sexual experiences of women and her partner have never been 
really discussed or examined, but they might be counterproductive [28]. However, because 
of the way both patients and clinicians currently approach situations where sexual difficulties 
are reported, it becomes difficult to clarify whether the problems are due to a poor or failed 
“You can have oral sex, but that is still something 
different. Intercourse . . . well, that gives me 
the impression that I had real sex. “ 
8 A term introduced by Masters and Johnson, i.e. to focus attention inward on the sensory aspects of a sexual experience rather 
than outward on sexual performance [88].
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reconstruction, to psychological barriers or to both (see also Figure 1). In general, it remains 
difficult to determine the relative contributions of physical and psychological factors in sexual 
difficulties in these groups of patients. Physical contributory factors may be an insufficiently 
large introitus or insufficient vaginal volume, numbing of the genital area, scarring and reduced 
stretch, vaginal dryness or maybe also an absence of libido due to androgen deficiency in 
some DSDs with an androgen action and synthesis deficiency. Lay criticism has also highlighted 
other factors including poor communication, humiliating encounters with health professionals 
(including medical photography, or clinicians being unable to hide their curiosity about non-
typical aspects of the anatomy), but also inadequate psychological support [28,29,65]. Two other 
important aspects, however, also deserve some further attention: the influence of pornography 
and the sex industry, and the cherished principle of choice in our society and in cosmetic 
surgery in particular.
“I had plenty of reasons to have self-confidence, 
but I was lacking it because I didn't have a penis. 
And you cannot accept it, because look at the commercials, 
just look everywhere, it 's all about sex. “ 
6.2.2.3 McSex and Individual choice
“You compare yourself and the biggest problem is 
pornography. There you see penises and somehow in your 
subconsciousness you think that this 20cm penis is normal. And you think 
that women like it. And if you read that these pornographic stars have to 
take painkillers sometimes, to make the movies, because it hurts so 
much, then you realize, but I mean, you don't know. “ 
Sex is everywhere in the consumer-oriented West, and we seem more sexually active and 
sexually conscious than any other generation [89]. Images of genitalia - although highly 
selective and/or subjected to digital enhancement- are exceedingly visible due to the 
increased availability and acceptability of pornography. Internet provided us furthermore the 
entry to multiple identities, numerous sexual partners and recreational methods –if we want 
to. Is this perceived as even more confrontational for men and women who feel limited in their 
sexual expression choices? ‘Choice’ can be fundamental to the ways we perceive ourselves, 
to our cultural values, and to how we theorize our actions and the actions of others, both 
consciously and unconsciously [90]. The question is however how real or viable all the options 
can be, when societal norms and expectations effectively mandate one course of action over 
another, the choice for ‘the norm’ [91].
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Feminist contributions, with autonomy and personal choice of the subject at its heart, appear 
to be drowned out by the powerful messages that are now influencing more and more women 
to have their standard genitals surgically enhanced [28,92,93]. Hymen reconstruction has 
existed for a long time, but ‘tidying up’ of the labia, injecting or suctioning of fat in different 
genital regions are only a few of the many newer additions in genital redesigning for ‘normal’ 
women [94]9. Likewise, the growth in the number of ‘normal’ men asking for surgical penile 
enhancement is worrisome [83]10. To date, there is no evidence to support the frequently made 
claim that sexual and/or psychological transformations will (or should) occur through cosmetic 
genital surgery [93]. 
In sum, although surgery is a domain where people are framed positively as making individual 
choices about their lives and framed as empowering by the media, people’s desires to achieve 
‘normality’ through surgery do raise questions about (individual) ‘choice’ [90]. Moreover, within 
the current make-over culture, and because surgical solutions are rendered a possibility, 
there is a social imperative towards taking up possible ‘improvements’ to one’s body – as to 
become something better. The likely effect is that cosmetic genital surgery will continue to 
increase in popularity, with more people ‘choosing’ it [90]. It seems vital that the level of debate 
about cosmetic surgery in general be kept broad and critical, because there remain troubling 
concerns related to areas such as ethics and choice, pathologization and medicalization [93] – 
with possible implications for the future (surgical) management and acceptance of individuals 
with an ‘atypical’ genital anatomy.
9 Why do so many women seek Female Genital Cosmetic Surgery (FGCS)? Both esthetic and/or functional concerns have been 
reported [94]. Esthetic concerns appear primarily linked to a dislike of some very specific aspect of vulval appearance, particularly 
the visibility of labia minora, or their shape, color, or asymmetry [94]. Reported functional concerns relate to vaginal ‘laxity’ during 
intercourse or discomfort or irritation from the labia when exercising, wearing tight clothing, or during intercourse. Psychological 
concerns (e.g., sexual or social embarrassment) are also noted as a reason why women seek surgery[90,93,95] 
10 Many men overestimate the size of the ‘normal’ penis and consequently feel inadequate about their own [96]. Worries about the 
length of the penis are, amongst others, attributed to the fact that in homosocial situations, such as changing-rooms, other men are 
seen frontally; apparently, the other person's penis looks larger because a man sees his own penis only from above. Looking down 
from above causes what visual artists refer to as 'perspective shortening'. Hence, the penis looks shorter than it actually is [97]. An 
additional problem is that men on the whole do not feel comfortable to raise the issue of penis size in conversations with others, 
resulting in little or no feedback on the perceived problem, and thus no opportunity to correct blurred ideas or thoughts [83,97]. 
Furthermore, many advertisements overtly suggest that women’s sexual satisfaction greatly depends on penis size [98], despite 
research evidence of the contrary [99-101]. Kinsey et al. had already established that very few women actually become sexually 
aroused by looking at a penis [102]. Masters and Johnson speculated in 1966 that penis size should also not predict women’s sexual 
pleasure or orgasm likelihood during intercourse - given the vagina’s elasticity and its allegedly poor innervation [37] - , but there 
is evidence that the chances of experiencing a vaginal orgasm are greater with a longer penis. In contrast, penis size is unrelated 
to frequencies of other sexual behaviors, including clitoral orgasm [103]. Indeed, it may be just this type of information that is most 
helpful to patients. Education for patients about physiological needs of a penis for sexual pleasure, and partner expectations may 
help men accept the penis they were born with. But as Kilmartin observed, as long as men continue to equate penis size with 
masculinity, they will continue to feel unnecessary sexual anxiety (p. 219)’[104].
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One of the recommendations of the Consensus Statement is that emphasis of surgical 
intervention in all cases should be on functional outcome rather than strictly on cosmetic 
appearance [24,26]. Some interesting findings are further added to this debate.
First, a review of the literature as well as the studies in this thesis, point in the direction that 
indeed often a trade-off between functionality and esthetics seems to be in order, as past and 
current surgical techniques could or still cannot guarantee both11. In the majority of the women 
with CAH for instance, medical and surgical therapy appeared to provide near satisfactory 
physical and genital appearance; however the frequency and importance of self-reported 
sexual dysfunction was problematic and highly impairing (e.g. as in [35]).Similarly, in women 
with MRKH or CAIS, despite a near-normal genital appearance after surgical treatment, sexual 
distress and difficulties were highly common (e.g. as in [105]). Other studies have indicated that 
women with CAIS and pure gonadal dysgenesis, who have female-looking external genitalia, 
were in general more satisfied with the appearance of their external genitalia and sexual quality 
of life than women with clitoris hypertrophy or ambiguous genitalia (as in PAIS, 17β HSD or 
5αRD), but perhaps because they had significantly less genital surgery affecting functional and 
cosmetic outcomes [79,106]. In contrast, in men with DSD, there was high dissatisfaction with 
penile appearance, causing great distress, however, the majority did not seem to experience 
significantly more functional problems compared to non-affected men (e.g. as in [23]). Similarly 
in adolescents with DSD, boys, but not girls, with DSD had a more negative body image. Sexual 
activities for boys did not differ from controls, while girls had less experience [107]. It is also 
striking that women with DSD (e.g. PAIS or GD) were less satisfied with their overall sex life and 
less engaging in sexual activity than men with the same DSD diagnoses [23,108,109], despite sex-
corrective surgery in both groups. 
The observed gender differences may be related to gender-specific differences in socialization. 
Boys are still more encouraged to show sexual interest and behavior than girls [79]. Gender-
specific social influences on the sexual quality of life of persons with DSD have been minimally 
discussed so far and should be given more attention in future studies. However, the above 
mirror image certainly also challenges the role of cosmetics besides sexual function in decision 
making about surgical interventions, as the perceived importance of both esthetics and 
functionality seem to differ between men and women.
If a trade-off needs to be made, would men for instance appreciate a non-functional, but 
esthetically pretty penis more than a functioning, but no so attractive penis? All of the men 
6.3 Clinical implications
6.3.1 A pendulum motion between cosmetic and functional outcomes
11 And even if they would, they do not take the ethical dilemma surrounding DSD treatment away [11]
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who had phalloplasty surgery would do it again, even if they had decreased genital sensation. 
This issue needs further consideration and long-term outcome data are highly needed, 
especially because one of the blocks to accepting evidence of poor outcomes of for instance 
feminizing surgery has been the difficulty of accessing a non-treated sample for comparison. 
Will cosmetic anomalies left uncorrected have an impact on psychosexual well-being? In 
that respect it is informative to further evaluate if children with clitoral hypertrophy, in which 
feminizing surgery is postponed because of the current conservative approach, will eventually 
opt for genital surgery. On the other hand, it is argued that we cannot yet know whether 
improvements in surgical techniques in the last decade will yield improvements in cosmesis 
and functional outcomes. Most adult women with CAH for instance typically underwent 
relatively unsophisticated surgical procedures that are no longer used, also reflected in the 
variable outcomes in terms of cosmesis, function, and patient satisfaction in the literature. 
However, we do tentatively suggest that all genital surgery in DSD must not be completely 
reviled. It can have a place in the medical treatment of certain DSD conditions, given that 
patients are fully informed on the consequences, and that their expectations are realistic and 
informed12. More specifically, the few reports in the literature suggest that phalloplasty might be 
a promising technique, but highlight that it remains an experimental treatment for the indication 
of micropenis. The pendulum (com)motion between surgery or non-surgery certainly is to be 
continued. 
Second, the subjective perception of genitals is more defining for sexual wellbeing than their 
objective appearance (e.g. as in [105]). Moreover, the concordance in ratings between patients 
and clinicians is variable (Chapter 2, 3, as in [73]). As might be expected, when it comes to later 
sexual satisfaction, the patients’ genital image is more important than outcome assessment 
by surgeons. The relationships between ‘objective’ and perceived genital anatomy and sexual 
function remain to be further investigated, but a negative perception or expectation might 
further strengthen sexual dysfunction and vice versa (Chapter 3). Therapists treating men or 
women with sexual dysfunction would be wise to assess patients’ perceptions of penis size or 
vaginal outlook importance as a potential source of sexual anxiety. Genital image measures, 
such as the Self -Assessment of Sexual Anatomy and Sexual Function Questionnaire (female 
and male version) would increase communication with surgeons about areas of dissatisfaction 
and allow for effective counseling. In general, healthcare professionals need to be aware of 
potential sexual impacts should changes occur to the penis, vagina or clitoris following medical 
treatments or their complications .
In general, in men and women struggling with this subjective ‘atypical’ genital image and 
the pressure to conform, having ‘successful’ sex (i.e. intercourse) might resolve some of the 
psychological issues associated with atypical genitalia. However, sex always represents a 
high risk, as it also could confirm all their fears of ‘being abnormal’ in case of failure. Precisely 
because of a negative genital image and/or unrealistic and idealized portrayals of sex, some 
men and women who have not taken the risk yet to get sexually involved are extra vulnerable. 
12 We cannot underestimate to what extent medical and surgical intervention is the primary means of demonstrating caring for 
many clinicians, patients and family members [11]. But as the history of intersex and DSD showed us, there are certainly other ways 
to care for people [11].
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13 ‘Spectatoring’, introduced by Masters and Johnson, refers to focusing on and evaluating oneself from a third person perspective 
during sexual activity. This focus of attention outward on sexual performance rather than inward on the sensory aspects of a sexual 
experience (i.e., sensate focus) is believed to have deleterious effects on sexual performance [88].
Psychological barriers are heightened, with a possible withdrawal from potential opportunities 
of sexual expression. These men and women can stay in this perpetual state of conflict for years 
(…and so you just keep postponing your sexuality). Others have described spectatoring13 of their 
own performance and their partners’ reactions (…can you feel it, is it different compared to 
others?). Problems become self-fulfilling [28, 37, 88]. 
Perhaps the main implication of this doctoral thesis is that (surgical or non-surgical) ‘correction’ 
of a genital anomaly does not necessarily ‘correct’ or affect the patient’s self-image. One 
participant described it as ‘desillusion, because I could still not deal with the image that I had of 
myself. I was seriously depressed, had to break up with my girlfriend because I felt I had nothing 
to offer her.
However, both men and women were reluctant to ask for professional support. Might this 
reluctance have been part of a greater feeling of isolation from all sources of information and 
understanding about their condition and its effects? Or by the fear to be ‘disqualified’ for certain 
genital treatment practices when they admit to experience emotional difficulties? Or have we 
failed in addressing their social, psychological and developmental needs? 
One of the recommendations of the Consensus Statement included that psychosocial care 
provided by mental health staff with expertise in DSD should be an integral part of management, 
recognizing that diagnosis and medical intervention are not the sole focus of treatment. In 
a recent follow-up study of practices in Europe following the consensus statement, the call 
for psychological support was in most centers answered [110]. Interestingly, the report also 
suggests that, while 100% of the parents who were charged with the daunting process of 
Overcoming psychological barriers
“You come in here and you feel like your sex life is 
destroyed for 100% and you have this operation where 100% 
of your sex life will depend on . This is bullshit [. . .] It 's 
like 30%. It 's a lot, but 70% are other things. “ 
Psychology and its connotation
6.3.2
6.3.2.1
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gender assignment were offered psychological support, only about 80% took advantage of 
the proposed service. While the reasons for this discrepancy are not entirely clear, it is possible 
that the emotionally charged nature of the process may make it difficult for parents to integrate 
fully various components of their circumstances. Further, the prospect of involving additional 
specialists in the process may be overwhelming [26]. In addition, there might be a wish to 
keep the treatment process strictly ‘medical’ as ‘psychological ‘ support could have certain 
connotations. 
In clinical practice, when the issue of psychological support is brought up, immediate resistance 
is likely to occur. People will basically say, “I don’t want to talk about this now.”
 
But when is it that they do want to talk about it? They don’t want to talk about it with family, 
because it may upset them. They don’t want to talk about it with friends, when they just 
want to relax. They don’t want to talk about it in the workplace or at school, because it’s too 
controversial. Essentially, there really is no appropriate time to talk about it -- which is what a 
secret is.
It might be taken for granted how difficult it is for most people to actually make the decision 
to seek out help for intimate issues, mental health or sexuality concerns. It is not like anybody 
wants to go see a psychologist or therapist. It’s not the type of thing someone wakes up in 
the morning and says, “Wow, I have been missing something in my life. I would love to chat 
to a stranger about my innermost personal fears, thoughts, and feelings and see exactly how 
screwed up I really am.” In fact, most people think just the opposite about almost any health or 
mental health appointment. It’s just not something you want to deal with [111].
There are no easy ways to ‘get over’ this fear and anxiety. Such anxiety is a normal part of 
life, and the psychological therapy journey might indeed be a scary journey of (self)discovery. 
Politely asking people if they want to take up psychological support has been shown to result 
in refusal. However, the best evidenced-based treatment for avoidance is exposure. Therefore, 
when people decline, they should be offered even more psychological support. Familiarity with 
the team psychologist might reduce confusion related to the notion that psychosocial support 
is needed/required and people cannot handle it on their own. Recognition of the psychological 
components of DSD care does not represent a presumption of psychological disorder, but rather 
an acknowledgment of the possible impact (as in other chronic conditions) on the patient’s 
psychological development and the wider family adaptation [112]. Psychological counseling 
should be a mandatory, additional service, integrated in the multidisciplinary care offered, in an 
attempt to ‘normalize’ DSD conditions and focused on the prevention of difficulties throughout 
medical care [112]. 
“No, not psychologists. If you come to me and 
say you are a psychologist, I go away. Because you feel 
again like a patient. You feel abnormal. “ 
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The context of patients’ lives and their social support is known to be a crucial factor in long- 
term psychosocial outcomes of many chronic medical conditions [113]. Thus, ideally, where 
appropriate, patients and parents should be encouraged to access support from their personal 
contexts. Families can act as interpreters, caretakers, support systems and buffers [66]. However, 
because of the specific intimate character of the involved conditions, asking for and receiving 
community support14 implicitly means giving up (part of the) privacy, which new parents of 
a child with a DSD not always want to do [58] (Figure 2), nor adolescents or young adults in 
their pursuit of formulating a social and sexual identity, possibly leading to social isolation. 
Therefore, ‘anonymous’ psychological support in different formats (e.g, with professionals or 
through internet platforms and peer support groups) can be of high value.
6.3.2.2 Psychological support: a journey through ‘taboo’ and ‘dilemma’
“I didn't feel judged and it was someone different.. . In the beginning 
it was strange, what was I going to say? (laughs). But she made me com-
fortable and she was really nice and I felt relieved. She helped me not 
trying to hide it. It's not something that has to be hidden. “ 
Figure 2
Figure 2. Parents’ decisions and experiences with sharing DSD-related information (adapted from [58]).
With whom and what to share?
LOW HIGH
Range of disclosure
1. Worries about stigma, 
rumors and gossip
2. Perceived ability of parents 
to accurately explain DSD 
to others and/or have their 
child's condition understood
3. Preserve the child's right 
to make decisions about 
disclosure
4. Personal comfort in talking 
to others about anatomical 
aspects of the condition (i.e. 
genitalia)
Disclosure decision 
depending on:
14 In counseling families about sharing information concerning their child’s DSD diagnosis with the wider community, Cohen-Kettenis 
rightly posed the question ‘Is living a “normal” life with a secret more harmful than living a life without secrets but with a reasonable 
chance for stigma or shame?’ (p. 328) [114]. However, secrecy may also carry a reasonable chance for stigma and shame (e.g. [65]). 
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Despite the clinical knowledge concerning the psychological demands of DSD, very little direct 
information is however available in the mainstream literature to conceptualize psychological 
practice in this field [115]. Also, it is difficult to articulate psychological-therapeutic input in 
much detail as one model cannot fit all [116]. Individualized care and psychological methods 
should perhaps reflect ‘technical eclecticism’, whereby the integration of therapy models is at 
the level of techniques rather than theory [116,117].
In order for patients to have greater control of their treatment, they need to become more 
expert about their own condition and attendant difficulties [28]. It’s like a book and it’s heavy. 
You have to carry the book, it’s a problem... But you can also say ‘I simply read it’ and get the 
knowledge out of it, implying that we should give affected individuals correct information on 
their condition.
Historically, withholding information about diagnosis and treatment to competent children, 
adolescents and parents was mainstream. From a paternalistic view, the goal has been for the 
patient to remain insulated from shock and despair subsequent to learning his/her circumstance 
[26]. However, such an approach has been shown to actually foster the development of negative 
psychological responses [65]. In the current climate, the question is less whether or not to 
disclose medical information, but more when and how to disclose [26]. 
Debate regarding the ‘right’ time to give information to children is ongoing. The tension evolves 
around the age at which information can be meaningfully understood, balanced against the 
impact of delivering possible painful information during the vulnerable teenage years [112]. It 
is suggested that children should know about their condition before adolescence, when a 
developing sexuality and changing parent-child relationships are evident and a child’s desire 
to minimize difference and conform to a group is amplified [118]. This desire to conform can 
also increase the pressure of surgery, seeking to eradicate difference as soon as possible [112]. 
Based on models of children’s cognitive development (e.g. Piaget, Kohlberg) [119, 120], it has 
become clear that from age 12 and onwards children are able to develop the ability to think 
in conceptual terms and may understand the more complex nature of their condition. Before 
this age, simplified information can already be given on biological and psychological aspects of 
normal sex differentiation. Children sometimes have a clearer technical understanding of their 
condition and treatment than their doctors or parents realize and can endure considerable 
distress, which might be intensified when there is a lack of access to direct discussions with 
an understanding doctor or parent [121]. In the sparse published guidance, disclosure of the 
chromosomal pattern (e.g. in XY women) is generally recommended to be given when the child 
is around the age of 14 years [122]. However, it may be that giving this information earlier would 
allow children to integrate this into their developing constructs of male and female and hence 
their self-concept, rather than having to accommodate the information later when constructs 
are already more fixed [112]. Some adults with a DSD advised that the sooner one is able to deal 
with the full psychological impact of the condition, the sooner one can get the immediate 
A Psycho-education and sensitive information delivery
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trauma over with and the sooner one can get on with one’s life [65]. Others advised that a 
phased truthful approach can also work, meaning a strategy in which each piece of information 
given is in itself truthful, so that there is no need for backtracking at a later stage (e.g. Saying 
‘malformed ovaries’ in stead of ‘testicular tissue’ can lead to anger and distrust if a teenager later 
finds out about her XY chromosomes) [123].
Furthermore, disclosure of fundamental and potentially stigmatizing information is a difficult 
process and must be considered carefully [58]. Families and patients have different beliefs and 
values, which need to be taken into account when considering the impact and meaning of 
information (e.g. cultural or individual values attached to infertility). Specific phrases used to 
explain an underlying condition may still be remembered many years after they were said 
and can continue to cause discomfort [65]. Professional clinical language has been shown to 
positively or negatively influence a patient’s experience of the diagnosis [124]. 
Lastly, sensitive and responsible disclosure also means that patients and significant others are 
not left to contemplate the implications of disclosure without support. High levels of emotional 
distress are correlated with increased cognitive confusion [59]. When irreversible interventions 
are proposed, it is essential that the emotional distress is addressed first (e.g. by opportunities 
for parents to speak to other parents who have lived through similar experiences) to ensure 
that cognitive impairment does not compromise decision-making. Real collaboration in 
treatment decisions (and true and meaningful informed consent), is reliant upon an effective 
communication process between the physician, patient and family [125]. This process requires 
time and a flexible open approach in line with patients’ and families’ differing needs. Therefore, 
repeat opportunities for questions and discussions are needed, to allow time to adjust to the 
diagnosis and to ensure that patients (or surrogates) understand the immediate and long-term 
implications of medical interventions and alternatives and are able to make decisions with the 
support of health care providers [56].
 
Fostering a positive self-identity
As with all of medicine, it is of vital importance to remember that patients are individual people 
who happen to have a disease or disorder, rather than a person intertwined with or defined by 
the disorder [26].
B Psychological counseling
“In the beginning I really thought I was not like the others. I cannot have 
children, I cannot have intercourse. I'm abnormal. But now it 's completely dif-
ferent. I am this person, I have friends, a good boyfriend, a good relationship 
with my family, I 'm happy. I don't see this as something that defines me. “ 
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For some, an important task might be to distinguish between ‘living the condition’ and “living 
with the condition” [28]. Some coping mechanisms, such as downward social comparisons (e.g. 
“there is cancer and I’m still alive”) should be discussed. They can help people to enhance well-
being and self-esteem, but may also become problematic if people identify too closely with the 
‘worse’ world they compare themselves with [66]. 
For others, it means providing support to develop adequate communications skills for explain-
ing body differences in social and sexual contexts, which are of major concern for many ado-
lescent and adult patients [65,78]. Some DSD diagnoses are associated with body differences 
that are internal (e.g. absent womb), and/or external but concealable (e.g.micropenis) and/or 
or external and visible (e.g. hirsutism). Bodily differences and experiences can have a formative 
influence on a person’s psychological development and identity experience [126, 127]. Although 
recent research appears to suggest that the majority of people with a DSD see their experience 
of gender as being adequately represented by a binary model, for some, it also means being 
able within a safe environment (of psychological therapy) to explore the spectrum of gender 
identities and gender experiences that transcend the male/female dichotomy [126]15. In addi-
tion, patients should be able to grieve for their losses associated with the diagnosis and con-
sider the implications for their identity, for instance regarding the infertility issue. Infertility can 
become central to a person’s identity [66].
Although group work has been suggested to be effective for negotiating identity and facilitating 
positive psychological changes [128, 129], certainly not all participants involved in this research 
were advocates of the idea. To date, there exists no patient support group in Belgium, only in 
the Netherlands. Whereas the support groups in the Netherlands have a lot of ’supporters’, Bel-
gian patients seem somewhat more reserved in joining the Dutch group, or setting up a Belgian 
initiative and sharing common concerns. Perhaps cultural differences play a role here. How-
ever, one- on-one contact was said to be helpful, but was mainly limited to subjects related to 
the shared condition [65]. 
15 ‘Mixed’ two-gender identies ( i.e. the experience of both male and female identification at different times) as well as third and 
undecided gender roles have all been described by participants (and in particular participants with GD, salt wasting CAH and 
ovotesticular DSD), even though the majority were satisfied with their gender assignment [126].
“Support groups? Feels like AA meetings. 
They give you a label and precisely then you feel 
something is wrong with you. “ 
Addressing barriers in relationships and intimacy
Whilst it is important to de-focus on penile-vaginal intercourse and to discuss sexual intimacy 
in broader terms, the importance of vaginal sex is of course culturally reinforced and will remain 
an important aspect of clinical management for some time. However, patients may need to 
develop a more questioning attitude towards some dominant discourses of sex and sexuality, 
which can be installed by using richer vocabularies and drawing on alternative discourses, and 
by using a positive language [28,106]. 
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In psycho-sexual counseling, a defocus from ‘normal sex’ and an increased emphasis on sen-
suality and pleasure can encourage people to become more open to opportunities for good-
enough sexual enjoyment and relating. Therapeutic exploration might focus on an exploration 
of sexual likes and dislikes and interaction skills in social and sexual situations [115]. It should also 
focus on expanding awareness of variations in male and female sexualities and undermining 
assumptions that all genitalia look the same and that partners are highly knowledgeable about 
the structure, function and appearance of genitalia [28].
Facilitating informed choice in medical treatment
The advent of internet and its 'anonymous' forums has patients given the confidence to express 
some of their concerns. Many good websites and initiatives exist, providing the patient with up-
dated information on some of the specifics of their condition and its management and where 
to find help (e.g. DSDNederland.nl, dsdfamilies.org). However, as the quote below illustrates, 
the overload of (negative) information might still be overwhelming. Within a context of coun-
seling and education that target psychological wellbeing and sexual awareness, information 
needs respectful consideration and clarification where incorrect or misleading information has 
been gained. This also might open the discussion regarding the different treatments options, 
including the choice of no treatment, based on all information sources, possibly reaching a 
more informed and hopefully positive decision for the patient.
“Not just say 'you have a pump now' . No ! 
'You have a penis, which functions. Enjoy it!  “ 
“When I didn 't have a vagina. . . there were other ways to have 
pleasure, other ways than intercourse. It's so wrong for us to think 
that we can't have a sexual life . “ 
“There is so much information on the internet, but it 's negative! 
I really wonder why? Do they want to exaggerate their situation?
Psychological support should parallel all key stages of medical intervention, and is best con-
sidered as a process (and not an event). This is also in recognition of the different stages of ad-
justment to the diagnosis and the temporo-developmental factors (e.g. peers starting to have 
children, can re-install psychological distress related to infertility, or parents fearing physical, 
C The role of time
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social, or emotional changes when their child enters puberty and adolescence) [66,78]. Planned 
episodes of medical care may not coincide with an individual's needs at particular points in 
time and, therefore, ideally the family and affected individual will also need to be able to initiate 
contact as and when it feels appropriate to them [130].
 
 
 
TABLE 1
Common clinical concerns, helpful strategies and pitfalls in clinical work with 
adults who have DSD’s (based on [10, 28, 36, 65-67, 78, 116, 117, 127, 132, 133]).
Concerns
Strategies
Self-disclosure to partners, friends and family (what, when and how)
Participation in sex to be 'normal', with less focus on pleasure
Loss of control and choice
Sexual anxiety, passivity, fear of rejection
Compromised gender, sense of damaged self
Avoidance or idealization of relationships
Loneliness and social isolation
Changes in life goals or expectations following diagnosis
Public intimate medical examinations
Getting full information on condition
Genital aversion through treatment
Beliefs that sexual lives can only be the doctor’s (surgeon) makings, indicating an absence of problem solving
Explore and question assumptions about ‘normal’ and ‘sex’
Assess genital and body image
Pleasure talk
Increase control over social and sexual situations
Be transparent, humble and empathic
Be realistic about limits of treatment, entertaining the possibility that surgery might damage   
the very thing that it tries to fix –appearance and normal sexual function
Facilitate least invasive treatment options
Deliver information sensitively
Let patient set agenda in counseling to increase control
Make time – despite brief therapy- to let them tell their story and grieve losses
Consult with multi-disciplinary team
Emotional support
Encourage social contact, including peer support
Anxiety and pain management
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Strategies
Pitfalls
To ensure good psychologist/patient communication by:
 Discussing treatment goals and treatment choice with patients, and maximizing    
 informed decision-making.
 Being responsive to the inherent power imbalance within the psychologist/patient relationship.
Lack of knowledge on conditions
Focusing on anatomy solely, rather than emotional experience of patient
Not knowing one’s feelings about DSD
Not consulting with multi-disciplinary team or supervision about possible counter-transference
Presuppositions that a vagina or penis of certain dimensions are pre-conditions for ‘sex’, as they only reinforce 
the idea of penile-vaginal intercourse as only valid avenue for sexual satisfaction
Table 1 summarizes common clinical concerns, helpful strategies and some pitfalls in clinical 
work with adolescents and adults who have a DSD. Clinical psychology has been critiqued for 
pathologizing, individualizing and categorizing suffering and human distress [39], not in the 
least the Diagnostic and Statistical Manual of Mental Disorders (DSM) and some of its narratives 
(e.g. Sexual dysfunction or heterosexual dysfunction? [131]). Alternative approaches to assess 
sexual (dys)function, can consist of assessing sexuality dimensions and developmental trajec-
tories of gender positioning of the self and gender(s) of the preferred partners besides body 
perceptions, relationship aspirations and attitudes relating to sexual practices and experiences 
[39]. Psychotherapy should perhaps also be defined differently [39]. Psychotherapy is usually 
seen as helping the client fit in with other people by reducing the behaviors, thoughts, and feel-
ings that separate the individual from the world of ordinary life. However, it can also be seen as 
helping the patient accept his or her individuality, the ways we all sometimes fail to meet our 
own or other people’s expectations, and occasionally rise above them [39]. In Liao’s model [39], 
there is a shift from a model of ‘correction’ to ‘adaptation’; a model in which difference can be 
tolerable and acceptance is possible; in which surgery can be an option and subject to inter-
rogation, but evidence (and not observation) is crucial; in which work with patients and families 
explores meaning and increases their expertise; in which sharing tasks with multidisciplinary 
team members leads to an optimal information delivery, research designs and interpretation 
of data. Such a collaborative clinical care framework will hopefully lead to more perceived 
control, optimal physical health and psychosexual wellbeing (as defined by the person) and a 
positive self-evaluation.
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Already briefly touched upon in Chapter 4, an individual-based approach with skillful evalua-
tion and negotiation with the patient can help to prevent failure, limited compliance, treatment 
drop-out and loss of confidence in the vaginal reconstruction process. As compliance affects 
the success of vaginal dilation therapy as first-line technique, it is extremely influential in clinical 
decision making [134]. Therefore, a set of clinical care recommendations is proposed, includ-
ing a self-management model of vaginal dilator treatment, based on a health belief model of 
behavior change [135], and on therapeutic interventions within a framework of behavioral and 
cognitive psychology, and motivational interviewing [136]. Merely informing people of sexual-
health practices rarely results in behavior change (e.g. sexually transmitted disease prevention 
or reproductive cancer screening) [137]. Encouraging women to adopt the practice of using 
vaginal dilators is similarly difficult. Figure 3 illustrates how an information-motivation-behavior 
skill model of behavior change would incorporate the influencing factors identified in this doc-
toral thesis. This model can offer useful pointers for understanding compliance difficulties with 
vaginal dilation, suggesting that vaginal dilator use can be increased by providing stronger cues 
to action, emphasizing the benefits, overcoming the barriers and minimizing the perceived 
threat, while accounting for modifying factors. 
6.3.3 Recommendations for vaginal dilation therapy
Figure 3
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Figure 3. Determinants of vaginal dilator use. 
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Information: additional information (e.g. information leaflets, websites) and (rebranded) 
psycho-educational support (e.g. the possibility of phoning/emailing physiotherapist with 
questions, contact with peers through chat or email) can be provided, resulting in certainty 
about vaginal dilator use. Standardized and easy-to-follow instructions may boost patient’s 
confidence to correctly use the dilators.
Dilator provision: Ideally, dilators should be purchased at the hospital pharmacy, websites or 
directly from the healthcare team, rather than going to an adult sex shop. By making the dilators 
as accessible as possible, women’s discomfort with the devices is potentially minimized. 
Vaginal changes through personal experience or medical examination: Regular check-
ups by clinicians and personal experience of anatomical and functional success can act as 
confirmation of the efficacy of dilators and increase the frequency of dilator use. Close follow-
up consultations are therefore an important forum for maintaining compliance. Asking patients 
to keep a record (e.g. diary chart) of the frequency and ease of their dilation use and setting 
goals for size progression may help women and clinicians to assess the further benefit of 
dilation treatment over time. However, as vaginal size in non-sexual situations can be a poor 
predictor of pleasurable intercourse upon sexual arousal, clinicians should reduce the level 
of preoccupation with vaginal size solely and also emphasize enjoyment and pleasure, also 
through not-penetrative activities. 
Dilator perception: Young women may experience embarrassment when being introduced to 
dilator treatment, as a dilator can be perceived as a sexualized object [138]. A conversation with 
the gynecologist/physiotherapist and/or sexologist/psychologist directly assessing uneasiness 
with the vaginal dilator and addressing any potential embarrassment may help women reframe 
their perception from a ‘sex toy’ to a more neutral, rehabilitative tool. Moreover, it is common 
for younger women to be quite appalled by the idea of inserting an instrument in the vulvar 
region. It may be that, despite concerns about amenorrhea, the woman might not have explored 
her genital area or even has developed a phobic reaction [139]. For some women, negative 
perceptions of the genitals may also be exaggerated by an idealization of ‘normal’; and negative 
social comparisons may raise the anxiety further [28]. The highly selective popular images of 
female genitalia represent an unnaturally narrow range instead of recognizing natural variation 
between women [91,140]. It is necessary to explore the nature and extent of these negative 
social comparisons, aversion or fears (including pain), to offer information and reassurance and 
estimate the impact of remaining anxiety on adherence to therapy. 
Diagnosis adjustment: The most significant recommendation is the need to be sensitive to the 
strong emotional reactions some women may have. Due to the intimate nature of the syndromes 
6.3.3.1
6.3.3.2
Cues to action 
Modifying factors
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associated with vaginal agenesis (including the fertility issue), women may experience a range of 
symptoms consistent with posttraumatic stress in reaction to the diagnosis and use of dilators. 
Thus, in addition to inquiring women about their adherence to vaginal dilation treatment, health 
care providers should also inquire about distress associated with the matters discussed. Dilation 
treatment must be delayed in the presence of psychological disorders such as depression, as 
they are likely to mitigate against adherence and therefore treatment outcome [139]. 
Maximizing support: psychological research in chronic diseases suggests that successful self-
management can be enhanced by the availability of social support [113]. Thus, ideally, where 
appropriate, patients should be encouraged to access support from their personal contexts. 
However, because of the nature of the syndrome, many women feel they cannot talk about 
it with their family or friends and wish to hear about other patients’ experiences in dilation 
treatment. Support can also be provided by clinical services, discussed above, and groups can 
provide a useful resource to share concerns or motivate each other during treatment. Regular 
appointments with a clinical psychologist or nurse specialist and/or physiotherapist can provide 
future opportunities for addressing anxiety and for problem-solving practical difficulties [28].
Timing of treatment: Vaginal dilation treatment should be planned on an individual basis as 
there is considerable variation in social and psychological development. This may also be 
influenced by cultural or religious beliefs. However, it is suggested that dilator treatment should 
not be started before the age of 16 years, as younger women might be less familiar with their 
genitalia and might therefore be less capable of dealing with treatment or have less motivation 
to remain active in the treatment process over a period of months. It has been shown that 
adherence is reduced in adolescence [139]. Every failed attempt at dilation might also jeopardize 
success of further attempts, including postsurgery dilation if the patient decides to undergo 
vaginoplasty. There are also differing opinions about whether treatment should be delayed until 
a women is in a relationship or whether treatment is best completed before forming personal 
relationships and women have decided to become sexually active. Current relationship status 
did appear to have influence on the motivation and frequency of dilator use. Women who 
were not in a current relationship, but who were highly motivated to start sexual activity, had 
fewer appointments and shorter treatment durations. This suggests that confidence to begin 
intercourse may be established during the treatment process and in a sense may form part of 
the treatment.
Perceived benefits and barriers: empathetically and non-judgmental exploring the benefits of 
dilator use (e.g. sexual function is possible by achieving greater vaginal length, aspirations of 
normalcy regarding sexual anatomy and sexual relationships) and overcoming the barriers (e.g. 
need for discretion, lack of time, effort, negative experience (e.g. having a sense that it is not 
‘right’ or ‘natural’ to touch her genitals or treatment triggers flashbacks to previous traumatic 
experiences such as embarrassing examinations or unsuccessful attempts at intercourse, 
pain), should be tailored to each woman’s reasons for adhering or not adhering to dilator 
treatment [133]. The extent of a positive attitude towards treatment is thought to be influential 
upon compliance and the perceived efficacy (i.e. personal beliefs of how likely it is dilation will 
work) will be central to a woman’s motivation to repeat the exercises regularly [139]. Improving 
information provision, providing examples of other women’s dilator use, or helping women 
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6.3.4 Recommendations for the psychosocial management of DSD 
conditions involving penile deficiency
plan to incorporate the dilator use in their daily routine, as well as providing dilators in attractive 
packaging could help women maintain discretion and feel more comfortable with the dilators, 
as well as build confidence in her ability to perform dilation [133].
Perceived threat: pain and the susceptibility to loss of vaginal depth. Women are advised 
to maintain dilation or have regular sexual intercourse, although it was suggested that this 
recommendation might be counterproductive in some women experiencing sexual difficulties 
(see supra). The way women react to the pain that comes with dilation (or with intercourse), 
will significantly influence compliance. Anxiety can lead to more anticipation of pain, thereby 
exacerbating the pain by intensifying muscular spams. Psychological pain management 
techniques in the treatment of dyspareunia associated with other gynecological conditions 
such as vulvar vestibulitis, might be useful [141]. Effective techniques include helping patients 
become more aware of their thoughts and emotions in relations to anticipation and experience 
of pain. Further cognitive techniques modify the elicited thoughts and emotions (see Figure 1). 
Relaxation training can be a useful adjunct in reducing muscular tension and pain management, 
and can come in many forms (e.g. biofeedback, Kegel's pelvic exercises, respiratory training, 
yoga).
Supporting the parents– by providing them with correct information on the specific DSD 
condition involved and emotional support-is an essential first step, as informed and supported 
parents will hopefully equip their children with knowledge and resilience so that they can take 
over the responsibility for their own health and wellbeing as they grow up [59, 142]. Patients 
and parents should in any case be encouraged to maximize social support from their personal 
contexts, which can provide a buffer against the demanding and possibly adverse diagnosis 
related events along the way.  Offering patients as well as parents the possibility to get in touch 
with support groups or affected peers can additionally be empowering and reduce possible 
social isolation and inhibition, especially during adolescence, when communication and mutual 
support between close family members is (more) likely to be affected.
Further professional counseling will be guided by  the stresses perceived by the patient (and those 
close to him), and available strategies for coping with the psychological challenges imposed by 
the condition and treatment. Specific psychosocial domains that need consideration are the 
assault on the sense of self  and body image (i.e. the penis being an organ associated with self-
esteem, sexuality, fertility, and psychosocial-masculinity issues). Asking boys and men about 
other aspects of their lives will also remind them that there is an identity beyond that of being a 
patient with DSD. 
In addition,  hormonal and surgical treatment options - both hypospadias repair (if needed) and 
its timing, as well as possible phalloplasty - and their likely psychosexual effects need further 
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exploration [143]. Patients (or parents) should be given sufficient time before the initiation of 
any treatment to psychologically process the information. In particular, clinicians may be under 
huge pressure from parents or adolescents to make the penis larger. The problem may be worse 
if pediatricians have avoided discussing penile size and have implied that something definitely 
can be done, if not by hormonal treatment in childhood, then definitely when the patient grows 
up. Young men with a micropenis  may arrive at an adult clinic with unrealistic expectations [68]. 
To prevent later disappointment or difficulties, the multidisciplinary management team needs 
to truthfully inform the involved parties about treatment risks and benefits and continuously 
address and educate about psychosexual function,  in an age-appropriate way. Understanding 
children’s’ and teenage cognitive skills is critical to providing the optimal care and in further 
informed decision-making processes. For instance, 15 to 17-year-olds may typically understand 
the possibility of negative consequences of the risks involved in phalloplasty procedures, but will 
perceive them as unlikely to occur. Those 18-years-old and older often understand the risks and 
that they apply to them [144]. 
Recommendations for the further content of discussions about sexual matters are included in 
Table 2. Psychosexual counseling of young men should always proceed from an understanding 
of their life contexts (e.g. age, living conditions, partner status) and then include questions 
about prior sexual experiences, level of sexual desire, frequency of self-stimulation or sex with 
partner, quality of erections and ability to reach orgasm and ejaculate semen, and whether they 
experience pain during sexual activity [143]. Giving details on penile anatomy may help their 
perception of structure and sexual function [145]. Some specific standardized visual tools, such 
as the Self-Assessment of Genital Anatomy and Sexual Function –Male version (SAGAS-M), might 
pinpoint specific (genital) areas of concern and can be useful to guide the consultations [146]. It 
should be emphasized that genital size as such is not related to sexual function or satisfaction. 
Because most men by early teenage years have already viewed pornography, it is also worth 
mentioning that the men depicted in pornography are often selected and photographed in 
ways to overemphasize size. Health-care providers offering concrete information and healthy 
dialogues about penile matters can allow an otherwise already self-conscious teenager the 
chance to develop a realistic, healthy body and penile image [145]. Rather than focusing solely 
on building knowledge on sexuality topics, however, clinicians should further help young men 
problem solve (e.g. use of sexual positions that are easiest for patient, applying relaxation 
techniques when being tense),  and communicate more effectively (e.g. about sexual likes and 
dislikes, or about the diagnosis).  In some cases, brief cognitive behavioral therapies (CBT) and 
techniques, to address body/penile image concerns or feelings of discreditment (as men) can 
be of extra value [78,147-149]. Restraining thoughts, which produce undesirable behaviors and 
feelings, are replaced by enhancing self-affirming thoughts, backed up by adequate stress and 
coping strategies. This enables patients to become more skilled in problem solving, as well as 
become more focused on (and therefore being able to recognize) other physical sensations 
(see also Figure 1). CBT is generally short term and proven to be successful for men with other 
penile conditions, such as penile cancer, or  small penis syndrome (i.e. a fear-fuelled subjective 
perception that the penis is considerably smaller than average, in some cases part of a body 
dismorphic disorder) [150]. 
  
 
TABLE 2
Recommendations for education and psychosocial support of   
patients with micropenis or penile deficiency [115, 147, 151].
Technique
Content
 
Ask, advise, assess, assist, arrange follow-up (the 5 A’s)
1. Discuss sexual status and clarify expectations of possible treatment (hormonal and/or   
surgical, including phalloplasty)
2. Discuss possible sexual changes, review side effects and potential management
3. Individualize needs assessment and personalize care
4. Encourage open communication with possible partner, promoting couples’ mutual    
coping and support processes
5. Include nongenital foreplay to minimize performance pressure
6. Focus on pleasure/arousal rather than orgasm to limit performance pressure, explain relation   
of penile size to sexual ability and satisfaction
7. Use sexual positions that are physically easiest, possibly avoiding pain, bodily tension   
and inhibition of arousal
8. Consider sex therapy with appropriate professional
9. Provide possibility to talk to affected peers or support group
10. Apply objective, validated tools to assess patient satisfaction and the impact     
of psychotherapy, education, and counseling 
Lastly, if the patient decides to proceed to phalloplasty surgery, close collaboration with 
surgeons who have experience with transsexual individuals is essential, as the same techniques 
for female-to-male gender reassignment are applied. Based on the current status of science, 
phalloplasty surgery for micropenis or penile deficiency conditions is still experimental and 
should be limited to research or university institutions with extensive clinical experience and 
supervising ethics committees [147]. Great care must be taken when selecting men for such 
phalloplasty surgery since there is the danger that a small but functioning penis will be changed 
to a large but relatively inert one [68]. Well-informed, and counseled patients are aware of the 
risks involved. Routine data collection on patients’ experiences is further recognized as the key 
marker of care quality and can inform service improvement strategies [115]. Finally,  psychosocial 
adjustment to the diagnosis is an extended process and does not end with the completion of 
treatment. Men should be given the opportunity to receive support and long-term follow up, 
beyond the treatment period. 
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Without some understanding of what is happening and why, physicians, patients, parents and 
others cannot thoroughly evaluate current practices and devise ways to improve treatment. The 
main aim of this doctoral thesis was to provide a snapshot of some of the past and current (and 
future) treatment practices, its efficacy and long-term impact. By using a qualitative, mixed-
methods approach, and giving affected persons a voice, valuable and richer insights into their 
lived treatment experience were hopefully offered.
However, participants were only recruited from several hospital clinics, making the scope of 
some of the conducted research limited and less generalizable. The range of recruitment 
sources, including support groups, should be broadened. By adopting a quantitative and 
standardized methodology we were able to compare the results with those of non-affected 
men and women and some other medical conditions (e.g. hypospadias). However, sample sizes 
and power to detect differences, remained small. That so little research, in general, has been 
dedicated to examining associations between sociodemographic (e.g., age, assigned gender, 
current gender role), psychosocial (e.g., traumatic experiences, attachment to parents) and 
medical aspects (e.g., diagnosis, treatment measures) and psychosexual wellbeing is partly 
because small sample sizes do no enable association analyses. Further collaborative national 
and international projects (such as iDSD), working according to standardized research protocols 
ensuring high-quality outcome data, are highly welcome [152].
This doctoral thesis also falls short of a discussion of endocrine treatment and prevention of 
aspects of DSD. For example, the issue of gonadal management, which is an important area of 
further decision making in some specific DSD conditions and possible adding to the experienced 
distress , is not further considered. The goals of gonadal management are to preserve gonadal 
function (sex hormone production in accord with sex of rearing and fertility) and avoid gonadal 
malignancy, which may exceed 30% in some conditions [153]. The approach varies depending 
on the underlying DSD and its manifestation. As a general rule, Y chromosome bearing 
gonads that remain within the abdomen will function poorly from a reproductive standpoint 
and are at high risk for malignancy [154]. Such gonads are either removed or, depending on 
their functional capacity, brought into the scrotum. Müllerian structures of a significant size in 
individuals raised male may also require removal, whilst smaller Müllerian remnants can be left 
in situ as usually they do not cause significant problems [130]. Extirpation of gonads in complete 
(pure) gonadal dysgenesis, PAIS raised female, DSD due to WT1 mutations (e.g. Denys-Drash 
and Frasier syndromes) is generally recommended before pubertal age. The exception is CAIS, 
where retention of gonads through puberty is acceptable so spontaneous puberty can be 
experienced. Although the risk of malignancy is not precisely known, especially at an adult age 
it is significantly lower than the risk with dysgenetic gonads [154]16. 
16 For instance, it is estimated that the risk of gonadal malignancy in CAIS is less than 1% compared to approximately 25% for women 
with complete gonadal dysgenesis [153].
6.4 Limitations
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17 As Liao & Simmonds remark, it is peculiar that academics, journalists and program makers alike assume that the only way to 
understand DSD is via research on affected people. It is as if the non-DSD world has nothing to do with how DSD is experienced. 
Public engagement about DSD via research and interventions with non-affected populations should also become a key psychosocial 
focus in the future [115] 
Furthermore, recent reports challenge the need to perform gonadectomy at all, since there 
have been anecdotal reports of loss of libido following gonadectomy, concerns about long-
term hormonal replacement and even the potential of the gonads harboring viable germ cells 
- cells within the ovary or testis that eventually develop into eggs or sperm- that could be used 
for procreation with future advanced technology [155]. Optimal modalities of surveillance and 
screening intervals for gonadal tumors remain to be defined [153]. 
More research is needed to assess the effects of psychological counseling and education and 
to delineate factors associated with differential psychological and sexual outcomes. Further 
qualitatative psychology studies are needed to improve our understanding of patients’ and 
parents' perspectives and their lived experience. Some also suggest it would be worthwhile 
investigating the explicit and implicit psychological gender models not only of affected persons 
but also of clinical professionals working with them [156]. In addition, it is important for all 
services to further audit the effects of (genital) treatment on sexual experience and wellbeing 
along a number of different dimensions such as quality of intimate relationships, partner-
independent sexual activities [149], or predictors of persisting gender dysphoria [114], by using 
an improved research methodology. Standardized psychometric instruments designed for a 
normative sample may not be well designed to detect the specific distresses experienced by 
affected individuals. Some psychologists have already responded to this problem with better 
tailored instruments e.g. for assessing pediatric penile perception [157] and for assessing health-
related quality of life [158]. What is still needed, includes decision aid tools e.g. for facilitating 
disclosure and shared decision-making processes and screening tools to help identify parents 
who may have more substantial coping issues and may require particular psychological support 
[114]. Prospective outcomes studies, in which a baseline psychological assessment of emotional 
wellbeing and sexual quality of life can be compared with post-treatment assessments on the 
short and long term, are paramount. Theoretical formulations of psychological questions should 
be included to address gaps of psychological knowledge in living with atypical genitalia [116]. 
On the note of research however, it is worth reminding that because conditions associated 
with atypical genital characteristics are relatively rare -, whilst the number of questions that 
need answering is large- the same group of people may have to participate in one research 
project after another [28]. The quest for knowledge in order to assist these people may actually 
reinforce the message that they are ‘interesting’, with all the negative connotations attached. An 
additional responsibility must be assumed to strike a balance between repeatedly investigating 
the small populations and tangible achievements for those populations [116]17. 
Further participant-centered psychological research might, for example, include projects that 
investigate family members’ relationships to the condition in question, factors that can affect 
personal adjustment and the impact of genetic testing on family relationships. Patient-driven 
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Since medical management of DSD came under criticism over a decade ago, there have been 
a number of attempts by the medical community to respond to the criticism. Before Chicago, 
none of these attempts had been very successful. The Chicago Consensus conference did a 
better job of including and listening to patient advocates and also benefited from much more 
diversity of discipline and geography than previous attempts [159]. Figure 4 summarizes some 
of the successes of the meeting and the clinical standard of care translated in the Consensus 
Statement on Management of Intersex Disorders [24, 160]. Perhaps the most remarkable product 
of the Statement, is the complete overhaul and adoption of a new medical lexicon pertaining 
to DSD. Such a rapid uptake is unparalleled in clinical medicine [26]18. By updating the medical 
nomenclature, DSD was brought into line with other genetic and endocrine disorders, and with 
a hope and expectation that these conditions would be brought as well into the mainstream of 
evidence-based medicine [159]. Furthermore, the role of psychologists has been emphasized, 
not only to assess potential psychosocial/ psychosexual outcomes, but also to offer immediate 
support to families in distress [26]. Peer and parent support for many chronic medical conditions 
is widely accepted, and DSDs, being lifelong conditions which affect developmental tasks at 
many stages of life, are no exception [159]19 .
After the meeting, however, the call for more efforts remains open. The skills of qualified mental 
health professionals and professionals in the field need to be further built, and recent initiatives 
including e-learning portals [162] and e-consultations as platform for expert advice [163] are 
very valuable towards reaching this goal. Second, the call for establishing patient registries in 
the context of longitudinal and prospective studies has been responded by the European Union 
18 DSD terminology is not uniformly accepted by those whose bodies the terminology describes, but most affected are familiar with 
the term, indicating how prevalent DSD has become [161].
19 In the wake of the consensus conference, a non-profit organisation –Accord Alliance- was created with the mission to ‘promote 
comprehensive and integrated approaches to care that enhance the health and well-being of people and families affected by DSD 
by fostering collaboration among all stakeholders’ [160]. Together with DSD syndrome-specific advocacy and support organisations, 
the active involvement of these stakeholders augurs well for constructive collaborations among ‘consumers’, health care providers, 
representatives of health care organisations and researchers [160] 
“ You can make us a good car, but we have to drive it ourselves. 
Meaning, give us self-confidence. [.. .] But you have to let the person go. 
And you have to see how he falls down, and stands up again. 
But with the self- confidence, he can do it.“ 
research will hopefully give patients the control and minimize potential negative effects; it will 
hopefully also lead to even more positive changes in clinical services for DSD in the future.
6.5 
Future perspectives: 
reasons for optimism
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Commission and many countries [164, 165], but further collaborative and international projects 
on the pathophysiology and natural course of DSD remain essential. Third, investigations of 
the eff ects of low-cost psychological interventions on self-evaluation, stress and distress, 
relationship and sexual experiences and adherence to medically essential treatments, are 
SUCCESSES
at the Chicago Conference
Progress in
Patient-centered 
Care
More Cautious
Approach
To Surgery
Support gender 
change as needed 
in accord with 
patient wishes
Promote open
communication with
patients & family:
essential in 
decision making
More focus 
on the stigma, 
not solely gender 
and genital 
appearance
Limit 
genital exams,
medical
photography
Psychological
Care 
Integral in 
Management
Disclose facts
about karyotype, 
gonadal status 
prospects for 
future fertility
Disclosure is 
associated with 
enhanced
psychosocial
adaptation
Quality of life:
intimate 
relationships
Atypical
gender role
more common,
not indicator for 
reassignment
Life-long
condition:
behavioral support
as needed 
long term
Consensus
on Nomenclature
Change
Eliminate
“ pseudo-
hermaphrodite”
New
nomenclature
rapidly entering
medical usage
“Google” search
produces 
relevant results
No vaginal
dilation before
puberty
Consider clitoral
surgery only 
in severe cases
No vaginoplasty
in infants with 
short or 
absent vaginas
Will promote
better use 
of evidence
Surgeon has 
responsibility to
outline the surgical 
consequences
from infancy 
to adulthood
Figure 4
Figure 4. Successes at the 2005 Chicago conference and the clinical standard of care trans-
lated in the Consensus Statement (adapted from [24, 159]).
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critically important in the DSD field [115]. Fourth, as the protocol for case management becomes 
a part of routine practice, it seems appropriate to turn to the meta-cognitive task of assessing 
how we think about and disclose the diagnosis of DSD to patients and their families in the 
earliest stages of interaction. To explicate the process and incorporate a best practices protocol 
should be a new focus for improving patient care [26]. In addition, decision aid tools, assisting 
parents and patients to better understand the biological basis of DSD and the importance of 
their family and cultural preferences in shaping treatment decisions, should be developed [159]. 
Finally, the challenge remains to establish a productive dialogue between neuropsychology 
and psychosocial approaches: for psychosocial research to incorporate new understandings 
from hormonal and genetic research as they come to light, and for neuropsychological studies 
to more fully take into account diverse and psychosocial factors that may impact on the very 
conceptualization of gender and gendered well-being [62].
Evidence-based standardization of diagnostic and treatment (medical, surgical and behavioral 
health) protocols will hopefully be associated with higher rates of definitively diagnosed DSD, 
reduced variation in clinical practice, and enhanced patient/family health care experiences [159]. 
An evidence-based practice is supported by drawing critically on available research evidence. 
keeping up to date with recent literature and advances, and contributing to the knowledge of 
pathophysiological mechanisms, molecular diagnoses and DSD health psychology. Openness, 
critical awareness and reflexivity can be encouraged by utilizing peer support, regular peer 
reviews and supervision [117].
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Disorders of sex development present a unique challenge, both diagnostically and in terms 
of acute and longer-term management. DSD can present to many different healthcare 
professionals and at different ages. Whilst the majority of infants with DSD present with genital 
ambiguity at or shortly after birth, an increasing number of individuals are identified either 
prenatally or during childhood and adolescence. Adults diagnosed with DSD will sometimes 
present through infertility clinics. Therefore, an awareness of these potential diagnoses, 
appropriate terminology and the need to involve specialist services early is required by all 
practitioners. These are relatively rare conditions requiring a holistic and multidisciplinary 
approach from the outset (Figure 5) [160].
Many individuals with DSD will, at some point, require genital treatment or reconstructive 
surgery, especially when functionality remains being characterized in terms of successful 
penile-vaginal intercourse. Whilst there is agreement that genital procedures should only be 
performed by clinicians and surgeons with specific expertise working within the context of a 
specialist multidisciplinary team, there is ongoing debate as to both the timing of treatment/
surgery and which procedure should be chosen. Despite the increasing number of publications 
on this topic, evidence-based guidelines are lacking beyond expert recommendations [69, 
152]. The following recommendations for genital treatment of certain DSD conditions are 
based on the findings in this dissertation; however, they do not define optimal treatment for 
any specific individual, and every person with DSD has aspects of his/her condition that need 
an individualized approach. 
We believe that vaginal dilation therapy constitutes the first-line treatment for the majority 
of women with vaginal hypoplasia, and that phalloplasty in male patients with a DSD offers 
perspectives when these men are extremely dissatisfied with their penile size and sexual 
function (i.e.possibilities for sexual intercourse).  The optimal time to perform vaginal dilation 
therapy (or vaginoplasty if vaginal dilation therapy fails) and phalloplasty, is after puberty. As 
Conclusion
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young adults, patients will be more sexually mature and motivated to undergo such procedures 
and  well-informed and counseled patients are aware of the risks involved. No specific 
recommendations can be made regarding the type or ‘right’ timing of vaginoplasty and/or 
clitoroplasty (if necessary) in women with ambiguous genitalia, nor hypospadias repair in men 
with DSD. It remains surprisingly difficult to quantify the numbers and types for surgeries for 
girls and women with CAH as a group, and from country to country. Each study of this type 
should shed further light on practices and experiences. It seems, however, that femizining 
genitoplasty may in many cases be deferred to adolescence, with the exception in some 
severe cases, in which genital ambiguity signals severe hormonal dysfunction and a necessity 
of early surgery to avoid urinary tract infections. Even in the most experienced of hands, 
there is often a need for re-intervention and a surgical risk of damage to clitoral sensation 
and future orgasmic capacity. Likewise, parents need to be aware that severe hypospadias 
in DSD often requires multiple surgeries and may be associated with problems such as scar 
tissue formation, affecting both genital sensitivity and cosmetic appraisal, which should not 
be underestimated in boys and men with DSD. In general, choices should always depend 
on individual characteristics and detailed discussions with the patient (and, as applicable, the 
parents) regarding perceptions of advantages and disadvantages of the various approaches. 
The goals of genital treatment/surgery and, in particular their consequences for sexual function 
and satisfaction –as defined by the patient- need to be explicitly addressed.
Finally, it can be questioned that treatment, research, and critics still often focus mainly on the 
consequences of genital surgery and efficacy of medical interventions. Critical but constructive 
in-depth discussion about what constitutes professional treatment and support of persons 
and families affected by DSD is timely and needed [168]. The importance of a psychologist, or 
similar professional, in the management of DSD is not about pathologizing DSD, but rather 
the recognition of the exceptional personal and social challenges that a diagnosis of DSD 
presents [130]. Psychological support and intervention should remain an integral part of care, 
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and is most effectively provided within this multidisciplinary approach, in which all the different 
actors have the same goals: more social acceptance of DSD and empowerment of individuals 
and their family to successfully address challenges as they arise. However, the results in this 
dissertation also suggest that additional experience has to be gained concerning the format 
of acceptable and efficient psychological care and how to integrate this in the regular medical 
follow-up. Furthermore, it is essential that there is a seamless pathway of transition, from 
pediatric through adolescent and into adult services. This will not only serve to optimize the 
clinical care of individuals with DSD, but it will also ensure that both short- and long-term 
outcome data are collected and translated into better future management strategies.
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Figure 5. An overview of the multidisciplinary team (adapted from [130]).
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Many researchers have found that researching ‘taboo’, ‘private’ or ‘sensitive’ subjects can be 
problematic. Research on sex is a prime example and sexology has ‘suffered the slings and 
arrows of ridicule and delegitimation because of its risqué subject matter (p.192) [86]. In this 
case, the topic disturbs the constructed division between ‘public’ and ‘private’, and because of 
the charged nature of the topic, the writer risks association with the unseemly role of voyeur 
[166].
When I have to talk about my research, I find myself oscillating between a devil-may-care 
attitude and a sense of dis-ease. I am not embarrassed by the topic, but I certainly feel the 
social code or pressure of not talking about ‘private parts’ with strangers or acquaintances. 
What is also interesting is, that by not talking about it, I somewhat imagine the dialogue partner 
to be protected from being in the possibly uncomfortable position of having to respond – 
‘that their jaws would (metaphorically) drop, and I would single-handedly rob them of all the 
interactional tools of social convention’ (p.368) [166]. I also admit making judgments about 
whether people can ‘handle’ the information, which obviously leads to omissions. I refer to this 
as the ‘grandparent-friendly’ version – a completely stripped-down version that excludes every 
detail. I say ‘I evaluate the psychological outcome of different urological and gynecological 
treatments’, which doesn’t put ‘sex’ on the agenda, nor ‘genitalia’, thereby blocking the possibility 
of unwanted comments. Although I want to de-stabilize the status quo, my own experiences 
could be analyzed as serious difficulties with breaching taboos and social conventions [166].
Despite my embarrassment and omissions, I have told many different people about my 
research. The responses have ranged from fascination and interest to horror and complete 
disbelief. When it comes to the subject of sex and genitalia, or something of which we have 
‘hands-on’ experience, we all have opinions and why not? We can all claim to be sexperts. But 
myths, assumptions and preconceptions take hold, even when there is rational evidence to the 
contrary [167].
Afterplay
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Methods of scientific inquiry are a useful template for finding out what is true and false in the 
realm of human society and sexuality. In recent years, a large number of researchers from 
different disciplines have systematically looked into an area of human experience previously 
assumed to be untestable, whilst sharing their methods. It becomes harder and harder to 
pass off opinion and unverifiable stories as proof [167]. The results of this new generation of 
studies can be controversial, because they have the power to contradict our assumptions. But 
challenges are good. Being able to re-examine what we think about the truth is one of the 
hallmarks of good science and of human achievement. So let’s further explore the intimate 
geography, but more importantly: let’s keep the conversation going.
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It is estimated that one in every four thousand five-hundred people is born with genitals, 
gonads and genetic material sufficiently equivocal to make doctors and parents wonder to 
which sex they belong. Disorders of Sex Development (DSD), standing at the intersection of sex 
and gender, have from the beginning been understood to be a ‘problem’. Within this doctoral 
dissertation we want to address how these problematic bodies are regarded and medically 
treated today, as both a binary gender ideal and anxiety over uncertainty persist. The body, to 
paraphrase the feminist artist Barbara Kruger (1989) remains a battleground.
Chapter 1 provides the reader with basic information about the process of typical sex 
determination and differentiation. We characterize the biological factors responsible for the 
development of an undifferentiated, bipotential—or should we say multipotential?—embryo 
into a human being with either a male or a female appearance.  We further explore the early 
and current medical responses to variations in genital anatomy as medical practice cannot be 
understood apart from the broader culture in which it is embedded. The treatment paradigm 
determined by John Money and colleagues in the 1950’s has dominated the DSD field for over 
50 years.  The postulates of their approach are summarized as 1) individuals are psychosexual 
neutral at birth and gender identity arises primarily from psychosocial rearing (nurture) and 
not biology (nature) and 2) a healthy psychosexual development and psychosocial adjustment 
is dependent on the appearance of the genitals (i.e. adequate penis for boys, a vagina and no 
easily noticeable clitoris for girls). If penises are determined to be inadequate for successful 
adjustment as males, then patients are assigned as females. Diminishing genital incongruity 
in infancy  is essential so that parents can rear unambiguously identified children. In the last 
decade activists, former surgical patients surgeons, and scholars have come forward to reject 
any ‘fix’ based on social concerns rather than medical necessity. The current dissertation 
is a collection of clinical outcomes studies, providing a snapshot of some of the current 
genital treatment practices, its efficacy and long-term impact, guided by the voice of affected 
persons.
Summary
Intersex/ction
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In Chapter 2, satisfaction with medical management and genital surgery is examined, with 
special emphasis on functional and cosmetic outcomes in three groups of patients: 1) women 
with 46, XX DSD and congenital adrenal hyperplasia, in which genital appearance is often 
masculinized because of prenatal exposure to androgens. Severity of masculinization at birth 
is related to a higher number of genital surgeries (i.e. clitoral reduction  and vaginoplasty) and 
an earlier age at surgery, which is associated with worse cosmetic and functional outcomes, 
2) in women with vaginal hypoplasia (i.e. 46, XX  Mayer-Rokitansky-Küster-Hauser Syndrome 
and 46, XY Complete Androgen Insensitivity Syndrome), in which women who had a surgical 
vaginoplasty procedure to enlarge the vagina for sexual contact, report more functional 
problems, complications and genital cosmesis issues, compared to women who had followed 
nonsurgical vaginal dilation therapy and 3) in men with 46, XY DSD and multiple hypospadias 
repair in childhood, who report more dissatisfaction with their genital appearance compared to 
control men, and in whom a penile length of at least 6 to 7 cm seems to constitute a premise 
for successful sexual contact.  
Chapter 3 examines in more detail the influence of the perception of genital image and 
genital sensitivity and its implications for sexual functionality outcomes in a large sample of 
women without DSD and a history of genital surgery.  As the clitoris is perceived as the most 
sensitive genital area for sexual pleasure and orgasm experience - consistent with maximum 
nerve density in this area-,  surgery to the clitoris could disrupt neurological pathways and 
compromise erotic sensation. 
Chapter 4 further focuses on the efficiency of vaginal dilator treatment as first line technique 
in women with vaginal hypoplasia. A review of the literature indicates that in at least 75% of 
the women dilation therapy can normalize vaginal length and sexual function. Start vaginal 
length is not an exclusive criterion for obtaining success. The available evidence suggests 
further that continued dilation is needed to maintain patency in periods of coital inactivity. The 
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role of psychological counseling in optimizing treatment outcomes remains however unclear. 
Moreover, in a prospective study it is further underlined that continued follow-up (>1 year)  is 
necessary to fully evaluate the impact of treatment on both anatomical and functional success. 
Although the majority of women have pleasurable sex and a vaginal length within normal 
ranges, emotional difficulties relating to infertility and disclosure with others remain significant, 
and necessitates continued psychological counseling. 
In Chapter 5 the importance of penile length for sexual wellbeing is further evaluated and a 
new treatment strategy for men with DSD examined.  In an updated review, it is shown that a 
micropenis (stretched penile length < 2.5 cm at birth or <7cm in adults) can jeopardize sexual 
quality of life and that the current hormonal and surgical lengthening procedures, including 
hypospadias repair, have no or limited effect on penile length. Phalloplasty, principally used 
in the transgender population, can be transferred to 46, XY men with DSD and micropenis, 
and has promising results. However, there are limitations, such as urethral complications, and 
patient expectations need to be realistic. Psychological barriers for engaging in sexual activity 
remain at least as high as the physical ones, underlining the importance of continued and 
appropriate psychological counseling also in this group of patients.
Chapter 6 finally aims to contribute to the actual process of re-thinking the clinical 
management of patients with DSD, with a specific focus on how the shifting understandings 
and approaches can provide a basis for optimized medical and genital treatment care. Perhaps 
the main implication of this doctoral thesis is that surgical or non-surgical ‘correction’ of a 
genital anomaly does not ‘correct’ or affect the patient’s self-image nor genital image. Despite 
high levels of emotional distress, many refuse psychological support. Additional experience 
has to be gained regarding the optimal format of psychological support within an overall 
multidisciplinary approach and how to integrate it effectively in the medical follow-up, making a 
firm commitment to address the socio-emotional dimensions and not just sexual anatomy. The 
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thesis concludes with some implications for clinical practice, including a theory-based model 
of vaginal dilator treatment and strategies to facilitate compliance, and recommendations for 
the psychosexual management of men with penile deficiency, and offers future perspectives 
on sucsexful research.
296
Bent u een man of een vrouw? U kunt die vraag ongetwijfeld met stelligheid beantwoorden. 
Maar het is niet voor iedereen zo eenduidig. Eén op 4500 mensen wordt geboren met 
geslachtsorganen, geslachtsklieren of genetisch materiaal dat in die mate dubbelzinnig is 
dat het bij dokters en ouders tot twijfel over het geslacht leidt. Dit proefschrift beschrijft hoe 
aangeboren stoornissen van de geslachtsontwikkeling (Disorders of Sex Development, DSD) 
in het verleden en heden medisch worden behandeld. Bijzondere aandacht gaat uit naar 
de genitale en heelkundige behandelingen, om een bijdrage te kunnen leveren aan actuele 
pogingen om het medisch beleid bij deze patiënten te herzien en in overeenstemming te 
brengen met de vraag van patiënten voor een meer terughoudend beleid met betrekking tot 
heelkundige interventies, waar mogelijk.  
In Hoofdstuk 1 wordt kort het fundamentele proces van seksedeterminatie en differentiatie 
geschetst, met de belangrijkste biologische factoren die verantwoordelijk zijn voor de 
ontwikkeling van een ongedifferentieerd embryo in een menselijk wezen met een vrouwelijk 
of mannelijk (genitaal) uiterlijk. De huidige medische praktijken en responsen op variaties in 
genitale anatomie worden verder geëxploreerd en gekaderd binnen een historisch-culturele 
context die op verschillende manieren de binaire standaard van man/vrouw heeft proberen te 
waarborgen.  Het behandelingsparadigma opgesteld door John Money en collega’s in de jaren 
’50 heeft het DSD-veld meer dan 50 jaar gedomineerd.  Binnen dit paradigma wordt gesteld 
dat psychologisch en seksueel welzijn kan bereikt worden, wanneer kinderen ondubbelzinnig 
opgevoed worden als meisje of als jongen, en wanneer een ambigu genitaal uiterlijk operatief 
wordt gecorrigeerd in lijn met het gekozen geslacht. Dit beleid is in het laatste decennium 
fel betwist door patiënten, chirurgen en academici die genitale correcties gebaseerd op een 
sociale bekommernis, eerder dan een medische noodzaak, in vraag stellen. Dit proefschrift 
bestaat uit een verzameling van klinische outcome studies waarin de lange termijn impact van 
enkele genitale, medische praktijken op psychologisch en seksueel vlak wordt uitgediept, met 
de stem van patiënten als leidraad.
Nederlandstalige samenvatting
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In Hoofdstuk 2 wordt de tevredenheid met het functionele en cosmetische resultaat na genitale 
heelkunde geëvalueerd binnen drie groepen van patiënten: 1) vrouwen met 46, XX DSD en 
congenitale adrenale hyperplasie, waarbij het genitale uiterlijk vaak is vermannelijkt omwille 
van een prenatale blootstelling aan androgenen. De ernst van de graad van vermannelijking is 
geassocieerd met meer genitale operaties (clitorisverkleining en vaginoplastie) en een jongere 
leeftijd waarop genitale heelkunde wordt uitgevoerd, en wordt in verband gebracht met 
een verminderd cosmetisch en functioneel resultaat  2) in vrouwen met vaginale hypoplasie 
(i.e. 46, XX  Mayer-Rokitansky-Küster-Hauser Syndroom en 46, XY Compleet Androgeen 
Ongevoeligheidssyndroom) waarbij operatieve vaginoplastie technieken om de vagina te 
vergroten voor seksueel contact, geassocieerd zijn met meer seksuele en cosmetische 
problemen in vergelijking met vrouwen die een conservatieve vaginale dilatatiebehandeling 
hebben ondergaan en 3) in mannen met 46, XY DSD en hypospadie correctie in de kindertijd, 
die in vergelijking met een controlegroep mannen meer ontevredenheid rapporteren met 
betrekking tot hun genitale uiterlijk en waarbij een peniele lengte van minstens 6 tot 7 cm een 
voorwaarde lijkt in te houden voor succesvol seksueel contact.
Hoofdstuk 3 spitst zich verder toe op het belang van de perceptie van het genitaal uiterlijk en 
sensitiviteit en de implicaties daarvan op het seksueel functioneren in een grote groep vrouwen 
zonder DSD en een voorgeschiedenis van genitale heelkunde. Daarbij wordt het belang van 
de clitoris voor seksueel plezier en orgasmebeleving verder bevestigd, met mogelijks nefaste 
gevolgen indien zenuwverbindingen worden aangetast met clitorale heelkunde.
Hoofdstuk 4 onderzoekt of een vaginale dilatatiebehandeling in vrouwen met vaginale 
hypoplasie verder efficiënt en waardevol is als eerstelijnstechniek. Een overzicht van de 
literatuur geeft aan dat in ten minste 75% van de vrouwen met dilatatie een normale vaginale 
lengte en functioneel succes kan bekomen worden, en dat de start lengte niet van invloed is op 
het anatomische eindresultaat. De rol van psychologische hulpverlening in het optimaliseren 
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van de resultaten blijft evenwel onduidelijk. In een prospectieve studie wordt verder het belang 
aangegeven van lange termijn follow-up van deze vrouwen, omdat ondanks plezierige seks 
en een normale vaginale lengte, emotionele moeilijkheden gerelateerd aan infertiliteit en het 
delen van de diagnose met anderen, blijven spelen.
In Hoofdstuk 5 wordt het belang van peniele lengte op het seksueel functioneren verder 
bestudeerd en een nieuwe behandelingsstrategie voor mannen met DSD onderzocht. In 
een overzichtsartikel is aangetoond dat een micropenis (een gestrekte lengte < 7cm bij een 
volwassen man) het psychoseksueel welzijn van mannen in gevaar kan brengen, en dat de 
huidige medische behandelingen, zowel hormonale als heelkundige ingrepen niet of beperkt in 
staat zijn om de penis te verlengen. Een falloplastie - ingreep, die momenteel vooral uitgevoerd 
bij transgenderpatiënten, levert ook beloftevolle resultaten bij mannen met een micropenis, 
maar complicaties zijn reëel.  De psychologische barrières met betrekking tot het ondernemen 
van seksuele activiteit blijven aanzienlijk, wat het belang van gepaste psychologische 
ondersteuning ook bij deze groep patiënten verder benadrukt. 
Hoofdstuk 6 geeft ten slotte een samenvattende bespreking weer van de belangrijkste 
bevindingen met als doel een bijdrage te leveren aan een geoptimaliseerd zorgbeleid.  Het 
onderzoek gepresenteerd in deze doctoraatsthesis heeft als belangrijkste implicatie dat een 
heelkundige of niet-heelkundige ‘correctie’ van een genitale anomalie niet per definitie leidt 
tot een ‘correctie’ van het zelfbeeld noch genitale zelfbeeld van de patiënt. Ondanks de hoge 
mate van emotionele distress die deze patiënten ervaren, wordt psychologische hulp vaak 
geweigerd. De vorm en de manier waarop psychologische hulpverlening in de toekomst moet 
georganiseerd en geïntegreerd worden in de medische follow-up, verdient verder aandacht. 
Dit proefschrift besluit met verdere implicaties voor de klinische praktijk, met onder meer 
praktische aanbevelingen voor vaginale dilatatie therapie en het psychoseksueel beleid van 
mannen met een micropenis, en biedt toekomstige perspectieven voor sucsexvol onderzoek.
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